PEPTIDES, PROCESS FOR THEIR PREPARATION, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR INTERMEDIATES

Abstract: This invention relates to the new peptides of the general formula: More particularly, this invention relates to this new pep­ tide and the pharmaceutically acceptable salt thereof, which have pharmacological activities, to processes for the prepara­ tion thereof and to a new intermediate for preparing the active peptide, and to the pharmaceutical composition comprising the same and a method of use thereof.

Description: New Peptide; Process for Preparation Thereof And Use Thereof This invention relates to a new peptide. More particularly, this invention relates to a new peptide and the pharmaceutically acceptable salt thereof which have pharmacological activities, to processes for the preparation thereof and to a new intermediate for preparing the active peptide, and to the pharmaceutical composition comprising the same and a method of use thereof. Firstly, it is to be noted that this invention is originated from and based on the first and new discovery of the new active peptide, i.e. FR-900156 substance. That is, the FR-900156 substance was firstly and newly isolated in pure form from a culture broth obtained by fermentation of a new strain belonging to the genus Stseptomyces and characterized by the physico-chemical properties. Thereafter, as a result of extensive study, the inventors of this invention succeeded in determining: the chemical structure thereof by commanding physical and chemical techniques so that they could give the sequential structure of the formula (If) indicated below to FR-900156 substance and proposed with a firm belief the possible stereoisomeric structure of the formula (Ia) as indicated below for. the came. EMI2.1 EMI3.1 <tb> #D-Lactyl-L-alanyl-&gamma;-D-glutamyl-(L)-meso- <tb> diamonopimelyl(L)-glycine. <tb> Further, after the structural elucidation of FR-900156 as explained above, the inventors of this invention have continued extensive studies on total syntheses of the compound of the formula (If) including the compound of the formula (Ie) so that they have succeeded in completing the industrially advantageous and applicable synthetic processes for preparation of the same, and further have syntherized a lot of related compounds. A new peptidc of this invention is represented by the following formula (I): EMI3.2 wherein R1 is hydrogen or acyl; Rb1 is hydrogen, methyl, isopropyl, hydroxymethyl, protected hydroxymethyl or benzyl; Rê and Rq are each hydrogen, carboxy, protected carboxy, or a group of the formula: : EMI3.3 wherein Ra is mono- or di carboxy (or protected carboxy) lower alkyl or ar(carboxy or protected carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy. Rb2 os hydrogen or lower alkyl; RP is hydrogen, carboxy, protested carboxy with proviso that when one of R2 and R9 is hydrogen, then the other is carboxy or protected carboxy or a group of the formula: EMI4.1 2 wherein Ra and R2 are each as defined b above; Rr is hydrogen or amino protective group, m is an integer 1 to 3; and n is an integer 0 to 2, provided that when R is hydrogen, t-butoxycarbonyl or N-acetylmuramyl, R1 is methyl, m is an integer 2 and n is an b integer 1, then R2 is hydrogen, protected carboxy or a group of the fonnula: EMI4.2 wherein R2 is mono- or di-carboxy Cor protected carboxy) lower alkyl having 1 and 3 to 6 carbon atoms, a-carboxyethyl, a-protected carboxyethyl, ar-(carboxy or protected carboxy)lower alkyl whose aryl moiety may be substituted by hydroxy and Rb2 is as defined above, and when RÚ is lactoyl, Rb1 is methyl, m is an integer : :2, n is an integer 1, RP is car boxy, Rq is carboy mod Rr is hydrogen, then R2 is hydrogen, carbon, protected carboxy or a group of the formula: EMI4.3 d carboxy or a group of the form wherein Ra2 is mono or di-carboxy lower alkyl having 2 to 6 carbon atoms, mono or di-protected carboxy lower alkyl having 1 to 6 carbon atoms or ar-(carboxy or protected carboxy) (lower) alkyl whose aryl moiety may be substituted by hydroxy. Particulars of the various definitions, which are mentioned hereinabove, and hereinafter and preferred examples thereof are explained in the following. The term "lower" is intended to mean a group having 1 to 6 carbon atom(s), unless otherwise provided. (1) Re. Acryl for R1 and R1 Generally, "acyl" may be an acyl group derived from an acid such as organic carboxylic acid, carbonic acid, or carbamic acid, or the thio acid or imidic acid corresponding to each of the preceeding acids, or an organic sulfonic acid, each of which includes an aliphatic, an aromatic and/or a heterocyclic groups in its molecule ; carbamoyl; or carbamimidoyl. Suitable examples of said acyl are illustrated below. Aliphatic acyl means an acyl group derived from an aliphatic acid includes: alkanoyl (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoylm &alpha;-ethyl- hexanoyl, heptanoyl, lauroyl, stearoyl, docosanoyl, 2heneicosylpentacosanoyl, hexacosanoyl [CH3(CH2)24CO], tet pentacontanoyl [CH3(CH2)52CO], 2-hexadecyloctadecanoyl [[CH3(CH2)15]2CHCO], n-tetracosanoyl [CH3(CH2)22CO], 2-docosyltetracosanoyl [[CH3(CH2)21]2CHCO], etc.); cycloalkanecarbonyl (e.g cyclopentanecarbonyl, cyclopropanecarbonyl, cyclohexanecarbonyl, cycloheptane carbonyl, etc.); bridgedalicycliccarbonyl such as bicyclic or tricyclic alkaline or alkenecarbonyl (e.g. norbornane carbonyl, adamantanecarbonyl, etc.); ; alkenoyl (e.g. acryloyl, methacryloyl, crotonoyl, oleoyl, arachidonyl, etc.); lower alkylthio(lower)alkanoyl (e.g. methylthio acetyl, ethylthioacetyl, etc.); lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, t butoxycarbonyl, t-pentoxycarbonyl, etc.); lower alkanesulfonyl (lower) alkoxycarbonyl (e.g. 2-(mesyl)ethoxycarbonyl, etc.); lower alkylthio (lower) alkoxycarbonyl (e.g. 2 (ethylthio)ethoxycarbonyl, etc.); lower alkenyloxycarbonyl (e.g. allyloxycarbonyl, etc,) alkatetraenoyl $(e.g. 3,7-dimethylnona-2,4,6,8 tetraenoyl, etc); lower alkynyloxycarbonyl (e.g. 1,1-dimethyl-propargyloxycarbonyl, etc); lower alkylcarbamoyl (e.g. methylcarbamoyl, etc.); (N-lower alkyl) thiocarbamoyl [e.g. (N-methyl)-thiocarbamoyl, etc]; lower alkylcarbamimidoyl (e.g. methylcarba mimidoyl, etc.); oxalo; alkoxalyl (e.g. methoxalyl, ethoxalyl, propoxalyl, etc). In the above exemplified aliphatic acyl, the aliphatic hydrocarbon moiety, particularly the alkyl group and a:Lane moiety and the alkenyl group and alkene moiety may have optionally one or more suitable substituent(s) such as amino, halogen (e.g. fluorine, chlorine, bromine, etc,), hydroxy, hydroxyimino, carboxy, lower alkoxy (e.g. methoxy, ethoxy, propoxy, etc.), lower alkoxycarbonyl, acylamino suci as lower aL- kanoylamino (e.g. acetylamino, propionylamino, etc.), ar(lower)alkoxycarbonylamio (e.g. benzyloxycarbonyl amino, etc.), etc. or acyloxy such as lower alkanoyl oxy (e.g. acetoxy, propoxy, etc.), ar(lower)alkanoyl oxy (e.g. benzylcarbonyloxy, etc.), aroyloxy (e.g. benzoyloxy, etc.), or 5- or 6-membered cycloalkenyl (e.g 1,3,3-trimethyl-1-1cyclohexan-2-yl, etc.). Preferred examples of aliphatic acyl having such substituents may be exemplified by hydroxyalkanoyl (e.g. glycoloyl, lactoyl, 2-hy-4 droxybutyryl mycoloyl, 2-hydroxyhexacosanoyl [CH3 OH # (CH2)22CHCH2CO], etc. lower alkoxy (lower)alkanoyl (e.g. methoxyacetyl, 2-methoxypropionyl, etc.), carboxy)(lower)alkanoyl (e.g. carboxyacetyl, car boxypropionyl, etc.), (lower) alkoxycarbonyl (lower) alkanoyl (e.g. methoxalyl, ethoxalyl, methoxycarbonylacetyl, propoxycarbonylpropionyl, ethoxycarbonylbutyryl, etc.), halo (lower)alkoxycarbony (e.g. chloromethoxycarbonyl, tribromoethoxycarbonyl, trichloroethoxycarbonyl, etc.), 6-membered cycloalkenyl-alkatetraenoyl (e.g. retinoyl, etc.), and the like. Aromatic acyl means an acyl group derived from an acid having substituted or unsubstituted aryl group, in which the aryl group may include phenyl, tolyl, xylyl, naphthyl and the like, and suitable examples thereof are illustrated as follows: aroyl (e.g. benzoyl,- toluoyl, xyloyl, naphthoyl,- phthaloyl, etc.); ar(lower)alkanoyl (e.g. phenylacetyl, diphenylacetyl, etc.); ar(lower)alkenoyl (e.g. cinnamoyl, etc.); aryloxy(lower)alkanoyl (e.g. phenoxyacetyl, etc.); arylthio(lower)alkanoyl (e.g phenylthiacetyl, etc.); arylamino(lower)alkanoyl (e.g. N-phenylglycyl, etc.); arenesulfonyl (e.g. benzenesulfonyl, tosyl, naphtahlensulfonyl, etc.); aryloxycarbonyl (e.g. phenoxycarbonyl, tolyloxy carbonyl, etc.); aralkoxycarbonyl (e.g benzyloxycarbonyl, benzyhydryloxycarbonyl, trityloxycarbonyl, &alpha;-naphthyl- methoxycarbonyl, etc.); arylcarbamoyl (e.g. phenylcarbamoyl, tolylcÅarbamoyi, naphthylcarbamoyl, etc.); arylglyoxyloyl Ce.g. phenylglyoxyloyl, etc.); arylthiocarbamoyl (e.g. phenylthiocarbamoyl, etc.); arylcarbamimidoyl' (e.g. phenylcarbamimidoyl, etc.); and the like. In the above exemplified aromatic acyl,' the aromatic hydrocarbon moiety (particularly, aryl moiety): and/or aliphatic hydrocarbon moiety (particularly, alkane moiety) may have optionally one or more suitable substituent(s), such as the same as those exemplified as the suitable substituent for alkyl group and alkane moiety as mentioned above. Preferred example of aromatic acyl having such substituents may be exemplified by hydroxyaroyl te. g. salicyloyl, etc.) haloaroyl (e.g. chlorobenzoyl, etc.), haloar (lower)alkanoyl (e.g. chlorophenylacetyl, etc.), hydroxyar(lower)alkanoyl (e.g. mandelyl, etc.), methoxyaralkanoyl [e.g. 10-(2,3,4-trimetethoxy-6-methyl phenyl)-decanoyl, etc]. Eeterocvclic acyl means an acyl group derived from an acid having heterocyclic group and includes: heterocyclic carbonyl, in which the heterocycle moiety is 5 to 6 membered heterocycle containing at least one hetero- atom selected from nitrogen, oxygen and sulfur (e.g. thenoyl, furoyl, pyrrolecarbonyl, 5-oxo-2-pyrrolidinecarbonyl, nicotinoyl, etc.); heterocyclo(lower)alkanoyl, in which the hetero cycle moiety is 5 to 6 nembered heterocycle containing at least.one hetero atom selected rrom nitrogen, oxygen and sulfur (e.g. thienylacetyl, furylacetyl, imidazolylpropionyl, tetrazolylacetyl, 2-(2-amino-4 thiazolyl)-2-methoxyiminoacetyl, N-acetylmuramyl, etc.); and the like. In the above exemplified heterocyclic acyl, heterocycle moiety and/or the aliphatic hydrocarbon moiety may have optionally one or moTe suitable sub stituent(s) such as the same as those exemplified as the suitable substituent for aliphatic acyl as mentioned above. Further, in the above exemplified acyl, in case that these acyls have one or more functional group such as hydroxy, amino, carboxy and the like, such groups may be protected by conventional protective groups(s). (2) Re. Protected carboyx for Rê, Rp, R1p, and Rq A protective group of the protected carboxy includes a conventional protective group for tentatively protecting a carboxy group'whichis conventionally used in the field of amino acid and peptide chemistry. As preferred examples of protected carboxy, there may be exemplified an ester such as an ester with silyl compound (hereinafter referred to as silyl es-ter), an ester with an aliphatic hydroxy compound (hereinafter referred to 2s.apliShatic ester) and an ester with a hydroxy compound containing an aromatic group (hereinafter referred to as aromatic ester), and a protected carbazoyl of the formula: -COHNNhY (wherein Y is hydrogen or an amino protective group). Concrete examples of such a protected carboxy are exemplified as follows. suitable silyl ester such as trialkylsilyl (e.g. trimethylsilyl, triethylsilyl, etc.) ester, halo-alkylsilyl (e.g. chloro-dimethylsilyl, dichloro-methylsilyl, etc.) ester, trihalosilyl (e.g. trichlorosil?l, etc.) ester, alkylalkoxysilyl (e.g. methyl-diethoxysilyl, etc.) ester, trialkoxysilyl (e.g..tris(2-chloroethoxy)silyl, etc.) ester, and the like; suitable aliphatic hydrocarbon ester such as alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, tertbutyl, etc.) ester, cycloalkyl (e.g. cyclopentyl, cyclohexyl, etc.) ester and the like; and suitable ester containing an aromatic group such as aryl (e.g. phenyl, tolyl, xylyl, etc.) ester, aralkyl (e.g. benzyl, diphenylmethyl, phenethyl, etc.) ester, aryloxyalkyl (e.g. phenoxymethyl, phenoxyethyl, etc.) ester, aroylaklyl (e.g. phenacyl, toluoylethyl, etc.) ester, and the like, The ester forming group (e.g. substituted silyl, aliphatic hydrocarbon residue, aryl,. aralkyl, aryloxy alkyl, aroylalkyl and the like, zs exemplified above) may optionally have one or more appropriate substituent(s) such as alkyl (e.g. methyl, ethyl, etc.), cycloalkyl (e.g. cyclopropyl, cyclohexyl, etc.), alkoxy (e.g. methoxy, ethoxy, etc.), alkanoyloxy (e.g. acetoxy, etc.), alkylthio (e.g. methylthio, etc,), halogen (e,g. chlorine, etc.), cyano, nitro, etc. Examples of such substituted esters may be mono (di or tri)haloalkyl (e.g. chloromethyl, bromoethyl, dichloromethyl, 2,2,2-trichloroethyl, 2,2,2-tribromoethyl, 2,2,2-trifluoroethyl, etc.) ester, cyanoalkyl (e.g. cyanomethyl, cyanoethyl, etc.) ester, cycloalkyl substituted-alkyl (e.g. 1-cyclopropylethyl, etc.) ester, mono(di, tri, tetra or penta)halophenyl (e.g.- 4-chlorophenyl, 3,5-dibromophenyl, 2,4,5-trichlorophenyl, 2,4,6-trichlorophenyl, pentachlorophenyl, etc.) ester, and the like. With regard to the term "protected carboxyn for Rê, R, R1p and Rq, it is to be understood that this group bea the meaning not only in synthetic manufacture of the object compound by chemical process(es), but also in physiological and pharmaceutical properties of the object compound per.se. That is, in the meaning of the synthetic manufacture, free carboxy group for Rê, Rp, R1p and Rq may be transformed into the "protected carboxy" group as mentioned above before conducting the process(es): for preventing any possible undesired side reaction(s), and the "protected carboxy" group in the resultant compound may be transformed into free carboxy group after the reaction is conducted, This will be apparent from the explanation of the processes in the following. On the other hand, in the meaning of the physiological and pharmaceutical properties of the object compound, the compound bearing the "protected carboxy" group for Rê, Rp, R1p and/or Rq is optionally used for the physiologically and pharmaceutically active compound per se More particularly, as such a protected carboxy group, "esterified carboxy" group is optionally given as a preferable example, including a conventional esterified carboxy. As suitable examples of the "esterified carboxy", there may be exemplified the same esterified carboxy as illustrated above for explanation of the protected carboxy, among which, as preferred examples, there may be given an aliphatic hydrocarbon ester such as alkyl ester, i.e. alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, t-butoxycarbonyl, etc.) and the like. (3) Re. A group of the formula: EMI13.1 Suitable example of lower alkyl for Rbê and lower alkyl moiety of mono:¯or di-carboxy(lower)alkyl and of ar(carboxy)lower alkyl for Raê is one having 1 - 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl and the like. Suitable example of aryl moiety of ar(carboxy)- lower alkyl for Raê is phenyl, tolyl, xylyl, naphthyl and the like, In this respect, it is to be noted that "ar(carboxy)lower alkyl" can alternatively expressed by the wording Iliower alkyl which is substituted by carboxy and all group. Carboxy in "mono- or di-carboxy lower alkyl" for Raê and "ar (carboxy)lower alkyl whose aryl moiety may be substituted by hydroxy" for Ra2 may be protected by a conventional protective group; namely, Raê includes within its definition also protected carboxy-lower alkyl and ar(protected carboxy)lower alkyl which may be 'substituted by hydroxy. Suitable example of such a protected carboxy is the same as that exemplified for Rp and Rq. Most preferred examples of a group. of the formula: EMI13.2 are illustrated as follows: EMI14.1 the corresponding group, in which the carboxy group is protected by 2 conventional carboxy protective group. (4) Re. Protected hydroxymethyl for R1. Hydroxy group of hydroxymethyl for Rb1 may be protected by a conventional hydroxy protective group; namely, RbÚ includes protected hydroxymethyl. Some preferred examples of the hydroxy protective group say be exemplified by an acyl such as substituted or unsubstituted, alkanoyl (e.g. formic, acetyl, propionyl, butyryl, isobutyryl, valeryl, bromoacetyl, dichloroacetyl, trifluoroacetyl, etc.), substituted or unsubstituted aroyl (e.g. benzoyl, toluoyl,. xyloyl, nitrobenzoyl, bromobenzoyl, salicyloyl etc:), arylalkyl (e.g. benzyl) or the like. (5) Re. Amino protective group for Rr, R1r and Y: The amino protective group includes a conventional protective group for tentatively protecting an amino group, which is used in the field of amino acid and peptide chemistry. That is, in the peptide synthesis, it is understood that, for bonding a desired "reactive" amino group (-NH2) with a desired "reactive" carboxy group '(-COOH) to form a desired peptide bond (-COMH-) between them, it is preferable to tentatively protect the other undesired "reactive" amino group to convert it into an unreactive or less reactive protected amino group in the reaction in order to avoid the side reac tion between the undesired "reactive" amino group and desired "reactive" carboxy groups. Further, it is understood that it is preferable that a protective group in such protected amino group is easily eliminable according to the necessity in the post treatment of the object peptide. Accordingly, an amino protective group to. meet the above requirements can be used and suitable one should be selected according to the kind and property of the component to be used in this inven- tion. As preferred examples of the amino protective group the following examples are illustrated:- - Acyl, particularly. organic acyl, for example, sub stituted or unsubstituted aliphatic hydrocarbon oxycarbonyl such as alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, t-butoxycarbonyl, t-pentoxycarbonyl, etc.), haloalkoxycarbonyl (e.g. chloromethoxycarbonyl tribromoethoxycarbonyl, trichloroethoxycarbonyl, etc.3, an alkane- or arene- sulfonylai:koxycarbonyl (e.g. 2-(mesyl)ethoxycarbonyl, 2-(p-toluenesulonyl). ethoxycarbonyl, etc.), an alkylthio- or arylthioalkoxycarbonyl (e.g. 2 (ethylthio)ethoxycarbonyl, 2-(p-tolylthio)ethoxycarbonyl, etc.), substituted or unsubsttuted alkanoyl such as halo (lower)aikanoyl (e.g. formyl, trifluoroacetyl, etc), a monocyclic or fusedcyclic-alicyclic oxycarbonyl (e.g. cyclohexyloxycarbonyl, adamantyloxycarbonyl, isobornyloxycarbonyl, etc.), substituted or unsubstttuted alkenyloxycarbonyl (e.g. allyoxycarbonyl, etc.), substituted or unsubstituted alkynyloxycarbonyl (e.g. l,l-dimethylpropargyloxycarbonyl, etc.) or the like, substituted or unsubstituted aryloxycarbonyl (e.g. phenoxycarbonyl, p-methylphenoxycarbonyl, etc.), substituted or unsubstituted- aralkoxycarbonyl (e.g. benzyloxycarbonyl, p-nitrobenzyloxyc2rbonyi, p-phenylazobenzyloycarbonyl, p-(p-methoxyphenylazo) benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, &alpha;-naphthylmethoxycarbonyl, p-biphenylisopropoxycarbonyl, etc); substituted or unsubstituted arenesulfonyl (e.g. benzenesulfonyl, p-toluenesulfonyl, etc); substituted or unsubstituted dialkylphosphoryI (erg. dimethylphosphoryl, etc.); substituted or unsubstituted diaralkylphosphoryl (e.g. O,O-dibenzylphosphoryl, etc.); substituted or unsubstituted aryloxyalkanoyl (e.g. phenoxyacetyl, p-chlorophenoxyacetyl, 2-nitrophenoxyacetyl, 2-methyl-2-(2-nitrophenoxy)propyonyl, etc.) or the like; - substituted or unsubstituted aryl such as phenyl, tolyl or the like; - substituted or unsubstituted aralkyl such as benzyl, diphenylmethyl, trityl, nitrobenzyl, or the like; - substituted or unsubstituted alkylidene (e.g. ethylene, isopropylidene, etc.) or the like; - substituted or unsubstituted aralkylidene such as benzylidene, 2-hydroxybenzylidene, 2-hydroxy-5chlorobenzylidene or the like; - substituted or unsubstituted arylthio such as phenylthio, nitrophenylthio, dinitrophenylthio, trichlorophenylthio or the like; and substituted or unsubstituted aralkylthio such as tritylthio or the like. (6) Esterified carboxy for R3p, Rcê and R4q: The esterified carboxy and esterified carboxy moiety for R3p, Rc2 and R4q include a conventional esterified carboxy. As suitable examples of the esterified carbon, there may be exnDlified the same esters as illustrated above for explanation of protected carboxy for R2, Rp, R1p and Rq, among which, as preferred examples, there may be given an aliphatic hydrocarbon ester such as alkyl ester, i.e. alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, t-butoxycarbonyl, etc.) and the like. A pharmaceutically acceptable salt of the new peptides of the formula CI) may include a salt with an inorganic or organic base such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g. calcium salt, etc.), ammonium salt, ethanolamine salt, triethylamine salt, dicyclohexylamine salt or the like, and an acid addition salt with organic or inorganic acid such as methane sulfonate, hydrochloride, sulfate, nitrate, phosphate or the like. With regard to the formula (I) of the compound of this invention the following is to be noted. That is, partial formula: (I) particularly means EMI18.1 - in the formul R1- -, when n'is..an'intege'.r 0, EMI18.2 ,when m is an integer 1, and EMI18.3 when n is an integer 2. Further, partial formula EMI19.1 in the formula (I) particularly means EMI19.2 when m is an integer l, when m is -an integer 2, and when m is an integer 3. The compound (I) of this invention including FR-900156 can be prepared by chemical synthetic method details of which will be apparent from the following description. (1) Process 1: Peptide bond formation 1 EMI19.3 (2) Process 2 : Selective dcacylation EMI20.1 (3) Process 3 : Acylation EMI20.2 (4) Process 4 : Elimination of protective groups EMI20.3 (5) Process 5: Peptide bond formation 2 EMI20.4 (6) Process 6: Aminoprotection EMI21.1 (7) Process 7: Esterification EMI21.2 [RÚ, RbÚ, Rp, Rê, Rq, Rr, m and n are each as defined above provided that at least one of Rp, R2 and Rq is carboxy, or alternatively at least Ra is mono- or di- carboxy lower alkyl or ar(carboxy)Iower alkyl whose aryl moiety may be substituted by hydroxy; and RCê and R4q are each hydrogen, carboxy, protected carboxy, esterified carboxy or a group of the formula: EMI22.1 wherein Raê is mono- or di- carboxy (or protected carboxy) lower alkyl, esterified carboxy lower alkyl, ar(carboxy or protected carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy or ar(esterified carboxy) lower alkyl whose aryl moiety may' be substituted by hydroxy and Rbê is as defined above, Rep is hydrogen, carboxy, protected carboxy or esterified carboxy provided that at least one of Rc2, R4q and C3p is esterified carboxy, or alternatively at least Ra2 is mono- or diesterified carboxy lower alkyl or ar(esterified carboxy)lower alkyl whose aryl moiety may be substituted by hydroxy.] In the above formulae, Rc1 is acyl, R1p is hydrogen or protected carboxy, R2p is hydrogen or carboxy, 1 is hydrogen or protected carboxy, Rê and R7q are hydrogen, carboxy or a group of the formula EMI22.2 wherein Ra2 is mono- or di- carboxy lower alkyl or ar(carboxy)lower alkyl whose aryl moiety may be substituted by hydroxy, and Rbê is as defined above, R1r is amino protective group and m, n, R1, Rê, Rp, Rq, Rr, Raê and Rbê are each as defined above. Detailed explanation of processes for preparation of a new peptide of the formula (I) will be made in following. (1) Process 1 : Peptide bond formation. Compound (II) + Compound (III)-+ Compound (Ia) This process relates to a method for preparing Compound (Iz) by reacting Compound (II) or its salt with a Compound (III) or its salt. The reaction of this process. can be conducted as follows. That is, in one case, as the first step, the carboxy group of Compound nanner, its salt is usually activated in a conventional manner,, for example, in the form of its acid halide, azide, acid anhydride or a mixed anhydride, activated ester, and the like, and is reacted with the Compound (III) to give (II) or its s and in the other case, the Compound (II) or its salt is reacted with the Compound (IIT) or its salt directly in the, N,N-dicyclohexylcarbodiimide and the agent such as ese activation methods, pref and the like. Among these activation methods, preferred nd (II) in method for the carboxy group of the Compound (II) into its activated, form and preferred condensing agent as mentioned above are selected according to kinds of the carboxy protective action c of the Compound (11) and of th and to the reaction conditions (e.g. the kinds of the reaction solvent, reaction temperature and so on). This reaction is preferably carried out in a solvent such as methylene chloride, chloroform, ethanol, water c dioxane, ethyl acetate, methanol, ethanol, water or the like under ion in the to at ambient temperature and the reaction in the presence of a condensing agent is usually carried out in an anhydrous, but not critical, conditions. (2) Process 2: Selective deacylation Compound (Ia) EMI24.1 Compound (Ib) This process relates to a method for preparing Compound (Ib) br its salt by removing selectively an acyl group for R1 of Compound (Ia) or its salt. c This process is applied to c,ase that the acyl group for Rc1 reveals a different chemical property from that of'the amino protective group for Rr against each kind of the removal m-=thads and can selectively be removable by a method to be employed. This reaction is carried, out by conventional method such as catalytic reduction method, liquidammonia alkalimetal method, acid method. zinc acid method, base method, hydrazine method-and the like. Among these methods, preferred one is selected accord ing to. kind of the acyl gnup for R1 of Compound (Ia). Each of the above methods is explained as follows. i) Catalytic reduction method: This method is preferably applied to case that the acyl group for Rc1 of Compound (Ia) are one which is removable by catalytic reduction, As Preferred examples of such an acyl group for R1, there may be exemplified substituted or unsubstituted aralkoxycarbonyl (e.g. benzyloxycarbonyl, p-phenylazobenzyloxycarbonyl, p-(p'-methoxyphenylazo)benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, etc.); substituted or unstubstituted alkenyl-or alkynyloxy- carbonyl -(e.g. allyloxycarbonyl, I,I-dimethylproparglyloxycarbonyl, etc.); substituted or unsubstituted aryloxyalkanoyl (e.g. 2.nitrophenoxyacetyl, 2-methyl-2- (2-nitrophenoxy) propionyl, etc.); and the like. This catalytic reduction is carried out in a conventional manner, and suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalyst (e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide or platinum wire, etc.), palladium catalyst (e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalyst (e.g. reduced nickel, nickel aside, Raney ickel, etc.), cobalt catalyst (e.g. reduced cobalt, Raney cobalt, etc.), iron catalyst (e.g. reduced iron, Raney iron, etc.), copper catalyst (e.g. reduced copper, Raney copper, Ullman copper, etc.) or the like. The reduction is usually carried out in a solvent.. A suitable solvent to be used may be, e.g. water, methanol, ethanol, propanol, ethyl acetate, tetrahyiro- furan, dioxane, N,N-dimethylformamide, acetic acid, a mixture of water and alcohol Ce.g. methanol, ethanol, etc.) tetrahydrofuran, dioxane or ethyl acetate, and other conventional organic solvent or a mixture thereof. "Further, the reduction is preferably carried out in the presence of an acid such as acetic acid or the like. The reaction is preferably carried out under some what milder conditions such as cooling or warming. In this method, in case that Rq is a group of the formula: -CONHNHY and an amino protective group for Y is the same as the acyl for Rl, then, such an amino protective group also is simultaneously removed to give a Compound (Ib) wherein R9 is a group of the formula: -CONHNH2. Further, in case that a protected carboxy group for RP is, for example, substituted or unsubstituted aralkyl ester type one (e.g. benzyl":.ester p-nitrobenzyl ester, p-chlorobenzyl ester, p-phenylazo- benzyl ester, etc.), such a protective group also is simultaneously removed in this process to give a Compound (Ib) wherein RP is carboxy". ii) Acid method: iit-l Method of use of trifluoroacetic acid or 'formic acid: This method is preferably applied to case that the acyl group for Rc is one which is removable. by treating with trifluoro-acetic acid or formic acid. Preferred examples of such an acyl group may be exemplified by a group such as branched-or alicyclicoxycarbonyl, (e.g. t-butoxycarbonyl, t-pentoxycarbonyl, t-amyloxycarbonyl adamantyloxycarbonyl, isobornyloxycarbonyl, etc.); substituted or unsubstituted aralkoxycarbonyl (e.g. p-methoxybenzyloxycarbonyl, etc.). This reaction is conventionally carried out in a solvent such as methylene chloride, chloroform, acetic acid, water and the like in the presence of trifluoroacetic acid or formic acid, and anisole is preferably added thereto. Trifluoroacetic acid and formic acid are also used as the solvent. This reaction is usually carried out under Ice-cooling to at ambient temperature. In this method, in case that Rq is a group of the formula: -CONHNHY and an amino protective group for Y is the same as the acyl for Rc, then such an amino protective group also is simultaneously 'removed to give a Compound (Ib) wherein R9 is a group of the formula: - CONHNH2. Further, in case that a protected carboxy group for RP is, for example, a branched alkyl ester (e.g. t-butyl ester, etc.), or substituted or unsubstituted aralkyl ester- (e.g. diphenylmethyl ester, p-methoxybenzyl ester, etc.) such a protective group also is simultaneously removed to give a Compound (Ib) wherein RP is carboxy. ii)-2 Method of use of hydrochloric acid or p-toluenesulfonic acid: This method is preferably applied to case that an acyl group for Rc is one which ie removed by treating with hydrochloric acid or p-toluenesulfonic acid. Preferred examples of such an acyl group may be exemplified by e.g. substituted or unsubstituted branched alkoxycarbonyl (e.g. t-butoxycarbonyl, 1-(p-biphenyl)-l-methylethoxycarbonyl, etc.) and the like in addition to one as illustrated in the above ii)-l. This reaction is carried out in a solvent such as ethyl acetate, methylene chloride, chloroform, tetrahydrofuran and the like in the presence of an inorganic or organic strong acid such as hydrochloric acid, ptoluenesulfonic acid or the like, and anisole is preferably added thereto. This reaction is preferably carried out under ice-cooling to at ambient temperature. In this method, in case that R4 is a group of the formula: -CONHNHY and an amino protective group for Y is the same as the acyl for Rl then such an amino protective group also is simultaneously removed to give a Compound (Ib) wherein tq is a group of the formula: -CONHNH2. Further, in case that a protected carboy group for Rp is, for example, a branched alkyl ester (e.g. t-butyl ester ,etc.) or substituted or unsubstituted aralkyl ester (e.g. diphenylmethyl ester, p-methoxy benzyl ester', etc.), such a protective group also is simultaneously.removed to give a Compound (Ib) wherein RP is carboxy. ii)-3 Method of use of hydrogen bromide: This method is preferably applied to case that an acyl group for Rc1 is one which is removable by treating with hydrogen bromide. Preferred examples of such an acyl group may be exemplified by substituted or unsubstituted aralkory- carbonyl (e.g. benzyloxycarbonyl, p-chlorobenzyloxy- carbonyl, p-bromobenzyloxycarbonyl, p-tolyloxycarbonyl, p-phenylazobenzyloxycarbonyl, z-naphthylmethoxycarbonyl, etc.) and an alkoxycarbonyl (e.g. isopropoxycarbonyl, etc.) in addition to one as illustrated in the above ii)-l and ii)-2. This reaction is usually carried out in a solvent : such as ethyl acetate, acetic acid, trifluoroacetic acid or the like in the presence of hydrogen bromide. This reaction is preferably carried out under ice-cooling to at ambient temperature. In this method, in case that R9 is a group of the formula: -CONHNHY and an amino protective group for Y is the same as the acyl for Rc, , then. such an amino protective group also is simultaneously removed to give Compound (Ib) wherein Rq is a group of the formula: -CONHNH2. Further, in case that a protected carboxy group for RP is, for example, a branched alkyl ester or (e.g. t-butyl ester, etc.), substituted or unsubstituted aralkyl ester (e.g. diphenylmethyl ester, p-methoxybenzyl ester, etc.), such a protective group is simultaneously removed to give a Compound (Ib) wherein RP is carboxy. iii) Liquid-ammonia-alkali metal method: This method is preferably applied to case that the acyl group for is one which is removable by treating with liquid ammonia-alkali metal. As preferred examples of such an acyl group, there may be exemplified substituted or unsubstituted aralkoxy carbonyl (e.g. benzyloxycarbonyl, etc.), substituted or unsubstituted aryloxycarbonyl (e.g. phenoxycarbonyl, p-methylphenoxycarbonyl, etc.), an arenesulfonyl (e.g. benzenesulfonyl, p-toluenesulfonyl, etc.) and the like. This reaction is usually carried out by dis solving Compound (Ia) into liquid ammonia and then alkali metal is added thereto. This reaction is preferably carried out at a lower temperature, e.g. at -78 C to at boiling point of liquid ammonia. In this method, in case that Rq is a group of the formula: -CONHNHY and amino protective group for Y is the same as the acyl for R , then such an amino protective group also is simultaneously removed to give a Compound (Ib) wherein Rq fls.a.group of the formula: -CONHNH2. iv) Hydrazine method: This method is preferably applied to case that the acyl group for R1 is one which is removable by treating with a hydrazine compound or an amine compound. As preferred examples of such an acyl group, there may be exemplified phthaloyl, formyl, acetoacetyl, etc. Preferred examples of hydrazine compound are exemplified by hydrazine, methylhydrazine, phenylhydrazine and the like and those of amine compound are exemplified by hydroxylamine, dialkylaminoalkylamine (e.g. N,N-dimethylaminopropylamine, etc.) and the like. This reaction is usually carried out by treating Compound (Ia) with the hydrazine compound or amine compound in a solvent such as water, alcohol (e.g. methanol, ethanol, etc.) tetrahydrofuran, dioxane or the like at ambient temperature to under reflux. In this method, in case that R9 is a group of the formula: -CONHNHY and an amino protective group for Y is the same as the acyl for R1 then such an amino protective group also is simultaneously removed to give a Compound (Ib) wherein R9 is a group of the formula: -CONHNH2. v) Zinc-a=id method: This method is.preferably applied to case that the acyl group for Rc1 is one which is removable by treating with zinc acid. As preferred examples of such an acyl group, there may be exemplified trichloroethoxyzarbonyl, 4-piperidyloxy- carbonyl, 1-methyl-1-(4-pyridyl)ethoxycarbonyl and the like. This method is carried out by treating Compound (Ia) with sine in the presence of a weak acid such as formic acid, z acetic acid and the like. The reaction may be carried out in a solvent such as methylene chloride chloroform, tetrahydrofuran, ethyl acetate, alcohol (e.g. methanol, ethanol, etc.), dimethylformamide and the like, and in this case a weak, acid as mentioned above is added to such a solvent The reaction is usually carried out at -10 C to ambient. temperature. In this reaction, in case that R9 is a group of the -. formula: -CONHNHY and an amino protective group. for Y is the same as the acyl for Rc' then such an amino protective group also bs simultaneously removed to give a Compound (Ib) wherein Rq is a group of the formula: -CONHNH2. Further, in case that a protected carboxy group for RP of Compound (Ia) is, for example, a halo-alkyl ester type of group (e.g. trichloroethyl, etc.), sych a carboxy protective group also is simultaneously removed to give a Compound (Ib) wherein RP is carboxy. vi) Base method: This method is preferably applied to case that the acyl group for RcÚ is one which is removable by treating with a base. As preferred examples of such an acyl group, there may be exemplified haloalkanoyl Ce.g; trifluoroacetyl, .etc.), substituted or unsubstituted alkoxycarbonyl (e.g 2-(p-toluenesulfonyl)ethoxycarbonyl, 2-(p tolylthio)ethoxycarbonyl, etc.), substituted or unsub- stituted aryloxycarbonyl (e.g. 2-nitrophenoxycarbonyl, etc.) and the like. This method is carried out in the presence of a base under ice-cooling to at ambient temperature. Suitable base is an inorganic base such as alkali metal hydroxide or alkaline earth metal hydroxide, or thc corresponding carbonate or bicarbonate (e.g. sodium hydroxide, potassium hydroxide, sodium' "carbonate, potassium carbonate,, lithium carbonate, sodium bicarbonXe, calcium hydroxide, magnesium hydroxide, etc;), ammonium hydroxide or the like; an organic base such as an alkoxide or phenoxide of the above metal (e.g. sodium ethoxide, sodium methoxide, lithium phenoxide, etc.), an amine such as mono-, di- or tri alkylamine le.g. methylamine, ethylamine, propylamine, isopropylamine, butylamine, N,N-dimethyl-1, 3 propanediamine, trimethylamine, triethylamine, etc.), unsubstituted, mono- or disubstituted arylamine (e.g. aniline, N-methylaniline N,N-dimethylaniline, etc.), a heterocyclic base (e.g. pyrrolidine, morpholine, N-methylmorpholine, N-methylpiperidine, N,N-dimethyl" piperazlne, pyridine, etc.) or the like; a basic ion exchange resin and the like. This method is preferably conducted under somewhat milder conditions such as coolind or warming and usually in any solvent which does not have an adverse influence on the reaction, e.g. water, a hydrophilic solvent such as alcohol (e.g. methanol, ethanol, propanol, etc.), N,N-dimethylformamid,e, tetrahydrofuran, dioxane, dimethylsulfoxide, etc. or a mixture thereof. In case that the above-mentioned bases are in liquid, they can also be used as a solvent. In this method, in case that R4 is a group of the formula: -CONHNHY and an amino protective group for Y is the same as the acyl for RcÚ, , then such an amino protective group also is simultaneously removed to give a Compound (Ib) wherein R9 is a group of the formula: -CONHNI1. Further, in case that a protected carboxy group for RP of Compound (Ia) is, for example, an alkyl ester type of group (e.g. methyl ester, ethyl ester, etc.), an aralkyl ester type group (e.g. benzyl ester, etc.), such a protective group also is simultaneously removed to give a Compound, (Ib) wherein RP is carboxy. Rl-OH (3) Process 3 : Compound (Ib) Compound (Ia) This process relates to a method for preparing Compound (Ia) by reacting Compound (Ib) with an acylating agent. The acylating agent to be used in this reaction includes an organic acid (RcÚ-OH wherein Rc1 is acyl group) such as monobasic or dibasic organic carboxylic acid, an organic carbonic acid or an organic carbamic acid and the corresponding thio acid or imidic acid; and an organic sulfonic acid, and more particularly, aliphatic, aromatic or heterocyclic carboxylic acid, and the corresponding.carbonic, carbamic, thiocarboxy lic, thiocarbonic, thiocarbamic, carboximidic, carbamimidic acid, and sulfonic acid; their reactive derivatives; and also includes an isocyanate (e.g. potassium-, alkyl- or aryl- isocyanate), isothiocyanate (e.g. alkyl isothiocyanate) and an isothiourea (e.g. ethyl isothiourea). Suitable examples of these organic acid (RC-OH wherein Rl is acyl group) are the corresponding organic acid to those comprising the acyl group as exemplified hereinabove in details in the descriptions of suitable examples of acyl groups for RÚ and Rc1 of the compound (I). Said organic acid as an acylating agent can be used in the form of an activated-organic acid, i.e. as a reactive derivative of the acid. As such reactive derivatives of said organic acids,. there may be exemplified an acid halide, an acid azide, an acid anhydride, an'activated-amide, an activated ester, etc., and additionally isocyanate and isothiocyanate can preferably be used as reactive derivative of carbamic and thiocarbamic acids, respectively. Preferred examples of such reactive derivatives are illustrated by: an acid halide (e.g. acid chloride, acid bromide etc.); an acid snide; an acid anhydride including a mixed acid anhydride with an acid such as dialkylphosphoric acid, phenyl phosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, dialkyl phosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, monoalkylcarbonic acid, aliphatic carboxylic acid (e.g. acetic acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.), aromatic carboxylic acid (e.g. Fenzoic acid, etc.) or the like, and symmetrical acid anhydride; ; an activated amide with pyrazole, imidazole, 4 substituted imidazole, dimethylpyrazole, triazole or tetrazole; and an activated ester such as substituted or unsubstituted alkylthio ester (e.g. nethythio ester, carboxymethyl thioester, etc.), substituted or unsubstituted aryl thioester (e.g. phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, etc.), heterocyclic ester (e.g. pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.) or ester with N,Ndimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, Nhydroxysuccinimide, N-hydroxyphthalimide or 1-hydroxy- 6-chlorobenzotriazole, or the like. The above reactive'derivative is selected according to the kind of the acid to be used. In the reaction, when free acid is used as- an acylating agent, the acylation reaction may prcferably be conducted in the presence of a condensing agent such as carbodiimidic compound (e.g. N,N'-dicyclohexyl- carbodiimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide, N,N'-diethylcarbodiimide, N,N'diisopropylcarbodiimede, N-ethyl-N'-(3-dimethylamino propyl)carbodiimide, etc.), N,N'-carbonyldi(2- methylimidazole), pentamethyleneketene-N-cyclohexylimine, diphenylketene-N-cyclohexylimine, alkoxyacetylene l-alkoxy-l-chloroethylene, trialkyl phosphite, ethyl polyphosphate, isopropyl polyphosphate, phosphorus compound Ce.g, phosphorus oxychloride, phosphorus trichloride, etc.), thionyl chloride, oxalyl chloride, 2-ethyl-7-hydroxybenzisoxazolium salt, 2-ethyl-5-(msulfophenyl)isoxazolium hydroxide, (chloromethylene)dimethylammonium chloride,2,2,4,4,6,6,-hexachloro-l,3, 5,2,4,6-triazatriphosphorine, l-benzenesulphonyloxy6-chloro-lH-benzotriazole, p-toluenesulfonyl chloride, isopropoxyenzenesulfoxyl chloride or the like; or a mixed condensing agent such as a mixture of triphenyl phosphine and a carbon tetrahalide (e.g..carbon tetra chloride, carbon tetrabromide, etc.), a complex of N,N-dimethylformamide with phosphoryl chloride, phosgene or thionyl chloride, etc., or the like. The reaction is usually conducted in a solvent such as water, alcohol (e.g. methanol, ethanol, propanol, etc.), acetone, ethyl.ether, dioxane, acetonitrile, ethylacetate, N,N-dimethylformamide, dimethylsulfoxide, tetrahydrofuran, - dichloromethane, chlorofoxm, etc. or pyridine, N-methylmorpholine, N-,methylpyrrolidine or other conventional solvents, or a mixture thereof. The reaction can also be conducted preferably in the presence of an organic or inorganic base such as alkali metal (e.g. sodium, potassium, etc.), alkaline earth metal (e.g. calcium, etc.), alkali or alkaline earth metal hydride (e.g. sodium hydride, calcium hydrid, etc.), alkali or alkaline earth metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide, etc.), alkali or alkaline earth metal carbonate or bicarbonate Ce.g. sodium carbonate, potassium carbonate, sodium bicarbonate, lithium carbonate, etc.), alkali or alkaline earth metal alkoxide (e.g. sodium ethoxide, lithium methoxide, magnesium methoxide, etc.), trialk;-lamine Ce.g. triethylamine, etc.), pyridine, bicyclodiaza compound (e.g. 1,5-diazabicyclo [3,4,0]nonene-5, 1,5-diazabicyclo [5,4,0]undecene-5, etc.) or the like. Among said base, a liquid one can also be used as a solvent. There'is no limination to this reaction temperature, and this reaction may preferably be conducted within the range of cooling to ambient temperature. (4) Process4: Elimination of protective groups Compound (Ic) ? Compound (Id) This process relates to a method for preparing Compound (Id) by subjecting Compound (Ic) to removal reaction of protective groups of protected carboxy groups for RP and Rq and or amino protective group for r details of which are explained as follows: Process 4-l : Elimination of zn amino protective group for Rr The elimination of an amino protective group for Rr is carried. out substantially in the same manner as that of Process 2, and accordingly the detailed explanation for Process 2 as made hereinabove is to be referred to. Process 4-2 : Removal of carboy protective group of protected carboxy for RP and Rq The reaction for removal of protective group of the protected carboxy group is carried out by a conventional method such as hydrolysis and reduction or the like, details of which are explained in the following. i) For hydrolysis which refers to the same meaning as solvolysis including, for example, acidolysis, alcoholysis, aminolysis, hydroxinolysis, etc.: Hydrolysis is preferably carried out in the presence of an acid or base. Suitable acid includes an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, etc.), an organic acid (e.g. formic acid, acetic acid, trifluoroacetic acid, prop ionic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.), an acidic ion- - exchange resin and the like. Suitable base includes an inorganic base such as alkali or alkaline earth metal hydroxide or the corresponding carbonate or bicarbonate (e.g. sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate., lithium carbonate, sodium bicarbonate, calcium hydroxide, magnesium hydroxide, etc.), ammonium hydroxide or the:like; an organic base such as an alkoxide or phenoxide of the above metal (e.g. sodium ethoxide, sodium methoxide, lithium phenoxidc, etc.), al: amine such as mono-, di- or trialkylamine (e.g. methylamine, ethylamine, propylamine, isopropylamine, butylamine, N,N-dimethyl-1,3-propanediamine, trimethylamine, triethylamine, etc.), unsubstituted, mono- or disubstituted arylamine (e.g. aniline, N-methylaniline, N,N-dimethylaniline, etc.), a heterocyclic base (e.g. py:rolidine, morpholine, N-methylmorphollne, N-methylpiperidine, N,Ndimethylpiperazine, pyridinc, etc.), hydrazines (c.g. hydrazine, methylhydrazine, ethylhydrazine, etc.) or the like; a basic ion-exchange resin and the like. The hydrolysis is preferably conducted under some what milder conditions such as cooling or warming and usually in a solvent which does not have adverse influence to the reaction, e.g. water, a hydrophilic solvent such as alcohol (e.g. methanol, ethanol, propanol, etc.), acetone, N,N-dimethylformamide, tetrahydrofuran, dioxane, dimethylsulfoxide, etc. or a mixture thereof, and other hydrophobic solvent such as benzene diethylether, etc. may also be used as a solvent. A liquid abovementioned acid or base can also be used as solvent. ii) For reduction: Reduction, including chemical reduction and catalytic reduction, is carried out in a conventional manner. Suitable reducing agents to be used in chemical reduction are a metal (e.g. tin, zinc, iron, etc.), or a combination of. such metal a'nd/or metallic compound (e.,g. chromium chloride, chromium acetate, etc.) and an organic or inorganic acid (e.g. formic acid, acetic acid, prop ironic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochlric acid, hydrobromic acid, etc.). Suitable'catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g. platinum plate, spongy platinum platinum blacks, colloidal platinum, platinum oxide or platinum wire, etc.), palladium catalysts (e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g. reduced nickel, nickel oxide, Rabey nickel, etc.), cobalt catalysts (e.g. reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g. reduced iron, Raney iron,. etc.), copper catalysts (e.g. reduced copper, Raney copper, Ullman copper, etc.) or the like. The reduction is usually carried out in a solvent. A suitable solvent to be used may be, e.g. water, alcohol (e.g. methanol, ethanol, propanol, etc.) and other conventional organic solvent or a mixture thereof. Additionally, the afore-mentioned liquid acids to be used in chemical reduction ean also be used as solvent. Further, a suitable solvent to be used in catalytic reduction may be, e.g the above-mentioned solvent, and other conventional solvent, such as diethyl ether, dioxane, tetrahydrofuran, etc. or a mixture thereof. The reaction is preferably carried out under somewhat milder conditions such as cooling or warming. Among these methods for removal of protective groups, preferred one and appropriate combination methods are to be selected according to kinds of the protective groups of carboxy group aMd amino protective group to be removed off. It is noted that this process includes the following cases of removal o'f. protective groups and amino protective group, that is, one case that all of the carboy protective groups for RP and Rt and the amino protective group for Rr in the Compound (Ic) are simultaneously removed by a method to be employed to the reaction, and the other case that the carboxy protective groups and the amino protective group are sequentially and stepwise removed by a method which is appropriately selected according to the kinds of the protective group to be removed. Process 4-3 : Removal of hydrazino group A protected carbazoyl of the formula: -CONHNHY wherein Y is an amino protective group can be removed by subjecting the Compound (Ic) at first to the reaction of Process 4,-l for eliminating amino protective group (i.e. y,) to give -CO*NHNH2 group and then subjecting the redaction product to the reaction of this step to give -COOH group, and particular of this reaction step is as follows. The reaction of this step is carried out in a conventional manner by treating the Compound (Ic) with a conventional oxidizing agent which is capable of oxidizing a group of the formula: -CONHNH2 to form into a group of the formula: -COOH and accordingly preferred example of such an oxidizing agents may be halogen such as iodine, bromine etc., perhalogenic acid such as periodic acid or its salt (e.g. sodium salt, potassium shalt, etc.), perchloric acid, etc., N-haloimide such as N-bromosuccinimide, etc., lead tetraacetate, hydrogen peroxide or its salt (e.g. nickel peroxide, etc.), metal oxide such as zercuric oxide, manganese dioxide, nickel peroxide, etc., cupric compound (e.g. cupric acetate, culprit sulfate etc.) and the like. This reaction is usually carried out in a solvent such as water, acetic acid, methanol, ethanol, tetrah'ydrofuran, dioxane and the like and a mixture thereof, which should be appropriately selected, in accordance with the kind of oxidizing agent to be used. This reaction is usually carried out under ice cooling to at ambient temperature, or under reflux. As to Process 4 for Elimination of protective groups (i.e. Process 4-1, Process 4-2 and Process 4-3), it is to be noted that, in case that acyl for RÚ has one or more protective groups for hydroxy, amino and, (or) carboxy, such protective groups also may be simul taneously removed and such a case is included within 'the scope of this process. (5) Process .5: Peptide bond formation 2 Compound (Ig) EMI41.1 Compound (lah) This process relates to a method 'for preparing Compound (Ih) by reaction Compound (Ig) or its salt with a compound of the formula: EMI41.2 or its salt (wherein Raê and Rbê are each as defined abov This reaction is carried out in substantially the same manner as that of Process 1, and accordingly the detailed explanation for Process 1 as made hereinabove is to be referred thereto. (6) Process 6: Aminoprotection Compound (Ij) EMI42.1 Compound (Ia) This process relates to a method for preparing Compound (Ia) by reacting Compound (Tj'. with an amino protecting agent. The amino protecting agent to be used in this reaction is the same as one illustrated in Process explained hereinafter. The reaction is carried out substantially in the same manner as that of' Process 3. (7) Process 7: Esterification This process relates to a method for preparing Compound (I1) by reacting Coripound (Ik} with an esterifying agent. An esterifying agent tp be used in this reaction may include a conventional one such as alcohol (e.g. methanol, ethanol, propanol, butanol, benzylalcoh etc.) or its reactive equivalent Ce.g. halide, sulfate, aliphatic or aromatic sulfonate or the corresponding diazo compound, etc.) and the like. This reaction is carried out in a conventional manner and in case of using alcohol as an esterifying agent the redaction is usually carried out in the presence of an acid such hydrochloric acid, sulfuric acid, methanesulfonic acid or the like, and in case of using alkyl halide as an esterifying agent the reaction is usually carried out in the presence of a base as illustrated in the aforementioned Process 2. Preparation of Starting Compounds (II) and (II) The starting Compounds (II) and (III) each include new compound and can be prepared by methods as described below. Among the Compound (III), a new compound is represented by the following formula: EMI44.1 wherein RÚ, Raê, Rbê, Rq and Rr are each as defined above, provided that when RÚ is hydrogen or t-butoxycarbonyl and Rbê is hydrogen, then Raê is mono- or di-carboxy lower alkyl having 1 and 3 to 6 caron atoms, &alpha;-carboxyethyl or ar(carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy. Detailed explanation of preparation of the starting Compounds (II) and (III) are made in the following. Preparation of Compound (III), i.e. Compounds (III-1) to (III-15) EMI45.1 EMI46.1 EMI47.1 Prearation of Compound (II) EMI48.1 EMI49.1 In the above formula, R2r is an amino protective group, Raê' is mono or di-protected carboxy-lower alkyl or arCprotected carboxy)lower alkyl whose aryl moiety may be substituted by hydroxy,, is is carboxy or protected carboxy excepting protectcd carbazoyl, # Eq is esterified carboxy, and RcÚ, RbÚ, Rp, R1r, R1q, Rbê, Y, m and n are each as defined above. Particulars of the definitions for Rf, and Raê' and preferred example thereof are the same as those for Rar and 2 respectively, and preferred example of esterified carboxy for R5q is the same as those for R3p, Rcê and R4q. Cl) Process lS : Compound LV-I) + Compound (IV) EMI49.2 Compound (III-1) This process relates to a method for preparing Compound (III-1) by reacting Compound (V-l) or its salt with a Compound (TV) or its salt. The starting Compound (V-l) includes a known one described in e.g. Biochemistry, vol. 9, pages 823 831, 1971, and new one which can be prepared according to the method zs described in said literature. This reaction is carried out in substantially the same manner as that of Process 1 as explained hereinabove. (2) Process 25: Compound (III-1)#Compound (III-2) This process relates to a method for preparing Compound (III-2) by subjecting Compound (III-1) to elimination reaction of both of amino protective groups for Rf and R2r. This process is applied to case that both amino protective groups for Rr and R2 are ones which can be removed by a method to be employed in this process. This reaction is carried out by conventional methods suc as catalytic reduction method, liquid ammonia-alkalimetal method, acid method, zinc-acid method, base method, hydrazine method and the like. Among these methods, preferred one is selected accord ing to kind of the amino protective groups for R1r and R2 of Compound III-1). This reaction is carried out in substantially the same manner as that of Process 2 as explained herein above. (3) Process 35 : Compound (III-l)Compound (III-3) This process relates to a method for preparing Compound (III-3) or its salt by removing selectively an amino protective, group for Rr2 of Compound (III-1) or its salt This process is applied in case that the amino protective group for Rr2 reveals a different chemical property from that for R1r against each kind of the removal methods zs mentioned in the foregoing Process 2 and can selectively be removable by a method to be employed. This reaction is carried out by conventional methods as mentioned in explsnation for Process 2. Among these methods, preferred one is selected accord ing to kinds fo the amino protective group for Rr2. Each of such a method and the kinds of such amino pro tective group are to be referred to explanations in Process 2. (4) Process 45: Compound (III-1)#Compound (III-4) This process relates to a method for preparing Compound (III-4) or its salt by removing selectively an amino protective group for R1r of Compound (III-1) or its salt. This process is applied to case that the amino protective group for Rrl and the amino protective group of the protected carbazoyl for R9 reveals mutually the same chemical property and they reveal a different chemical property from that for R2 against each kind of the removal methods as mentioned in the foregoing Process 2 and they can selectively be removable by a method to be employed. (5) Process 55: Compound (III-4)#Compound (III-5) This process relates to a method for preparing Compound (III-5) or its salt by removing zn amino protective group for R2 or its salt. This reaction is carried out in substantially the same manner as that of Process 35 as explained hereinabove. (6) Process 65: Compound (III-5)#Compound (III-6) This process relates to a method for preparing Compound (III-6) by reacting Compound (III-5) with an amino protective agent. The amino protecting agent includes organic carboxylic, sulfonic, sulfinic, phosphoric and carbonic acids, aldehyde and ketone compounds which are composed of the same pT:otective group as explained for the amino protective group for Rr, R1r and Y and their reactive derivatives. The reactive derivatives include conventional ones such as halides, activated amides, activated esters, acid azide and the like. then a free acid form of such an amino protecting agent is employed, the reaction is preferably carried out in the presence of a condensing agent conventionally used in the ield of amino acid and peptide chemistry. This reaction is carried out in water or an aqueous organic solvent in the presence of a metal compound such as cupric chloride, cupric sulfate cupric carbonate, cupric acetate or the like.. (7) Process 75: Compound (III-5)#Compound (III-7) This process relates to a method for preparing Compound (III-7) by reacting Compound (III-5) with an amino protecting agent.. The amino.protecting agent to be used in this reaction is the same as one illustrated in Process 6S. This reaction is carried out in a conventional solvent, preferably within the range of pH 6-9, more preferably at pH of around neutrality under ice-cooling to at ambient temperature. (8) Process 85: Compound (III-6)#Compound (III-10) This process relates to a method for preparing Compound (III-10) by reacting Compound (III-6) with an amino protecting agent. The amino protecting agent is the same as that of Process 65 and the reaction condition is the same ¯as those of Process 3 as explained hereinabove. (9) Process 95: Compound (VI)#Compound (VI-1) This process relates to a method for preparing Compound (VI-1) by reacting Compound CVI) with an amino protecting agent. In this reaction, it is necessary that such an amino protecting group to be introduced into one of two amino groups of the Compound (VI) be different from the amino protecting goupffor Y in c'ase of obtaining stereospecific compound. The amino protecting agent to be used is the same as the one illustrated in Process 65. This reaction is carried out in substantially the same manner as that of Process 65. (10) Process 105: Compound (VI)#Compound (VI-2) This process relates to a method for preparing Compound (VI-2) by reacting Compound (VI) with an amino protecting agent. In this reaction, such an amino protective group to be introduced into the amino group may be the same as or different from that for Y. Preferred examples of an amino protecting agent are the same as that of Process 65 This reaction is carried out in water or an aqueous organic solvent and preferably within the range of pH 6-9, more preferably at pH,of around neutrality under ice-cooling to at ambient temperature. (11) Process llS : Compound (VI-l) ¯ Compound (VI-3) This process relates to a method for preparing Compound (VI-3) by reacting Compound (VI-1) with an amino protecting agnet. In this reaction, it is necessary that such an amino protective group to be introduced into the amino group is different from that for Rf of Compound (VI-l) in case of obtaining stereospecific compound, but may be the same as that for Y. This reaction is preferably carriea out at neutral - alkaline condition, and other reaction conditions are the same as that of Process 3 as explained hereinabove. (12) Process 125 : Compound (VI-2) EMI55.1 Compound (VI-3) This process relates to a method for preparing Compound (VI-3) by reacting Compound (VI-2) with an amino- protecting agent. In this reaction, it is necessary that such an. amino protective group to be introduced into the amino group (VI-3) is different from that for R1r and Y of Compound (VI-2) in case of obtaining stereospecific compound. Reaction conditions are the same as those of Process lis (13) ' Process 135 : Compound (VI-3) EMI55.2 Compound (III-8) This process relates to' a method for preparing Compound (III-8) by reacting Compound (VI-3) with a compound of the formula (IV) : EMI55.3 or its salt. This reaction is carried out in substantially the same manner as that of Process 1 as explained hereinabove. (14) Process 145: Compound (VI-3) EMI55.4 Compound (VI-4) This process relates to a method for preparing Compound (VI-4) by removing selectively an amino protective group for Y of Compound (VI-3). This process is applied to case that the amino protective group for Y reveals a different chemical property from that for R1r and Rr2 against each kind of the removal methods as mentioned in the foregoing Process 2 and'can selectively be removed by a method to be employed. This reaction is carried out in substantially the same manner as that of Process 2 as explained hereinabove. (15) Process lSs : Compound (VI-4) EMI56.1 Compound .CIII-ll) This process relates to a method for preparing Compound (III-11) by reacting Compound (VI-4) or its salt with a compound of the formula: EMI56.2 or its salt. This reaction is carried out in substantially the same manner as that of Process l. (16) Process lGs : Compound (III-11) EMI56.3 Compound (III-5) This process relates to a method'for preparing Compound (III-5) by removing both of amino protective groups for R1r and Rr of Compound (III-ll). 2 This reaction is carried out in substantially the same manner as that of Process w5. (17) Process 175: Compound (VI-5) EMI56.4 Compound (VI-6) This process relates to a method for preparing Compound (VI-6) by reacting Compound (VI-S) with an esterifying agent. An esterifying agent to be used in this reaction is the same as one illustrated in the aforementioned Process 7 and the reaction is carried out substantially in the same manner as that of Process 7. (18) Process 185 : Compound (VI-6) EMI57.1 Compound (VI-4) This process relates to a method for preparing Compound (VI-4) by removing selectively an amino protective group for Y of Compound (VI-6). This reaction is carried out in substantially the same manner as that of Process 145. (19) Process 195: Compound (III-12) EMI57.2 Compound (III-13) This process relates to a method for preparing Compound (III-13) by reacting Compound (III-12) with an esterifying agent. An esterifying agent to be used in this process is the same as that of Process 17S, This reaction is carried out in substantiall"y" the same manner as that of Process 175. (20) Process 205 : Compound (111-13) EMI57.3 Compound (III-5) This process relates to a method for preparing Compound (III-5) by removing both of amino protective groups 'for Rf and R1r of Compound (III-13). This reaction is carried out in substantially the same manner as that of Process l6. (21) Process 215 : Compound (V-2) EMI58.1 Compound (VI-7) This process relates to a method for preparing Compound (VI-7) by reacting Compound (V-2) with a halogenating agnet. A halogenating agent to be used in this reaction is to be such a halogenating agent as being capable: of halogenating a carboxy group to provide the corr.espond- ing acid halide and may include a conventional one such as phosphorus trihalide (e.g. phosphorus trichloride, etc.), phosphorus pentahalide (e.g. phosphorus penta chloride etc.), thionyl halide (e.g. thionyl chloride, etc.), phosgene and the like. In this reaction, the followings are to be noted: That This, in casc that a Compound (V-2), wherein both of Rr and Rr an:e a carbonic z c acyl group (e.g. alkoxy carbonyl, etc.), is employed as a starting compound, all of the halogenating agent as exemplified above can be used, and the reaction is conducted by reacting Compound (V-2) with the halogenating agent under warming or heating. - On the other hand, in case that a compound (V-2) wherein both of Rr and Rr are hydrogen, is employed as a starting compound, phosgene only is used as a haloge nating agent, and the reaction is carried out by react ing Compound (V- 2) with phosgene under cooling to warming. (22) Process 225 : Compound (VI-7) EMI58.2 Compound (VI-8) This process relates to a method for preparing Compound (VI-8) by reacting Compound (VI-7) or its salt with a compound of the formula: H2NNEY or its salt This reaction is preferably carried out in the presence of a weak acid such as acetic acid, oxalic acid or the like. This reaction is carried out in a conventional solvent under ice-cooling to at ambient temperature. (23) Process 235 : Compound (VI-8) EMI59.1 Compound (VI-9) This process relates to a method for preparing Compound (VI-9) by reacting Compound (VI-8) with a convntional leucineaminopeptidase. This reaction is preferably carried out in a conventional solvent, e.g water, a hydrophilic solvent such as alcohol (e.g. methanol, ethanol, etc.), acetone or the like or a mixture thereof within the range of pH 7 to 10, preferably pH 8 to 9, at 20 to 400C, preferably 37 C. (24) Process 245 : Compound (VI-93 EMI59.2 Compound (VI-lO) This process relates to a method for preparing Compound (VI-10) with an amino protecting agent. An amino protecting agent to be used are zsame as that of Process 65. This reaction is carried out in substantially the same manner as that of Process 3,as explained hereinabove. (25) Process 255: Compound (VI-10) EMI59.3 Compound-(VI-ll) This process relates to a method for preparing Compound (VI-11) by reacting Compound (VT-10) with a halogenating agent. A halogenating agent is the same as that of Process 215. This This reaction is carried out in substantially the same manner as that of Process 21S. In this respect, it is to be noted that, in case that a compound (VI-lO), wherein R2r is a carbonic acyl (e.g. alkoxycarbonyl), is employed as a starting compound, all of the halogen nating agent as exemplified in the explanation for Process- 215 can be explained. . @@@@@@@ @@@@ @@@@ @@@@ (26) Process 265: Compound (VI-11) EMI60.1 Compound (VI-1.2) This process relates to a method for preparig compound CVI-12) by subjecting compound (VI-11) to hydrolysis. This reaction is carried out in substantially the same manner as that of Process 4-2 as explained here- inabove. (27) Process 275: Compound (III-9) EMI60.2 Compound (III-9') This process relates to z method for preparing compound (III-9') by reacting compound (III-9) with an esterifying agent. An esterifying agent to be used is the same as that of Process 175. This reaction is carried out in substantially the same manner as that of Process 17S, -(28) Process 28S : Compound (III-3) EMI61.1 Compound CIII-14) This process relates to a method for preparing compound (III-14) by reacting compound (III-3) with an amino protecting agent. An amino protecting agent to be used is the same as that of Process 65. This reaction is carried out in substantially the same manner as that of Process 85. (29) Process 295: Compound (III-14) EMI61.2 Compound (III-4) This process relates to a method for preparing compound (III-4) by removing selectively an amino pro active group for R1r. This reaction is carried out in substantially the same manner as that of Process 45. (30) Process 30s : Compound (III-4) EMI61.3 Compound (III-15) This process relates to a method for preparing Compound (III-15) by reacting compound (III-4) with an amino protecting agent. An amino protecting agent to be used is the same as that of Process 65. This reaction is carried out in substantially the same manner as that of Process 85. (31) Process 315 : Compound (III-15) EMI62.1 Compound (III-6) This process relates to z method for preparing compound (III-6).by removing selectively an amino protective group for R2r. This reaction is carried out in substantially the same manner as that of Process 35. (32) Process 325: Compound (VI-11) EMI62.2 Compound (III-16) This process relates to a method for preparing compound (III-16) by reacting compound (VI-ll) with a Compound of the formula: EMI62.3 or its salt. This reaction is carried out in substantially the same manner as that of Process 225. (33) - Process 335: Compound (I1"'l) EMI62.4 Compound (II) This process relates to 2 method for preparing Compound (II) by reacting Compound (II-1) with an t acylating agent. The starting Compound (II-1) includes known one (e.g. Journal of Med. Chemistry, vol. 9, 971 (1966)) and new one, and said new compound can be prepared according to the method described in such literature. The acylating agent to be used in this reaction is the same as illustrated in the aforementioned Process 3. The acylation is carried out in substantially the same manner as that of Process 3 as explained hereinabove. (34) Process 345 : Compound (II-2) + + Compound (II-3) EMI63.1 Compound (II) This process relates to a method for preparing Compound (II) or its salt by reacting Compound CII-2) or its salt with Compound (II-3) or its salt. This reaction is carried out in substantially the same manner as that of Process 1 as explained hereinabove. (35) Process'335 : Compound (II-4) + Compound tII-5) EMI63.2 Compound (II) This process relates to a method for preparing Compound (II) or its salt by reacting Compound (II-4) or. its salt with Compound ,,(II-5) or its salt This reaction is carried out in substantially the same manner as that of Process 1 as explained hereinabove (36) Process 36 : Compound (VI.-3) EMI63.3 Compound (VI-2)- This process relates to a method for preparing Com- pound (VI-2) Cr its salt by removing relectively an amino protective group for Rr of Compound (VI-3). This reaction is carried out in substantially the same manner as that of Process Ss and accordingly the detailed explanation for Process 35 as made hereinabove is to be referred thereto. t372 Process 375 : Compound (III-17) EMI64.1 Compound (III-18 This process relates to a method for preparing Compound (III-18) by reacting Compound (III-17) with an oxidizing agent in the presence of alcohol, The oxidizing agent to be used in this process is the same as one illustrated in Process 4-3, The alcohol to be used in this process is a conventional one such as methanol, ethanol, propanol, butanol, benzylalcohol or the like. The reaction is carried out in substantially the same manner as that of Process 4-3 a (38) Process 3 8 : Compound (III-19) EMI64.2 Compound (III-20) This process relates to a method for preparing Compound CITI-20) by reacting Compound ÌZ-l9) wi.h an amino protecting agent. An amino protecting agent to be used is the same as that of Process 65. This reaction is carried out in substantially the same manner as that of Process 85. As to the object Compound (I) and starting Compounds (II) and (III) which are prepared according to the aforementioned Processes, it is to be noted that each of said compounds includes one or more stereo isomers which in due to the asymmetric carbon atoms in their molecule and all of such isomers are included within the scope this invention. The new peptide (I) and its pharmaceutically acceptable salts of this invention have been found to possess enhancing activities of immune response (i.e., enhancing activities of cellular immunity and humoral antibody production) and reticuloendotherial system, mitogenic activit,y7 inducing activity of interferon, protective efficacy in experimental infection and anticancer activity. Accordingly, the new peptide (I) and its pharmaceutically acceptable salts are useful for the therapeutic treatment of infectious diseases caused by pathogenic microorganism, especially gram-negative bacteria and gram-positive bacteria and fugi, and of c2ncer in human being and animals. Further, Compounds (11) and (III) are useful as intermediaLe for preparing Compound (I) having biologi cally active properties as mentioned above. For the purpose of showing pharmaceutical utility of the new peptide (I), pharmacological test data thereof are illustrated in the following 1. BLOOD STREAM CLEARANCE OF CARBON Reagents. 1. Carbon suspension. Rotoring drawing ink (170 mg carbon/ml.) was diluted to I/S of the original concentration in saline containing 1% gelatin. 2. 0,1% aqueous sodium carbonate solution. Procedure. Mice (DDY male 5 - 6 W) were injected via the tail vein with a dose of 0.01 ml/g body weight of carbon. Blood samples were taken by means of a pointed capillary pippet calibrated to hold a 50 p1 and previously washed in heparin. This was plunged into the retrooribital venous sinus at the nasal angle of the eye. The samples were removed at 3 and 6 min. The blood was immediately discharged into 3.0 ml. of the sodium carbonate solution. This- hemolyszed the blood and allowed the quantitation of carbon. The samples were then read in a spectrophotometer at 660 nm, the log concentration being obtained from a previously determined standard curve. The clearance value K may be determined by plotting log carbon concentration against time according to the following relationship; EMI66.1 in which T1 and T2 represent the time in min when the sample were withdrawn and C1 and C2 represent the concentrations of carbon in the blood ct the time T1 and T2, respectively. EXAMINATION OF EFFECT OF THE NEW PEPTIDE ON CARBON CLEARANCE ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ The aqueous solution of,, the test compound as given was administercd subcutaneously to mice. Thienty four hours later, blood stream clearance of carbon was measured. K value obtained with treated mice was compared with that of control mice. The test results are shown in Table I to 3. ¯¯¯¯¯¯ EMI66.2 TABLE 1 EMI67.1 <SEP> Rer <SEP> naerence <tb> <SEP> Dbse <SEP> ztreated <SEP> c=ttpound <tb> <SEP> (mg/ <SEP> K <tb> <SEP> R1 <SEP> " <SEP> Ra <SEP> *l <SEP> *2 <SEP> *3 <SEP> *4 <SEP> kg) <SEP> control <SEP> treated <tb> <SEP> Kcontro <SEP> 1 <tb> <SEP> CH <tb> <SEP> CR3DCO <SEP> CH3 <SEP> l-CH0XhS <SEP> L <SEP> D <SEP> - <SEP> L <SEP> D <SEP> 1 <SEP> 1.3 <SEP> 1.3 <tb> <SEP> D <SEP> L <SEP> L <SEP> 0.1 <SEP> 1.0 <SEP> 0.9 <tb> <SEP> 11 <SEP> II <SEP> IL <SEP> 11, <SEP> 11 <SEP> 11 <SEP> II <SEP> l <SEP> 1 <SEP> 1.6 <SEP> 1.3 <tb> <SEP> -CHCO{ <SEP> 0.1 <SEP> 1.1 <SEP> 0.9 <tb> <SEP> D <tb> <SEP> . <SEP> . <SEP> . <SEP> . <tb> <SEP> t3 <SEP> TI <SEP> 2.8 <SEP> TI <SEP> II <SEP> II <SEP> II <SEP> 1 <SEP> 2. <SEP> 8 <SEP> 2.3 <tb> <SEP> D <SEP> 0.1 <SEP> 2.6 <SEP> 1.2 <tb> <SEP> H <SEP> - <SEP> O- <SEP> A <SEP> li <SEP> rt <SEP> II <SEP> 100 <SEP> 1.8 <SEP> <tb> <SEP> 1 <SEP> l <SEP> 1.5 <SEP> 2.4 <tb> <SEP> II <SEP> II <SEP> II <SEP> II <SEP> . <SEP> "It <SEP> II <SEP> IT <SEP> 1 <SEP> 1.2 <SEP> 1.D <tb> <SEP> 0.1 <SEP> 0.8 <SEP> 0.8 <tb> <SEP> tt <SEP> \L <SEP> t <SEP> TI <SEP> II <SEP> 11 <SEP> 1. <SEP> 1 <SEP> 1.8- <SEP> 1.8 <tb> <SEP> 4 <SEP> 0.1 <SEP> 1.9 <SEP> 1,9 <tb> <SEP> ", <SEP> z <SEP> CO <tb> <SEP> ,' <SEP> z <tb> <SEP> X <SEP> TI <SEP> IT <SEP> IT <SEP> IT <SEP> II <SEP> TI <SEP> TI <SEP> 100 <SEP> 1.7 <SEP> <tb> o <SEP> N <SEP> CO <SEP> 1 <SEP> 1.5 <SEP> 1.8 <tb> <SEP> H <SEP> CH3 <tb> <SEP> H <SEP> " <SEP> "-CECOI <SEP> " <SEP> " <SEP> " <SEP> " <SEP> 100 <SEP> 2.7 <SEP> <tb> <SEP> 1 <SEP> 1.1 <SEP> 1.8 <tb> <SEP> 1 <SEP> 1.1 <SEP> 1.8 <tb> <SEP> IT <SEP> IT <SEP> II <SEP> TI <SEP> II <SEP> II <SEP> TI <SEP> 11 <SEP> 11; ;78 <tb> <SEP> 0.1 <SEP> 1.7 <SEP> 1.7 <tb> EMI68.1 <tb> <SEP> K <SEP> Reverence <tb> <SEP> R1 <SEP> 1 <SEP> n <SEP> R2 <SEP> *2 <SEP> *3 <SEP> *4 <SEP> Dose <SEP> treated <SEP> compound <tb> <SEP> a <SEP> "2 <SEP> 63 <SEP> "4 <SEP> Cmg/ <SEP> t-------- <SEP> 7- <SEP> Ktreat <tb> <SEP> kg) <SEP> control <tb> <SEP> control <tb> <SEP> II <SEP> " <SEP> " <SEP> II <SEP> L <SEP> D <SEP> 1. <SEP> 1' <SEP> 1 <SEP> 1.9 <SEP> 1.8 <tb> <SEP> O,1 <SEP> 2.5 <SEP> 1.7 <tb> <SEP> 3(CH2)10 <SEP> IT, <SEP> r <SEP> TI <SEP> IT <SEP> ' <SEP> 1 <SEP> 1.7 <SEP> 1.8 <tb> <SEP> 0.1 <SEP> 2.1 <SEP> . <SEP> 1.9 <tb> <SEP> M, <SEP> (C13. <SEP> CO <tb> <SEP> 3 <SEP> r <SEP> rv <SEP> rr <SEP> .II <SEP> II <SEP> (( <SEP> 1 <SEP> 1,5 <SEP> 1.3 <tb> <SEP> 1 <SEP> l <SEP> .... <SEP> " <SEP> " <SEP> 1 <SEP> r.s <SEP> 1.3 <tb> <SEP> 0.1 <SEP> 1.2 <tb> <SEP> 1 <SEP> 1 <SEP> 1.3 <SEP> 1.3 <tb> <SEP> tut <SEP> 2 <SEP> IT <SEP> -11 <SEP> It <SEP> 11 <SEP> 11 <SEP> 0.1' <SEP> 1.S <SEP> 0.9 <tb> <SEP> tI <SEP> TI <SEP> IT <SEP> II <SEP> IT <SEP> II <SEP> tI <SEP> 100 <SEP> 4.2 <tb> <SEP> 1 <SEP> 4r7 <tb> <SEP> I <tb> <SEP> ECO <SEP> H <SEP> 1 <SEP> " <SEP> " <SEP> II <SEP> IT <SEP> II <SEP> 100 <SEP> 2.0 <tb> <SEP> 1, <SEP> 0.9 <SEP> 2.0 <tb> <SEP> - <SEP> ,( <SEP> II <SEP> TI <SEP> IT <SEP> TI <SEP> IT <SEP> TI <SEP> r, <SEP> 100 <SEP> 2.3 <tb> <SEP> 1 <SEP> 1 <SEP> 1.1 <SEP> 2.0 <tb> <SEP> Q <tb> <SEP> ti <SEP> TI <SEP> II: <SEP> IT <SEP> IT <SEP> II <SEP> 100 <SEP> 2.3 <tb> <SEP> 1 <SEP> 1.7 <SEP> 2.0 <tb> <SEP> TI <SEP> . <SEP> TI <SEP> TI <SEP> II <SEP> " <SEP> II <SEP> II <SEP> 100 <SEP> 2.9 <tb> <SEP> 1 <SEP> 1.6 <SEP> 2.3 <tb> Q33 <SEP> II <SEP> II <SEP> IT <SEP> TI <SEP> II <SEP> IT <SEP> 1 <SEP> 1.4 <SEP> 1.8 <tb> ,aco <SEP> 0.1 <SEP> 1.8 <SEP> 1.9 <tb> <SEP> 0.1 <SEP> 1.8 <SEP> 1.9 <tb> EMI69.1 <tb> <SEP> K <SEP> Reterence <tb> <SEP> 2 <SEP> - <SEP> R2 <SEP> *1 <SEP> *2 <SEP> *3 <SEP> *4 <SEP> Dose <SEP> treated <SEP> compound <tb> <SEP> a <SEP> - <SEP> Cmg/ <SEP> K <SEP> (mg/ <SEP> Control <SEP> created <tb> <SEP> kg) <SEP> control <SEP> Kntro <SEP> 1 <tb> <SEP> "control <tb> <SEP> gL <SEP> " <SEP> " <SEP> .. <SEP> L <SEP> D <SEP> L <SEP> D <SEP> 0.1 <SEP> 1 <SEP> 6 <SEP> 1 <SEP> 8 <tb> <SEP> N <SEP> TI <SEP> TI <SEP> IT <SEP> L <SEP> D <SEP> L- <SEP> D <SEP> 1 <SEP> 2.0 <SEP> 1.8 <tb> <SEP> 0100 <SEP> 0.1- <SEP> 1.6 <SEP> 1.2 <tb> <SEP> TI <SEP> IT <SEP> TI <SEP> TI <SEP> TI <SEP> IT <SEP> IT <SEP> 100 <SEP> 2.2 <SEP> <tb> <SEP> o <SEP> NH,00 <SEP> 1 <SEP> 1.5 <tb> <SEP> 50, <SEP> " <SEP> " <SEP> tt <SEP> IT <SEP> IT <SEP> II <SEP> IT <SEP> '1 <SEP> 1.2 <SEP> l.s <tb> <SEP> 0.1 <SEP> a.6. <SEP> 1.7 <tb> <SEP> -CIOI[X <SEP> 1 <SEP> 2.0 <SEP> 1,8 <tb> <SEP> \=/ <SEP> Ir <SEP> 11 <SEP> 1( <SEP> 1) <SEP> 1 <tb> <SEP> 0.1 <SEP> 1.3 <SEP> 1.9 <tb> <SEP> I <tb> <SEP> GI,MCO <SEP> TI <SEP> 1. <SEP> 8 <SEP> TI <SEP> TI <SEP> TI <SEP> IT <SEP> 1.8 <SEP> 1.8 <tb> <SEP> D <SEP> 0.1 <SEP> 1.5 <SEP> 1.7 <tb> <SEP> TT <SEP> n <SEP> (1 <SEP> II <SEP> II <SEP> IT <SEP> IT <SEP> 1 <SEP> 1.8 <SEP> 1.8 <tb> <SEP> D <SEP> 0.1 <SEP> 1.2 <SEP> 1.9 <tb> <SEP> H0CH200 <SEP> { <SEP> 1 <SEP> CH2CO <SEP> TI <SEP> TI <SEP> TI <SEP> TI <SEP> 100 <SEP> 2.5 <SEP> <tb> <SEP> 1 <SEP> 0.9 <SEP> 2.1 <tb> <SEP> ci <tb> <SEP> dCJO <SEP> " <SEP> " <SEP> TT <SEP> IT <SEP> II <SEP> TI <SEP> IT <SEP> 1 <SEP> 2.3 <SEP> 2.4 <tb> <SEP> 0.1 <SEP> 1.5 <SEP> 1.4 <tb> .LK% <tb> <SEP> TI <SEP> TI <SEP> " <SEP> TI <SEP> " <SEP> IT <SEP> IT <SEP> TI <SEP> 100 <SEP> 2.0 <SEP> <tb> <SEP> D <SEP> 1 <SEP> 1.8 <SEP> 2.0 <tb> <SEP> Q-E2m" <SEP> " <SEP> " <SEP> " <SEP> " <SEP> IT <SEP> IT <SEP> 100 <SEP> 1.6 <SEP> <tb> <SEP> 1 <SEP> 1.9 <SEP> 2.2 <tb> EMI70.1 <tb> <SEP> Dose <SEP> Kt <SEP> ReEerence <tb> <SEP> Dose <SEP> treated <SEP> compound <tb> <SEP> R1 <SEP> e <SEP> n <SEP> a <SEP> *1 <SEP> 2 <SEP> *3 <SEP> *4 <SEP> compound <tb> <SEP> R <SEP> Rb <SEP> - <SEP> a <SEP> *1 <SEP> *2 <SEP> *3 <SEP> *4 <SEP> (mug/ <SEP> control <SEP> reated <tb> <SEP> kg) <SEP> K,onol <tb> <SEP> TI <SEP> IT <SEP> " <SEP> " <SEP> D <SEP> L <SEP> T <SEP> D <SEP> 100 <SEP> 2.1 <tb> <SEP> 1 <SEP> 1.9 <SEP> .2.2 <tb> <SEP> TI <SEP> IT <SEP> TI <SEP> TI <SEP> IT <SEP> TI <SEP> II <SEP> 100 <SEP> 1.6 <tb> . <SEP> - <SEP> 1 <SEP> 2.2 <SEP> 1.7 <tb> <SEP> ts, <tb> ei <SEP> II <SEP> II <SEP> TI <SEP> t( <SEP> " <SEP> IT <SEP> TI <SEP> 100 <SEP> 1,.9 <tb> H,CMCO <SEP> 1 <SEP> 0.7 <SEP> . <SEP> 2.0 <tb> <SEP> ( <SEP> 3)3 <SEP> " <SEP> II <SEP> IT <SEP> IT <SEP> IT <SEP> TI <SEP> TI <SEP> 100 <SEP> ' <SEP> 2.9 <tb> <SEP> 1 <SEP> 2.3 <SEP> 1.8 <tb> <SEP> TI <SEP> II <SEP> IT <SEP> II <SEP> IT <SEP> TI <SEP> It <SEP> 100 <SEP> 2.1 <tb> <SEP> 1 <SEP> 2.0 <SEP> 2.2 <tb> <SEP> TI <SEP> TI <SEP> IT <SEP> TI <SEP> TI <SEP> II <SEP> " <SEP> 1 <SEP> 1.7 <SEP> 1.3 <tb> <SEP> 0.,1 <SEP> 1.6 <tb> <SEP> eCO <SEP> II <SEP> TI <SEP> II <SEP> II <SEP> II <SEP> II <SEP> 1 <SEP> 1.6 <SEP> 1.3 <tb> <SEP> 0,1 <SEP> z <SEP> 0.1 <SEP> 1.2 <SEP> 0.9 <tb> <SEP> PL <tb> <SEP> IT <SEP> (22) <SEP> 3 <SEP> TI <SEP> II <SEP> II <SEP> II <SEP> II <SEP> IT <SEP> 1 <SEP> 3.0 <SEP> 3.6 <tb> <SEP> C2Hs; ;, <SEP> 0.1 <SEP> 1.7 <SEP> 1.6 <tb> <SEP> TI <SEP> II <SEP> Z <SEP> IT <SEP> TI <SEP> IT <SEP> II <SEP> '1 <SEP> 2.1 <SEP> 1.6 <tb> <SEP> 0.1 <SEP> 1.0 <SEP> 1.1 <tb> <SEP> H <SEP> ç <SEP> TI <SEP> II <SEP> II <SEP> t <SEP> 11 <SEP> 100 <SEP> 2.1 <tb> <SEP> 1 <SEP> 0.8 <SEP> 2.1 <tb> EMI71.1 <tb> <SEP> Reference <tb> <SEP> 2 <SEP> 1 <SEP> 2 <SEP> Dose <SEP> Retreated <SEP> comoound <tb> <SEP> R <SEP> n <SEP> Ra <SEP> *1 <SEP> *2 <SEP> *3 <SEP> *4 <SEP> (mg/ <SEP> Kcontroi <SEP> K <SEP> treated <tb> <SEP> a <SEP> kg) <SEP> ^control <SEP> F'control <tb> <SEP> IT <SEP> " <SEP> II <SEP> L <SEP> D <SEP> L <SEP> D <SEP> 100 <SEP> 1.0 <SEP> - <tb> <SEP> 1 <SEP> 1 <SEP> 0.7 <SEP> 1.0 <tb> <SEP> ir <SEP> TI <SEP> II <SEP> TI <SEP> TI <SEP> TI <SEP> IT <SEP> L <SEP> ' <SEP> 10 <SEP> 4.3 <SEP> 5.0 <tb> <SEP> 1 <SEP> 1 <SEP> 1.2 <SEP> 4.5 <tb> <SEP> IT <SEP> TT <SEP> It <SEP> TI <SEP> z <SEP> t <SEP> TI <SEP> " <SEP> D <SEP> 100 <SEP> 2.8 <tb> <SEP> 1 <SEP> 1.4 <SEP> 3.6 <tb> <SEP> a <SEP> t <SEP> II <SEP> IT <SEP> t <SEP> D <SEP> IT <SEP> 'IT <SEP> 100 <SEP> 2.6 <tb> <SEP> z <SEP> 1 <SEP> 2.4 <SEP> 2.2 <tb> <SEP> 1 <SEP> 1 <SEP> 2.2 <SEP> 1.8 <tb> <SEP> TT <SEP> II <SEP> TI <SEP> IT <SEP> IT <SEP> TT <SEP> 0.1 <SEP> S.9 <SEP> 1.2 <tb> <SEP> 3D <tb> <SEP> 23atCs <SEP> ft <SEP> TI <SEP> t. <SEP> " <SEP> ... <SEP> IT <SEP> 100 <SEP> 2.0 <tb> <SEP> 1.6 <SEP> 2.1 <tb> <SEP> CH3CO <SEP> TI <SEP> TI <SEP> IT <SEP> TI <SEP> II <SEP> TI <SEP> TI <SEP> 100 <SEP> 2.0 <tb> <SEP> 1 <SEP> 1. <SEP> 1.1 <SEP> 2.2 <tb> <SEP> O <SEP> ) <SEP> TI <SEP> II <SEP> II <SEP> TI <SEP> t. <SEP> s <SEP> 1 <SEP> 2.3 <SEP> 2.0 <tb> <SEP> 0.1 <SEP> ' <SEP> 0.1 <SEP> 1.4 <SEP> 1.1 <tb> <SEP> TI <SEP> TT <SEP> " <SEP> II <SEP> IT <SEP> TI <SEP> II <SEP> 100 <SEP> 2.0 <tb> 1 <SEP> 3 <SEP> 1 <SEP> 2.4 <SEP> 1.7 <tb> <SEP> ( <SEP> TI <SEP> IT <SEP> TI <SEP> TI <SEP> TI <SEP> TI <SEP> TI <SEP> 100 <SEP> 2.3 <SEP> <tb> <SEP> 1 <SEP> 1 <SEP> 2.0 <SEP> 2.6 <tb> TI <SEP> - <SEP> )I <SEP> lr <SEP> TI <SEP> IT <SEP> TI <SEP> TI <SEP> 1 <SEP> 2.5 <SEP> 2.0 <tb> <SEP> D <SEP> 0.1 <SEP> 1.3 <SEP> 1.1 <tb> <SEP> 3 <tb> <SEP> (3CHCO <SEP> TI <SEP> " <SEP> " <SEP> " <SEP> " <SEP> IT <SEP> TI <SEP> 100' <SEP> 1.5. <tb> <SEP> Dt; <tb> <SEP> 1 <SEP> 1 <SEP> 1.3 <SEP> 1.4 <tb> <SEP> IT <SEP> IT <SEP> TI <SEP> TI <SEP> IT <SEP> II <SEP> TI <SEP> 100 <SEP> 1.5 <tb> <SEP> 1 <SEP> 1.3 <SEP> 1.4 <tb> Note : Reference compound is a compound wherein R1 is EMI72.1 RbÚ, is CH3, n is 1, Raê is CH2COOH, *1 is L, *2 is D, *3 is L and *4 is D. TABLE 2 Drug Dose (mg/mouse) Ktreated/Kcontrol Krestin 10 1.1 1 1.0 Levamisol 10 - (death) 1 0.5 Tuftsin 400 1.4 125 1.0 FR-900156 substance 0.25 2.9 0.06 1.3 Control (saline) 1.0 (2) Test Compound 2 EMI73.1 TABLE 3 Test Compound Dose Reference *1 *2 *3 *4 *5 (mg/kg) Ktreated/Kcontrol Compound FR-900156 substance D L L L D 100 2.0 1 0.9 1.9 D D L L D 100 1.7 1 1.6 D L D L L 100 - 2.7 L 0.9 . 2.5 L L D L D 100 2.6 . 1 2.4 2.2 D D D L D 1 2.2 1.8 0.1 1.9 1.2 2; ENHANCING ACTIVITIES OF CELLULAR IMMUNITY AND HUMORAL ANTIBODY PRODUCTION Guinea pigs- (groups of five) were given 0.1 ml of FIA (Freund's Incomplete Adjuvant) emulsion containing 500 g of ovalbumin in both posterior footpads. Control groups received antigen in FIA only, whereas the test groups received the antigen with the following test compounds" in FIA. The animals were, skin-tested on day 14 and bled on day 16. (1) Test Compound (1) EMI74.1 TABLE 4 Dose Cellular Humoral immunity RÚ RbÚ n Raê ( g/ immunity *1 hemag- hemolysin site) skin reaction gluti- titer (mn diameter, nation S.E. M#S.E.) titer log2)*2 (M#S.E. log2)*2 H CH3 1 CH2COOH 1 1.8#0.7 *3 11.9#0.5 *3 5.6#0.5 10 8.9+0.9 *3 12.3#0.2 *3 6.6t0.3 100 10.8#3.3 *3 12.0#0.3 *3 6.7#0.5 EMI75.1 <tb> tl <SEP> CH3CH2CO <SEP> % <SEP> 1 <SEP> CH2OXE <SEP> 1, <SEP> 2.0".0 <SEP> 12.3Q.2 <SEP> *3 <SEP> 7.3S,4 <SEP> *3 <tb> <SEP> 10 <SEP> 8.6'1.0 <SEP> *3. <SEP> 11.4Y).S <SEP> *3 <SEP> 7.8: <tb> <SEP> 100 <SEP> 3.1.3 <SEP> *3.-" <SEP> 9.720.4 <SEP> 7.2it.3 <SEP> "3 <tb> <SEP> hUl <SEP> CO <SEP> tT <SEP> " <SEP> TT <SEP> TT <SEP> 1 <SEP> 10.4-2+,.4 <SEP> *3 <SEP> 11.8m.5 <SEP> *3 <SEP> 7.4+0.6 <SEP> *3 <tb> <SEP> 2 <tb> <SEP> 10 <SEP> 14.6+i.1 <SEP> *3&num;2 <SEP> 12.4+0.5 <SEP> *3 <SEP> 7.3+0.5 <SEP> 23 <tb> <SEP> 100 <SEP> 6.64""'3 <SEP> 3 <SEP> 10.8+0.2 <SEP> *3 <SEP> 6.0"0.2 <tb> <SEP> Control <SEP> o <SEP> 0. <SEP> 9.4+0.4 <SEP> 5.4-+0.5 <tb> <SEP> Oil <tb> <SEP> CH <SEP> I <SEP> 1 <SEP> CH <SEP> 1 <SEP> 6.7A,0.8 <tb> <SEP> 3 <SEP> CH3 <SEP> 1 <SEP> CH2CO3 <SEP> 1 <SEP> 6.70.8 <SEP> *3 <SEP> 8.2+0.1 <SEP> *3 <tb> <SEP> L <SEP> 10 <SEP> 10. > 1.6 <SEP> X3 <SEP> 7.6+0.s <SEP> *3 <tb> <SEP> Q <SEP> tT <SEP> " <SEP> " <SEP> " <SEP> TI <SEP> 1 <SEP> 8.7to.8 <SEP> *3 <SEP> 8.y0.2 <SEP> "3 <tb> <SEP> 10 <SEP> 7.7L--2.4 <SEP> ç3 <SEP> 8.7+9.2 <SEP> 23 <tb> <SEP> ContI <SEP> ,fl <SEP> " <SEP> II <SEP> 0 <SEP> 0 <SEP> 6.S0.3 <tb> EMI76.1 <tb> <SEP> CH <tb> <SEP> which <SEP> CO <SEP> CH3 <SEP> 1 <SEP> A <SEP> oxy <SEP> 1 <SEP> 11.5'2.1 <SEP> *3l <SEP> lid.8 <SEP> 0.3 <SEP> *3 <SEP> 7.1"0,4 <SEP> *3 <tb> <SEP> 10 <SEP> 11.1+0.7 <SEP> *3r2 <SEP> 12.3'0.5 <SEP> *3 <SEP> 8.5+0 <SEP> *3 <tb> <SEP> 100 <SEP> 1.141.1 <SEP> 9.1'0.6 <SEP> 4.3 <SEP> 0+6 <SEP> *3 <tb> <SEP> Control <SEP> O <SEP> 0 <SEP> 9.2'0.3 <SEP> 5.9+0.1 <tb> <SEP> CH3CiCD <SEP> H <SEP> .1 <SEP> ci2oXE <SEP> 1 <SEP> ccrxf <SEP> 1 <SEP> 10.0+0.3 <SEP> *3 <SEP> 5.9+0.3 <tb> <SEP> D <SEP> - <SEP> .10 <SEP> = <SEP> 9.6+0.3 <SEP> 6.9+0.5 <SEP> *3 <tb> <SEP> 100 <SEP> 10.0+0.4 <SEP> 7.0to0.4 <SEP> *3 <tb> <SEP> D <tb> <SEP> TI <SEP> z <SEP> zTI <SEP> " <SEP> TI <SEP> 1 <SEP> 10.6-+0.3 <SEP> *3 <SEP> 6.9to0.3 <SEP> *3 <tb> <SEP> 10 <SEP> 10 <SEP> 9.9+1.0 <SEP> *3 <SEP> 7.0'0.4 <SEP> *3 <tb> <SEP> 100 <SEP> 10.5+0.4 <SEP> *3 <SEP> 6.3+0.5 <SEP> 3 <tb> <SEP> II <SEP> " <SEP> " <SEP> II <SEP> 1 <SEP> 10.1+1.1 <SEP> *32 <SEP> 10.5+0.2 <SEP> *3 <SEP> 1.0.3 <SEP> *3 <tb> <SEP> 10 <SEP> 10.7'1.3 <SEP> *3 <SEP> 9.810.4 <SEP> 7.3+0.3 <SEP> *3 <tb> <SEP> 100 <SEP> 5.4F2.2 <SEP> 9.6+0.4 <SEP> 7.l+02 <SEP> e <tb> <SEP> Control <SEP> 0 <SEP> 0,9+0.9 <SEP> 8,5+0.5 <SEP> 5,5+0,3 <tb> <SEP> 9L, <tb> <SEP> 2 <tb> <SEP> TI <SEP> E3 <SEP> " <SEP> a2Z <SEP> IX > C <SEP> 1 <SEP> 5.0+2.2 <SEP> 8.5+-0.2 <SEP> *3 <tb> <SEP> 10 <SEP> 7.1+0.9 <SEP> t3 <SEP> 7.9+0.4 <SEP> *3 <tb> <SEP> Z <SEP> 0 <tb> <SEP> tw <SEP> II <SEP> 11 <SEP> 1 <SEP> 5.42.2 <SEP> "3 <SEP> 7.60,4 <SEP> "3 <tb> HO <SEP> r <SEP> kC023 <SEP> 10 <SEP> 12.6'0.9 <SEP> *3 <SEP> 8.4*0.2 <SEP> *3 <tb> B-'CC0O <tb> <SEP> 3 <SEP> <tb> <SEP> Control <SEP> O <SEP> <SEP> S.8t0.3 <tb> EMI77.1 <tb> <SEP> CH3(CH2)SOO <SEP> a <SEP> 1 <SEP> ICOCH <SEP> 1 <SEP> 10.0+1.2 <SEP> *3 <SEP> 9.5+0.4 <SEP> *3 <tb> <SEP> 10 <SEP> 7.5+2.2 <SEP> *3 <SEP> 9.2+0.6 <SEP> *3 <tb> <SEP> . <tb> <SEP> TI <SEP> " <SEP> " <SEP> II <SEP> II <SEP> 1 <SEP> S.S+1.4 <SEP> *3 <SEP> 8.7+0.S <SEP> *3 <tb> <SEP> 10 <SEP> 10 <SEP> 8.5+-l.0 <SEP> *3 <SEP> 7.4+0.6 <SEP> *3 <tb> <SEP> 3 <tb> <SEP> Control <SEP> O <SEP> 0 <SEP> 6. <SEP> 6+0. <SEP> 6 <tb> <SEP> ¯¯ <SEP> CCH2CO <SEP> % <SEP> 1 <SEP> CH2 <SEP> =H <SEP> 1 <SEP> 10.24 <SEP> *3 <SEP> 8 <SEP> 8.3+0.3 <SEP> *3 <tb> <SEP> 10 <SEP> 6.3-1.3 <SEP> *3 <SEP> .7.7+0.3 <SEP> *3 <tb> . <SEP> CH3CO <SEP> 2 <SEP> " <SEP> 2 <SEP> " <SEP> 1 <SEP> 9.0+1.0 <SEP> *3 <SEP> 7,7+0.5 <tb> <SEP> D <SEP> 10 <SEP> 8.1'2.5 <SEP> *3 <SEP> 8.40.s <SEP> 23 <tb> <SEP> L <tb> <SEP> 1 <SEP> it <SEP> 1 <SEP> " <SEP> 1 <SEP> .8.0+1.1 <SEP> *3 <SEP> 8.8+0.3 <SEP> W3 <tb> <SEP> 10 <SEP> 15.942.S <SEP> *3 <SEP> 8.3+Q.3 <SEP> *3 <tb> <SEP> Control <SEP> O <SEP> 0 <SEP> 7.1i0.l <tb> <SEP> O <SEP> ,0s <SEP> ; <SEP> 1 <SEP> 22m.1 <SEP> 1 <SEP> 31.2'1.1 <SEP> 4°'3 <SEP> 10.4+0.3 <SEP> *b <tb> <SEP> 1 <SEP> 7.6+2.2 <SEP> *3. <SEP> 10.220.3 <SEP> *3 <tb> <SEP> 10 <SEP> 6.4for2.5 <SEP> 9.3+0.2 <SEP> *3 <tb> s3-CH3CO <SEP> TI <SEP> " <SEP> II <SEP> 0.1 <SEP> 6.4+2.7 <SEP> 9.9+0.5 <SEP> *3 <tb> <SEP> 1 <SEP> 10.2"2.6 <SEP> *3 <SEP> 10.6+0.3 <SEP> *3 <tb> <SEP> 10 <SEP> 10 <SEP> 8.6+1.8 <SEP> *3 <SEP> 10.6+0.3 <SEP> *3 <tb> .. <SEP> 43-NECO <SEP> " <SEP> TI <SEP> " <SEP> 0.1 <SEP> 10.so+2.3 <SEP> *3 <SEP> 9.1+0.4 <tb> <SEP> 1 <SEP> 9.3+0.7 <SEP> *3 <SEP> 9.1+-0.4 <tb> <SEP> 10 <SEP> 4,3'1.3 <SEP> 9.8+0.2 <tb> <SEP> Control <SEP> 0 <SEP> 0.N0.9 <SEP> 8.z0.4 <tb> <SEP> a <SEP> O <SEP> QI2C021 <SEP> 1 <SEP> 6.4'2.1 <SEP> *3 <SEP> 8.8+0.3 <tb> <SEP> 10 <SEP> 8.7+1.0 <SEP> *3 <SEP> 9.1+0.4 <tb> <SEP> (i <tb> <SEP> a-ci{ <tb> <SEP> 1 <SEP> CH <SEP> a3 <SEP> 1 <SEP> COC <SEP> I <SEP> U.71.6 <SEP> *3 <SEP> .1+-0.5 <tb> <SEP> 10 <SEP> L <SEP> 10 <SEP> 10 <SEP> 10.8'0.9 <SEP> * <SEP> 10.7+0.3 <tb> (2) Test Compound (2) EMI78.1 TABLE 5 EMI78.2 <tb> <SEP> Cellular <SEP> Humoral <SEP> immunity <tb> <SEP> Test <SEP> Compouna <SEP> Dose <SEP> immunity <SEP> *1 <SEP> Hemag- <SEP> hemolysin <SEP> <tb> *1 <SEP> *2 <SEP> *3 <SEP> *4 <SEP> *5 <SEP> ( g/ <SEP> skin <SEP> reaction <SEP> gluti- <SEP> titer <tb> site) <SEP> (mm <SEP> diameter, <SEP> nation <SEP> (M#S.E. <tb> <SEP> M#S.E.) <SEP> <SEP> titer <SEP> (log2)*2 <tb> <SEP> (M#S.E. <tb> <SEP> log2)*2 <tb> <SEP> D <SEP> L' <SEP> I) <SEP> L <SEP> D, <SEP> 0 <SEP> 0 <SEP> 9.1+0,19 <SEP> 4.5#0.45 <SEP> <tb> <SEP> 0.1 <SEP> 8.2#2.8 <SEP> <SEP> *3 <SEP> 9.9#0.10*3 <SEP> <SEP> 6.4#0.76 <tb> <SEP> 1 <SEP> 14.5#2.1 <SEP> <SEP> *3 <SEP> 11.5#0.61*3 <SEP> <SEP> 7.7#0.64 <SEP> <SEP> *3 <tb> <SEP> 10 <SEP> 11.0#1.3 <SEP> <SEP> *3 <SEP> 12.2#0.56*3 <SEP> <SEP> 7.1#0.58 <tb> <SEP> 100 <SEP> 4.2+1.7 <SEP> *3 <SEP> 10.0+1.01 <SEP> 5.9#0.89 <SEP> <tb> <SEP> D <SEP> L <SEP> L <SEP> L <SEP> D <SEP> 0 <SEP> 0.9#0.9 <SEP> <SEP> 8.5#0.4 <SEP> <SEP> <tb> <SEP> 1 <SEP> 2.4#1.5 <SEP> <SEP> 41.4#0.5/*3 <SEP> <SEP> <tb> <SEP> 10 <SEP> 7.9#2.1 <SEP> <SEP> *3 <SEP> 11.0#0*3 <SEP> <SEP> <tb> <SEP> D <SEP> L <SEP> D <SEP> # <SEP> <SEP> 0 <SEP> 0 <SEP> 9.2#0.3 <SEP> <SEP> 5.9#0.1 <tb> <SEP> DL <SEP> 1 <SEP> 4.3#1.8*3 <SEP> <SEP> 10.2#1.1*3 <SEP> <SEP> 6.5#0.4 <tb> <SEP> 10 <SEP> 9.0#3.2*3 <SEP> <SEP> 10.4#0.3*3 <SEP> <SEP> 7.5#1.2*3 <tb> <SEP> 100 <SEP> 6.4#1.7*3 <SEP> <SEP> 10.9#0.2*3 <SEP> <SEP> 6.7#1.2*3 <tb> <SEP> L <SEP> L <SEP> D <SEP> L <SEP> D <SEP> O <SEP> 0 <SEP> 6.8#0.3 <SEP> <SEP> <tb> <SEP> 1 <SEP> 6.7#0.8*3 <SEP> <SEP> 8.2#0.1*3 <SEP> <SEP> <tb> <SEP> 10 <SEP> 10.2#1.6*3 <SEP> <SEP> 7.6#0.5*3 <SEP> <SEP> Note: *1: : The skin test was performed on the back by intradermal injection of 4 g of antigen dissolved in 0.1 ml of saline. Skin reaction Of the' test site was measured at 48 hours. *2: # : Antibody estimation was carried out as follows: Ovalbumin-coated sheep red blood cells were prepared by chromium chloride. Antibody titer was expressed as the reciprocal o tfie highest dilution of serum evoking threshold hemogglutination and hemolys in. The results were converted to log2 unit. *3: Signi'ficance was calculated by Students t-test; P < 0.05 21 : 2/5 of animal, Central necrosis &num;2: 1/5 of animal, Central necrosis 3. MITOGENIC ACTIVITIES FOR MOUSE SPLEEN CELLS (Materials and Methods) (1) Animal Mice used for this experiment were male BALB/C Strain, aged 13 weeks (Test I) or female BALB/C strain, aged 9 weeks (Test 2). C2) Tissure Culture Medium : The tissure culture medium employed was a complete medium designated Roswell Park Memorial Institute (RRMI)-1640. All media employed contained 100 units/ml of penicillin G and 100 g/ml of streptomycin sulfate and 10% fetal calf serum. (3) Cell Preparation : Spleens were removed under sterile conditions, and washed with Hanks solution and then teased in the tissue culture medium. The cells were suspended in-the tissue culture medium to con tain 8 x 106 celis/ml. (4) Culture Conditions : Into each hole of Microtest II tissue culture plate (8 x 12 hole) (maker: Falcon Plastics Co.) were poured 0,1 ml of the above cells suspension and 0.1 ml of the prescribed con centrate of the test compound as described below and then the cultures we. incubated intriplicate at 370C in a humidified atmosphere (958 air, 5% CO2.) for 48 hours. The control culture contained 0.1 ml of the culture medium instead of the medium containing the test compound. r5) (SH) Thymidine uptake : In' all tests, 20 l of 10 micro-curine Cu Ci)/ ml of tritiated thymidine (3H-thymidine) was added to each hole for the final 24 hours of culture. After the culture was completed, the resultant cells were filtered with a filter paper, Whatman GF83 and washed successively with saline and with 5% trichloroacetic acid. The filter paper was dried and placed in a scintillator (toluene 1l, containing 0.1 g of p-bis(5-phenyloxazoyl] benzene an'd 4 g of 2, 5-diphenyloxa'zoyl ), and 3H-thy"midine incorporated into DNA was measured. (6) Stimulation Index 3H-thymidine uptake (net cpm) at treatment Stimulation Index= 3H-thymidine uptake (net cpm) at control (7) Test Compound (1) EMI81.1 (Results) (1) Test 1 Table 6. Concent- 3H-thymidine Stimulation RÚ Rê ration uptake net ( g/ml) cpm:av#S.E. Index EMI82.1 <tb> <SEP> CH3(CH2)5CO <SEP> CH3 <SEP> 100 <SEP> 2,728+73 <SEP> 5.2 <tb> <SEP> 10. <SEP> 2,660+45 <SEP> 5.0 <tb> <SEP> 1 <SEP> 2,899+126 <SEP> 5.5 <tb> <SEP> OH <tb> <SEP> CH3CHCO <SEP> OCHz <SEP> lQO <SEP> 2,174+142 <SEP> 4.1 <tb> <SEP> D <SEP> 10 <SEP> 1,547-' <SEP> 79 <SEP> 2.9 <tb> <SEP> 1 <SEP> 1,103-+ <SEP> 76 <SEP> . <SEP> 2.1 <tb> <SEP> CH <tb> <SEP> 3, <SEP> 100' <SEP> 3¯ <SEP> . <SEP> 234f <SEP> 17d' <SEP> 4,2 <tb> <SEP> 3' <SEP> ' <SEP> 10 <SEP> 2,046+138 <SEP> 3.9 <tb> <SEP> 1 <SEP> 1,378+112 <SEP> 2.6 <tb> <SEP> 95120CO <SEP> CH3 <SEP> 100 <SEP> 2,312+158 <SEP> 4.4 <tb> <SEP> 1D <SEP> 2,388+ <SEP> 97 <SEP> 4;5 <tb> <SEP> 1 <SEP> 1,775+ <SEP> 94 <SEP> 3.4 <tb> <SEP> Control <SEP> 528+- <SEP> 28 <SEP> 1.0 <tb> <SEP> OH <SEP> 100 <SEP> 2,306" <SEP> 54 <SEP> 5.5 <tb> <SEP> CH3 <SEP> CH3 <SEP> la <SEP> . <SEP> l'788-+314 <SEP> 4.3 <tb> <SEP> D <SEP> 1 <SEP> 1 <SEP> 1,928+ <SEP> 87 <SEP> 4.6 <tb> <SEP> .HOCH2CO <SEP> CH3 <SEP> 100 <SEP> 2,6051117 <SEP> 6.2 <tb> 10 <SEP> 10 <SEP> 1,725' <SEP> 86 <SEP> 4.1 <tb> <SEP> 1 <SEP> 1,120+ <SEP> 55 <SEP> 2.7 <tb> <SEP> CH3CH2CO <SEP> CH3 <SEP> 100 <SEP> 2,023-'142 <SEP> 4.9 <tb> <SEP> 10 <SEP> 10 <SEP> 1,474+ <SEP> 44 <SEP> 3.5 <tb> <SEP> 1 <SEP> 732l <SEP> 28 <SEP> 1.8 <tb> EMI83.1 <tb> <SEP> ?H. <SEP> 100 <SEP> 1,5414 <SEP> 73 <SEP> 3.7 <tb> <SEP> CH3CHCO <SEP> H <SEP> 10 <SEP> 1,119 <SEP> 1 <SEP> 63 <SEP> 2.7 <tb> <SEP> D <SEP> 1 <SEP> 937t <SEP> 30 <SEP> 2.2 <tb> <SEP> OH <SEP> CH3 <tb> <SEP> cEs <tb> <SEP> CH <SEP> CHCO <SEP> sCH <SEP> 100 <SEP> 1,675 <SEP> l <SEP> 22 <SEP> 4.0 <tb> <SEP> D <SEP> CH3/ <SEP> - <SEP> 10 <SEP> 1,679+ <SEP> 98 <SEP> 4.0 <tb> <SEP> 1 <SEP> - <SEP> 1,019 <SEP> 2.4 <tb> <SEP> 100 <SEP> 1,541+ <SEP> 41 <SEP> 3.7 <tb> <SEP> CH3CHCO <SEP> ' <SEP> CHO <SEP> HOOCH <SEP> 10 <SEP> 1,468+ <SEP> 12 <SEP> 3.5 <tb> <SEP> , <SEP> D <SEP> 1 <SEP> 9Z7+ <SEP> 33 <SEP> 2.2 <tb> <SEP> NH2 <SEP> 100 <SEP> 1,635+1 <SEP> 92 <SEP> 3.9 <tb> <SEP> CH3CHCO <SEP> CH3 <SEP> 10 <SEP> 1,573+ <SEP> 69 <SEP> 3.8 <tb> <SEP> D <SEP> 1 <SEP> 1,001+ <SEP> 73 <SEP> 2.4 <tb> <SEP> Control <SEP> - <SEP> - <SEP> 417- <SEP> 13 <SEP> 1.0 <tb> <SEP> '---'CH2CO <SEP> CH3 <SEP> 100 <SEP> 1,979t174 <SEP> 5.0 <tb> <SEP> 10 <SEP> 2,343' <SEP> 22 <SEP> 5.9 <tb> <SEP> - <SEP> 1 <SEP> 1,469+224 <SEP> 3.7 <tb> <SEP> ?CH3 <tb> <SEP> CH3CHCO <SEP> CH3 <SEP> 100 <SEP> 1,537+113 <SEP> 3.9 <tb> <SEP> DL <SEP> 10 <SEP> 1,788+ <SEP> 30 <SEP> 4.5 <tb> 1 <SEP> ' <SEP> 1 <SEP> 1,144+142 <SEP> 2.9 <tb> EMI84.1 <tb> <SEP> .Cf3 <SEP> <tb> <SEP> CH3COiCHCO <SEP> CH3 <SEP> 100 <SEP> 1,627in <SEP> 38 <SEP> 4.1 <tb> <SEP> D <SEP> 10 <SEP> 1,837+138 <SEP> ' <SEP> 4.6 <tb> <SEP> 1 <SEP> 1,338t <SEP> 74 <SEP> 3.4 <tb> <SEP> (3Neco <SEP> CH3 <SEP> 100 <SEP> 1,528 <SEP> l122 <SEP> 3.8 <tb> <SEP> 10 <SEP> 1,225 <SEP> l <SEP> 42 <SEP> 3.1 <tb> <SEP> 1 <SEP> 866+ <SEP> 37 <SEP> 2.2 <tb> 100 <SEP> . <SEP> 1,588+167 <SEP> 4.0 <tb> 5CHzCO <SEP> CH3 <SEP> 10 <SEP> 1,469+ <SEP> 87 <SEP> 3.7 <tb> <SEP> 1 <SEP> . <SEP> 1,0.65+ <SEP> 89 <SEP> 2.7 <tb> <SEP> Control <SEP> 399+ <SEP> 51 <SEP> 1.0 <tb> (2) Test 2 Table 7 EMI84.2 <tb> <SEP> 2 <SEP> Concent- <SEP> 3H-thymidine <SEP> Stimulation <tb> <SEP> R <SEP> ration <SEP> uptake <SEP> net <SEP> Index <tb> <SEP> (llg/ml) <SEP> cpm: :av"5.E <SEP> n <tb> <SEP> CH3CO <SEP> CH3 <SEP> 100 <SEP> 1,92 <SEP> 0135 <SEP> 4.2 <tb> <SEP> 10 <SEP> 1,06'7+ <SEP> 63 <SEP> 2,4 <tb> <SEP> 1 <SEP> 7855 <SEP> 33 <SEP> 1.7 <tb> <SEP> QH <tb> <SEP> CH,3CHCO <SEP> CH3 <SEP> 100 <SEP> 2,77h215 <SEP> 6.1 <tb> <SEP> L <SEP> zL <SEP> 10 <SEP> 2,326+140 <SEP> 5.1 <tb> <SEP> 1 <SEP> 1,71-9102 <SEP> 3.8 <tb> CH3 <SEP> Cm <SEP> 100 <SEP> 2,9795199 <SEP> 6.6 <tb> <SEP> 10 <SEP> 2,177+ <SEP> 66 <SEP> 4.8 <tb> <SEP> 1 <SEP> 1,477+:46 <SEP> 3.3 <tb> EMI85.1 <tb> HWo <SEP> 100 <SEP> 2,1864164 <SEP> 4.8 <tb> <SEP> < ¯ > OH <SEP> CH3 <SEP> 10 <SEP> 1,370 <SEP> 8 <SEP> 3.0 <tb> HO' <SEP> H <SEP> CH3 <SEP> 10 <SEP> 1,370f58 <SEP> 3.0 <tb> <SEP> I <SEP> I <SEP> 7S6t <SEP> 42 <SEP> 1.7 <tb> <SEP> ,.: :CH3CHCO <tb> Control <SEP> - <SEP> 4 <SEP> 5 <SEP> 2* <SEP> 30 <SEP> 1.0 <tb> <SEP> 3 <SEP> ' <SEP> ' <SEP> 4 <SEP> , <SEP> 12 <SEP> 100 <SEP> 4±2'27-+217 <SEP> 4.2 <tb> OHNHCO, <SEP> .CH3 <SEP> 10 <SEP> '3,664*122 <SEP> 3.7 <tb> <SEP> 1 <SEP> : <SEP> 2,809 <SEP> 83 <SEP> 2.8 <tb> CH3(CH2)10CO <SEP> CH3 <SEP> 100 <SEP> 4,027 <SEP> 87 <SEP> 4.0 <tb> <SEP> 10 <SEP> 3,963+198 <SEP> 4.0 <tb> <SEP> 1 <SEP> 4,210+255 <SEP> 4.2 <tb> <SEP> CO <tb> <SEP> W <SEP> as3 <SEP> 96 <SEP> 100 <SEP> 3,967+348 <SEP> 4.0 <tb> <SEP> 10 <SEP> 2,935'126 <SEP> 2.9 <tb> <SEP> 1 <SEP> 2,134+ <SEP> 32 <SEP> 2.1 <tb> Control' <SEP> 1,000+ <SEP> 94 <SEP> 1,O <tb> (8) Test Compund (2) EMI85.2 TABLE 8 EMI86.1 <tb> <SEP> Concent- <SEP> 3H-thymidine <SEP> Stimulation <tb> <SEP> Test <SEP> Compound <SEP> Test <SEP> ration <SEP> uptake <SEP> net <tb> 1* <SEP> 2* <SEP> 3* <SEP> 4* <SEP> 5* <SEP> ( g/ml) <SEP> cpm. <SEP> av#S.E. <SEP> Index <tb> <SEP> D <SEP> L <SEP> D <SEP> L <SEP> D <SEP> 1 <SEP> 100 <SEP> 2,028#89 <SEP> <SEP> 4.9 <tb> <SEP> 10 <SEP> 1,486#120 <SEP> <SEP> 3.6 <tb> <SEP> 1 <SEP> 833#64 <SEP> <SEP> 2.0 <tb> <SEP> 0 <SEP> ' <SEP> 417#13 <SEP> <SEP> 1.0 <SEP> <tb> <SEP> 2 <SEP> 100 <SEP> 3,666#42 <SEP> <SEP> 4.1 <tb> <SEP> 10 <SEP> 3,223#402 <SEP> <SEP> 3.6 <tb> <SEP> 1 <SEP> 2,741#319 <SEP> <SEP> 3.0 <tb> <SEP> 0 <SEP> 901#105 <SEP> <SEP> 1.0 <tb> <SEP> D <SEP> L <SEP> D <SEP> # <SEP> <SEP> 1 <SEP> 100 <SEP> 1,274#131 <SEP> <SEP> 3.1 <tb> <SEP> DL <SEP> 10 <SEP> 1,414#38 <SEP> <SEP> 3.4 <tb> <SEP> 1 <SEP> 996#35 <SEP> <SEP> 2.4 <tb> <SEP> 0 <SEP> 417#13 <SEP> 1.0 <tb> <SEP> L <SEP> L <SEP> D <SEP> L <SEP> D <SEP> 2 <SEP> 100 <SEP> 2,772#215 <SEP> <SEP> 6.1' <tb> <SEP> 10 <SEP> 2,326#140 <SEP> <SEP> 5.1 <tb> <SEP> 1 <SEP> 1,713#102 <SEP> <SEP> 3.8 <tb> <SEP> 0 <SEP> 452#30 <SEP> <SEP> 1.0 <tb> <SEP> L <SEP> D <SEP> L <SEP> L <SEP> 1 <SEP> 100 <SEP> 1,271#29 <SEP> <SEP> 3.2 <tb> <SEP> 10 <SEP> 1.003#50 <SEP> <SEP> 2.5 <tb> <SEP> 1 <SEP> 742#61 <SEP> <SEP> 1.9 <tb> <SEP> 0 <SEP> 399#51 <SEP> <SEP> 1.0 <tb> 4. PROTECTIVE EFFICACY, IN EXPERIMENTAL INFECTION IN MICE (/) In determining the protective efficacy against experimental infections in mice, the test compound was dissoloed in and diluted with 'sterile saline to provide prescribed concentrations of drug. Male ICR-strain mice, aged 4 weeks were used in groups of ten mice. E. coli 22 was cultivated overnight at 370C on frypticase so',y agar and then were suspended in a sterile saline to obtain microbial cell concentration of 9.0 x 107 CE.U/± . Ece were inoculated intraperitoneally with 0.2 ml of the suspension. Ezch of the test drugs was given intra peritoneally in various doses to a group of ten mice 24 hours before challenge. Survival percent were found from the number of the surviving animals after four days of injection. Results are shown in Table 9. )Test Compound (1): EMI87.1 Table 9. RÚ Rê Survival ((%) Dose Dose 10 mg/kg 1 mg/kg CH3(CH2)sCO CH3 60 70 (CH3)3CCO CH3 70 70 EMI88.1 <tb> <SEP> CH3(CH2)10CO <SEP> CH3 <SEP> 50 <SEP> 60 <tb> <SEP> 3 <tb> <SEP> CH3COHSCHCO <SEP> CH3 <SEP> CH <SEP> 100 <SEP> 88.9 <tb> <SEP> D <tb> <SEP> OCH <tb> <SEP> 13 <SEP> <tb> <SEP> CH3CHCO <SEP> CH3 <SEP> 88.9 <SEP> 100 <tb> <SEP> DL <tb> <SEP> CM <SEP> CHO <SEP> CH3 <SEP> . <SEP> 100 <SEP> 88. <SEP> 9 <tb> <SEP> OH <tb> <SEP> \)-CflCO <SEP> CH, <SEP> 87,5 <SEP> 75.0 <tb> <SEP> D <tb> <SEP> OCO <SEP> CH3 <SEP> 30 <SEP> 50 <tb> <SEP> CH <tb> <SEP> H3x <tb> <SEP> CHCO <SEP> CH <SEP> 20 <SEP> 60 <tb> <SEP> CH3/ <SEP> ' <tb> <SEP> DcH2oCo <SEP> CH3 <SEP> 5D <SEP> 30 <tb> <SEP> D'\HCO <SEP> CH3 <SEP> 70 <SEP> 70 <tb> CH3 <SEP> 50 <SEP> 50 <tb> <SEP> rg <SEP> CH3 <SEP> 50 <SEP> 50 <tb> <SEP> . <tb> <SEP> rCOHN <SEP> HCO <SEP> CH; <SEP> 50 <SEP> 50 <tb> <SEP> 3 <SEP> 50 <SEP> 50 <tb> EMI89.1 <tb> q- <SEP> CO <SEP> CH3 <SEP> 80 <SEP> 60 <tb> <SEP> OH <tb> <SEP> OH <tb> <SEP> CH3HCO <SEP> CH243 <SEP> 60 <SEP> 60 <tb> <SEP> D <tb> <SEP> SCH2CO, <SEP> CH3 <SEP> 40 <SEP> 70 <tb> <SEP> HOCH2CO <SEP> CH3 <SEP> 75 <SEP> 100 <tb> <SEP> CH3CH2CO- <SEP> CH3 <SEP> .100 <SEP> 87.5 <tb> <SEP> QH <tb> <SEP> I <SEP> MS-CH <SEP> 87.5 <SEP> 100 <tb> <SEP> CH <SEP> HCO <tb> <SEP> D <SEP> C}13 <tb> <SEP> CH3CHCO <SEP> HOCH2 <SEP> 87.5 <SEP> 87.5 <tb> <SEP> D <tb> <SEP> CH3tHCO <SEP> H <SEP> 100 <SEP> 100 <tb> <SEP> 3 <tb> <SEP> 1 <tb> <SEP> CH3CHCO <SEP> CH3 <SEP> 87.5 <SEP> 62.i <tb> <SEP> 3 <tb> <SEP> NHi2 <tb> <SEP> I <SEP> CH3. <SEP> 100 <SEP> 37.5 <tb> <SEP> D <tb> EMI90.1 <tb> HO <tb> <SEP> HO4OH, <SEP> CH3 <SEP> 100 <SEP> 87.S <tb> <SEP> HO <tb> <SEP> ,/NHCOCH3 <tb> <SEP> CH3CHCO <tb> <SEP> CH3CO <SEP> . <SEP> CH3 <SEP> 62.5, <SEP> 25.0 <tb> (2) Test Compound (2) EMI90.2 TABLE 10 EMI90.3 <tb> <SEP> Surrival <SEP> (%) <tb> <SEP> R1 <SEP> Ra2 <SEP> *2 <SEP> *2 <SEP> *3 <SEP> *4 <SEP> Survival <SEP> Dose <tb> <SEP> Dose <SEP> Dose <SEP> Dose <tb> <SEP> 1,0 <SEP> mg/kg <SEP> 1 <SEP> mg/kg <tb> <SEP> 9ECO <SEP> CH3 <SEP> 1 <SEP> CH2COOH <SEP> L <SEP> D <SEP> L <SEP> 1) <SEP> 75.0 <SEP> 50.0 <tb> EMI91.1 <tb> oMLO <SEP> CH3 <SEP> lCH2COOH <SEP> L <SEP> D <SEP> L <SEP> o <SEP> .8,7.5 <SEP> 75.0 <tb> <SEP> d <SEP> L0 <tb> <SEP> DCO <SEP> fl <SEP> II <SEP> tri <SEP> II <SEP> 75.0 <SEP> 87. <SEP> S <tb> <SEP> bo <SEP> II <SEP> TI <SEP> TT <SEP> ZitTI <SEP> 75s0 <SEP> 87.s <tb> <SEP> 2 <tb> <SEP> TT <SEP> IT <SEP> 8 <SEP> II <SEP> II <SEP> II <SEP> IT <SEP> 87.5 <SEP> 62,5 <tb> <SEP> w=cHco <SEP> H <tb> <SEP> COOH <tb> <SEP> 3CO <SEP> II <SEP> II <SEP> 22CH2 <SEP> II <SEP> II <SEP> 87. <SEP> 5 <SEP> 8,7.5 <SEP> 87.5' <tb> <SEP> D <tb> <SEP> OH <SEP> ' <SEP> CH <tb> <SEP> I <SEP> 13 <SEP> <tb> <SEP> CH3CHCO <SEP> IT <SEP> " <SEP> -CHCOOH <SEP> " <SEP> " <SEP> IT <SEP> TI <SEP> 70.0 <SEP> 70. <SEP> o <tb> <SEP> D <SEP> L <tb> <SEP> rt <SEP> II <SEP> It <SEP> \ <SEP> 11 <SEP> cr <SEP> TI <SEP> TI <SEP> 90.0 <SEP> 80.0 <tb> <SEP> EICOOH <tb> <SEP> D <tb> <SEP> CH <tb> <SEP> 3 <tb> <SEP> TI <SEP> II <SEP> -CH-COOH <SEP> TI <SEP> " <SEP> TI <SEP> stt <SEP> 60 <SEP> 60 <tb> <SEP> I) <tb> <SEP> E <SEP> - <SEP> 0 <SEP> -M,COOH <SEP> -- <SEP> " <SEP> TI <SEP> 66.6 <SEP> 22.2 <tb> <SEP> CM <SEP> CHO <SEP> " <SEP> " <SEP> IT <SEP> II <SEP> II <SEP> IT <SEP> 100 <SEP> 88.9 <tb> <SEP> IT <SEP> II <SEP> II <SEP> II <SEP> 87. <SEP> 5 <SEP> 75 <SEP> . <SEP> 0 <tb> <SEP> I <SEP> II <SEP> IT <tb> <SEP> CO <tb> EMI92.1 <tb> <SEP> R1 <SEP> R <SEP> R2 <SEP> Doe <SEP> ose <tb> <SEP> n <SEP> a <SEP> *1 <SEP> *2 <SEP> 10 <SEP> mg/kg <SEP> l <SEP> mg/l;g <tb> <SEP> O <SEP> L <SEP> ¯' <SEP> O <SEP> -CH2COOH <SEP> - <SEP> D <SEP> L <SEP> D <SEP> 87.5 <tb> <SEP> oeco <tb> <SEP> .H <tb> <SEP> H <SEP> fl <SEP> I! <SEP> FCOOH <SEP> " <SEP> II <SEP> It <SEP> ;w <SEP> 75.0 <SEP> 87.5 <tb> <SEP> .-D <tb> <SEP> OH <tb> <SEP> $:ECO <SEP> TI <SEP> It <SEP> II <SEP> II <SEP> t <SEP> 6 <SEP> 2. <SEP> 62. <SEP> 5 <SEP> 50,0 <tb> <SEP> D <tb> <SEP> 3(CH2)5C11O <SEP> II <SEP> 11 <SEP> II <SEP> II <SEP> II <SEP> IT <SEP> 62. <SEP> s <SEP> 62.5 <tb> <SEP> CH3(CH2)10C0 <SEP> 'IT <SEP> IDCO <tb> <SEP> i <SEP> t <SEP> t <SEP> tt <SEP> , <SEP> ts. <SEP> tt <SEP> 87.5 <SEP> lpD <tb> <SEP> H <SEP> II <SEP> IT <SEP> 2COOH <SEP> (I <SEP> IT <SEP> II <SEP> II <SEP> 87.5 <SEP> 100 <tb> <SEP> - <SEP> DL <tb> <SEP> % <SEP> (cm2) <SEP> ,CHCO <tb> <SEP> ; <SEP> 3 <SEP> L <SEP> 31 <SEP> 1 <tb> C5 <SEP> 1, <SEP> 1 <SEP> L <SEP> IT <SEP> TI <SEP> 7 <SEP> . <SEP> 87.5 <SEP> 50.0 <tb> <SEP> MMCO <SEP> " <SEP> " <SEP> " <SEP> "- <SEP> ?' <SEP> 'I <SEP> L <SEP> 100 <SEP> 88.9 <tb> <SEP> I3CHCO <SEP> " <SEP> " <SEP> " <SEP> "- <SEP> " <SEP> '.' <SEP> L <SEP> 100 <SEP> ' <SEP> 88.9 <tb> <SEP> D <tb> <SEP> ts, <SEP> IT <SEP> II <SEP> IT <SEP> IT <SEP> L <SEP> " <SEP> D <SEP> - <SEP> 50 <SEP> . <SEP> 0 <tb> <SEP> OH <SEP> <tb> <SEP> M <SEP> MCO <SEP> 1( <SEP> IT <SEP> IT <SEP> II <SEP> " <SEP> " <SEP> 100 <SEP> 87.5 <tb> EMI93.1 <tb> <SEP> 1 <SEP> 2 <SEP> Sflrv'iVal <SEP> (-%) <tb> <SEP> 'Survival <SEP> ('t) <tb> <SEP> R1 <SEP> Rb <SEP> fl <SEP> Ra <SEP> *1 <SEP> *2 <SEP> *3 <SEP> *4 <SEP> Dose <SEP> Dose <tb> <SEP> 10 <SEP> mg/kg <SEP> 1 <SEP> mg/kg <tb> <SEP> OH <tb> CH <SEP> CH3 <SEP> 1 <SEP> C}'9OOH <SEP> D <SEP> D <SEP> L <SEP> I) <SEP> 7S.0 <SEP> 75.0 <tb> <SEP> 3 <SEP> H3 <SEP> 1 <SEP> CCOOH <SEP> D <SEP> D <SEP> L <SEP> D <SEP> 75.0 <SEP> 75.0 <tb> <SEP> D <tb> CH3 <SEP> (CH2) <SEP> sCO <SEP> a3 <tb> <SEP> II <SEP> ' <SEP> IT <SEP> -CHCOOH <SEP> L <SEP> II <SEP> TI <SEP> TI <SEP> 100. <SEP> '44.4 <tb> <SEP> D <tb> (2) Test Compund (2) EMI93.2 Survival EMI93.3 <tb> <SEP> n <SEP> R- <SEP> n <SEP> "L <SEP> *1 <SEP> *2 <SEP> *3 <SEP> *4 <SEP> Dose <SEP> Dose <tb> <SEP> 10 <SEP> mg/kq <SEP> :1 <SEP> iilg/kg <tb> <SEP> CH3 <SEP> (CH2) <SEP> 5CO <tb> <SEP> CH3 <SEP> 1 <SEP> COOH <SEP> L <SEP> D <SEP> L <SEP> D <SEP> 66.6 <SEP> 88.9 <tb> IT <SEP> - <SEP> " <SEP> TT <SEP> " <SEP> II <SEP> TI, <SEP> TT <SEP> 88.9 <SEP> 100 <tb> <SEP> H <SEP> IT <SEP> Ii <SEP> 11 <SEP> TI <SEP> Ii <SEP> II <SEP> II <SEP> 8 <SEP> 8 <SEP> . <SEP> 9 <SEP> 8 <SEP> 8 <SEP> . <SEP> 9 <tb> <SEP> OH <tb> CH <SEP> MCO <SEP> CH <SEP> 1 <SEP> " <SEP> L <SEP> TI, <SEP> TI <SEP> .'! <SEP> 100 <SEP> 62.5 <tb> <SEP> D <SEP> CH <tb> <SEP> 1 <SEP> 3' <tb> <SEP> IT <SEP> IT <SEP> TI <SEP> CONCOOH'.IT <SEP> -" <SEP> " <SEP> " <SEP> 87.5 <SEP> 75.0 <tb> <SEP> IT <SEP> IT <SEP> II <SEP> H <SEP> It <SEP> IT <SEP> - <SEP> TI <SEP> 40 <SEP> . <SEP> 0 <SEP> 60 <SEP> .0 <tb> (2) In determining the protective efficacy against experimental infections in mice, the FR-900156 substance was dissolved and diluted in sterile water to provide three-fold concentrations of drug for testing. Maie DDY-strain nice, aged 6 weeks and: averaging 24 - 26g in weight, were used in groups of four mice each. Overnight cultures of Escherichia coli No.22 in Difco Nutrient Broth was diluted to 1/100 in fresh medium and incubated at 30 C with shaking. When the cell density of 1 x 108/ml was obtained, 0.2 ml of the culture was injected challenge and not All the animals died wit the challenge and, not treated with One died within 48 hours of the infection. One-fifth ml of the FR-900156 substance solution was injected subcutaneously, 1, 4, 5, and 6 days before the infection. Two days after infection, the test was considered complete and survival records of that day were made. The test results are shown in Table 11 TABLE 11 Dose (mg/mouse/day) Survival/infected 0.01 10/10 0.003 10/10 0.001 10/10 0.0003 8/10 0.0001 4/10 Control 0/10 5. Antitumor Activity Methylchoianthlene-induced fibrosarocoma (Meth-A) was used. A mixture of the tumor cells (1 x 105) and the test compound was suspended in a 0.5 % methylcellulose saline solution. The suspension was inoculated intradermally in male BALB/c mice. Four weeks after inoculation, tumor size was measused. Results are shown in the following table. Test Compound: EMI95.1 EMI95.2 <tb> <SEP> Test <SEP> compound <SEP> 2 <SEP> R2 <SEP> Dose <SEP> Suppresion' <SEP> of <tb> a <SEP> RP <SEP> Ra <SEP> Rq <SEP> /ug/s <SEP> ite' <SEP> Meth-A <SEP> growth' <tb> CH3 <SEP> (CH2) <SEP> 16CO <SEP> H <SEP> H <SEP> H <SEP> 10 <SEP> 8/10 <tb> Control <SEP> ¯ <SEP> 1/20 <tb> CH3(CH2)16C0 <SEP> H <SEP> CH3 <SEP> CH <SEP> 100 <SEP> 10/10 <tb> L <SEP> y <tb> Control <SEP> 1/20 <tb> <SEP> [CH3(CH2)21]2 <SEP> CHC0 <SEP> CH\ <SEP> CH3 <SEP> CH3 <SEP> 100 <SEP> ' <SEP> 7/10 <tb> Control <SEP> ¯ <SEP> 1/20 <tb> Note: Values gives Number of tumor-free mice / Number of mice tested, provided that when the perpendi- cular diameter of the tumor was less than 5 mm, the animal was defined as free of tumor. 6. INDUCING ACTIVITY OF INTERFERON Test Compound: EMI97.1 Male ICR strain mice aged 4 to 6 weeks were used in these experiments. Spleens of these mice were removed and the capacity of spleen cells to produce interferon in vitro by the treatment of test compound was tested. Single spleen cell subpensious ere prepared in medium RPMI-1640 supplement with streptomycin (100&gamma;/ml), penicillin G (100 &gamma;/ml), 18 glutamine and 2 mercaptoethanol (5 x 10-5 M). These were cultured at 37 C at a concentration of 4 x 107 cells/ml,with or without test compound dissolved with' culture medium (dose: 100, 10, 1 g/ml). After 24 hours, supernatants of these cultures were collected and those interferon activities. were titrated by cytopathic effect (CPE) inhibition test in L cell VSV system. Antiviral titer was expressed in IU/ml base on standard interferon. The results are as the following table 13, TABLE 13 EMI98.1 <tb> <SEP> Test <SEP> Compound <SEP> Dose <SEP> IF <SEP> Titer <SEP> (IU/ml) <tb> <SEP> *2 <SEP> *3 <SEP> *4 <SEP> *5 <SEP> ( g/ml) <tb> D <SEP> L <SEP> D <SEP> L <SEP> D <SEP> 100 <SEP> 14 <tb> <SEP> 10 <SEP> 16 <tb> <SEP> 1 <SEP> 10 <tb> <SEP> 0 <SEP> < 6 <tb> L <SEP> D <SEP> DL <SEP> 100 <SEP> 62 <tb> <SEP> 10 <SEP> 40 <tb> <SEP> 1 <SEP> 39 <tb> <SEP> 0 <tb> D <SEP> D <SEP> D <SEP> L <SEP> D <SEP> 100 <SEP> 29 <tb> <SEP> 10 <SEP> 23 <tb> <SEP> 1 <SEP> 11 <tb> <SEP> 0 <SEP> < 11 <tb> D <SEP> D <SEP> L <SEP> L <SEP> D <SEP> 100 <SEP> 38 <tb> <SEP> 10 <SEP> 11 <tb> <SEP> 1 <SEP> < 11 <tb> <SEP> .0 <SEP> < 11 <SEP> <tb> 7. ACUTE TOXICITY IN MICE of FR-900156 1 g/kg (i.v.) : no toxicity 8. CELL TOXICITY (mouse L cell) of FR-900156 500 vg/ml: no toxic effect The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in' solid, semisolid-or liquid form, which contains an active substance of this invention in admixture wiih an organic or inorganic carrier or excipient 'suitable for external, enteral or parenteral applications. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptab.le carriers for tablets, pellets, capsules, Suppositories, solutions, emulsions, suspensions, and any' other form suitable for use. The, carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol., starch paste, magnesium trisilicate, talc, corn starch, keratin, collidal silica, potatpo starch, urea' zad other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening and coloring agenWs,and perfumes may be used. The pharmaceutical compositions can also contain preservative or bacteriostatic agents to keep the active ingredient in'the desired preparations stable in activity. The active object compound is included in the pharmaceutical composition in an amount sufficient to produce the desired therapeutic effect upon the process or condition of diseases For applying this composition to humans, it is preferably to apply it by intravenous, intramuscular or oral administration. While the dosage or therapeutically effective amount of the object compound of this invention varies from and also depends upon the age aid condition of each individual patient to be treated, a daily dose of about 2-100 mg of the active ingredient/kg of a human being or an animal is generally given for treating diseases, and an average single dose of about 50 mg, 100 mg, 250 mg, and 500 mg is generally administered. The following examples are given for purpose of illustrating this invention. In the following examples, starting compounds and object compounds are expressed by using the following abbreviations: Lac : Lactyl Ala : Alanyl Glu : Glutamyl Gly : Glycyl DAP : &alpha;, #-Diaminopimelyl Z : benzyloxycarbonyl Boc : t-butoxycarbonyl 3zZ : benzyl Me : methyl Et : ethyl Su : N-hydroxysuccinimide Bzh : benzhydryl Ac : acetyl Val : Valyl Ser : Seryl Phe : - Phenylalanyl Asp : Aspartyl Lys : Lysyl Leu : Leucyl Sar : Sarcosyl &gamma;-Abu : &gamma;-Aminobutryl Aad : 2-Aminoadipyl Tyr : Tyro sol Tfa : Trifluoroacetyl Preparation 1 EMI102.1 meso-DAP (D)-NHNH#Boc (1) (5.4 g) and cupric chloride (dihydrate) (1.52 g) were dissolved in a mixture of water (30 mil) and O.SN aqueous sodium hydroxide (60 ml). The solution was stirred for thirty minutes at ambient temperature, The solution was cooled to 0 C and benzyloxycarbonyl chloride (4.6 g)' was added, dropwise thereto in the course of twenty minutes, maintaining the pE over 11. The stirring was continued for an additional one hour at the same temperature. After the reaction was completed, the solution was adjusted to pH 7 with 5% aqueous hydrochloric acid then hydrogcn sulfide gas was passed through the solution for about fifteen minutes. To the reaction mixture was added. ethyl acetate (5Q ml) and the mixture was adjusted to pK 4 with 5% aqueous hydrochloric acid. - The ethyl acetate layer and the aqueous layerf were divided out, and the ethyl acetate layer was extracted four times with water (30 ml). All of the aqueous layers were combined and concentrated to 40 ml under reduced pressure to give a crystals. The crystals were collected by filtration,washed'with water to give Z-(L)meso-DAP(D)- NHNH#Böc (2=(3.5 g). The mother liquor and the washings were collected and extracted twice with nbutanol (40 ml). The extracts were combined and concentrated under reduced pressure to give a residue. The residue was triturated with ether and collected by filtration to give additional Z-(L) meso-DAP(D) NHNH.Boc (2)(1.2 g) as a crude solid, which was re crystallized from water. =p 194-196 (dec.). N.M.R. (CD3OD), #(ppm): 1.67 (PH, s), 1.6-2.1 (6H, m), 3.6-4.2 (2H, m), 5.12 (2H, s), 7.43 (5H, s) [&alpha;]D=20.8 (C:0.5 methanol) Preparation 2 EMI103.1 3N Aqueous sodium hydroxide (6.0 ml) was added to a solution of meso-DAP-(D)-GlyOH (1)(1.85 g) and cupric chloride (dihydrate)(1.28 g) in water (190 ml) at 5 C. To the solution was added benzyloxycarbonyl chloride (5.4 ml), and the resulting solution was stirred at 5 C, maintaining the pH 11-12 with 3H aqueous sodium hydroxide. The stirring was continued for 4.5 hours and an additional benzyloxycarbonyl chloride (3.2 ml) was added to the reaction mixture. The mixture was stirred at 5 C for six hours, maintaining the pH 11-12 with 3H aqueous sodium hydroxide. The reaction mixture was acidified to pH 2 with SN aqueous hydrochloric acid and washed twice with ether. The separated aqueous layer w-as adjusted to pH 4.5 with 3N aqueous sodium hydroxide and buffled with hydrogen sulfide gnd then filtered. The filtrate was con centrated to about 100 ml and the concentrate was allowed to stand in a refrigerator to give crystals. The crystals were collected by filtration and washed successively with water, methanol and ether to give, Z-(L)-meso-DAP-(D)-GlyOH (2)(230 mg). mp 161.5 162.0 (dec.) N.M.R. (CD3OD-D2O) #(ppm) : 1.2-2.2 (6H, m), 3.7-4.3 (4H, m), 5.10 (2H, s), 7.39 (5H, s), [&alpha;]D=-25.3 (C:0.5 methanol). The filtrate was concentrated and chromatographed on a macroporous non-ionic adsorption. resin, HP20 (trade mark, maker: Mitsubishi Chemical Industry Co., Ltd.) (125 ml). After washing with water, elution was carried out with 508 aqueous methanol and then 80% aqueous methanol. . The eluates were combined and evaporated to dryness and the crude crystals thus obtained was dissolved in hot methanol (80 ml) and filtered. To the filtrate was added water (15 ml) and the solution was concentrated to give crude crystals. The crude' crystals 'were washed successively with isopropanol ,.and ether to give Z,-(L)-meso- DAP-(D)-GlyOH (2)(2.22 g). The same object compound (2)(165 mg) was additionally obtained from the mother liquor. Preparation 3 EMI104.1 meso, DAP(OH)GlyOEt (1)' (4.10 g) was dissolved in water (30 ml) and cupric chloride (dihydrates)(2.08 g) was added to the solution. The mixture was stirred at 5-7 C for five hours, maintaining pH 11 with 2% aqueous sodium hydroxide. To the reaction mixture was added benzyloxycarbonyl chloride (10.0 g) and the resulting mixture was. stirred: at 5-7 C for five hours, maintaining pH 11. An additional benzyloxycarbonyl choride (4.0 g) was added to the reaction mixture. The resulting mixture was stirred for four hours and adjusted to pH 1 witb. dil hydrochloric acid and washed with ethyl zcetate. The aqueous'layer was adjusted to nH 7 and hydrogen sulfide gas was passed through the solution. The precipitates were filtered off and the filtrate was concentrated. The concentrate was adjusted to pH 3.2- 3.4 and passed through a column packed with a macro porous non-ionic adsorption resin, HP20 (180 ml). Elution was carried out with 50% aqueous methanol and the eluate was evaporated to dryness to give Z-meso DAP(OH)GlyOH (2)(4.3 g) as a solid. N.M.R- (D2O#NaHCO3) #(ppm) : 1.38-1.88 (6H, m), 3.75 (2H, s), 3.79 (1H, t, J=4Hz), 3.96 (1H, t, J=4Hz), 5.11 (2H, s), 7.44 (5H, s). Preparation 4 EMI105.1 Cupric carbonate (1.173 5 was added to a solution of DAP(OH)GlyOH (1)(1.7 g) in water (50 ml) and the mix ture was refluxed for two hours. The reaction mixture was filtered and the filtrate was adjusted to pH 11.5 with 2N aqueous sodium hydroxide. Benzyloxycarbonyl chloride (3.23 ml) was added to the reaction mixture at 0 C and the resulting mixture was stirred at 0 C for six hours, maintaining pH 11.5. The reaction mixture was, neutralized with dil. aqueous hydrochloric acid and dechelated by hydrogen sulfide gas The resulting mixture was filtered and the filtrate was chromatographed on a macroporus non-ionic adsorption resin, HP20 (100 ml). Elution was carried out with 80% aqueous methanol and the eluate was evaporated to dryness to give, Z-DAP(OH)GlyOH (2)(1.4 g) as a solid. N.M.R.(CD3OD) #(ppm) : 1.38-1.88 (6H, m), 3.75 (2H, s), 3.79 (1H, t, J=4Hz), 3.96 (1H, t, J=4Hz), 5.11 (2H, s), 9.44 (5H, s). Preparation 5 EMI106.1 (1)b Preparation 5-1 Z-(L)meso-DAP(D)-NHNHBoc (1)(5.0 g), t-butylcarbonic anhydride (3.0 g) and triethylamine (2.54 g) in a mixture water (50 ml) and dioxane (50 ml) were stirred for three hours at ambient temperature. Dioxane was distilled off under reduced pressure and the resulting aqueous layer was washed with ether. The aqueous layer was adjusted to pH 2 with 5% aqueous hydrochloric acid and extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride and then dried over anhydrous magnesium sulfate to give Z-(L)-Boc(D)meso-DAP(D)NHNHBoc (2)(6.0 g), which was recrystallized from isopropyl ether. mp 146-148 (dec). N.M.R. (CDCl3), #(ppm) 1.4-2.1 (6H, m), 1.67 (9H, s), 4.1-4.5 (2H, m), 5.13 (2H, s), 5.50 (1H, broad s), 6.0 (lH, broad s), 7.05 (1H, broad s), 7.33 (5H, s), 8.37 (1H, broad s), 8.90 (1H, broad s) (2) Preparation 5-2 Z-(L)-Boc(D)meso-DAP(D)-NHNHBoc (2)(0.50 g) was obtained from Z-(L)meso-DAP(D)-NHNHBoc (1)(438 mg) by substantially the same manner as that of Example 5-1 provided that t-butyl S-4, 6-dimethylpyrimidine2-ylthiocarbonate (288 mg) was employed in place of t-butylcarbonic anhydride. Preparation 6 EMI107.1 Z-(L)-Boc(D)meso-DAP(D)HNHNHBoc (1) (10.8 g) and N-methyl-morpholine c2.02 g) were dissolved in methylene chloride (110 ml) and stirred at 10 -15 C. 'Isobutyl chlorocarbonate (2.73 g) was added dropwise to t"ie solution and the mixture was stirred for thirty minutes at ambient temperature. To the solution was added dropwise a solution of glycine benzyl ester p-toluenesulfonate (6.75 g) and N-methyl norpholine (2.02 g) in methylene chloride (110 ml). The solution was stirred for two hours at -10 - -150C ani for Am hour 'at ambient temperature. Methylene chloride was distilled off under reduced pressure and toe residue was dissolved into a mixture of ethyl acetate (150 ml) and 1% aqueous hydrochloric acid (60 ml). The ethyl acetate layer was separated and washed successively with water 2% aqueous sodium bicarbonate and aqueous sodium chloride in turn. The ethyl acetate layer was dried over anhydrous magnesium sulfate and evaporated to dryness under reduced pressure. The residue thus obtained was recrystallized from other to give Z-(L)-Boc(D)-mesoHDAP(L)GlyoBzl (D)-NHNHBoc. (2)(12.3 g), mp. 85-87. N.M.R. (CDCl3), #(ppm) : 1.43 (18H, s), 1.5 2.2 (6H, m), 4.10 (2H, d, J=6Hz), 4.1 4.5 (2H, m), 5.10 (2H, s), 5.17 (2H, s), 5.40 (1H, d, J=8Hz), 5.90 (1H, d, J=8Hz), 6.75 (1H, broad s), 7.33 (10H, s), 7.73 (1H, broad s), 8.4-8.6 (1H, m). Preparation 7 EMI108.1 To a solution of di-Z-meso-DAP(L)oBzl-(D)-NHNH2 trifluoroacetic acid salt (1)(6.435 g) in dimethylformamide (25 ml) was added 3.29N hydrochloric acid in dimetrhylformamide (5.80 ml) at .50 C and then isoanylnitrite (1.41 ml) was added. The solution was allowed to warm to -200C and then stirred for ten minutes. The resulting solution was cooled to -50 C and triethylamine c3.97 ml) was added thereto. To the solution was added a mixture of glycine benzyl ester p.toluensulfonate (6.41 g) and triethy lamine (7.95 ml) in dimethyformamide (12 m). The heterogeneous mixture was stirred at 3-7 C for six hours and allowed to stand, in a refrigerator for 48 hours. The reaction mixture was diluted with z mixture of ethyl acetate (170 ml) and methylene chloride (30 ml) and washed succEssively with 5% aqueous phosphoric acid, water dil. sodium: bicarbonate, water, and brine. The mixture was dried over anhydrous magnesium sulfate and the solvent was evaporated to dryness to give crystalline materials (6.4 g). The crystalline materials were chromatographed on silica gel (90 g) and eluted with a mixture of methylene chloride and ethyl acetate C :l). The eluate was evaporated to give a residue. Crystallization was carried out from ethyl acetate atom give crude crystals of di-Z-meso-DAP(L)oBzl-(D)-GlyoBtl (2)(5.32 g), mp 131-133 C. An aliquote c450 mg) of the above crystals were further purified by ch: oratography on silica gel (eluted with 2 mixture of methylene chloride and ethyl acetate (1:3), followed by recrystallization from 2 mixture of ethyl acetate and ether (5:2) to give fine needles. mp 138-139.5 C. [&alpha;]DZO=+4.6 (C=1, chloroform) N.M.R. (CDCl3), #(ppm) : 1.1-2.1 (6H, m), 3.98 (2H, d, J=6Hz), 3.8-4.5 (2H, m), 5.04 (4H, s), 5.08 (2H, s), 5.10 (2H, s), 5.49 (2H, t, J=7Hz), 6.64 (1H, t, J=6Hz), 7.28 (2OH, s). Preparation 8 EMI110.1 A solution of sodium nitrite (0.97 g) in water (10 ml) was added to a two-phase solution of di-Z-meso-DAP(D)- NHNH2 (6.50 g) in a mixture of 1N aqueous hydrochloric acid (42 ml) and ethyl acetate (30ml) at 0 C. The' resulting mixture was stirred at 0 C for five minutes and a cooled ethyl acetate (30 ml) was added thereto. The ethyl acetate layer was collected and washed four times with dil. sodium, chloride, dried over anhydrous magnesium sulfate and then filtered. .To the filtrate was added a solution of H-GlyoBozl in methylene chloride (30 ml), which, was prepared by desalting glycine benzyl ester p-toluenesulfonate (11.6 g) with pota-ssium carbonate in a mixture of methylene chloride and water in a conventional manner, and then tri ethylamine (1.92 ml) was added. The resulting mixture was kept at 4 C for 20 hours. The reaction mixture was washed successively with dil. hydrochloric acid and (three times), brine, dried over anhydrous magnesium sulfate'and evaporated to dryness to'give an oil (6.S g), which was chromatographed on silica gel C45 g). Elution was carried out with a mixture of methylene chloride and methanol (100:5) to give amorphous solid (5.15 g). The solid was crystallized from a mixture oi ethyl acetate and ether (1:2) to give di-Z-meso-DAP(D)GlyoBzl (2)(1.54 g). N.M.R. (acetone-d6), #(ppm):1.3-2.4 (6H, m), 3.9-4.6 (2H, m), 4.06 (2H, d, J=6Hz), 5.12 (4H, s), 5.18 (2H, s), 6.3-6.9 (2H, broad d, J=8Hz), 7.38 (15H, s), 7.77 (1H, t, J=6Hz) Preparation 9 EMI111.1 A mixture of di-Z-meso-DAP(D)-NHNHBoc (1)(8.83 g), benzyl bromide (3.66 ml) and triethylamine (4.30 ml) in dimethylformamide (40 ml) 'was stirred at ambient temperature for 19 hours. The reaction mixture was diluted with ethyl acetate (150 ml) nod the solution was washed successively with dil. phosphoric acid, water, dil. sodium bicarbonate, water and brine. The solution was dried over anhydrous magnesium sulfate and evaporated to give an amorphous solid (9.0 g), which was purified by column chromatography using silica gel (90 g), and fractions eluted with a mixture of methylene chloride and ethyl 'acetate (1:3) were combined and evaporated to dryness to give a solid (9669 g). Recrystallization from a mixture of ether and hexane gave di-Z-meso-DAP(L)oBzl-(D)-NHNHBoc 8")(7.40 g). N.M.R. (CDCl3), #(ppm) : 1.40 (9H, s), 1.1-2.0 (6E, m), 4,0-4.7 (2H, m), 5.17 (4H, s), 5.23 (2H, s), 6.87 (1H, broad s), 7.48 (15H, s), 8.57 (1H, broad s) 23 [&alpha;]D20=+13.2 (C=1, chloroform). Preparation 10 EMI112.1 To a cold mixture of di-Z-(D)meso-DAP (1)(13.8, g) and triethylamine (6.1 g) in methylene chloride (150 ml) was added dropwise in the course of five minutes a cold solution of isobutoxycarbonyl chloride (5.33 g) in methylene chloride (30 ml) at -10 C. The mixture was stirred at -10 C - -12 C for twenty five minutes. To the mixture was added dropwise a 'solution oZ glycine ethyl ester hydrochloride (5.44 g) and triethylamine (3.94 g) in methylene chloride (200 ml) at -10 C # -12 C in the course of twenty minutes. The solution was stirred at -10 C for thirty minutes. To the reaction mixture was added water and-the mixture was adjusted to pH 2 with IN aqueous hydrochloric acid, and then washed with saturated aqueous sodium chloride and' with 58 aqueous sodium bicarbonate. The methylene chloride layer was washed with water and then concentrated. To the concentrate was added ethyl acetate and insoluble materials were filtered off and the filtrate was extracted three times with 5% aqueous sodium bicarbonate (p,H 8). The extract was adjusted to pH 2 with IN aqueous hydrochloric acid and then extracted three times with ethyl acetate. The extract was washed twice with water and dried over anhydrous magnesium sulfate. The extract was filtered and the filtrate was concentrated. The oily residue thus obtained was, allowed to stand in a refrigerator to give crysta'ls. The crystals was washed with isopropyl ether and dried over anhydrous magnesium sulfate to give di-Z-meso-DAP(OH)GlyOBt (7.73 g). N.M.R. (DMSO-d6), #(ppm) : 1.20 (3H, t, J=7Hz), 1.0-1.9 (6H, m), 3.7-4.2 (2H, m), 3.80 (2H, d, J=6Hz), 4.03 (2H, q, J=7Hz), 5.00 (4H, s), 7.33 (10H, s). Preparation 11 EMI113.1 A mixture of di-Boc-meso-DAP di-dicycl,ohexylamine sal. salt (1)(18.5 g) in methylene chloride (160 ml) was added to a solution of triethylamine hydrochloride (8.0 g) in methylene chloride (200 ml) and the mixture was stirred at ambient-temperature for two hours and cooled to -10 C. To the cold mixture was added dropwise a solution of ethoxycarbonyl chloride (3.46 g) in methylene chloride (10 ml), maintaining the temperature at -10 C, The solution was stirred at -100C- for thirty minutes. To the reaction mixture was added dropwise a mixture of glycinethyl ester hydro- chloride (4.45 g) and triethylamine (3.23 g) inmethylene chloride (200 ml) in the course of thirty minutes, maintaining the temperature at -10 C. - The mixture was stirred at the same temperature for thirty minutes. The reaction mixture was adjusted to pH 2 with 1N aqueous hydrochloric acid and then washed twice with water and twice with saturated aqueous sodium, chloride. The organic layer was concentrated and the concentrate was dissolved in e.thyl zcetate. Extraction was carried out twice with ; ;1 aqueous sodium bicarbonate. The extract was adjusted to pH 2 with 1N aqueous hydrochloric acid. Extraction was carried out with ethyl acetate and the organic layer was washed successively with saturated aqueous sodium chloride, S. aqueous sodium, bicarbonate, and further'washed with saturated aqueous sodium chloride. The organic layer was dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated to give an oily di-Boc-meso-DAP(OH)GlyOEt (2)(5.16 g). N.M.R. (CDCl3), #(ppm) : 1.30 (3H, t, J=7Hz), 1.43 (18H, s), 1.1,2.1 (6H, m), 4.07 (2H, t, J=6Hz), 3.8-4.5 (2H, m), 4.15 (2H, q, J=7Hz). Preparation 12 EMI115.1 A solution of diazomethane (1 g/100ml, 6ml) was added to a solution of di-Z-meso-DAP-(D)-NHNHboc (l)(0.62 g) in ether (15ml) at 0 C until the solution became yellow.The reaction mixture was evaporated to dryness and the residue was chromatographed on silica gel (14 g ) and solution was carried out with a mixture of methylene chloride and ethyl acetate (5:3) to give di-Z-meso-DAP(L) oME-(D)NHNHBoc. N.M.R. (CDCL3); #(ppm): 1.2-2.2 (6H,m), 1.33 (oH,s), 3.72(3H,s), 4.1-4.6 (2H,m) 5.12 (4H,s), 5.74 (1H,d,J=8Hz), 5.78 (1H,d, J=8Hz), 6.68 (1H, broad s), 7.35 (1OH,s), 8.50 (1H,broad s) 23 [&alpha;]D=+12.7 C (C=1, ethanol) Preparation 13 EMI115.2 To a suspension of Z¯(L)-meso-DAP-(D)-GlyOH (1) (2.072 g) in wa.ter (20 ml) was added triethylamine' (Z.90 ml) and the mixture was stirred at 0 C for a few minute. A solution of t-butylcarbonic anhydride (1.54 g) in dioxane (20 ml) was added to the resulting solution. The solution was stirred at ambient temperature for 6.5 hours and concentrated. The concentrate was diluted with water (50 ml) and ethyl acetate (100 ml) as added thereto. The mixture was cooled to 0 C and acidified to pH 2 with In aqueous hydrochloric acid The organic layer was separated and washed with water and brine, dried over magnesium sulfate and then. evaporated to give Z-(L)-Boc(D) meso-DAP(D)GlyOH (2) (2.88 g) as an amorphous solid N.M.R. (DMSO-d6), #(ppm): 1.37(9H,s) 1.1-1.9 (6H,m), 3.6-4.2(2H.m) 3.73(2H,d, J=5. 5Hz), 5.02(2H,s) 6.75(1H,m),7.33(5H,s),7-50(1H, broad d, J=9Hz), 8.07 (1H, broad t, J=5.5Hz), 12.6(2H,m) Preparation 14 EMI117.1 Triethylamine (0.84 ml) was added to a solution of di-Z-meso-DAP-(D)-GlyBzl (1)(3.0g) in dimethyl formamide (15 ml) at 0 C and then benzyl bromide (0.72 ml) was added thereto. The mixture was stirred at ambient temperature for 7.5 hours and triethylamine (0.42 ml) and benlyl bromide (0.36 ml) were added thereto The mixture was stirred at ambient tempe- rature overnight and poured into dil. phosphoric acid and then extracted with ethyl acetate (100 ml) The extract was washed successively with dil. phosphoric acid, water, dil.sodium bicarbaonate, dil.sodium chloride and saturated sodium chloride, and then dried over anthydrous magnesium sulfate. The solvent was evaporated to give an oil (3.4 g) The oil was cromatographed on silica gel (55g) and elution was carried out with a mixture of ethyl acetate and methylene chloride (35.65 g) to give. crude crystals. The crude crystals were recrystallized from ethyl acetate to give di-Z-meso-DAP(L)oBzl-(D)-GlyOBzl (2) (1.38g) N.M.R. (CDCL3), #(ppm): 1.1-2.1(6H,m),3.98 (2H,d, J=6HZ), 3.8-4.5 (2H,m), 5.04(4H,s), 5.08 (2H, s), 5.10 (2H,, s), 5.49 (2H, t, J=7Hz), 6.64(1H,t, J=6H7), 7.28(2OH,S) Preparation 15 EMI118.1 Di-Z-DAP(OH)2 (1)(4.58 g) was dissolved in tetra hydrofuran (50ml) and N-hydroxysuccinimide (1.15 g) was added to the solution. To the resulting solution was added a mixture of glycine benzyl ester p-tolwener sulfonate(3.21G) and triethylamine (1.4ml) in tetra hydroforan. N,N'-Dicyclohexyarbodiimide (2.06 g) was added to the resulting, solution under ice-cooling and the solution was stirred at ambient temperature. N,N'-Dicyclohexylurea aws filtered off and the filtrate was evaporated to dryness.The residue was dissolved in ethyl acetate and washed successively with dil hydrochloric acid, saturated sodium chloride, saturated sodium bicarbonate and saturated sodium chloride, in turn. The organic layer was dried over magnesium sulfate and caoncentrated. The concectrate was chro matografphed on silica gel (100 g) and eluted with a mixture of chloroform' and methanol 1). The eluate was concentrated to dryness to give crystals of di Z-DAP(OH)GlyoBzkl (2)(2.67G). N.M.R.(CDCL3), #(ppm): 0-83-2.0(6H,m), 3.3-4.5 (4H, m), 4.97 (6H, broads), 5.0-5.6 (2H,m), 5.8-6.6 (2H,m), 7.18 (15H,m) Preparation 16 EMI119.1 A solution of di-Z-DAP(OH)GlyoBzl (1)(5.1 g) in methanol (80 ml) was hydrogenated over 5% palladium black (2 g). The reaction mixture was filtered and the filtrate was evaporated to give DAP (OH)GlyOR (2)(1.77g). N.M.R. (D20), #(ppm): 1.3-2.3 (6H, m), 3.73 (lH,t, J=5.Hz), 3.80 (2H, s), 4.00 (1H, t, J=6Hz) Preparation 17 EMI119.2 To a solution of di-Boc-DAP(OH)GlyOEt (1)(6.0 g) in ethyl acetate (10 ml) was added 6N hydrochloric acid/ ethyl acetate (20 ml) under cooling. The mixture was stirred under cooling for four hours to give crystals. The crystals were collected and washed with ethyl acetate to give DAPGlyOEt-di-hydrochloric acid salt monohydrate (2) (4.18 g). N.M.R.(D2O), #(ppm): 1.30 (3H,t, J=7Hz), 1.1-2.2(6H,m),3.8-4.3 (2H,M) 4.11 (2H,s), 4.26 (2H,q, J=7Hz) Preparation, 18 EMI120.1 A mixture of di-Z¯messo-DAP(D)-GlyoBzl (1)(60 mg) and 10% palladium blank (25 mg) in acetic acid (1ml) was stir' red at ambient temperature under hydrogen atmosphere for 4.3 hours. Tne reaction mixture was filtered throigh Celite. The filtrate was evaporated to give meso-DAP(D)GlyOH (2) (39mg). N.M.R. (D2O), #(ppm): 1.3-2.3 (6H,m) 3.73 (1H,t, J=5.5HZ), 3.80 (2H,s), 4.00 (1H,t, J=6Hz) ,Preparation 19 EMI120.2 To a solution of di-Z-meso-DAP(L)oBzl-(D)GlyoBzl (L) (6.20 g) in acetic acid (100 Ml) was added 10% palladiun black (1.73 g) and the mixture was stirred at ambient temperature under hydrogen atmosphere for twenty hours. The reaction mixture was filtered and the catalyst was washed with acetic acid. The filtrate and the washing were combined and concetrated. The concentrate was dissolved in a small amount of water and the solution was evaporated to dryness, This operation was repeated twice The residue was cromatographed on a macroporous non-iionic adsorption resin, HP20 '(150 ml) and elution was carried out with, water. The desired fraction was evaporated. The residue was dissolved in a small amount of water and lyophilized to give amorphous solid (2.28 g) . A 300 mg portion, of this amorphous solid was dissolved in water' (3 ml) and the solution warmed to 50 C and then ethanol was added thereto until becoming cloudy Occasional addition of methanol was required for completion of crys'tallization. The crystals were collected by filtration to give meso-DAP-(D)GlyOH (2)(270 mg). mp 235 C(dec). N.M.R. (D2O), #(ppm) : 1.3-2.3 (6H,m), 3.73 (1H, t, J=5.Hz), 3.80 (2H,s), 4.00 (1H, t, J=6Hz), [&alpha;]D20 =-60.6 (C=0.507, water) Preparation 20 EMI121.1 Z-(L)-Boc(D)-meso-DAP(L)-GlyoBzl-(D)-NHNBoc (1) (12.0 g) was hydrogenated in a mixture of methanol (100 ml) and acetic acid (2.4 ml) over 10% palladium black (2 g). After completion of the reaction, the catalyst was removed by filtration and the filtrate was evaporated to dryness under reduced pressure. To the residue was added water (30 ml) and the solution was' evaporated to dryness. This operation was repeated three times. The residue thus obtained was triturated with ether to give Boc(D)-MESO-DAP(L)GlyOH-(D)-NHNBoc (2) (7.80 g). mp 130-138 C(dec). N.M.R. CCD3OD), # (ppm) : 1.60 (9H, s), 1.63 (9H,S), 1.7-2.0 (6H,m) 3.92 (2H, s), 3.8-4.1 (2H, m) Preparation 21 EMI122.1 Di-Z-meso-DAP(OH)GlyOET (1)(9.33 g) was hydrogenated in acetic acid (8C ml) with 10% palladium black (0.93 g) under conditions of two atmospheric pressure of hydrogen. The reaction mixture was filtred and the filtrate was concentrated. Ethyl acetate was added to the concentrate @-and-dried over. magnesium sulfate to give meso-DAPGlyOEt acetic acid salt (2) (5.74 g). mp 188-189 C(dec) N.M.R. (D20), #(ppm): 1.44(3H,t, J=7Hz), 1.2-2.2 (6H,m), 1.93 (3H,s), 3,76 (1H, t, J=6Hz), 3.9-4.2 (1H, n), 4.10 (2H, s), 4.20 (2H, q, J=7Hz) Preparation 22 EMI123.1 Boc-L-Ala-D-Glu(&alpha;-oBzl) (1) (298 mg)and anisole (0.2 ml) were added to trifluoroacetic acid (1ml) at 0 C and the mixture was stirred at the sa'me temperature for two hours.Trifloroacetic acid was evaporated to dryness and the residue was triturated with ether. The resulting compound was dissolved in water (3 ml) and adjusted to pH 7 with triethylamine and addition nal 0.1 ml of trithylamine was added to -,he solut ion. To the resulting solution was added a solution of Lac (oAC)OSu (2) (167 mg) in dimethylformamide (3 ml) at 0 C The resulting mixture was stirred overnight at ambient temperature and the reaction mixture was acidified with a diluted aqueous hydro chloric acid and then extracted with ethyl acetate. The extract was washed with water and' evaporated to dryness. The residue thus obtained was purified by preparative thin layer chromatography . using ? pre-coated silica gel plate, developing with 2 mixture of chloroform and methanol (3:2) to give. D-Lac(oAC)-L-Ala-&gamma;-D-Glu(OH)(&alpha;-oBzl)(3)(270mg) N.M.R. (CD3OD), #(ppm) : 1.40(3H, d, J=7Hz), 1.47 (3H, d, J=7Hz), 2.13 (3H, s), 2.1-2.5 (4H,m), 4.4-5.3 (3H,m), 5.20 (2H,s), 7.40(5H,s) Preparation 23 EMI124.1 Dicyclohexycarbaodiimide (32 mg) was added to a mixture of D-Lac(oAC)-L-Ala-D-Glu(&alpha;-oBzl) (OH) (1) (65 mg) and N-hydroxysuccinimide ( 18 mg3 in dioxane,(3 ml) at 0 C. The resulting mixture was stirred overnight at ambient temperature and filtered. The filtrate was evaporated, to dryness to give D-Lac(oAC)-L-Ala-D-Glu(&alpha;-oBzl)(oSu) (2) (80 mg). Preparation 24 EMI125.1 Boc-L-Ala-D-Glu(&alpha;-oBzl)(OH) (1)(65 g) was dissolved in trifluoroacetic acid (260 ml) and the solution was stirred for fifteen minutes at ambient temp,era- ture. The solution was evaporated under reduced pressure. The residue thus obtained was dissolved in 50% aqueous aacetone (600ml) O-acetyl-D-lactic chloride' (28.8 g) was added dropwise to the solution while stirring under ice- cooling, maintaining the pH 7-8. The stirring was continued for an hour at the same temperature and then aacetone was evaporated under reduced pressure. The resulting aqueous solution was washed with ethyl acetate (300 ml) and adjusted to pH 2 with 10% aqueous hydrochloric acid. Extraction was carried oout twice with ethyl acetate (600 ml and 300 ml),.,, The ethyl acetate layer was washed with saturated aqueous sodium chloride "solution and dried over anhydrous magnesium sulfate and then evaporated under reduced pressure to give D-Lac(oAC)-L-Ala-&gamma;-D-Glu(&alpha;-0Bzl) (OH) (2) (64.7 g). N.M.R. (CDCL3), #(ppm) : 1.40 (3H, d, J=7Hz), 1.47 (3H, d, J=7Hz), 1.13 (3H,s), 2.1-2.5 (4H,m), 4.4-5.3 (3H,m), 5.20 (2H,s), 7.40 (5H,S) Preparation 25 EMI126.1 Z-(L)-Boc-(D)meso-DAP-(D)GlyOH (1)(2.80 g) was hydrogenated in methanol (56ml) over 10% palladium black (0.82 g) under conditions, of ordinary atmospheric pressure of hydrogen at ambient ;temperature for four hours. To the reaction,mixt'ure was added methanol (50 ml) and the resulting mixture was warmed to 40 C and then filtered. The catalyst was washed well with methanol and filtered. The filtrate and, washings were combined, and concentrated to give crystals. The cry- stals was diluted with isopropanol and cooled in a refrige'rator and then washed with ether to give 3oc (D)meso-DAP(D)GlyOH (2)(1.687g) N.M.R. (CD3OD+D2O), #(ppm): 1.3-2.2 (6H,m), 1.40 (9H, s), 3.66 (1H, t, J = 5Hz), 3.7-4.2 (1H,m),3.88(2H,s) [&alpha;]D23= +12.2 (C=0.5, methanol) Preparation 26 EMI126.2 To a solution of Z-(L)-Boc-(D)-mesoDAP-(D)-NHNBoc (L)-GlyoBzl (1)(105 mg) in methanol was added 0.1N aqueous sodium hydroxide (1.5ml). The mixture was stirred at ambient temperature for two hours and evaporated. The resulting aqueous solution was acidified ta pH 2 with 5 aqueous hydrochloric acid and extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and evaporated to give Z-(L)-Boc- (D)-mesoDAP(D)-NHNBoc-(L)GlyOH (2)(85 mg). N.M.R. ' (CDCL3), # (ppm): 1.43 (18H, s), 1.3-2.1 (6H, m), 3.9-4.5 (4H, m), 5.10 (2H, s), 6.2-6.4 (4H, m), 7.10 (IH, broad s), 7.33 (SH, s), 8.95 (lH, broad s) Preparation 27 EMI127.1 Z-(L)-Boc-(D)-mesoDAP-(D)-NHNBoc-(L)-GlyoBzl (1)(2.0 g) was added to trifluoroacetic acid (10 ml) and the mixture was stirred at ambient temperature for 15 minutes. Trifluoroacetic acid was distilled off and the residue was dissolved in 50% aqueous dioxane (30 ml) and When cooled to 0 C. To this solution was added N-bromosuccinimide (1.04 g) and the mixture was stirred at the same temperature for dh hour. Dioxane was distilled off and the residue was adjusted to pH 6 with saturated 'aqueous sodium bicarbonate. The precipitated crystalline solid was filtered and washed with water to give Z-(L)-mesoDAP- (L) -GlyoBzl (2) (1.15 g). N.M.R. (DMSO-d6), 6 (ppm) : 1.2-2.0 (6H, m), 3.8-4.2 (4H, m), 5.05 (2H, s), 5.15 (2H, s), 7.40 (10H, s) Preparation 28 EMI128.1 A solution of Z-(L)-mesoDAP-(L)GlyBzl (1)(100 mg) in a mixture of methanol (10 ml) and water, (3 ml) was hydrogenated over 10% palladium-blank (50 mg) under @ordinary atmospheric pressure of hydrogen. The reaction mixture was filtered ,and the filtrate was evaporated. The residue was pulvelized to give mesoDAP-(L)GkyOH (2)(44 mg). N.M.R. (D2O), #(ppm) : 1.3-2.1 (6H,m) 3.73 (1HH, t, J=6Hz), 3.80 (2H,s) 4.01 (1H, t, J=6Hz) Preparation 29 EMI128.2 P-Toluenesulfonic acid (monohydrate) (0.56 g) was added to 2 solution of Boc-(D)-mesoDAP-(D)-NHNBoc- (L)-GlyoH (1)(1.39 g). To the mixture was, added a solution of diphenyldiazomethane (0.62) in methanol (1 ml). The resulting mixture was stirred at ambient temperature for 30 minutes. To the reaction mixture was added an additional diphenyldia=omethane ( 0.78 g) until the starting material (1) was disappeared on thin layer chromatography. An excess of the reagent was distroyed by adding acetic acid, and the mixture was adjusted to pH 8 with saturate aqueous sodium bicarbonate and then evaporated. The'residue was dissolved in ether (3 ml) and triturated with n-hexane (5 ml). The solvents were removed by decantation. This operation was further repeated twice. The residue was put on a column of silica-gel (30 g) and -eluted with a mixture of ethyl acetate and methanol (10:1). The fractions containing the object compound (2) were combined and evaporated to give a solid, which, was purified by reprecipitation from a mixture o- ethe.r and n-hexane (1:2) to give Boc-(D)-mesoDAP-(D) NHNBoc-(L)-GlyoBzl (2) (1.22 g) N.M.R. (CDCL3), #(ppm) : 1.33 (18H,s), 1.1-1.8 (6H, m), 3.1-3.5 (1H,m), 3.9-4.3 (3H,m), 5.2-5.5 (1H,m), 6.75 (1H,s), 7.3 (10H,s) 7.6-8.0 (1H,m) Preparation 30 EMI129.1 To a mixture of Z-(L)-Boc-(D)-mesoDAP-(D)-NHNBoc (19 (1.40 g) and glycine methyl ester hydrochloride (392 mg)in dimethyl formamide (10 ml) were added N-hydroxysuccinimide (0.45 g)and dicyclohexylcarbodi imide (0.645 g) at 0 C, and the resulting mixture was stirred at the sane temperature for 30 minutes and at ambient temperature for overnight. The resulting precipitate was filtered off and the filtrate was concentrated. The concentrate was dissolved in ethyl acetate (50 ml) and the solution was washed successively with 0.5N hydrochloric acid, water, 2.58 sodium bicarbonate and water. The organic layer was dried over magnesium sulfate and evaporated to give Z-(L)-Boc-(D)-mesoDAP-(D) NHNHBoc-(L)GlyoMe (2) (1.45 g). N.M.R. (CDCl3), # (ppm): 1.40 (18H, s), 1.5-2.0 (6H, m), 3,70 (3H, s), 3,98 (2H, d, J=6Hz), 4.0-4.5 (2H, m), 5.07 (2H, s), 5,45 (1H, d, J=8Hz), 5.93 (1H, d, J=8Hz), 6.83 (1H, broad s), 7.1-7.3 (1H, m), 7.33 (5H, s), 8.63 (1H, broad s) Preparation 31 EMI130.1 To a solution of Z-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc (L)-GlyOMe (1)(1.41 g) in a mixture of water (14 ml) and methanol (10 ml) was added 1N sodium hydroxide (2.3 ml) at 0 C. The mixture was stirred at the same temperature for 30 minutes and at ambient temperature for 3,5 hours. Methanol was distilled off and the resulting solution was washed with ethyl acetate. The aqueous layer was adjusted to pH 3 with 5% hydrochloric acid and extracted with ethyl acetate. The extract was washed with a saturated sodium chloride, dried over magnesium sulfate and then evaporated to give Z-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (2) (1.24 g). N.M.R. (CDCl3), # (ppm): 1.43 (18H, s), 1.3-2.1 (6H, m), 3.9-4.5 (4H, m), 5.10 (2H, s), 6.2-6.4 (4H, m), 7.10 (1H, broad s), 7.33 (5H, s), 8.95 (1H, broad s) Preparation 32 EMI131.1 Z-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (1)(270 mg) was added to trif"',uoroacetic acid (5 ml) and the mixture was stirred at ambient temperature for 15 minutes. Trifluoroacetic acid was distilled off and the residue was pulverized with ether. The solvent was removed by decantation and the solid material thus obtained was dissolved in 60% aqueous acetic acid (30 ml) and manganese dioxide (180 mg) was added to the solution. The resulting mixture was stirred at ambient temperature for an hour. The reaction mixture was filtered and the filtrate was evaporated. The seridue was dissolved and water and the solution was evaporated. The residue was dissolved in 50% ethanol (60 ml) and adjusted to pH 9 with dil. aqueous ammonia and stored in a refrigerator. The solution was treated with zn active carbon (30 mg) and filtered. The filtrate was concentrated and the concentrate was dissolved in water (20 ml) and put on a column of carbon (15 ml3. The column was washed with water and eluted with 70% aqueous acetone. The extract was evaporated to give Z-(L)-mesoDAP-(L)-GlyOH (2) (85 mg). M.p. 210 C (dec.) I.R. (Nujol): 3300, 2600 --2400 (shoulder), 1710 (shoulder), 1680, 1640 cm-1. N.M.R. (DMSO-d6), #(ppm): 1.10-2.20 (6H, m), 3.30 (1H, m), 3.65 (2H, d, J-7Hz), 4.00 (1H, m), 5.00 (2H, s), 7.30 (5H, s). Preparation 33 EMI132.1 A solution of di-Z-meso-DAP(L)oBzl-(D)-NHNHBoc CI) (6.68 g) in trifluoroacetic acid (30 ml) was. stirred at ambient temperature for twenty minutes. The r'esulting solution was concentrated and the residue was dissolved in methylenechloride. The solution, was evaporated under reduced pressure and the residue was crystallized from ether to give di-Z-meso-DAP(L)oBzl- (D)-NHNH2 trifluoroacetic acid salt: (2) (6:627 g). mp 113 - 114 C N.M.R. (DmSo-d6) #(ppm): 1.1-2.0 (6H, m), 3.6-4.3 (2H, m), 5.03 (4H, s), 5.11 (2H, s), 7.33 (15Ha s), 7.1-8.4 (6E, m) Preparation 34 EMI133.1 A mixture of di-Z-meso-DAP(D)-NHNHBoc (1) (6.41 g) and anisole (3 ml) in trifluoroacetic acid (17 ml) was stirred at 0 C for 1.5 hours. The reaction mix ture was concentrated under reducing pressure and ether (50 ml) was added to the concentrate. The ether solution was triturated to gove precipitates. The precipitates were washed twice with ether and pumped to give di-Z-meso-DAP(D)NHNH2 trifluoroacetic acid salt (2) (7.0 g). N.M.R. (CD OD) 6 (ppm): 1.2-2.1 (6H, m), 3.9-4.5 (2H, m), 5.05 (4H, s), 7.25 (10H, s) Preparation 35 EMI134.1 To a mixture of di-Z-L-DAP (1) (4.59 g) and, Nmethylmorpholine (2.2 ml) in methylene chloride (50 ml) was added iso-butoxycarbonyl chloride ('.69 ml) at -20 C and the mixture was stirred at -10 C # -15 C for 30 minutes. The reaction mixture was cooled to -30 C and a mixture of H-GlyoBzl p-toluenesulfonate (4.38 g) and N-methylmorpholine (1.43 ml) i methylene chloride (25 ml) was added thereto. The mixture ras stirred at -10 C for an hour and then allowed to warm to ambient temperature. The reaction mixture was concentrated and the concentrate was poured into a mixture of ethyl acetate and dil. hydrochloric acid. Insoluble materials were filtered off and the organic layer was separated and washed successively with dil. sodium bicarbonate, dil. hydrochloric acid, water and brine. During this operation, crystals were separated out which was collected by filtration, to give di-Z-L DAP-mono-GlyoBzl (2)(0.79 g). The filtrate was dried over magnesium sulfate and evaporated. The residue was combined with the insoluble materials described above and then, recrystallized from ethyl acetate to give additional di-Z-L-DAP-mono-GlyoBzl (2)(2.55 g). N.M.R. (DmSo-d6): 1.1 - 1.9 (6H, m), 3.89 (2H, broad d, J=5Hz), 3.7 - 4.4 (2H, m), 5.00 (4H, s), 5.10 (2H, s), 7.1 - 7.6 (2H, m), 7.32 (15H, s), 8.31 (1H, t, J=5Hz). Preparation 36 EMI135.1 Di-Z-L-DAP-mono-GlyoBzl (1)(3.12 g) was dissolved in a mixture of methanol (10 ml) and acetic acid (60 ml) by warning. To the solution was added 10% palladium black (8,50 mg) and the mixture was stirred under an atmospheric pressure of hydrogen overnight, during which time an white precipitate e was appeared. The catalyst and the precipitate were collected by filtration and the filter cake was washed with 50% aqueous acetic acid and water. The filtrate and the washings were combined and evaporated. The residue was dissolved in water and the solution was evaporated in order to remove acetic acid. This operation was repeated twice and the residue was' triturated with hot water and then methanol was added thereto. The suspension was cooled in n refrigerator and the resulting precipi-ate was filtered and washed with methanol and ether to give L-DAP-monoGlyOH (2) (1.295 g). I.R. (Nujol): 1660, 1640 (shoulder), 1590 (broad), 1530 cml' N.M.R. (D2O) #(ppm): 1.2 - 2.3 (6H, m), 3.5 - 4.3 (2H, m), 5.87 (2H, s) Preparation 37 EMI136.1 To a mixture of L-DAP-monoGlyOH (1) (1.25 g) and cupric chloride (dihydrate)(1)(0.86 g) in water (120 ml) were added 3N sodium hydroxide (5.5 ml) and carbobenzyloxy chloride (3.6 ml) at 5 C. The mixture was stirred at SOC for 4.25 hours, during which time the pH of the reaction mixture was kept at 11 - 11.5 by adding 3N sodium hydroxide. To the reaction mixture was added an additional carbobenzyloxy chloride (1.08 ml) and the resulting mixture was stirred at the same temperature for 6 hours, maintaining pH 11 - 11.5 with 3N sodium hydroxide. Another portion of ca,rbobenzyioxy' chloride (1.08 ml) was added to the reaction mixture and the resulting mixture was stirred at SOC for 2.5 hours, keeping the pE at 11 - 11.5. The reaction mixture was acidified to pH 2 with dil. hydrochloric acid and washed twice with ether. The aqueous layer was adjusted to pH 4.5 with dil. sodium hydrochloride and then hydrogen sulfide gas was bubbled at 5 C. The resulting precipitate was filtered off and the filtrate was concentrated to 50 ml. The concentrate was adjusted to pH 2 and chromatographed on a column of a macroporous non-ionic adsorption resin, HP 20 c70 ml). Fractions eluted with 50% aqueous methanol were collected and evaporated. The residue was triturated with ether containing a small amount of methanol to gve Z-()- L-DAP-(#)-GlyOH (2)(1.30 g). N.M.R. (D2O), #(ppm): 1.2-2.2 (6H, m), 3.88 (2H, d, J=2.5Hz),, 3.8-4.3 (2H, m), 5.10 (2H, s), 7.43 (SH, s) Preparation 38 (1) Step 1 EMI137.1 D-Glu(&alpha;-oBzl)(1)(4.74 g) was dissolved in a mixture of dioxane (60 ml) and water (60 ml) containing triethylamine (2.02 g). To this solution was added Boc-Gly-N-Su (2)(5.16 g), and the mixture was allowed to stand overnight at ambient temperature. The resulting reaction mixture was evaporated to give an oily residue which was dissolved in ethyl acetate and then washed with water. The organic layer was dried over magnesium sulfate and evaporated. to give an oily residue (5.40 g). Analytical sample, of the compound (3) was purified as dicyclohexylamine salt which was recrystallized from ethyl acetate-diisopropyl ether to give dicyclohexylamine salt of Boc-Gly-D-Glu(&alpha;-oBzl). mp 127-129 C N.M.R. (CDCl3), #(ppm): : 1.40 (9H, s), 0.84-2.40 (24H, m), 2.92 (ZH, m), 3.80 (2H, d, J=7Hz), 4.08 1H, q, J=7Hz), 4.48 (1H, m), 5.12 (2H, s), 5.64 (1H, m), 7.32 (5H, s), 8.54 (1H, d, J=7Hz), 9.18 (1H, s) (2) step 2 Compound '(3) EMI138.1 EMI138.2 Boc-Gly-D-Glu(&alpha;-oBzl)(3)(4.30 g) was dissolved in trifluoroacetic acid "(20 ml) and the solution was kept at ambient temperature for 30 minutes. Evaporation of the solvent under reduced pressure gave an oily residue, to which toluene was added and evaporated in vacuo. The resulting oily residue was dissolved in 50% aqueous acetone (20 ml) and the solution was adjusted to pH 7.0-8.0 by adding saturated sodium bicarbonate solution. To this stirred solution cooled in an ice-bath, was added dropwise acetyl-D-lactyl chloride (1.97 g) and the mixture was stirred at the same temperature for an hour. The reaction mixture was extracted with ethyl acetate and the aqueous layer was treated with conc.hydrochloric acid to adjust the pH to 3.0. The aqueous layer was extracted with ethyl acetate and the organic layer was washed with water, dried over magnesium sulfate and evaporated to give an oily residue (2.8 g). The residue was purified as cicyclohexylamine salt which was recrystallized from ethyl acetate-diisopropyl ether to give D-Lac(oAc)-Gly-D-Glu(&alpha;-oBzl) (4)(2.1 g). mp 117-118 C. N.M.R. (CDCl3), #(ppm): 0.80-2.52 (24H, m), -1.48 (3H, d, J=7Hz), 2.14 (3H, s), 2.96 (2H, m), 3.96 (2H, d, J=7Hz), 4.46 (1H, q, J=7Hz), 5.16 (2H, s), 5.20 (1H, q, J=7Hz), 7.32 (5H, s), 8.92-9.28 (3H, m) The following compounds were prepared in substantially the same manner as that of Steps 1 and 2 of Preparation 38. Preparation 39 (1) Step 1 Dicyclohexylamine salt of Boc-L-Val-D-Glu(&alpha;-oBzl) mp. 1300C. N.M.R. (CDCl3), , # (ppm) : 0.91 (3H, d, J=7Hz), 0.94 (3H, d, J=7Hz), 1.0-2.60 (25H, m), 2.96 (2H), 4.00 (1H, m), 4.44 (1H, m), 5.14 (2H, s), 5.36 (1H, m), 7.24 (1H, m), 7.32 (5H, s), 8.54 (1H), 9.38 (1H, s) (2) Step 2 Dicyclohexylamine salt of D-Lac(oAc)-L-Val-D-Glu (&alpha;-oBzl). mp. 121-122 C. N.M.R. (CDCl3), #(ppm): 0.91 (3H, d, J=7Hz), 0.94 (3H, d, J=7Hz), 1.00-2.60 (25H, m), 1.46 (3H, d, J=7Hz), 2.14 (3H, s), 3.00 (2H, m), 4.28-4.60 (2H, m), 5.16 (2H, s), 5.20 7.00 (1H, d, J=7Hz), 7,32 (5H, s), 9.04 (1H, d, J=7Hz), 9.28 (1H, s) Preparation 40 (1) Step 1 Boc-L-Ser(oBzl)-D-Glu(&alpha;-oBzl). mp 84-85 C N.M.R. (CHCl3), #(ppm): 1.44 (9H, s), 1.76-2.48 (4H, m), 3.60, 3.65 (2H, doublet of A3 quartet, J=4Hz, 7Hz), 4.36 (1H), 4.52 (2H, s), 4.68 (1H), 5.16 (2H, s), 5.56 (1H), 7.28 (5H, s), 7.32 (5H, s), 7.04-7.40 (1H, m), 9.62 (IH, broad s) (2) Step 2 Dicyclohexylamine salt of D-Lac(oAc)-L-Ser(oBzl) D-Glu(&alpha;-oBzl). mp 124-125 C. N.M.R. (CDCl3), #(ppm): 1.00-2.40 (24H, m), 1.46 (3H, d, J=7H2), 2.12 (3H, s), 2.92 (2H, m), 3.62, 3.88 (2H, doublet of AB quartet, J=4Hz, 10Hz), 4.40-4.72 (2H, m), 4.52 (2H, s), 5.16 (2H, s), 5.17 (1H, q, J=7Hz), 7.12 (1H, d, J=7Hz), 7.28 (SH, s), 7.32 (5H, s), 8.44 (1H, d, J=7Hz), 8.56 (1H, broad s) Preparation 41 (1) Step 1 Boc-L-Phe-D-Glu(&alpha;-oBzl). mp 131 C. N.M.R. (DMSO-d6), #(ppm): 1.30 (9H, s), 1.60-2.33 (4H, m), 2.67-3.0 (2H, m), 3.90-4.66 (ZH, m), 5,.13 (2Ht s), 7.21 (5H, s), 7.33 (5H, s), 8.30 (1H, d, J=7Hz) (2) Step 2 D-Lac(oAc)-L-Phe-D-Glu(&alpha;-oBzl). mp 148-150 C (dec.) N.M.R. (DMSO-d6), #(ppm): 1.13 (3H, d, J=7Hz), 2.00 (3H, s), 1.80-2.40 (4H, m), 2.67-3.30 (2H, m), 4.20-4.83 (2H, m), 4.91 (1H, q, 7Hz), 5.17 (2H, s), 7.23 (5H, s), 7.36 (5H, s), 8.25 (2H, t, J=7Hz) Preparation 42 EMI141.1 To a solution of L-Ala-D-Glu(&alpha;-oBzl) (1) hydrochloric acid salt (5.40,g) in 50% aqueous dioxane (100 ml) were added triethylamine (3.16 g) and Boc-D-AlaoSu (4.48 g), and the mixture was stirred overnight at ambient temperature. After evaporation of dioxane, the aqueous layer was acidified to pH I with dil hydrochloric acid and extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and evaporated. The residue was crystallized from 2 mixture of ethyl acetate and, ether and filtered to give Boc-D-Ala-L-Ala-D-Glu(&alpha;-oBzl) (3) (6.90 g). - N.M.R. (acetone-d6), #(ppm) : 1.32 (6H, d, J=7Hz), 1.40 (9H, s), 2.09-2.54 (4H, m), 3.88-4.72 (3H, m), 5.15 (2H, s), 6.17 (1H, d, J=7Hz), 7.37 (5H, s), 7.34-7.67 (2H, m) Preparation 43 (1) Step 1 EMI143.1 To a solution of Z-(L)-Boc-(D)-mesoDAP (D)-NHNHBoc (2) (1.50 g.) and N-methylmorpholine (0.32 ml.) in methylenechloride (15 ml.) was added isobutyl chloro carbonate 0.375 ml.) at -25 C. After stirring at -15 C for 30 minutes, the solution was cooled to w QC, To the resulting solution were added a solution of B- AlaOBzl,. P-toluenesulfonate (1.075 g.) and N-methylmorpholine (0.34 ml.) in methylenechlorid - dimethyl formamide (10 ml. - 1 ml.). The reaction mixture was stirred at -15 ZC - -10 C for an hour, allowed to warm to ambient temperature and then concentrated. The concentrate was taken up into ethyl a'acetate (600 ml.) and washed in turn with dil hydrochloric acid, water (x2), dil sodiumbicarbonate, water and brine. The concentrate was dried over magnesium sulfate and the solvent was distilled off to give Z-(L)-Boc-(D)-meso DAP-(L)-ss-AlaOBzl-(D)-NHNHBoc (2) (2.00 g.). N.M.R. (DMSO-d6), #(ppm): 1.1-1.9 (6H, m), 3.1-3.5 m), 3.7-4.1 (2H, m), 4.98 (2E, s), 5.06 (2H, s), 6.5-6.8 (1H, m), 7.3 (1H, m). 7.95 (1H, m), 8.66 (1H, broad s), 9.53 (1H, broad s). (2) Step 2 EMI144.1 A suspension of 10% ot palladium - carbon (0.50 g.) in water (5 ml.) was added to a solution of compound (2) (1.95 g.) in methanol (40 ml.). The mixture was stirred under hydrogen atmosphere. The reaction mixture was filtered and the filtrate was conentrated. Water was coevaporated with ethanol to give an amorphous solid. Trituration with ether and filtration gave Boc (D) mesoDAP-(L)-ss-AlaOH-(D)-NHNHBoc (3) (1.25 g.). N.M.R. (D2O), #(ppm): 1.0-2.2 (6H, m), 1.45 (18H, s) 2.41 (2H, t, J=7Hz), 3.47 (2H, t, J=7Hz). 3.7-4.2 (2H, m). The following compounds were prepared in subs tan- tially the same manner;:as steps 1 and 2 of Preparation 43. Preparation 44 (2) Step 1 EMI144.2 N.M.R. (DMSO-d6), #(ppm): 1.1-2.5 (10H, m), 1.35 (18H, s), 3.5-4.6 (3H, m), 4.97 (2H, s), 5.01 (2E, s), 5.07 (2E, s), 6.6-6.8 (1H, m), 7.30 (15H, s), 7.7-8-8 (2H, m). (2) Step 2 EMI145.1 N.M.R. (D2O), #(ppm): 0.6-2.6 (28H, m), 3.5-4.4 (3H, m). Preparation 45 (I) step 1 EMI145.2 N.M.R. (DMSO-d6), #(ppm): 1.33 (18H, s), 1.25-2.00 (9H, m), 3.66.4.50 (3E, m), 5.02 (2s, s), 5.11 (2E, s), 7.33 (10E, 5). EMI145.3 N.M.R. (D2O), #(ppm): 1.50 (18H, s), 1.15-2.15 (9H, m), 3.83-4.33 (3E, m). Preparation 46 (1) Step 1 EMI146.1 I.R. (Nujol): 3270, 1695 (broad), 1640 cm-1 EMI146.2 N.M.R. (D2O), #(ppm): 1.2-2.2 (6H, m), 1.41 (18H, s), 2.93 and 3.10 (3H, a pair of singlets), 3.5-4.5 (4H, m). Preparation 47 (1) Step 1 EMI146.3 N.M.R. (DMSO), #(ppm): 1.0-1.9 (6H, m), 1.37 (18E, s), 2.8-3.2 (2E, m), 3.5-4.3 (2H, m), 4.3-4.8 (1H, m), 4.99 (2E, s), 5.08 (2E, s), 6.4-6.8 (1H, m), 7.1 (1H, m), 7.15 (5H, s), 7.28 (10H, m), 8.28 (1H, broad d, J=7Hz), 8.4-8.8 (lEr m), 9.50 (1H, broad s). EMI147.1 N.M.R. (D2O), #(ppm): 0.8-2.0 (6H, m), 1.53 (18H, s), 2.5-4.2 (5H, m), 7.41 (5H, s). Preparation 48 (1) Step 1 EMI147.2 N.M.R. (DMSO-d6), (ppm): 1.0-2.0 (9H, m) 1.42 (18H, s), 3.7-4.7 (3H, m), 5.05 (2H, s), 5.15 (2H, s), 6.6-7.0 (1H, s), 7.1-7.9 (1H, m) 7.38 (10E, s), 8.40 (1H, broad s, J-7Hz), 8.5-8.9 (1H, m), 9.65 (1H, broad s). EMI148.1 N.M.R. (CD3OD-D2O), #(ppm): 1.38 (3H, d, J=7Hz), 1.44 (9E, s), 1.46 (9E, s), 1.1-2.2 (6E, - m), 3.8-4.3 (3E, m). EMI148.2 To a cooled solution of di-Z-mesoDAP (1) (3.50 g.) in methylene c:hloride (70 ml.) was added phosphorus penta chloride (3.50 g.) at 0 OC, and the mixture was stirred at the same temperature for 15 minutes. The temperature' was raised to ambient temperature and then the mixture was stirred for 15 minutes. The reaction mixture was then warmed to 50 C and stirred for 20 minutes. After standing for 20 minutes at O C, the resulting crystalline solid was filtered and washed with methylene chloride to give mesoDAP-N-carboxylic anhydride (2) (1.68 g.). I. R. (Nujol): 3250, 1840, 1765 cml N.M.R. (DMSO-d6), #(ppm): 1.2 2.0 (6H, m), 4.43 (2H, t, J=5Hz), 9.06 (2E, s). Preparation So EMI149.1 To a cooled mixture of t-butylcarbazate (1.58 g,.) and oxalic acid hydrate (1.26 g.) in methanol (7 ml.) was added a solution of mesoDAP N-carboxylic anhydride (1.23 g.) in methyl cyanide (7 ml.). After stirring at 0 C for 10 minutes; methyl cyanide (7 ml.) z ) was added to the solution and the mixture was- stirred at the same temperature for 30 minutes. The resulting crystalline solid was filtered and washed with ,methyl cyanide to give' mesoDAP-di NEBoc oxalate (2) (2.66 g.). -1 I.R. (Nujol): 3600-2200, 1720, 1680, 1610 cm N.M.R. (D2O), #(ppm): 1.47 (18H, s), 1.3 2.3 (6H, m) 4.10 (2H, t, J=6Hz). Preparation 51 EMI149.2 MesoDAP di-NHNH Boc acetate (2) was prepared from meso DAP N-carboxylic anhydride (1) in substantially the same manner as that of Preparation 50. N.M.R. (D2O), #(ppm): 1.52 (18H, s), 1.95 (6H, s), 1.4-2.3 (6H, m), 4.08 (2H, t, J=7Hz). Preparation 52 (1) Step 1 EMI151.1 Z-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc (1) (2.26 g) was added to trifluoroacetic acid (6 ml) and stirred for 15 minutes at room temperature. After evaporation of trifluoroacetic acid, the resulting oily residue was dissolved in 0.1 N sulfuric acid (42 ml) and cooled in an icebath. To this solution was added a solution of sodium periodate (1.078 g) in water (15 ml) and the mixture w2s stirred 'for I hour at the same temperature. The reaction mixture was treated with an aqueous solution of sodium bisulfite until the dark color was clear. After adjusting the pE of the solution to 7.0, the solution was concentrat- ed to about 10 ml and the pE, was adjusted to 2.0. This solution was applied to a column of a macroporous nonionic adsorption resin, EP-20 (100 ml), which was elutecR with water and then with water-methanol 1 (3 : 2). Evaporation of the latter fractions gave Z-(L)-mesoDAP (2) (1.0 g) as a white crystalline residue. m.p. -245 C (dec) I.R. (Nujol) : 3500, 3350, 3200, -2600 (broad) 1690 cm-1 N.M.R. (DMSO-d6): 6 (ppm): 1.16-2.0 (6 E, m), '3.30 (1 ±, broad signal), 3.90 (1 , broad signal), 5.00 (2 H, s), 7.33 (5 H, s) (2) Step 2 EMI152.1 To a mixture of Z-(L)-mesoDAP (2) (1.50 g) and tri ethylamine (1.0 g) in aqueous dioxane (dioxane 30 ml and water 20 ml) was added Boc-D-Ala-OSu (3) (1.32 g) and the mixture was allowed to stand overnight at room temperature. Dioxane was evaporated, and the resulting aqueous solution was acidified with diluted hydrochloric acid and extracted, with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and evaporated to give Boc-D Ala-(D)-Z-(L)-mesoDAP (4) (1.90 g) as a white foam. I.R. (Nujol): 3300, 1700 (broad) cm-1 N.M.R. (DMSO-d6), #(ppm): 1.20-2.0 (18 H, m), 3.70-4.40 (3 H, m), 5.00 (2 H, s), 7.37 (5 H, s) (3) Step 3 EMI152.2 A solution of Boc-D-Ala-(D)-Z-(L)-mesoDAP (4.1 g.) in acetic acid (40 ml.) was hydrogenated over 10 % palladium-charcoal (0.40 g.). The catalyst was removed by filtration and the filtrate was evaporated to give a. pasty residue, to which toluene was added and evaporated to give Boc-D-Ala-(D)-mesoDAp (5). (1.50 g.) as a white powder. I.R. (Nujol): 3300, 2600-2400 (broad), 1720 1600 (broad) cm-1 N.M.R. (D2O), #(ppm): 1.17-2.0 (18H, m), 3.30 (1H, broad signal), 3.80-'4.30 (2H, m) Preparation 53 (1) Step 1 EMI154.1 To a suspension of D-alanine C2.89.g) in a mixture of methylene chloride (-30 ml) and dimethylformamide (12 ml) was added bis(trimethylsilyl)acetamide (30 ml) and the mixture was stirred for is hours at room temperature to give a clear solution. To a solution of the mixed anhydride of Z-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc (1) (13.45 g) in methylene chloride (140 ml), prepared by adding N-methylmorphorine (3.03 g) and isobutyl chloroformate (4.10 g) at -15 and stirring the mixture for 40 minutes at the same temperature, was added in one portion the above solution of D-alanine trimethylsilyl ester at -400C. Then the reaction mixture was allowed to warm up to 0 C and stirred for 2 hours. The . reaction mixture was evaporated and the residue was dissolved in water, acidified with diluted hydrochloric acid and extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and concentrated to give a white powder (12.25 g) of Z-(L)-Boc-(D)-mesoDAP-(D) NHNHBoc-(L)-D-AlaOH (2). I.R (Nujol): 3300, 2600, 2400 (broad), 1720-1640 (broad) cm-1 NMR (DMSO-d6), #(ppm): 1.20-2.00 (27H, m), 3.70-4.40 (3H, m), 5.00(2H, s), 7.36(SH, s) (2) Step 2 EMI155.1 Z-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-D-AlaOH (2) (14.60 g) was dissolved in trifluoroacetic acid (20 ml) and stirred for 15 minutes at room. temperature. Trifluoroacetic acid was removed, by evaporation and the residual oil was dissolved a mixture of IN sulfuric acid (25 ml) and water (30 ml). The resulting solution was'treated with a solution of' sodium periodate (5,.60 g) in water (20 ml) under cooling in an ice-bath and kept for 1 hour at the same temperature. The reaction mixture was then treated with an aqueous sodium bisulfite solutlon until the color of the solution became clear, This solution was applied to a column of HP-20, an macroporus non-ionic adsorption resin (300 ml), which was eluted successively with water and methanol-water (1:2). Evaporation of the 'latter fractions gave a crystalline residue (6.80 g) of. Z-(L)-mesoDAP-(L)-D-AlaOH (3). m.p. #150 C (dec) I.R (Nujol): 3300, 2600-2400 (broad), 1720 (shoulder), .1700, 1640 cm 1 NMR (DMSO-d6), d #(ppm): 1.30 (3H, d, J=7Hz), 1.10- 2.30 (6H, m), 3.43 (1H, broad s), 3.80-4.50 (2H, m), 5.10 (2H, s), 7.40 (5H, s) (3) Step 3 EMI155.2 To a mixture of Z-(L)-mesoDAP-(L)-D-AlaOH (3) S. 70 g) and triethylamine (4.50 g) in water (50 ml) was added a solution 2-t-butoxycabronyloxyimino-2-phenylacetonitrile (3.55 g) in aceton (50 ml) and the mixture was stirred for 1 hour at room temperature. After standing overnight at the same temperature, the reduction mixture was concentrated and the resulting aqueous solution was . washed with ethyl acetate. - The aqueous layer was acidified with 1N hydrochloric acid and extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and evaporated to give a white foam (6.0 g) of Z-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOH (4). I.R. (Nujol): 3300, 2600-2400, 1720-1620 (broad) cm-1 NMR (DMSO-d6), #(ppm): 1.30-2.0 (18H, m), 3.70-4.3 (3H, m), 5.10 (2H, s), 7.40 (5H, s) (4) Step 4 EMI156.1 Z-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOH (4) (5.80 g) was dissolved in acetic acid (60 ml) and hydrogenated over 10 % palladium-charcoal (O.50,g). The catalyst was removed by filtration and the filtrate was evaporated to give an oily residue, which was dissolved in water (30 ml) and applied to a column of HP-20 (150 ml), a macroporous non-ionic adsorption resin. The column was eluted successively with water and methanol-water (X:7). The latter fractions were combined and evaporated to give a white powder (3.80 g) of Boc-(D)-mesoDAP-(L)-D- AlaOH (5). I.R (Nujol): 3250, 2600-2400 Cbroad), 1720 (shoulder) ,. 1670 cml NMR (D2O), #(ppm): 1.20-2.20 (18H, m), 4.00 (2H, t, J57Hz), 4.30 (1H, q, J=7Hz) Preparation' 54 (1) Step 1 EMI157.1 Z- (L)-mesoDAP- (.L)-G1yOH(2) was prepared from Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (1) in substantially the same manner as that of trepsration 27 . M. p. #210 C (dec.) I. R. (Nujol): 3300, 2600 - 2400 shoulder), 1710 (shoulder), 1680, 1640 cm N. M. R. (DMSO-d6), #(ppm): 1.10 - 2.20 (6H, m) 3.30 (1E, m), 3.65(2E, -d, J=7Ez), 4.00 (1H, m), 5.00 (2H, s), 7.30 (5H, s) EMI157.2 Z-(L)-Boc-(D)-mesoDAP-(L)-GlyOH (3) was prepared from Z-(L)-mesoDAP-(L)-GlyOH (2) in substantially the same manner as preparation 5-l. N. M. R. (DMSO-d6), #(ppm): 1.30 - 2.30 (15H, m), 3.80 (2H, d, J=7Hz), 3.80 - 4.3 (2H, m), 5.05 (2H, s), 7.40 (5H, s). EMI157.3 Boc-(D)-mesoDAP-(L)-GlyOH (4) was prepared from Z-(L)-Boc-(D)-mesoDAP-(L)-GlyOH (3) in substantially the same manner as that of Preparation 20. I.R. (Nujol): 3300, 2600-2400 ?broad) , 1680 (broad) cm 1 N.M.R. (D2O), #(ppm): 1.10 - 2.20 (15 H, m), 3.86 (2E, s), 3.80-4.20 (2E, m). Preparation 55 (1) Step 1 EMI159.1 To a solution of Z-(L)-Boc-(D)mesoDAP-(D)-NHNHBoc (1)(5.72 g) and N-methylmorpholine (1.18 g) in methylene chloride (60 ml) was added isobuthyl chloroformate (1.60 g) at -10 to'-150C, and the mixture was stirred at the same temperature for an hour. To the reaction mixture was added a solution of glycine trimethylsilyl ester (0.96 a) was added and stirred for 1.5 hours at -10 to -15 C. ,, Methylene chloride was removed in vacuo, and the residue was dissolved in a mixture of ethyl acetate (60 ml) and 2.5% hydrochloric acid. The organic layer was washed with 2.5% hydrochloric acid (50 ml) and water (50 ml) and dried over magnesium sulfate. The solvent was removed in vacuo and the residue was triturated successively with ethyl acetate (10 ml) and isopropylether - - (120 ml) and the precipitate was filtered and washed with isopropylether to give Z-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH (2)(6.1 g). NMR (CDCl3), 6(ppm) : 1.43 (18H, s), 1.3-2.1 (6H, m), 3.9-4.5 (4H, m), 5.10 (2H, s), -6.2-6.4 (4H, m), 7.10 (1H, broad s), 7.33 (5H, s), 8.95 (1H, broad s) (2) Step 2 EMI160.1 (3) was obtained in subtantially the same manner as that of .Preparntion 20. NMR'(CD3OD), #(ppm): 1,60 (9H, s), 1.63 .(9H, s), 1.7-2.0 (6H, m), 3.92 (2H,'s), 3.8-4.i (2H, m), Preparation 56 EMI160.2 D-Lac(OAc)-L-Ala-D-Asp(OH)OBzl (3) was prepared from L-Ala-D-Asp(OH)OBzl (2) and acetyl-D-lactyl chloride (1) in substantially the same manner as that of Preparation 22. m.p. 109 - 111 C (dec.) I.R. (Nujol) : 3400, 3300, 1740, 1720,1670 1550, 1520 cm-1 NMR (CDCl3), #(ppm): 1.36 (3H, d, J=7Hz), 1.45 (3H, d, J=7Hz), 2.15 (3H, s), 3.00 (2H, m), 4.4-5.4 (3H, m), 5.20 (2H, s), 7.16 (1H, d, J=8Hz), 7.33 (SH, s), 7.60 (2H, d, J=8Hz), 8.56 (1H, s) Preparation 57 EMI161.1 Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-D-Ala (1) (14.60 g) was dissolved in a mixture of acetone (60 ml) and watter '(60 ml). The pH of the solution was adjusted to about 8.0 with sodiumbicarbonate. The solution was stirred and cooled, and carbo benzyloxy chloride (5.30 g) was added thereto. The mixture was reacted for an hour at the same - temperature. Removal of acetone under reduced -pressure gave an aqueous layer which was acidified with 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate and evaporated to give Z-(L)-Boc-(D)-MesoDAP-(D)-NHNHBoc-(L)-D-Ala (2) (14.60 g). NMR (DMSO-d6), 6 (ppm) : 1.0-2.0 (27H, m), 3.70-4.50 (3H, m), 5.03 (2H, s), 6.70 (1H, d, J=7Hz), 7.20 (1H, broad), 7.33 (5H, s), 8.10 (1H, d, J=7Hz), 8.63 (1H, s), 9.63 (1H, s) Preparation 58 EMI162.1 'A solution of mesoDAP N-carboxyanhydride (1) (17.0 g) in acetonitrile (130 ml) was cooled to 10 C and a solution of carbobenzyloxyhydrazine (24.0 g) in acetic acid (80 ml) was added. The mixture was stirred for 30 minutes at the same temperature, After concentra- tion of the reaction mixture, the resulting residue was pulverized with ether to give mesoDAP-di-NHNHZ; ZACOH (2) (40.3 g) m.p 65-70 C I.R. (Nujol): 3600-2200, 1700 cm-1 NMR (CD3OC) #1.5-1.9 (6H, m), 1.92 (6H, s), 3.70 (2H, t, J=5Hz), 5.13 (4H, s), 7.38 (10H, s) Acetic acid salt of mesoDAP-di-NHNHZ was dissolved in water, and neutralized with 1N sodium hydroxide and then the resulting oil was crystallized from water to give mesoDAP-di-NHNHZ. m.p. 93-95 C I.R. (Nujol) : 3260, 1750, 1720, 1660 cm 1 NMR(CD3OD), #1.5-1.8 (6H, m), 3.30 (2H, m), 5.13 (4H, s), 7.35 (10H, s) Preparation 59 EMI163.1 A solution of mesoDAP-di-NHNHZ (1) 40.2 g) in a mixture of water (1.2 t) and (0.6 l) was adjusted to pH 8.5 with 1N sodium hydroxide. To this solution was added leucine amino peptidase (from hog kidney) (Boehringer Manheim GmbH) (20 mg) and the mixture was shaken for 6 hours at 370C. After evaparation of methanol, the resulting aqueous layer was washed with ethyl acetate and concentrated to about 200 ml. The concentrate was applied to a column of HP-20 resin (800 ml). The column was washed with water and eluted with 50%':aqueous methanol. - The eluate was evaporated and the residue was pulverized with ether to give mesoDAP-(D)-NHNHZ (2) (15.0 g) m.p. 205-209 C (dec) I.R. (Nujol): 3600-2200, 1720, 1640, 1580 cm 1 NMR (CD3OD), 8 1.4-2.1 (6H, m), 3.50 (2H, m), 5.17 (2H, s), 7.40 (SH, s) Preparat'ion 60 EMI163.2 To a suspension of mesoDAP-(D)-NHNHZ (1.40 g) in methylene chloride (30 ml) was added bis(trimethylsilyl)- acetamide (6 ml) and the mixture was stirred for 1 hour at room temperature. The resulting solution was cooled to -15 C and carbobenzyloxy chloride (2.00 g) was added. After stirring for 1 hour at the same temperature, the mixture was poured into a mixture of ethyl acetate (100 ml) and 2.5% hydrochloric acid (50 ml). The organic layer was separated, washed with saturated aqueous solution of sodium chloride, dried over magnesium sulfate and evaporated. The residue was crystallized from chloroform to give di-Z-mesoDAP-(D)-NHNHZ (2) (2.20 m.p. 139-141 C I.,R. (Nuj 1): 3300, 1740, 1720, 1695, 1660 cm 1 NMR (CD3OD), #: 1.40-2.0 (6H, m), 4.10 (2H, m), 5.10 (6H, s), 7.33 (15H, s) EMI164.1 di- Z-mesoDAP- (D) -NtrINHZ (1) 0.40 g) was added to thionyl chloride (4 ml) and the mixture was stirred for 30 minutes at room temperature. Evaporation gave Z-(D)-mesoDAP-(D)-NHNHZ-(L)-N-carboxyanhydride (2) as an oil. I.R. (CH2Hl2): 3400, 3270, 1850, 1780, 1700 cm-1 Preparation '62 EMI165.1 Z-(D)-mesoDAP-(D)-NHNHZ-(L)-N-carboxyanhydride (1), prepared from 0.40 g of di-Z-mesoDAP-(D)-NHNHZ as described above in Preparation 60, was dissolved in a mixture of acetic acid. (4 ml) and 1N hydrochloric acid (2 ml) and the mixture was stirred. for 6 hours a't room temperature. The reaction mixture was concentrated and the residue was dissolved in water (3 ml) and neutralized with dilute aqueous sodium bicarbonate. The precipitated crystalline solid .was filtered and washed with water to give Z-(D)mesoDAP (D)-NHNHZ (2) (0.25 g) m.p. 205-209 C (dec) I.R. (Nujol) #: 3300, 1715, 1690, 1665, 1605 cm-1 NMR (CF3COOH), #: 1.6-2.5 (6H, m), 4.43 (2H, m) 5.20 (2H, s),.'5.25 (2H, s), 7.38 -(1OH, s). Preparation 63 EMI166.1 A mixture of glycine (80 mg) and sodium carbonate ( 200 mg) in a mixture of 1N sodium hydroxide (1 ml) and water (S ml) was cooled to -50C and a solution of Z-(D)-mesoDAP-(D)-NHNHZ-(L)-N-carboxyanhydride, prepared from di-Z-mesoDAP-(D)-NHNHZ (1) (602 mg), in acetonitrile (5 ml) was added. The mixture was stirred for 2 hours at the same temperature and overnight at room temperature. The aqueous layer was separated and the organic layer was extracted with 2% aqueous sodium chloride (5 ml). The aqueous layers were combined and neutralized with 1N hydrochloric acid. The precepitated crystalline solid,was filtered and washed with water to give Z-(D) mesoDAP-(D)-NHNHZ-(L)-GlyOH (2) (120 mg) m.p. 204-7 C (dec) I.R. (Nujol): 3600-2200, 3250, 1720, 1700, 1690, 1660 cm-1 NMR (CF3CO2H) #: 1.5-2.5 (6H, m); 4.0-4.6 (4H, m), 5.30 (4H, s), 7.38 (10H, s) . , Preparation 64 EMI166.2 A solution of phenylhydrazine (4.30 g) in acetic acid (10 ml) was cooled to 10 C and a solution of mesoDAP N-carboxyanhydride (4.80 g) in acetonitrile (35 ml) was added. The mixture was stirred for 1 hour at the same temperature and the solvent was evaporated.. The residue was pulverized with ether to give mesoDAP- di-NHNHC6HS (acetic acid salt) (2) (10.10 g). The compound (2) was dissolved in a mixture of water (300 ml) and methanol (150 ml) and the pH was' adjusted to 8.5. This solution was treated with leucine amino peptidase (from Hog Kidney) ,(5 :mg) at 37 C for 5 hours. After evaporation of methanol, the resulting aqueous layer was washed with ethyl acetate and concentrated to about 100 ml. The concentrate was applied to a columnof,HP-20 resin (200 ml). The column was eluted with 50% aqueous methanol,': The eluate was evaporated to give mesoDAP-(D)-NHNHC6H5 (3)' (2.50 g) I.R. (Nujol) - 3600-2200, 1640, 1600 cm NMR (CF3CO2H) 6: 1.9-2.6(6H ), - 4.0-4.5 (2H, m), 7.43 (SH, s). Preparation 65 EMI167.1 A mixture of mesoDAP-(D)-NHNHZ (1) (3.38 g) and cupricchloride dihydrate (853 mg) in 0.25 N sodium hydroxide (50 ml) was cooled to 0 C and di-t-'butyldicarbonate (2,83 g) was added. The mixture was stirred for 2 hours at the same temperature, during which time the pH of the reaction mixture was maintained at 9.5-10.0 by adding IN sodium hydroxide. Hydrogen sulfide was bubbled into the mixture for 10 minutes andthe precipitate was filtered off. The filtrate was nentralized to pH.5 with 1N hydrochloric acid: and washed with ethyl acetate. The aqueous layer was concentrated to about 10 ml and stood overnight at 5 C. The precipitated crystalline solid was filtered and washed with water to give Boc-(L)-mesoDAP-(D)-NHNHZ (2) (2.92 g) m.p. 201-3 C (dec) I.R. (Nujol) : 3300, 3280, 1725, 1700 cm-1 NMR (CD3OD) #: 1.40 (9H, s), 1.3-2.1 (6H, m), 3.8-4.1 (2H, m), 5.17 (2H, s), 7.38 (5H, s). Preparation 66 (1) Step 1 EMI169.1 Z-(L)-mesoDAP-(L)-D-AlaOH (1) 1.80 g) was suspended in a mixture of methylene chloride (60 ml), bis (trimethylsilyl)acetamide (5.60 g) and dimethylformamide (6 ml). The suspension was stirred for 4 hours at ambient temperature and treated with trifluoroacetic anhydride ,(l.0 g) and further stirred for an hour. The reaction mixture was concentrated under reduced pressure and the residual oil was extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate and then evaporated to give Z-(L)-Tfa-(D)-mesoDAP-(L)-D-AlaOH (2). NMR (DMSO-d6), #(ppm): 1.18 (3H, d, J=7Hz), 1.10-2.0 (6H, m), 3.90-4.30 (3H, m), 5.03 (2H, s), 7.33 (5H, s), 8.18 (1H, d, J=7Hz), 9.55 (1H, d, J=7Hz) (2) Step 2 EMI169.2 Tfa-(D)-mesoDAP-(L)-D-AlaOH (3) was prepared in substantially the same manner as Preparation 25 from compound (2). IR (Nujol) : 3250, 2600-2400 (broad), 1700, 1670 NMR (D20), 6(ppm) : 1.33 (3H, d, J=7Hz), . 1.20-2.20 (6H, m), 3.83-4.43 (3H, m) Preparation 67 (1) Step 1 EMI170.1 Z-(L)-Tfa-(D)-mesoDAP-(L)-GlyOH (2) was prepared in substantially the same manner as step 1 of Preparation 66 from compound (1). NMR (DMSO-d6), &gamma;(ppm), : 1,10-2.10 (6H, m), 3.73 (2H, d, J=7Hz), 3.90-4.50 (2H, m), 5.06 (2H,'s'), 7.33 (5H, s), 7.0-7.30 - (lH, broad); 8.13 (1H, t, J=7Hz), 9.56 (1H, d, J=7Hz) (2) Step 2 EMI170.2 Tfa-(D)-m,esoDAP-(L)-GlyOH (3) was prepared in substantially the same manner as Preparation 25 from compound (2). IR (Nujol) : 3250 (shoulder) , 2600-2300 (broad), 1720 (shoulder), 1700, 1680 (shoulder), 1210, 1180, 1150 cm 1 NMR (D2O), &gamma;(ppm) : 1.20-2.20 (6H, m), 3.90 (2H, s), 4.00-4.50 (2H, m) Preparation 68 EMI171.1 D-Glu(&alpha;-oBzl)(1)(4.74)g) was added to a mixture of methylene chloride (50 ml) and bis (trimethylsylyl) acetamide (4.10 g). The mixture was stirred until a clear solution was obtained and n-octanoyl chloride (3.17 g) was added dropwise thereto. The mixture was reacted for an hour at ambient temperature and then evaporated to give an oily residue to which water was added. The mixture was extracted with ethyl acetate a -and the extract was washed with water, dried over magnesium sulfate and then evaporated to give a crystalline residue (7.10 g). The residue was recrystallized from diisopropyl ether to give n-octanoyl-D-Glu(DH)oBzl (2) (6.0 g). NMR (CD.Cl3), &gamma;(ppm) : 0.87 (3H, t, J=7Hz), 1.0-2.60 (16H, m), 4.50-5.10 (1H, m), 5.20 (2H, s), 6.35 (1H, d, J=7Hz), 7.40 (SH, s), 9.90 (1H, broad s) The following compounds were prepared in substantially the same manner as Preparation 68. Preparation 69 n-Heptanoyl-D-Glu(OH)oBzl. NMR (CD Cl3), 6 (ppm) : 0.86 (3H, t, J=7Hz), 1.0-2.60 (14H, m), 4.50-5.10 (1H, m), 5.16 (2H, s), 6.45 (1H, d, Jz7Hz), 7.35 (5H,.s), 10.00 (1H, s) Preparation 70 Phenoxyacetyl-D-Glu(OH)oBzl NMR (CDCl3), &gamma; &gamma;(ppm) : 1.80-2.56 (4H, m), 4.50 (2H, s), 4.50-5.10 (1H, m), 5.20 (2H, s), 6.80-7.20 (5H, m), 7.35 (5H, s), 9.40 (1H, broad s) Preparation 71. D-Acetylmandelyl-D-Giu(OE) oBzl' NMR (CDCl3)@ &gamma;(ppm) : 1.90-2.50 (4H, m), 2.10 (3H, s), 4.20-4.8O (1H, m), 5,10 (2H, s), 6.00 (1H, s), 7.20-7.50 (10H, m) Preparation 72 n-Hexanoyl-D-Glu(OH)oBzl NMR (CDCl3), &gamma;(ppm) ; 0.90 (3H, t, J=7Hz),$(1H, 1.0-2.70 (2H, m), 4.50-5.0 1H, m), 5.17 (2H, s), 6.50 (1H, d, J=7Hz), 7.37 (5H, s), 10.60 (1H, s) Preparation 73 N-Phenylcarbamoyl-D-Glu(OH)oBzl@ NMR (DMSO-d6), &gamma;(ppm) : 1.70-2.50 (4H, m), 4.15-4.60 (1H, m), 5.13 (2H, s), 6.57 (1H, d, J=8Hz), 6.70-7.60 (10H, m), 8.50 (1H, s) Preparation 74 O-Benzylsalicyloyl-D-Glu(OH)oBzl NMR (CDCl3), &gamma;(ppm) : 0.83-2.30 (26H, m), 2.83 (2H, broad s), 4.70-5.0 (1H, m), 5.13 (2H, s), 5.20 (2H, s), 7.0-7.68 (14H, m) Preparation 75 D-Lac(oAc)-D-Glu(OH)oBzl dicyclohexylamine salt NMR (CDCl3), &gamma;(ppm) : 0.80-2.40 (26H, m), 1.43 (3H, d, J=7Hz), 2.10 (3H, s), 2.90 (2H, broad s), 4.40 (1H, q, J=7Hz), 5.17 (2H, s), 5.17 (1H, q, J=7Hz), 7.40 (5H, s), 7.90 (1H, d, J=7Hz), 9.10 (1H, s) Preparation 76 Nicotinoyl-D-Glu(OH)oBzlo NMR (DMSO-d6), &gamma;(ppm) : 1.83-2.67 (4H, m), 4.40-4.85 (1H, m), 5.20 (2H, s), 7.40 (5H, s), 7.50-7.70 (1H, m), 8.10-8.40 (1H, m), 8.67-9.20 ((3H, m) Preparation 77 EMI174.1 To a mixture of bis(trimethylsilyl)acetamide (2.4 ml) and methylene chloride (25 ml) was added Boc-(L)mesoDAP-(D)-NHNHZ (l)(l.0 g). The resulting mixture was stirred for two hours at ambient temperature and cooled to; 15 C and then carbobenzyl chloride (505 mg) was added thereto. The reaction mixture was stirred for an hour at ambient temperature and concentrated to about 5 ml. To the concentrate were added ethyl acetate (30 ml) and 2% hydrochloric acid (10 ml). Ethyl acetate layer was separated and washed with water and dried over magne- sium sulfate. Ethyl acetate. was evaporated to dryness under reduced pressure and the residue was pulverized with isopropylether to give Boc-(L)-Z-(D)-mesoDAP-(D)- NHNHZ (2)(0.60 g). NMR (CD3OD), 6(ppm) : 1.43 (9H, s), 1.3-2.1 (6H, m), 3.9-4.3 (2H, m), 5.08 (2H, s), 5.13 (2H, s), 7.32 (lOH, s). Preparation 78 EMI175.1 Boc-(L)-Z-(D)-mesoDAP-(D)-NHNHZ (1) (500 mg) was dissolved in trifluoroacetic acid (5 ml) and the solution was stirred for 15 minutes at ambient temperature. After evaporation of trifluoroacetic acid, the residue was dissolved in water (3 ml) and neutralized with 5% sodium bicarbonate. The resulting crystal was filtered and washed with water to give Z-(D)-mesoDAP (D)-NHNHZ (2)(280 mg), which was identical with that of product prepared in P'reparation 62. Preparation 79 EMI175.2 To a solution of 50% aqueous dioxane (20 ml) were added Z-(D)-mesoDAP-(D)-NHNHZ (1)(.500' mg) and triethylamine (250 mg). Di-tert-butyldicarbonate (300 mg) was added to the mixture. The resulting mixture was stirred for three hours at ambient temperature and then evaporated. The resulting aqueous solution was acidified to pH 3 with 5% hydrochloric acid and extracted with ethyl acetate (30 ml). Ethyl acetate layer was separated and the residue was washed with water, dried over magnesium sulfate. Ethyl acetate was evaporated to dryness under reduced pressure and the residue was pulverized with isopropyl ether to give Boc-(L)-Z-(D)mesoDAP-(D)-NHNHZ (2)(0.47 g), which was identified with that of the product prepared in Preparation 77. Preparation 80 (1) Step 1 EMI176.1 Z-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-&gamma;-AbuoBzl (2) was prepared in substantially the same manner as step 1 Df Preparation 43 from compound (1). NMR (DMSO-d6), < (ppm) : 0.9-2.0 (26H, m), 2.3 (2H, m), 2.9-3.4 (2H, m), 3.6-4.2 (2H, m), 5.02 (2H, s), 5.09 (2H, s), 6.7 (1H, m), 7.2 (1H, m), 7.35 (10H, s), 7.80 (1H, m), 8.65 (1H, m), 9.58 (1H, broad s). (2) Step 2 EMI177.1 Boc- (D) -mesoDAP- (D) -NHNH.Boc-(L)- Y-AbuOH (3) was prepared in substantially the-same manner as step 2 of Preparation 43 from compound (2). NMR (D2O), < (ppm) : 1.0-2.6 (10H, m), 3.28 (2H, t, J-6.SHz), 3.7-4.3 (2H, m). Preparation 81 (1) Step 1 EMI177.2 Z-(L)-Boc-(D)-mesoDAP-(D)-NHNH.Boc-(L)-D-LeuOH (2) was prepared in substantially the same manner as step 1 of Preparation 43 from compound (1). NMR (DMSO-d6), 6 (ppm) : 0.6-2.0 (33H, m), 3.6-4.6 (3H, m), 5.01 (2H, s), 5.10 (2H, s), 6.7 (1H, m), 7.2 (1H, m), 7,34 (10H, s), 8.1-8.9 (2H, m), 9.57 (1H, broad s). (2) Step 2 EMI178.1 (3) Boc-(D)-mesoDAP-(D)-NHNH.Boc-(L)-D-LeuOH (3) was prepared in substantially the same manner as step 2 of Preparation 43 from compound (2). IR (Nujol) : 1680 (broad) and 1540 (broad) cm 1 NMR (CD3OD), < (ppm) : 1.0 (6H, m), 1.50 (18H, s), 1.2-2.3 (9H, m), 3.6-4.6 (3H, m). Preparation 82 EMI178.2 Heptanoyl-ss-D-Asp(OH)oBzl (3) was prepared in substantially the same manner as Preparation 56 from compounds (1) and (2). NMR (CDCl3), < (ppm) : 0.7-1.0 (3H, m), 1.0-2.0 (8H, m), 2.95 (t 2H, 4Hz), 4.90 (t,t, 1H, 4Hz, 8Hz), 5.14 (2H, s), 6.72 (1H, 8Hz), 7.25 (SH, s), 10.00 (1H, s). Preparation 83 EMI179.1 Heptanoyl-#-D-Aad(=H)8Bzl (3) was prepared in substantially the same manner as Preparation 56 from compounds (1) and (2). (as dicyclohexylamine salt) N.M.R. (CDCL3), #(ppm) : 0.7-1.1 (3H,m), 1.1-2.5 (34H, m), 2.5-3.1 (2H, m), 4.3-4.8 (1H, m), 5.13 (2H,s), 6.60 (1H, d, J=8Hz), 7.33 (5H,s) 8.50 (3H, s) Preparation. 84 EMI179.2 Mandelyl (oAc)-#-D-Aad(OH)oBzl {3) was prepared in substantially the same manner as Preparation 56 from compounds (1) and (2). NMR (CDCL3), #(ppm) : 1.5-2.0 (4H, m), 2.13 (3H, s), 2.0-2.5 (2H, m), 4.4-4.8 (1H, m), 5.13 (ZH, s), 6.07 (1H, s), 6.7-7.0 (1H, m), 7.33 (1OH, s), 9.33 (1H, broad s). Preparation 85 EMI180.1 L-Ala-D-Glu(OH)oBzl (1) (942 mg) was suspended in methylene chloride (40 m1), and bis (trimethylsilyl) acetamide (1.20 g) was added to the suspension under stirring. The resulting s,olution was treated with stearoyl chloride (900 mg) at ambient temperature and left for an hour. Evaporation of the solvent gave an oily residue which was treated with water to give white solides The solides were collected by filtration, washed with water and dried over magnesium sulfate to give stearoyl-L-Ala-D-Glu(OH) OBzl (2) (1.60 g) IR(Nujol) : 3300, 2700-2500 (broad), 1720, 1710, 1660 (sh), 1640 cm-1 NMR(Pyridine-d5) : # 0.90 (3H,m), 1.0-3.0 (36H,m); 1.55 (3H, d, J=7Hz), 4.90-5.40 (2H,m); 5.23 (2H,s) Preparation 86 EMI180.2 S tearoyl-L-Ala-D- Glu (OB) OBzl (1) (1.41 g) and Nhydroxysuccimide (280 mg) were dissolved in tetrahydrofuran (50 ml). To the solution was added N,N'-dicyclo- hexylcarbodiimide (500 mg) under ice-cooling and the resulting solution was left in a refrigerator overnight. The precipitates separated were filtered and the filtrate was evaporated to give a white solid, which was recrystallized from a mixture Of isopropylalcohol and isopropyl ether to give stearoyl-L-Ala-D-Glu (&alpha;-OBzl)OSu (2) (1.45 g). IR(Nujol) : 3300, 1805, 1780, 1740, 1660 (sh), 1640 cm-1 NMR(CDC13) : # 0.87 (3H, m), 1.0-2.90 (39E, m), 2.80 (4E, s), 4.20-4.80 (2H, m), 5.17 (2H,s), 6.20 (1H, d, 7Hz), 7.37 (5H,s) Preparation 87 2-Hexadecyloctadecanoyl-L-Ala-D-Glu(OH)OBzl was prepared in substantially the same manner-as that of Preparation 85. IR(Nujol) : 3300 (sh), 3280, 1740 (broad), 1640 (sh), 1625 cm NMR(CDCL3) : # 0.83-2.67 (73H,m), 4.33-5.00 (2H,m), 5.15 (2H, s), 6.42 (2H, d, J=8Hz), 7.16(5H,s) Preparation 88 2-Hexadecyloctadecanoyl-L-Ala-D-Glu(&alpha;-OBzl)(&gamma;-OSu) was prepared in substantially the same manner as that of Preparation 86. IR(Nujol) ': 3300, 1810, 1780, 1740, 1650 (sh), 1635 cm NMR(CDCL3) : # 0.67-2.83 (73H, m), 2.80 (4E, s), 4.40-4.86 (2E, m), 5.16 (2H, s), 6.60 (2E, d, J=7Ez), 7.16 (5E, s) Preparation 89 Stearoyl-D-Glu(OH)OBzl was prepared in substantially the same manner as that of Preparation 85. IR(Nujol) : 3300, 1750, 1710, 1650 cm-1 NMR(CDCL3) : 6 0.87 (3E, m), 1.0-2.70 (34E, m), 4.50-5.00 (1H,m), 5.17 (2H,s), 6.33 (1H, d, J=8Hz), 7.33 (5H,s), 10.30 (1H,s) Prepration 90 Stearoyl-D-Glu(&alpha;-OBzl)OSu was prepared in substantially the same manner as that of Preparation 86. IR (Nujol) : 3300, 1810, 1780, 1740, 1650 cm-1 NMR(CDCL3) : #0.87 (3H,m), 1.0-2.80 (36H,m), 2.76 (4H, s), 4.50-5.00 (1H, m), 5.16 (2H,s), 6.32 (1H, d, J=8Hz), 7.33 (5H,s) Preparation 91 2-Hexadecyloctadecanoyl-D-Glu(OH)OBzl was prepared in substantially the same manner as that of Preparation 85v IR(Nujol) : 3280, 1740, 1710, 1640 cm NMR(CDCL3) : # 0.83-2.63 (70H,m), 4.33-5.00 (1H,m), 5.15 (2H,s), 6.20 (1H, d, J=7Hz) 7.30 (5E, s) Preparation 92 2-Hexadecyloctadecanoyl-D-Glu(&alpha;-OBzl) OSu was prepared in substantially the same manner as that of Preparation 86. IR(Nujol) : 3300, 1810, 1780, 1745, 1640 cm-1 NMR(CDCL3) : 6 0.83-2.83 (71E, m), 2.80 (4H, s), 4.50-5.00 (1H,m), 6.20 (1H,d, J=7Hz), 7.35 (5H,s) Preparation 93 2-Docosyltetracosanoyl-L-Ala-D-Glu(OH)OBzl was prepared in substantially the same manner as that of Preparation 85. IR(Nujol) : 3270, 1740, 1640 (sh), 1625 cm-1 NMR(CDCl3) : 6 0.67-2.50 (98E, m), 4.40-4.80 (2E, m), 5.10 (2H, s), 6.16-6.40 (2E, m), 7.28 (5H, S) Preparation 94 2-Docosyltetracosanoyl-L-Ala-D-Glu(&alpha;-OBzl)OSu was prepared in substantially the same manner as that of Preparation 86. IR(Nujol) : 3300, 1815., 1780, 1750, 1650 (sh), 1640 cm-1 NMR(CDCL3) : (2H, 0.67-3.00 (98H, m), 2.76 (4H, s), 4.40-4.83 (2H, m), 5.13 (2E, s), 6.13 (2H, d, J=7Hz), 7.30 (5E, s) Preparation 95 2-Docosylttracosanoyl-D-Glu(OH)OBzl was prepared in substantially the same manner as Preparation 85. IR(Nujol) : 3250, 2600 (broad sh), 1740, 1710, 1640 cm-1 -NMR(CDCL3) : 0.67-2.83 (95H, m), 4.50-5.00 (lH, m), 5.20 (2H, s), 6.20 (lH, d, J=7Hz), 7.36 (5H, s) Preparation 96 2-Docosyltetracosanoyl-D-Glu (&alpha;-OBzl) OSu was prepared in substantially the same manner as that of Preparation 86. IR(Nujol) : 3300, 1810, 1780, 1740, 1640 cm-1 NMR(CDCL3) : # 0.68-2.87 (96E, m), 2.87 (4E, s), 4.50-5.00 (1H, m), 5.20 (2E, s), 6.25 (1H, d, J=7Hz), 7.36 (5H,s) Preparation 97 EMI184.1 To a solution of Boc-(L)-Z-(D)-mesoDAP-(D)-NHNHBoc (1) (2.16 g) and N-methylmorpholine (404 mg) in methylene chloride (40 ml) was added isobutylchloroformate (546 mg) at -10#-15 C. The mixture was stirred for 30 minutes at ambient temperature. A solution of D-AlaOEt, prepared from D-AlaOEt hydrochloric acid salt (614 mg) and N-methylmorphorin (404 mg) by. stirring 10 minutes in methylene chloride at ambient temperature, was added to the mixture. The resulting mixture was stirred for 1.5 hours at -10#-15 C. Methylene chloride was evaporated in vacuo and the residue was dissolved in a mixture of ethyl acetate (100 ml) and 2.5% hydrochloric acid (50 ml). The organic layer was separated and washed ,with water (50 ml) and 2% sodium bicarbonate (50 ml), dried over magnesium sulfate and then the solvent was evaporated in vacuo. The residue was crystallized from ether (30 ml) to give Boc-(L)-Z-(D)-mesoDAP-(L)-D- AlaOEt-(D)-NHNHBoc (2) (2.2 g). IR(Nujol) : 3300, 3230, 1720, 1705, 1675, 1645, 1630 cm-1 NMR(CD3OD), , # # : 1.45 (18E, s), 1.2-2.20 (12E, m), 4.0-4.6 (5H,m), 5.13 (2H,s), 7.37 (10E, s) Preparation 98 EMI185.1 Boc- (L) -Z- (D) -mesoDAP- (L) -GlyOEt- (D) -NENEBoc (2) was prepared in substantially the same manner as that of Preparation 97. IR(Nujol) : 3270, 1670 (broad), 1240, 1160, 1040, 1020, 860 NMR(CD3OD), 6 : 1.28 (3E, t, J=7Hz), 1.48 (18H, s), 1.4-2.0 (6H,m), 3.98 (2H,s), 4.20 (2H, q, J=7Hz), 3.9-4.2 (1H,m), 5.10 (2H,s), 7.35 (5H,s) Preparation 99 EMI185.2 Boc- (L) -Z- (D) -mesoDAP- (L)-GlyOMe- (D) -NHNHBoc (2) was prepared in substantially the same manner as that of Preparation 97. IR(Nujol) : 3300, 3230,1730, 1710, 1680, 1650, 1640 cm-1 NMR(CD3OD), # : 1.47 (18H,s), 1.4-2.0 (6H,s), 3.68 (3H,s), 3.94 (2H,s), 3.9-4.3 (2H, m), 5.04 (2H, s) , 7.30 (5H,s) Preparation 100 EMI186.1 Boc-(L)-Z-(D)-mesoDAP-(L)-D-AlaOme-(D)-NHNHBoc (2) was prepared in substantially the same manner as that of Preparation 97. IR(Nujol) : 3300, 3230, 1725, 1705, 1680, 1645, 1630 cm-1 NMR(CD3OD), # : 1.33 (3E, d, J=7Ez), 1.48 (18E, s), 1.4-2.1 (6H,m), 3.67 (3H,s), 3.8-4.3 (2H,m), 4.35 (1H, q, J=7Hz) 5.02 (2H,s), 7.30 (5H,s) Preparation 101 EMI186.2 Z-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOEt-(D)-NHNHBoc (2) was prepared in substantially the same manner as that of Preparation 97. IR(Nujol) : 3300, 3220 (schoulder), 1735, 1710, 1680, 1645, 1630 cm 1 NMR(CD3OD), 6 : 1.23 (3H, t, J=7Hz), 1.37 (2E, d, J=7Hz), 1.40 (9E, s), 1.4-2.0 (6H, m), 3.9-4.6 (5H,m), 5.10 (2H,s), 7.33 (5E, s) Preparation 102 EMI187.1 Z- (L) -Boc- (D) -mesoDAP- (L) -D-AlaOEt- (D) -NHNHBoc (1) (0.5 g) was added to trifluoroacetic acid (5 ml) and the mixture was stirred for 30' minutes at ambient temperature. After evaporation of trifluoroacetic -acid,-the residue was dissolved in ethanol (10 ml) and the solution was cooled to 0 C. To the solution was added N-bromosuccinimide (420 mg) and the mixture was stirred for 10 minutes at 0 C. Ethanol was evaporated in vacuo and the residue was dissolved in water (10 ml). The solution was cooled to OOC and the excess reagent was decomposed with aqueous sodium bisufite. The mixture was neutralized to pH 8.0 with sodium bicarbonate and extracted with methyl acetate (30 ml). The extract was dried over magnesium sulfate and 2N hydrochloric acid in ethyl acetate (4 ml) was added to the extract. The solvent was evaporated in vacuo and the residue was crystallized from ether to give hydrochloric acid salt of Z-(L)-mesoDAP-(L)-D-AlaOEt- (D)-OEt (2) (280 mg). IR(Nujol) : 3280, 1730, 1690, 1650 cm NMR (CD30D), 6 : 1.23 (3E, t, J=7Hz), 1.30 (3H, t, J=7Hz), 1.35 (3H,d, J=7Ez), 1.5-2.1 (6E, m), 3.9-4.6 (7H, m), 5.10 (2H, s), 7.32 (5E, s) Preparation 103 EMI188.1 Z- (D) -mesoDAP- (L) -GlyOMe- (D) -OMe hydrochloric acid salt (2) was prepared in substantially the same manner as that of Preparation 102. IR(CHCL3) : 1745, 1720, 1680 cm-1 Preparation 104 EMI188.2 z-(D)-mesoDAP-(L)-D-OEt hyodrochloric acid salt (2) was prepared in substantially the same manner as that of Preparation 102. IR(Nujol) : 3300, 1725, 1680, 1655 NMR(CD3OD) 6 : 1.1-2.0 (15E, m), 3.9-4.5 (7H, m), 5.08 (2E, s), 7.32 (SE, s) Preparation 105 EMI189.1 Z- (D) -mesoDAP- (L) -D-AlaOMe- (D)-OMe hydrochloric acid salt (2) was prepared .in substantially the same manner as that of Preparation 102. NMR(CD3CD), 6 : 1.42 (3H, d, J=7Hz), 1.4-2.0 (6H, m), 3.72 (6E, s), 3.95 (1H, t, J=6Hz), 4.23 (1H, t, J=6HZ), 4.47 (1H, q, J=7Hz), 5.10 (1H,s), 7.38 (5H,s) Preparation 106 EMI189.2 To a solution of bis(trimethyösilyl) acetamide (15 ml) and methylene chloride (60 ml) was added Boc-(L) mesoDAP-(D)-NENEBoc (1) (6.08 g). . The mixture was stirred for an hour at ambient temperature and cooled to OOC and carbobenzyloxy chloride (5.1 g) was added thereto. The resulting mixture was stirred for an hour at ambient temperature. After evaporation of methylene chloride, the residue was poured into a mixture of ethyl acetate (60 ml) and 2.5% hydrochloric acid (50 ml). The organic layer was separated and washed with aqueous sodium chloride, dried over magnesium sulfate and then evaporated. The residue was pulverized with isopropyl ether to give Boc-(L)- Z-(D)-mesoDAP-(D)-NHNHBoc (2) (5.4 g). NMR(CD3OD), # :1.43 (18H,s), 1.42-2.0 (6H,m), 3.9-4.3 (2H,m), 5.08 (2H,s), 7.32 (5H,s) IR(Nujol) : 3270, 3100-2200, 1690, 1370, 1240, 1160, 1050, 1020 cm-l Preparation 107 EMI190.1 Diz-mesoDAP-(L)-D-AlaOEt-(D)-OEt (2) was prepared in substantially the same manner as that of Preparation 106. [&alpha;]D = +16.3 (C=1, MeOH) IR(Nujol) : 3300, 1740 (schoulder), 1730,1685, 1650 cm 1 NMR(CD3OD), 6 : 1.20 (6E, t, J=7Ez), 1.37 (3H, d, J=7Hz), 1.4-2.0 (6H,m), 4.0-4.5 (7E, m), 5.10 (4E, s), 7.33 (10H, s) Preparation 108 EMI190.2 Diz-mesoDAP-(L)-(D)-AlaOET-(D)-OET (2) was prepared in substantially the same manner as that of Preparation 106. This compound was identified with the product prepared in Preparation 107. Preparation 109 EMI191.1 Z- (L) -Boc- (D) -mesoDAP (2) was prepared in substantially the same manner as that of Preparation 106. IR(Nujol) : 3300, 2600 (broad, sh), 1750-1650 '-1 (broad) cm 1 # : 1.20-2.0 (15H,m), 3.63-4.16 (2H,m), 5.06 (2H,s), 6.93 (1H, d, J=8HZ), 7.33 (5H, s) Preparation 110 EMI191.2 O-acetylbenziloyl-D-Glu (OH) OBzl (2) was prepared in substantially the same manner as that of Preparation 85. NMR(CDCL3), # : 2.16 (3H,s), 1.9-2.5 (4H,m), 4.5-4.9 (13, m), 5.16 (2H, s), 7.03 (13, d, J=8Ez), 7.1-7.7 (lSH, m), 9.55 (1H,s) IR(film) : 1730, 1680, 1510, 1210, 1025, 750, 695 Preparation 111 EMI192.1 Diphenylacetyl-D-Glu(OH)OBzl (2) was prepared in substantially the same manner as that of Preparation 85. NMR(CDCL3), # :1.7-2.5 (4H,m), 4.5-4.9 (1H,m), 4.95 (1H,s), 5.10 (2H,s), 6.37 (1H, d, J=8Ez), 7.23 (10E, s), 7.30 (5H, s), 9.40 (1H,s), IR(CHCL3),: 3400, 1730, 1710, 1670, 1490 cm 1 Preparation 112 EMI192.2 Cinnamoyl-D-Glu(OH)OBzl (2) was prepared in substantially the same manner as that of Preparation 85. NMR(CDCL3), # : 1.9-2.7 (4H,m), 4.7-5.0 (1H,m), 5.17 (2H,s), 6.43 (1H, d, J=16Hz), 6.74(1H, d, J=8Ez), 7.30 (10E, s), 7.63 (1H, d, J=16Hz), 10.07 (1H,s) IR(Nujol) : 3300, 1735, 1690, 1650, 1620, 1525, 1280, 1205, 975, 750, 695 cm Preparation 113 EMI193.1 Adamantane-l-carbonyl-D-Glu (OH) 03zl (2) was prepared in substantially the same manner as that of Preparation 85. NMR(CDC13), 6 : 1.5-2.6 (19H, m), 4.5-4.9 (lH, m), 5.16 (2H,s), 6.52 (1H, d, J=8Hz), 7.33 (5H,s), 9.80 (1H,s) IR (filrn) : 4300, 1730, 1710, 1630, 1520, 1210 cm Preparation 114 EMI193.2 Z-(L)-BOc-(D)-mesoDAp (1) was dissolved in acetic acid (50 ml) and hydrogenated over palladium black (450 mg) at ambient' temperature. The catalyst was removed by filtration and the filtrate was evaporated in vacuo to give a white solid. The solid was dissolved in water (100 ml) and chromatographed on a column of macroporous non-ionic adsorption resin, HP 20 (200 ml). The column wa's eluted successively with water and 50% aqueous methanol. The latter fractions were combined and evaporated to give Boc-(D)-mesoDAP (2) (3.80 g). IR (Nujol) : 3400, 2600 (broad),, 1710, 1640, 1580 cm 1 NMR (D20) :61.16-2.16 (15H, m), 3.60-4.20 (2H, m) Example 1 step Step 1 EMI195.1 L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc- (L)-GlyOH (1) (662mg.) was dissolved in 50% aqueous acetone C8 ml.) and sodium bicarbonate (168 mg.) was added to the solution. To the mixture was added propionic chloride (408 mg.) at 0 C and the resulting mixture was reacted at the same temperature for an nor, maintaining the pH 7-8 with sodium bicarbonate. The reaction mixture was adjusted to pH 3.0 with 1N hydrochloric acid and concentrated to about 2 ml. in vacuo. To the resulting residue were added ethyl acetate (150 ml.), methanol (10 ml.) and brine (30 ml.). The organic layer was separated, dried over sodium sulfate and then concentrated to dryness in tacuo. The concentrate was treated with ether to give propionyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-GlyOH (2) (400 mg) as a white powder. IR(Nujol) : 3250, 1720(sholder), 1650 cm-1 NMR(CD3OD), #(ppm) : 1.0 # 2.5 (36H,m), 3.97(2H,s), 3.90 # 4.60(4H,m) Step (2) EMI196.1 Trifluoroacetic acid (1.8 ml) was added to propionyl- L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc(D)-mesoDAP-(D)-NHNHBoc- (L)-GlyOH (2) (350 mg) and the mixture was allowed to stand at ambient temperature for 15 minutes. r,The reaction mixture was evaporated in vacuo and the residual oil was triturated with ether to give a white Solid. The solid was dissolved in water (10 ml) and to the solution were added 0.1 N sulfuric acid (12.'2 ml) and a solution of sodium periodate (260 mg) in water t4 ml) with stirring under ice-cooling. The stirring was continued for two hours :and ;sodium bisulfite was added to the reaction mixture until the iodine colour was disappeared. ,The resulting mixture was evaporated to about 3 ml and the concentrate was adjusted to pH 2.3 with IN hydrochloric acid, and then chromatographed on Z macroporous non-ionic adsorption resin, HP20 (50 ml) (trade mark, maker : Mitsubischi Chemical Industry Co., Ltd.). -lution was carried out with a mixture of water and methanol (9 : 1). The fractions containing the bbject compound (3) were collected and freeze-dried to give propionyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-meso- DAP-(L)-GlyOH (3) (102 mg) as a white solid. NMR (D2)), #(ppm) : 1.11 (3H, t, J=8Hz), 1.39 (3H, d, J=8HzY, 2.31 (2H, q, J=8Hz), 3.81 (1H, t, J=8Hz), 3.96 (2H, s), 4.15#4.40 (3H, m) [&alpha;]D = -37.0 (C=0.20 water) The following compounds were prepared in substantially the same manner as that of Steps 1 and 2 of Example 1, respectively. Example 2 (1) Step 1 Acetyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D) mesoDAP (D)-NHNHBoc-(L)-GlyOH IR(Nujol) : 3250,1720, 1630,1525 cm-1 NMR(CD3OD), #(ppm) : 2.00 (3H,s), 3.91(2H,s) (2) Step 2 Acetyl-D-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH mp 110#114 C(dec.) [&alpha;]D =-28.3 (C=0.36, water) NMR(D2O), #(ppm): 1.39 (3H, d, J=7Hz), 2.03 (3H,s), 3.79 (1H, t,J=7Hz), 4.02 (2H, s), 4.20#4.50 (3H, m) Example 3, (1) Step 1 Heptanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH I.R (Nujol): 3280, 1720, 1650, 1520cm-1 NMR (CD3OD), #(ppm): 0.70#1.07 (3H, t), 3.92 (2H, s), 4.15#4.60 (3H, m) (2) Step 2 Heptanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH mp 175#180 C NMR (D2O + NaHCO3), #(ppm): 0.83 (3H, t), 1.40 (3H, d, J=8HZ), 3.77 (2H, s), 4,1#4.5 (3H, m) Example 4 (1) Step 1 Isobutyryl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH I.R. (Nujol): 3260, 1720, 1650 cm-1 NMR (CD3OD), #(ppm): 1.13 (3H, d, J=7Hz), 1.24 (3H, d, J=7Hz), 3.96 (2H, s) (21) Step 2 Isobutyryl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH NMR (D2O), #(ppm): 1.07 (6H, d, J=7Hz), 1.31 (3H, d, J=7Hz), 2.50 (1H, hept, J=7Hz), 3.83 (1H, t, J=7Hz), 3.98 (2H, s), 4,2#4.5 (3H, m) [&alpha;]D= -31.2 (C=0.17, water) Example 5 (1) Step 1 Benzoyl-L¯Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (D)NHNHBoc-(L)-GlyOH I.R (Nujol). #(ppm): 32690, 1720, 1640 (broad), 1530 cm-1 NMR (CD3OD), #(ppm): : 3.94 (2H, s), 7.45#7.70 (3H, m), 7.88#8.04 (2H, m) (2) Step 2 Benzoyl-L-ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH [&alpha;]D=-4.2 (C=0.19, water) NMR (D2O), #(ppm): 1.53 (3H, d, J=7Hz), 3.83 (1H, t, J=7Hz), 3.98 (2H, s) 4.15#4.60 (3H, m), 7.40#7.65 (3H, m), 7.70#7.90 (2H, m) Example 6 (1) Step 1 D-mandelyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH I.R. (Nujol:) 3280, 1720, 1650, 1520 cm-1 NMR (CD3OD), #(ppm): : 3.94 (2H, s), 4.25#4.55 (3H, m),5.12 (1H, s), 7.40 (5H, m) (2) Step 2 D-mandelyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH [&alpha;]D= -40.5 (C=0.18, water) NMR (D2O), #(ppm): 1.46 (3H, d, J=7Hz), 3.83(1H, t, J=7Hz), 3.97 (2H, s) 4.13#4.50 (3H, m), 5.23 (1H, s), 7.48 (5H, s), Example 7 (1) Step 1 2-Methoxypropionyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc- (D)mesoDAP-(D)-NHNHBoc-(L)GlyOH NMR (CD3OD), #(ppm): 3.41 (3H, s), 3.80 (1H, q, J=7Hz), 3.95 (2H, s), 4.25#4.55 (3H, m). (2) Step 2 2-Methoxypropionyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- mesoDAP-(L)-GlyOH [&alpha;]D=-30.0 (C=0.21, water) NMR (D2O), #(ppm): 1.33 (3H, d, J=7Hz), 1.41 (3H, d, J=7HZ), 3.36 (3H, s), 3.75#4.03 (2H, m), 3.96 (2H, s), 4.2#4.5 (3H, m) Example 8 (1) Step 1 Phenoxyacetyl-L-Ala-&gamma;-D-(Glu(&alpha;-oH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(LO)-GlyOH I.R. (Nujol): 3280, 1650, 1520cm-1 NMR (CD3OD), #(ppm): 3.92 (2H, s), 4.58 (2H, s), 6.85#7.10 (3H, m), 7.20#7.40 (2H, m) (2) Step 2 Phenoxyacetyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP- (L)-GlyOH [&alpha;]D = -19.6 (C=0.23, water) NMR (D2O), #(ppm): : 1.43 (3H, d, J=7Hz), 3.82 (1H, t, J=7Hz), 3.96 (2H, s), 4.20#4.55 (3H, m), 4.64 (2H, s), 6.97#7.15 (3H, m), 7.30#7.43 (2H, m) Example 9 (1) Step 1 EMI200.1 EMI201.1 Acetyloxyacety-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso- DAP-(D)-NHNHBoc-(L)-GlyOH(2) (570 mg) was prepared from L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso-DAP-(D)-NHNHBoc- (L)-GlyOH (1) (794 mg) and acetylglycolic chloride of (246 mg) in substantially the same manner as that Step 1 of Example 1. I.R. (Nujol): 3270, 1710, 1650, 1525cm-1 NMR (DMDC-d6), #(ppm):1.24 (3H, d, J=7Hz), 2.08 (3H, s). (2) Step 2 EMI201.2 Acetyloxyacetyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso- DAP-(D)-NHNHBoc-(L)-GlyOH (2) (490 mg) was dissolved in 50% aqueous methanol (20 ml) and the solution was adjusted to pH 9.0 with 5% potassium carbonate and then allowed to stand at ambient temperature for an hour. The, solution was adjusted to pH 5 and concentrated in vacuo and then water ( 1 ml) was added to the concentrate. The mixture was adjusted to pH 2.5 with IN hydrochloric acid and chromatographed on a column of macroporous non-ionic adsorpiton resin, HP 20 (20 mi). After washing the column with water, elution, was carried out with 50% aqueous methanol. The fractions containing the object compound (3) were collected and concentrated to give hydroxyacetyl-L- ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso-DAP-(D)-NHNHBoc- (L)-GlyOH (3) (370 mg) as a white solid. I.R. (Nujol): 3300, 1720 (shoulder), 1650, 1530cm-1 NMR (D2O), #(ppm): 3.95 (2H, s), 4.11 (2H, s) (3) Step 3 EMI202.1 Hydroxyacetyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-meso-DAP-(L)- GlyOH (4) (234 mg) was prepared from hydroxyacetyl-L-A L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso-DAP-(D)-NHNHBoc- (l)-GlyOH (3) (345 mg) in substantially the same manner as that of Step 2 of Example 1. [&alpha;]D = -25.2 (C=0.21, water) NMR (D2O), #(ppm): 1.43 (3H, d, J=7Hz), 3.91 (1H, t, J=7Hz), 3.99 (2H, s), 4.15 (2H, s), 4.20#4.55 (3H, m) Example 10 The 'following compounds were prepared in substantially 'the same manner as that of steps 1 and 2 of Example 1. (1) Step 1 L-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP (L)-GlyOH-(D)-NHNHBoc I.R.(Nujol): 3300, 1720, 1650cm-1 NMR (CD3OD), #(ppm): 2.13 (3H, s), 3.93 (2H, s) (2) Step 2 L-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH mp 170 174 C (dec.) [&alpha;]D = -33.2 (C=0.25, water) NMR (D2O), #(ppm): 1.38 (3H, d, J=7Hz), 1.45 (3H, d, J=7Hz), 3.89 (1H, t, J=7Hz), 4.01 (2H, s), 4.20#4.55 (4H, m) Example 11 (1) Step 1 . EMI203.1 To a mixture of Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (1) (0.922 g) and triethylamine (0.202 g) in 50% aqueous dioxane (30 ml) was added Boc-D-Ala-L-Ala-D- Glu(oSu)oBzq1. The resulting mixture was stirred at ambient temperature overnight and then evaporated, The residue was adjusted to pH 8 with dil sodium bicarbonate and washed 'with ethyl acetate. The aqueous layer was acidified to pH 1 with dil hydrochloric acid ana then extracted with ethyl acetate. , The extract was 'washed, with water, dried over magnesium sulfate and, evaporated., The residue was crystallized from a mixture of ethyl acetate and ether, and then filtered. The crystal was washed with ether to give Boc-D-Ala-L-Ala-&gamma;-D-Glu(&alpha;-oBz1) (L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (3) (1.45 g). NMR (CD3OD), #ppm: 1.29 (3H, d, J=7Hz), 1.32 (3H, d, J=7Hz), 1.40 (27H, s), 3.87#4.47 (4H, m), 5.14 (2H, s), 7.52 (5H, s). (2) Step 2 EMI204.1 A solution of Boc-D-Ala-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc (d)-meso-DAP-(D)-NHNHBoc-(L)-GlyOH (3) (1.2 g) in a mixture (25 ml) of ethanol and water (2 : 1) was hydrogenated over 5 ; palladium-black (0.2 g) at two atmospheric pressures of hydrogen, gas. After the reaction was completed, the catalyst was filtered off and the filtrate was evaporated. The residue was pulverized wish isopropyl ether and filtered to give Boc-D-Ala-L-ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso-DAP (D)-NHNHBoc-(L)-GlyOH (4) (l.1 g). NMR (CD3OD), #(ppm): 1.24 (3H, d, J=7Hz), 1.33 (3H, d, J=7Hz), 1.44 (27J, s), 1.34#2.50 (10H, m), 3.94 (2H, s), 3.87#4.50 (4H, m) (3) Step 3 EMI205.1 Boc-D-Ala-L-ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso-DAP- (D)-NHNHBoc-(L)-GlyOH (4) (1.0 g) was dissolved in trifluoroacetic acid (5 ml) and the solution was stirred it ambient temperature for 30 minutes. The reaction mixture was evaporated and the residue was pulverized with ethyl acetate and filtered to give D-Ala-L-Ala &gamma;-D-Glu(&alpha;-OH)-(L)-meso-DAP-(D)-NHNH2-(L)-GlyOH (5) trifluoroacetic acid salt (0.81, g). NMR' (D20), #(ppm): i.42 (3H, d, J=7Hz), 1.57 (3H, d, J=7Hz), 1.34#2.50 (10H, m), 3.74 (2H, s), 3.67#4.27 (4R, m) (4) Step 4 EMI206.1 N-Bromosiccinimide (178 mg) was added to P solution' of D-Ala-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-meso-DAP-(D)-NHNH2-(L)- GlyOH (5) trifluoroacetic acid salt (552 mg) in 50% aqueous dioxane (10 ml). The mixture was stirred at ambient temperature for "an hour. and adjusted to pH 3.5 with dil sodium bicarbonate and then evaporated. The residue was dissolved in water and 'chromatographed on a column of a macroporus non-ionic adsorption resin, HP 20 (150 ml) and then eluted with water. Eluates containing the object compound (6) were combined and evaporated. The resine was washed with methanol and dissolved in water. The solution was adjusted to pH 3.0 and3 chromatographred again on z column of macroporous non-ionic adsorption resin, ,-HP 20- (100 ml) and eluted with water. Fractions containing the object compound (6) were combined and evaporated to give n solid. The solid was dissolved in water and lyophilized to give D-Ala-L-Ala-&gamma;-D- Glu(&alpha;-OH)-(L)-meso-(L)-GlyOH (6) (120 mg). NMR (D2O), #(ppm): 1.45 (3H, d, J=7Hz), 1.57 (3H, d, J=7Hz), 1.34#2.34 (lDH, m), 3.88 (2H, s), 3.74#4.50 (4H, m) Example 12 EMI207.1 D-Lac(oAc)-Gly-&gamma;-D-GluoBzl dicyclohexylamine salt (2) (1.20 g) was dissolved in 2 mixture of ethyl acetate (40 ml) and methylene chloride (10 m,,l). To the solution was added 1N hydrochloric acid C2 ml) and the precipitates thus formed were filtered off. The organic layer was washed with water, dried over magnesium sulfate and then evaporated to give an oily residue. The residue was dissolved in methylene chloride (20 ml) and to the solution were added N methyl morpholine (200 mg) and isobutyl chlorocarbonate (270 mg) at 0 C. The mixture was reacted at the same temperature for 20 minutes. To the reaction mixture was added a solution of Boc-(D)-mesoDAP-(D)-NHNHBoc- (L)-Gly'OH (1) (860 mg) in a mixture of methylene chloride (40 ml) and dimethylformamide (50 ml) containing bis(trimethylsilyl)acetamide (2 ml) at 0 C. The resulting mixture was stirred at the same temperature for two hours and concentrated in vacuo to give an oily residue. The residue was dissolved in ethyl acetate and the solution was washed with 2% hydrochloric acid. The organic layer was washed with suCcessively with water and aqueous saturated sodium chloride solution and dried and then evaporated. The residue was throughly washed with ether and collected by filtration to give D-Lac(oAc)-Gly-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-Gly(OH) (3) (1.0 g). NMR (DMSO-d6), #(ppm): 0.80#2.60 (3H, m), 2.06 (3H, s), 3.76 (4H, broad s), 3.60#4.52 (3H, m), 5.00 (1H, q, J=7Hz), 5.12 (2H, s), 6.70 (1H, d, J=7Hz), 7.38 (5H, s), 7.80#8.80 (5H, m), 9.58 (1H, s) (2) Step 2 EMI208.1 D-Lac(oAc)-Gly-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-GlyOH (3) (0.9 g) 'was dissolved in glacial acetic acid (9 ml) and hydrogenated over 10% palladium black (200 mg) at ambient temperature for 1.5 hours. The catalyst was filtered off and the filtrate was evaporated in vacuo to give an oily residue which was pulverized with ether to, give D-Lac(oAc)-Gly-&gamma;-D- glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (4) (0.76 g). NMR (DMSO-d6), #(ppm): 0.80#2.80 (31H, m), 2.08 (H, s), 3.72 (4H, broad s), 3.60#4.36 (3H, m), 5.00 (1H, q, J=7Hz), 6.76 (1H, m), 7.72#8.40 85H, m), 8.70 (1H, m), 9.60 (1H, s) (3) Step 3 EMI209.1 D-Lac(oAc)-Gly-&gamma;-D-Glu(&alpha;-OH)-(L)-boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-GlyOH (4) (0.70 g) was dissolved in 50% aqueous methanol (20 ml) and the solution was adjusted to pH 9.0 with 5% aqueous potassium carbonate. The' solution was allowed to stand at ambient temperature 'for 3 hours and adjusted to pH 7.0 with 5 hydrochloric acid. The solution was chromotographed on a column of macroporous non-ionic adsorption resin, HP 20 (25 ml) and eluted successively with water (100 ml) and 50% aqueous methanol (100 ml). The latter fraction was evaporated to give a posty residue which was pulverized with ether to give D-Lac-Gly-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH (5) (0.40 g), ""1 I. (Nujol): 3500, 1730, 1690 1650 (broad) cm NMR (D2O), #(ppm): 1.02#2.60 (31H, m), 4.00 84H, s), 4.20#4.60 (4H, m) (4) Step 4 EMI210.1 D-Lac-Gly-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-GlyOH (5) (335 mg) was dissolved in trifluoroacetic acid (3 ml) and the solution was stirred at ambient temperature for 15 minutes. The solution was evaporated in vacuo and the residue thus obtained was pulverized with ether to give a white powder. The powder was dissolved in a mixture of water (8 ml) and 0.1N sulfuric acid (11.6 ml) and the solution was cooled in an ice-bath. To the solution was added an aqueous sodium metaperiodate solution (240 mg in 3 ml of water) and allowed to react at ODC for an hour. The resulting reaction mixture was treated with an aqueous sodium bicarbonate until the purple color of the solution was disappeared. The solution was adjusted to pH 3.0 and concentrated to about 3'm1. The concentrate was adjusted to pH 2.0 and then chromatographed on a column of macroporous non-ionic adsorption resin, HP 20 (80 ml) and eluted with water. Fractions containing the object compound (6) were collected and evaporated in vacuo to give a pasty resin which was dissolved in water and lyophillized to give D-Lac-Gly-&gamma;-D-Glu(&alpha;-OH)-(L)- mesoDAP-(L)-GlyOH (6) (0.150 g). [&alpha;]D = -5.0 (C=0.2 in water) NMR (D2O), #(ppm): 1.38 (3H, d, J=7Hz), 1.20#2.60 (10H, m), 3.82 (1H, t, J=7Hz), 3.96 (2H, s), 4.00 (2H, s), 3.68#4.52 (3H, m) Example 13 (1) Step 1 . EMI211.1 D-Lac(oAc)-L-Ser(oBzl)-D-GluoBzl) (2) dicyclogexylamine salt (1.40 g) was dissolved in a mixture of ethyl acetate (40 ml) and chloroform (10 ml). To the solution was added 1H hydrochloric acid (2 ml) and the precipitates thus formed were filtered off. The organic layer was separated, washed with water, dried over magnesium sulfate and then evaporated to give an oily residue (1.08 g). The residue was dissolved in methylene chloride (20 ml) and the solution was treated with N-methylmorpholine (198 mg) and cooled to -10 C and then isobutylchlorocarbonate (270 mg) was added thereto. To the mixture was added Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (1) (860 mg) in a mixture'of methylene chloride (40 ml) and dimethylformamide (5û ml) containing bis (trimethyl silyl ) acetamide (2 ml). The resulting mixture was allowed to react at -10 C for two hours. The reaction mixture was concentrated in vacuo to give an oily residue which was dissolved in ethyl acetate. The solution was washed with 2% aqueous hydrocnloric acid and the ethyl acetate layer was separated, washed with water and dried over magnesium, sulfate, and then evaporated. The crystalline residue thus obtained was washed with ether to give D-Lac-(oAc)-L-Ser(oBzl) &gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)- GlyOH (3) (1.55 g). NMR (DMSO-d6), #(ppm): 1.00#2.36 (10H, m), 1.38 (18H, s), 1.32 (3H, d, J=7Hz), 2.04 (3H, s), 3.44#4.84 (8H, m), 4.48' (2H, s), 5.06 (IH, q, J=7Hz), 5.14 (2H, s), 6.72 (1H, broad s), 7.34 (5H, s), 7.40 (5H, s), 7.92 (1H, broad s), 8.04#8.44 (4H, m), 8.72 (lH, broad s), 9.60 (IH, s) Succesively, the following compounds were prepared in substantially the same manner as that of Steps 2 to 4 of Example 12, respectively. (2) Step 2 D-Lac(oAc)-L-Ser(OH)-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH NMR (DMSO-d6), #(ppm): 1.00#2.40 (10H, m), 1.38 (18H, s), 1.32 83H, d, J=7Hz), 2.08 (3H, s), 3.40#4.52 (8H, m), 5.06 (1H, q,J=7Hz), 6.76 (1H,d, J=7Hz), 7.64#8.32 (4H, m), 8.72 (1H, s), 9.60 (1H, s) (3) Step 3 D-Lac-L-Ser-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-GlyOH NMR (D2O), #(ppm): : 1.00#2.60 (10H, m), 1.42 (3H, d, J=7Hz), 1.44 (18H, s), 3.60#5.00 (9H, m) (49 Step 4 D-Lac-L-Ser-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH [&alpha;]D = -18.5 (C=0.2 water) NMR (D2O), #(ppm): 1.20#2.60 (10H, m), 1.40 (3H, d, J=7Hz), 3.60#5.10 (7H, m), 3.98 (2H, s) Example 14 EMI213.1 D-Lac(oAc)-L-Val-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-GlyOH (3) (1.20 g) was prepared from Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (1) (800 mg) and D-Lac(oAc)-L-Val-&gamma;-D-GluoBzl (2) (0.90 g) in substantially the same manner as that of Step 1 of Example 12. NMR (DMSO-d6), #(ppm): 0.80 (3H, d, J=7Hz), 0.84 (3H, d, J=7Hz), 1.83 (18H, s), 1.0#2.40 (14H, m), 2.04 (3H, s), 3.60#4.48 (6H, m), 5.08 81H, q, J=7Hz), 5.14 (5H, s), 6.74 (1H, d, J=7Hz), 7.36 (5H, s), 7.80#8.40 (5H, m), 8.68 (1H, s), 9.54 (1H, s) Succesively, the following compounds were prepared in substantially the same manner as that of Steps 2 to 4 of Example 12, respectively. (2) Step 2 D-Lac(oAc)-L-Val-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- meso-(D)-NHNHBoc-(L)-GlyOH NMR (DMSO-d6), #(ppm): 0.82 (3H, d, J=7Hz), 0.86 (3H, d, J=7Hz), 1.00#2.40 (14H, m), 2.04 (3H, s), 3.60#4.40 (6H, m), 5.04 (1H, q, J=7Hz), 6.76 (1H, d, J=7Hz), 7.80#8.40 (4H, m), 8.70 (1H, s), 9.60 (1H, s) (3) Step 3 D-Lac-L-Val-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-GlyOH NMR (D2O), #(ppm); 0.96 (6H, d, J=7Hz), 1.12#2.56 (32H, m), 3.96 (2H, s), 3.80#4.52 (5H, m) (4) Step 4 D-Lac-L-Val-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP(L)-GlyOH [&alpha; ;]D = -28 (C=0.2, water) NMR (D2O), #(ppm): 0.96 (6H, d, J=7Hz), 1.37 (3H, d, J=7Hz), 1.20#2.60 (11H, m), 3.96 (2H, s), 3.68#4.50 (5H, m) The following compounds were prepared in substantially the same manner as that of Steps 1 and 2 of Example 1, respectively. Example 15 (1) Step 1 Theinylacetyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH NMR (CD3OD), #8ppm): 3.76 (2H, s), 3.87 (2H, s), 4.15#4.40 (3H, m), 6.90 (2H, m), 7.20 (1H, m) (2) Step 2 Theinylacetyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP- (L) -GlyOR [&alpha;]D = -33.5 (C=0.20 water) NMR (D2O), #(ppm): : 1.40 (3H, d, J=7Hz), 3.81 (3H, t, J=7Hz), 3.89 (2H, s), 3.97 (2H, s), 4.13#4.44 (3H, m), 7.02 (2H, m), 7.35 (1H, m) Example 16 (1) step 1 a Phenylcarbamoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH I.R (Nujol): 3300, 1730, 1650, 1595, 1540cm-1 NMR (CD3OD), #(ppm): 3.95 (2H, s), 4.2#4.6 (3H, m), 6.9#7.1 (5H, m) (2) Step 2 Phenylcarbamoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP (L) -GlyOR [&alpha;]D = -38.5 (C=0.20, DMSO) NMR (D2O + NaHCo3), #(ppm): : 1.43 (3H, d, J=7Hz), 3.96 (1H, m), 3.76 (2H, s), 4.05#4.5 (3H, m), 7.35 (5H, m) Example 17 EMI216.1 Triethylamine (720 mg) and benzyloxy'carbonyl-L-Aia-D- Glu(oSu)oBzl (1) (3.51 g) was added to a solution of Boc-(D)-meso-DAP-(D)-NHNHBoc-(L)-GlyOH (2) (3.00 g) in a mixture of dioxane (90 ml) and water (70 ml). The resulting mixture was allowed to stand at ambient temperature for 18 hours, and concentrated to about 50 ml . The concentrate was adjusted to pH 3 with. IN hydrochloric acid and extracted with ethyl acetate, (300 ml) containing methanol (20 ml). The organic layer was washed with brine (100 ml), dried over sodium sulfate and then evaporated in vacuo. The residue was washed with ether and filtered to give benzyloxycarbonyl-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)- meso-DAP-(D)-NHNHBoc-(L)-GlyOH (3) (5.53 g). NMR (DMSO-d6), #(ppm): 1.07 (3H, d, J=7Hz), 3.64#4.48 (6H, m), 5.04 (2H, s), 5.12 (2H, s), 6.56 (1H, d, J=8Rz), 7.35 (10H, s), 7.95 (1H, d, J=8Hz), 8.15 (1H, m), 8.35 (1H, d, J=8Hz), 8.70 (1H, s), 9.56, (1H, s) c2) Step 2 EMI217.1 Benzyloxycarbonyl-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)- meso-DAP-(D)-NHNHBoc-(L)-GlyOH (3) (1.43 g) was added to trifluoracetic acid (6 ml) and the mixture was stood at ambient temperature for an hour. The mixture was evaporated in vacuo and the residual oil was triturated with isopropyl, ether to give a solid. The solid was dissolved in a mixture of water (35 ml) and methanol (10 ml). To this solution were added 1N sulfuric acid (40 ml) and sodium periodate (860 mg) at 0 C. The mixture was stirred at the same temperature for 1.5 hours and concentrated to 10 ml, and adjusted to pH 4 with 1N, sodium hydroxide. The precipitate thus obtained was collected and dried over phosphorus pentoxide to give benzyloxycarbonyl-L-Ala-&gamma;-D-Glu(&alpha;-oBzl) (L)-mesoDAP-(L)-GlyOH (4) (1.09, g). I.R (Nujol): 3300, 1700, 1660, 1540cm-1 NMR (D2O + NaOCO3), #(ppm): 3.78 (2H, s), 5.04 (2H, s), 5.13 (2H, s), 7.40 (1OH, m) (3) Step 3 EMI218.1 To a suspension of benzyloxycarbonyl-L-Ala-&gamma;-D- Glu(&alpha;-oBzl)-(L)-mesoDAP-(L)-GlyOH (4) (600 mg) in water (10 ml) was added 1N sodium hydroxide (35 ml). The mixture was stood at ambient temperature for an hour. The reaction mixture was adjusted to pH 2.0 with 1N hydrochloric acid and concentrated to about 3 ml. The residual solution was chromatographed on a column of a macroporous non-ionic adsorption resin, HP 20 (60 ml) and eluted with in a mixture of water and methanol (7 : 3). The fraction containing the object compound (5) was collected and concentrated to dryness in vacuo to give benzyloxycarbonyl-L-Ala-&gamma;-D- Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH (5) (190 mg). mp 205 207 C [&alpha;]D = -12.1 (C=0.19, water) NMR (D2O), #(ppm): 1.37 (3H, d, J=7Hz), 3.78 (1H,m), 3.93 (2H, s), 4.05#4.40 (3H, m), 5.14 (2H, s), 7.45 (5H, s) EMI219.1 To mixture of 1-O-&alpha;-benzyl-4,6-O-benzylidene-N- acetyl-muramyl-L-Ala-&gamma;-D-GluoBzl (2) (0.76 g) and triethylamine (0.10 g) in methylene chloride (5 ml) was added dropwise iso-butyl chloroformate (0.13 g) at -18 C. The resulting mixture was stirred at -15 C for 50 minutes and to this mixture was added at -28 C silyl ester of Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (1) which was prepared from Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-GlyOH (0.46 g) and bis(trimethylsilyl)acetamide in a mixture (5 ml) of methylene chloride and dimethylformamide (5 : 1) with stirring at ambient temperature. The mixture was stirred at -150C for 1.5 hours and allowed to warm up to ambient temperature. The solution was distilled off and to the residue thus obtained was added 2% aqueous hydrochloric acid (10 ml) to give 2 powder. The powder was collected by filtration and washed with water to give 1-O-&alpha;-benzyl-4,6-O-benzylidene- N-acetyl-muramyl-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)- mesoDAP-(D)-NHNHboc-(L)-GlyOH (3) (1.14 g). NMR (DMSO-d6), #(ppm): 1.48 (18H, s), 1.1#1.6 (8H, m), 1.85 (3H, s), 1.8#2.3 (8H, m), 3.7#4.0 (8H, m), 4.0#4.5 (5H, m), 4.7 (2H, m), 4.90 (1H, d, J=7Hz), 5.15 (2H, s), 5.72 (1H, s), 7.33 (5H, s), 7.40 (5H, s), 7.34 (5H, s), 8.1#8.3 (4H, m), 8.3#8.7 (3H, m) EMI220.1 1-O-&alpha;-benzyl-4,6-O-benzylidene-N-acetymuramyl-L-Ala &gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)- GlyOH (3) (0.81 g) was added to trifluoroacetic acid (4 ml) and the mixture was stirred at ambient temperature for 15 minutes. The solvent was distilled off and the residue was pulvelized with ether and filtered to given 1-O-&alpha;. benzyl-N-acetyl-muramyl-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)- mesoDAP-(D)-NHNH2-(L)-GlyOH (4) trifluoroacetic acid salt (0.65 g). NMR (D2O), #(ppm): 1.38 (6H, d, J=7Hz), 1.84 (3R, s), 1.2#1.5 (2H, m), 1.7#2.1 (6H, m), 2.2#2.4 (2H, m) 3.6#4.0 (8H, m), 4.2#4.5 (5H, m), 5.18 (2H, s), 7.4 (10H, s) EMI221.1 To 2 solution of 1-O-&alpha;-benzyl-N-acetymuramyl-L-Ala-&gamma;- D-Glu(&alpha;-oBzl)-(L)-mesoDAP-(D)-NHNH2-(L)-GlyOH (4) trifluoroacetic acid salt (0.58 g) in 60 % aqueous acetic acid was added manganese dioxide (0.15 g) and the mixture was stirred at ambient temperature or 4 hours. The reaction mixture was filtered and the filtrate was concentrated. ,The concentrate was dissolved in water (3 ml) and the solution was adjusted to pH 8 with conc. ammonium hydroxide. To the solution was added methanol (3 ml) and the mixture was allowed to stand in a refrigerator. An additional 14 ml of 5% aqueous methanol was added to the mixture and the resulting mixture was filtered. The filtrate was concentrated, and the concentrate was dissolved in 1N acetic acid (30 ml) and the solution was put on a column of a chelate resin. The column was eluted with water and the fractions containing the object compound (5) were collected and concentrated to give an oil. The oil was dissolved in water and the solution was adjusted to pH 2.6 and put on a column of a macroporous non-ionic adsorption resin, HP 20. The column was washed with ;water and eluted with 50% aqueous methanol,. The fractions containing the object compound (5) were combined and concentrated to give 1-O-&alpha;-benzyl-N-acetylmuramyl-L-Ala-&gamma;-D- Glu(&alpha;-oBzl)-(L)-mesoDAP-(L)-GlyOH (5) (0.25 g). NMR (D2O); #(ppm): 1.35 (3H, d, J=7Hz), 1.38 (3h, d, J=7Hz), 1.2#1.6 (2H, m), 1.80 (3H, s), 1.6#2.0 (6H, m), 2.2#2.4 82H, m), 3.5#3.9 (8H, m), 4.2#4.5 (5H, m), 4.90 (1H, d, J=7Hz9, 5.20 (2H, s), 7.38 (5H, s), 7.'40 (SH, s) EMI222.1 A solution of 1-O-&alpha;-benzyl-N-Acetylmuramyl-L-Ala-&gamma;- D-Glu(&alpha;-oBzl)-(L)-mesoDAP-(L)-GlyOH (5) (0.20 g) in a mixture of water (20 ml) and acetic acid (1.5 ml was hydrogenated over 10% palladium black (0.10 g) under an atmospheric pressure of hydrogen. The catalyst was filtered off and the filtrate was evaporated to give a white solid (0.15 g). The solid was dissolved in water (2 ml) ,and lyophilized to give N-acetylmuramyl-L-Ala-&gamma;-D- Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH (6) (0.12 g). NMR (D2O), #(ppm): 1.38 (3H, d, J=7Hz), 1.41 (3H, d, J=7Hz), 1.2#1.6 (2H, m), 1.99 (3H, s), 1.6#2.2 (6H, m), 2.2#2.4 (2H, m), 3.4#4.0 (5H, m), 3.82 (2H, s), 4.1#4.5 (6H, m), 5.19 (1H, m) Example 19 (1) Step 1 EMI223.1 D-lac(oAc)-L-Phe-D-GluoBzl (2) (1.0, g) was dissolved in methylene chloride C40 mlj and N-methy1morpoline (200 mg) was added thereto. To this stirred solution colled at -10 C in an ice salt-bath, isobutylchloro carbonate (270 mg) was added and the mixture was Allowed to react at the same temperture for 20 minutes. To the reaction mixture was added the silyl ester, prepared from Boc-(D)-mesoDAP-(D)-NHNHBoc- (L)-GlyOH (1) (920 mg) in a mixture of methylene chloride (20 ml) and dimethylformamide (10 ml) containing bis(trimethylsilyl)acetamide (2 ml). The reaction mixture was stirred for' 2 hours and, concentrated under reduced pressure to give an oily residue which was dissolved in ethyl acetate and washed with 2% hydrochloric acid. The organic layer was washed successively with water and saturated sodium chloride and then dried. Evaporation of the solvent geve a residue which was throughly washed, with ether and collected by filtration to give D-Lac(oAc)-L-Phe-&gamma;-D- Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (3) (1.660 g). NMR (DMSO-d6), #(ppm): 1.10 (2H, d, J=7Hz), 1.23#2.43 (28H, m), 2.00 (3H, s), 2.86#3.23 (2H, m), 3.71#4.70 (6H, m), 5.17 (2H, s), 7.23 C5H, s), 7.36 (5H, s), 7.70#8.90 (5H, m) 9.60 (1H, s) EMI224.1 D-Lac(oAc)-L-Phe-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-GlyOH (3) (1.50 g) was dissolved in 50% aqueous methanol (20 ml). To this solution was added 1N sodium hydroxide (5 ml) and the resulting solution was allowed to stand at ambient temperature for 2 hours. The solution was concentrated to about 3.0 ml after adjusting the pH of the solution to pH 7.0. The pH of the solution was, adjusted again to about 2.0 and th precipitates thus formed was extracted with ethyl acetate. The organic c layer was washed with saturated sodium chloride and dried over magnesium sulfate and then the solves was evaporated to give D-Lac(OH)-L-Phe-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH (4) (0.960 g). NMR (DMSO-d6), #(ppm): 1.12 (3H, d, J=7Hz), 1.0#2.32 (28H, m), 2.72#3.20 (2H, m), 3.60#4.80 (7H, m), 6.72 (1H, m), 7.20 (5H, s), 7.48#8.80 85H, m), 9.52 (1H, s) (3) Step 3 EMI225.1 D-Lac(OH)-L-Phe-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-GlyOH (4) was dissolved in trifluoroacetic acid (5 ml) and the solution was stirred at ambient temperature for 15 minutes. Evaporation of the solvent under reduced pressure gave an oily-residue, which was pulverized with ether to, give 9 white powder. The powder was dissolved in z mixture of water (15 ml) and 0.1N sulfuric acid and the solution was cooled in an ice-bath. To this stirred solution was added an aqueous sodium' periodate solution, (528 mg in & ml of water) and the mixture was 'allowed to react at the same temperature for an hour. The resulting reaction mixture was treated with sodium bisulfite until the brown color of the mixture became clear and the pH of the solution was adjusted to about 3.0. Then, the solution was concentrated to about 4 ml and the pH of the solution was adjusted again to pH 2.0. The solution was applied to a column of a macroporous non-ionic adsorption resin HP 20 (60 ml) and eluted with water,. Evaporation of fractions containing the object compound (5) was carried out to give D-Lac(OH)- L-Phe-&gamma;-D-Glu(&alpha;-OH)-(L)-GlyOH (5) (0.45 g). [&alpha;]D = -5.0 (C=0.2, water) NMR (D2O), #(ppm): 1.28 (3H, d, J=7Hz), 1.32#2.28 (10H, m), 3.08 (2H, ABq, J=16Hz), 3.80 (1H, t, J=7Hz), 3.96 (2H, s), 4.0#4.44 (4H, m), 7.32 CSR, s) The following compounds were prepared in sub stantially the sane manner as that of Steps 1 and 2 of Example 1, respectively. Example 20 (1) Step 1 Pivaloyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-GlyOH N.M.R. (CD3OD), #(ppm) : 1.22 (9H, s),'1.38 (2H, d, J=7Hz), 1.48 (18H, s), 1.34-2.42 (1OH, m), 3.95 (2H, s), 4.27-4.60 (4H, m) (2) Step 2 Pivaloyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- GlyOH N.M.R. (D2O), #(ppm) : 1.20 (9H, s), 1.37 (3H, d, J=7Hz), 1.34-2.42 (10H, m), 3.80 82h, s), 4.10-4.45 (4H, m). Example 21 (1) Step 1 Adamante-1-carbonyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH I.R. (Nujol) : 3280, 1720 (shoulder), 1630, 1520 cm-1 (2) Step 2 Adamante-1-carbonyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- mesoDAP-(L)-GlyOH [&alpha;]D = 18.9 (c=0.18, water) N.M.R. (D2O), #(ppm) : 1.46 (3H, d, J=7Hz), 3.83 (1H, t, J=7Hz), 3.98 (2H, s), 4.25-4.5 (3H, m) Example 22 (1) Step 1 Lauroyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-GlyOH I. R. (Nujol) : 3300, 1730 (shoulder), 1650, 1520 cm-1 N.M.R. (CD3OD), #(ppm) : 0.96 (3H, m), 3.96 (2H, s) (2) Step 2 : Lauroyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- GlyOH [&alpha;]D=-30.0 (c=0.14, 1N NaOH) N.M.R. (D2O + NaHCO3), #(ppm) : 0.88 (3H, m9, 3.65-3.85 (3H, m), 4.10-4.60 (3H, m) Example 23 (1) Step 1 Salicyloyl(oBzl)-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc- (D)-mesoDAP(D)-NHNHBoc-(L)-GlyOH N.M.R. (CD3OD), #(ppm) : 1.42 (9H, s9, 1.44 (9H, s), 3.87 (2h, s), 5.23 (2H, s), 6.93-7.55 (8H, m), 7.94 (1H, d,d, J=2 and 7Hz) (2) Step 2 Salicyloyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- ,GlyOH [&alpha;]D=4.6 (c=0.13 water) N.M.R. (D2O), #(ppm) : 1.51 (3H, d, J=7Hz), 3.77 (1H, t, J=7Hz), 3.91 (2H, s), 6.97-7.10 (2H, m), 7.40-7.55 (1H, m), 7.71-7.79 (1H, m) Example 24 (1) Step 1 &alpha;-ethylhexanol-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH N.M.R. (CD3OD), #(ppm), #(ppm) : 0.88 (6H, t, J=7Hz), 1.42 (9H, s), 1.54 (9H, s), 1.80-2.36 (19H, m), 3.94 (2H, s) (2) Step 2 &alpha;-ethylhexanol-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- GlyOH [&alpha;]D=-46.7 (C=0.12, water) N.M.R. (D2O), #(ppm) : 0.81 (6H, t, J=7Hz9, 1.37 (2H, d, J=7Hz), 3.81 (1H, t, J=7Hz), 3.96 (2H, s), 4.2-4.5 (3H, m) Example 25 (1) Step 1 Nicotinyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH N.M.R. (CD3OD), #(ppm) : 1.40 (18H, m), 3.90 (2H, s), 7.50 (1H, d,d, J=8 and 5Hz), 8.31 (1H, m), 8.69 (1H, m), 9.11 (1H, m) (2) Step 2 Nicotinyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- GlyOH [&alpha;]D=-7.7 (c=0.22, water) N.M.R. (D2O), #(ppm) : 1.56 (3H, d, J=7Hz), 3.83 (1H, t, J=6Hz), 3.95 (2H, s), 7.94 (1H, d,d, J=8 and 4 Hz), 8.85 (1H, m), 9.10 (1H, m) Example 26 (1) Step 1 Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (L)-GlyOH I.R. (Nujol) : 3300, 1720, 1630, 1530 cm-1 N.M.R. (CD3OD + CDCl3), #(ppm) : 0.80 (3H, m) 3.95 (2H, s) (2) Step 2 Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH [&alpha;]D=-30.8 (c=0.13, 1N, NaOH) I.R. (Nujol) : 3280, 1730, 1630, 1530 cm-1, NMR (NAOD-+D2O) #(ppm) 0.83 (3H,m), 3.24 (1H,m), 3.82 (2H, s) Example 27 (1) Step 1 EMI230.1 To 2 mixture of Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)- GlyOH (1) (0.46 g) and triethylamine (0.11 g) in a mixture (20 ml) of dioxane and water (2:1) was added benzoyl-D-Ala-L-Ala-D-Glu(&gamma;-OSu)oBzl (2) (0.58 g). The resulting mixture was stirred at ambient tem perature for 18 hours. After evaporation of dioxane, the remaining aqueous layer was acidified to pH 1 wish' dil. hydrochloric acid and extracted with ethyl acetate. The extract was washed with water:, dried and evapo rated. The residue was triturated with ether to give benzoyl-D-Ala-L-Ala-&gamma;-D-glu(&alpha;-oBzl)-(L)-Boc-(D) meso-DAP-(D)-NHNHBoc-(L)-GlyOH (3) (0.64 g). I.R. (Nujol) : 3290, 1720, 1680, 1640 cm-1 (2) Step 2 EMI231.1 To a solution of benzoyl-D-Ala-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)- (L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (3) (0.58 g) in a mixture (30 ml) of methanol and water (2:1) was added 10% palladium carbon and the mixture was shaken under there atmospheric pressure of hydrogen for 3 hours. The catalyst was filtered off and the filtrate was evaporated. The residue was triturated with ether to give benzol-D-Ala-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (4) (0.44 g). I.R. (Nujol) : 3250, 1720, 1660-1360 EMI232.1 Benzoyl-D-Ala-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH (4) (0.40 g) was dissolved in trifluoroacetic acid (6 ml) at 0 C and the solution was stirred at the same temperature' for an hour. After evaporation of trifluoroacetic acid, a small amount of benzene was added to the residue and the mixture was evaporated. The resulting was dissolved in water (3 ml) and the solution was acidified with 1N sulfuric acid (0.5 ml). To the solution was added dropwise a solution of sodium periodate (0.14 g) in water (3 ml) at 0 C. After stirring for an hour, sodium bisulfite was added thereto until the color of the' reaction mixture became clear. After adjustment of the pH to 3.2, the reaction mixture was concentrated to about 4 ml. The concentrate was put on a column of a macroporous non-ionic adsorption resin, HP 20 (20 ml) and, after washing with 'water, eluted with 30% aqueous methanol. The fractions containing the . Obj ect compound (5) were concentrated and the concentrate was lyophilized to give benzoyl-D-Ala L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH (5) (120 mg). N.M.R. (D2O), #(ppm) : 1.50 (3H, d, J=7Hz), 1.57 (3H, d, J=7Hz), 1.42-2.42 (10H, m), 3.95 (2H, s), 3.37-4.67 (5H, m), 7.54 7.95 (5H, m) The following compounds were prepared in sub stantially the same manner as that of Steps 1 - 3 of Example 27. Example 28 (1) Step 1 Acetyl-D-Ala-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH N.M.R. (CD3OD), #(ppm) : 1.40 (18H, s), 1.33 (6H, d, J=7Hz), 1.92 (3H, s), 1.84-2.30 (10H, m), 3.88 (2H, s), 3.84-4.25 (5H, m9, 5.12 (2H, s), 7.30 (5H, m) (2) Step 2 Acetyl-D-Ala-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-mesoDAP- (L)-GlyOH N.M.R. (CD3OD), #(ppm) : 1.32 (6H, d, J=7Hz), 1.34-2.32 (10H, m), 1.90 (3H, s), 3.79-4.25 (SH, m), 3.89 (2H., s), 5.12 (2H, s), 7.30 (5H, s) (3) Step 3 Acetyl-D-Ala-L-Ala-&gamma;-D-glu(&alpha;-OH)-(L)-mesoDAP- (L)-GlyOH N.M.R. (D2O), #(ppm) : 1.32 (3H, d, J=7Hz), 1.40 (3H, d, J=7Hz), 1.25-2.38 (10H, m), 3.80 (1H, t, J=6Hz), 3.96 (2H, s), 4.24-4.42 (4H, m) Example 29 EMI234.1 L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-GlyOH (1) (662 mg) was added to trifluoroacetic'acid (4 ml) and the mixture was stirred at ambient temperature for 50 minutes. After removal of trifluoroacetic acid by evaporation, the residue was dissolved in water (20 ml) and cooled to 0 C. To this cooled solution were added 0.1N sulfuric acid (25 ml) and a solution of sodium periodate (535 mg) in water (i ml). The mixture was stirred at the same temperature fo an hour, during which time the reaction solution turned dark brown. Sodium bisulfate was added until the color was clear and the mixture was adjusted to p'n 3 with dil. sodium bicarbonate. After concentration of the mixture, the residue was dissolved in S small amount of water and adjusted again to pH 3. The solution was put on a column of 2 a macroporous non-ionic adsorption resin, HP 20 (130 ml) and eluted with water. The faction containing the object compound (2) was concentrated. This chromatograph operation was repeated, and the fraction containing the object compound (2) was lyophilized to give an amorphous solid (220 mg). A 180 mg portion of the solid was further purified by column chromatograph using an active carbon (20 ml) and eluted with a mixture of water and acetone (4:1). The eluate was evaporated and the rsru was s pulverized with acetone to give L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- GlyOH (2)(90 mg). [&alpha;]D - -10.6 (C=0.34 water) N.M.R. (D2O), #(ppm) : 1.55 (3H, d, J=7Hz), 3.75 (1H, t, J=7Hz), 3.86 (2H, s), 4.05-4.45 (m) Exsample 30 EMI236.1 To a solution of 2-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP- (L)-GlyOH (1)(2.04 g) and sodium bicarbonate (890 mg) in a 50% aqueous dioxane (40 ml) case added ditert- butyldicarbonate (1.53 g). After stirring for 4 hours at ambient temperature, additional ditertbutyldicarbonate (770 mg) IN sodium hydroxide (0.6 ml) was added thereto and the mixture was stirred for 2. -flours. To the mixture was added acetic acid (s ml) and the resulting mixture was hydrogenated over 10% palladium black (300 mg) under an atmospheric pressure' of hydrogen. After the catalyst was filtered off, the filtrate was evaporated in vacuo. The residue was dissolved in water (5 ml) and put on a column of macroporous non-ionic adsorption resin, HP 20 (120 ml). The fractions eluted with a a mixture of water and methanol (7:3) were combined and concentrated to give L-Ala-y-D- Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)-GlyOH (2)(1.17 g). I. R. (Nujol) : 3280, 1650 (shoulder), 1520 (shoulder) N.M.R.' (D20), 8 #(ppm) : 1.42 (9H, s), 1.55 (3H, d, J=7Hz), 3.93 (2H, s), 4.04-4.50 (4R,, m) Example 31 (1) Step 1 EMI237.1 To a suspension of benzyloxycarbonyl-L-Ala-&gamma;-d- Glu(&alpha;-Bzl)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)- GlyOR (1)(4.43 g) in 2 mixture of 50% aqueous methanol was added IN sodium hydroxide 11 ml) at 0 C. After stirring for an hour at the same temperature, the reaction mixture was concentrated to about 30 ml, adjusted to pH 2 with IN hydrochloric acid, and then extracted with ethyl acetate (300 ml). , The organic layer, was washed with 0.5N hydrochloric acid (30 ml) and brine, dried over magnesium sulfate and then concentrated in vacuo to give z white powder which was washed with ether. The powder was collected by filtration to give benzyloxycarbonyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (2) (3.46 g). N.M.R. (CD3OD), #(ppm) : 1.50 (18H, s), 3.98 (2H, s), 4.00-4.70 (4H, m), 5.17 (2H, s), 7.40 (5H, s) EMI238.1 Benzyloxycarbonyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH (2)(3.30 g) was added to trifluoroacetic acid (15 ml) and the mixture was allowed to stand at ambient temperature for 30 minutes.' The mixture was evaporated in vacuo and the residual oil was triturated with ether to give 2 powder (3.38 g). The solid was dissolved in water (60 ml) and to the solution were added IN sulfuric acid and sodium periodate (1.78 g) at 0 C. After stirring at the same temperature for an hour, the reaction mixture was treated with sodium bisulfite, concentrated to about 5 ml, adjusted to pH 2 with 1N sodium hydroxide and put on ? column of macroporous non-ionic adsorption resin, HP 20 (400 ml). The fraction eluted with a mixture of water and methanol (6:4) were combined and evapo- rated in vacuo to give benzyloxycarbonyl-L-Ala-&gamma;- D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH (3)(1.03 g). mp 206-207 C. N.M.R. (D2O), #(ppm) : 1.37 (3H, d, J=7Hz), 3.78 (1H, m), 3.93 (2H, s), 4.05-4.40 (3H, m), 5.14 (2H, s), 7.45 (5H, s) Example 32 (1) Step 1 EMI239.1 EMI240.1 Triethylamine (720 mg) and Z-L-Ala-D-Glu(oSu)oBzl (1)(3.51 g) was added to z solution of Boc-(D)- meso-DAP-(D)-NHNHBoc-(L)-GlyOH (2)(3.00 g) in a mixture of dioxane (90 ml) and water (70 ml). T"ne resulting mixture was allowed'to stand at ambient temperature for 18 hours, and concentrated to about SO ml. The concentrate' was adjusted to pH 3 with 1N hydrochlorc acid and extracted with ethyl acetate (300 ml) containing methanol (20 ml). The organic layer was washed with brine (100 ml), dried over sodium sulfate and then evaporated in vacuo1 The residue was washed with 'ether and filtered to Z-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc- (D)-meso-DAP-(D)-NHNHBoc-(L)-GlyOH (3)(5.53 g). N.M.R. (DMSO-d6), #(ppm) : 1.07 (3H, d, J=7Hz), 3.64-4.48 (6H, 5.04 (2H, s), 5.12 (2h, s), 6.56 (1H, d, J=8Hz9, 7.35 (10H, s), 7.95 (1H, d, J=8Hz), 8.15 (1H, m), 8.35 (1H, d, J=8Hz), 8.70 (1,R, s), 9.56 (1H, s) (2) Step 2 EMI241.1 A solution of compound (3)(5.26 g) in acetic acid (120 ml) was hydrogenated over 10% palladium black (2.0 g) under an atmospheric pressure of hydrogen. After the catalyst was filtered off and washed with acetic acid, the filtrate and the washings were combined and then evaporated in vacuo. The residual oil was triturated with ether to give L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-glyOH (4)(3.90 g). I.R. (Nujol) ; 3250, 1660 (shoulder), 1515 cm'1 N.M.R. (D2O), #(ppm) : 1.54 (3H, d, J=8Hz), 3.88 (2H, s), 3.95-4.50 (4H, m) 'The following compounds were prepared in sub stantially the same manner 25 that of Steps 1 and 2 of Example 1, respectively. Example 33 (1) Step 1 Diphenylacethyl-L-Ala-#-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)GlyOH N.M.R. (CD3OD), 6(ppm : 1.42 (18H, S), 3.92 (2H, s), 3.83-4.52 (4H, m), 5.08 (1H, s), 7.92 (10H, s) (2) Step 2 Diphenylacethyl-L-Ala-#-D-Glu(c-OH)-(L)-mesoDAP-: CL) -GlyOR N.M.R. (D2O+NaHCO3), #(ppm) : 1.40 (3H, d,J=7Hz), 1.20-2.25 (10H, m),3.71 (1H, m), 3.80 (2H, s), 4.10-4.50 (3H, m), 5.17 (1H, s), 7.35 (10H, s) Example 34 (1) Step 1 N-(N-Benzyloxycarbonyl-L-5-oxo-2-pyrrolidine carbonyl)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-GlyOH N.M.R. (CD3OD), #(ppm) : 1,47 (18H, s), 3.97 (ZH, s), 5.27 (2H, s), 7.39 (SH, s) (2) Step 2 N-(N-Benzyloxycarbonyl-L-5-oxo-2-pyrrolidine carbonyl)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH [&alpha;]D=-55.0 (C=0.14, water) N.M.R. (D2O), #(ppm) : 1,18 (3H, d, J=7Hz), 1.3-2.8 (14H, m), 3.80 (1H, t, J=7Hz), 3.94 (2H, s), 5.19 (2H, ABq), 7.39 (5H, s): (3) Step 3 L-5-oxo-2-pyrrolidinecarbonyl-L-Ala-#-D-Glu(&alpha;-OH) (L)-mesoDAP-(L)-GlyOH N.M.R. (D2O), #(ppm) : 1.42 (3H, d, J=7Hz), 3.79 -(1H, t, J=7Hz), 3.95 (2E, s), 4.15-4.50 (4H, m) Example 35 (1) Step 1 EMI244.1 D-Lac(OAc)-L-Ala-#-D-Glu(&alpha; ;-OBzl)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-ss-AlaOH(3) was prepared in substantially the sane manner as the step 1 of Example 12 from compound (1) 2nd, (2), N.M.R. (DMSO-D6) # (ppm): 0.9-2.6(16H, m), 1.38(18H, s), 2.05(3R, S), 2.9-4.7(8H, m), 5.00 (1H, q, J=7EZ), 5.14(2H, s), 6.5-6.7(1H, m) 7.39(5H, S), 7.7-8.4(4H, m), 8.65(1H,broad S), 9.55(1H, broad S) (2) Step 2 EMI244.2 D-Lac-Ala-#-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-ss-AlaOH (4) was prepared in substantially the same manner as the step 2 of Example 12 from compound (3). N.M.R.(D2O), #(ppm): 1.2-2.8(16H, m), 1.38(18H, S), 2.55(2H, t, J=7Hz), 3.43(2H, t, J=Hz), 3.8-4.5(5H, m) (3) Step 3 EMI245.1 Di-trifluoroacetic acid sald of D-Lac-L-Ala-#-D Glu(&alpha;-OH)-(L)-mesoDAp-(D)-NHNH2-(L)-ss-AlaOH (5) was prepared in substantially the same manner the step 3 of Example 12 from compound (4). N.M.R.(D2O), #(ppm): 1.1-2.8(10H, m), l.37(3E, d, J=7Hz), 1.42(3H, d, J=7EZ), 2.58(2H, t, J=6Hz),3.47(2H,t, J=6Hz), 2.9-4.6(5H, m) (4) Step 4 EMI245.2 D-Lac-L-Ala-#-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-ss-AlaOH (6) was prepared in substantially the same manner as the step 4 of Example 12 for compound (5). N.M.R.(D2O), #(ppm): 1.37(3H, d, J=7Hz), 1.44(3H, d, J=7Hz), 1.2-2.7(10H, m), 2.61(2H, t, J=7Hz), 3.47(2H, t, J=7Hz), 3.83(1H, t, 4.0-4.6(4H,m) Example 36 (1) Step 1 EMI246.1 D-Lac-L-Ala-#-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-D-GluOH (3) was prepared in substantially the same manner as the step 1 of Example 12 from compounds (1) and (2) N.M.R.(DMSO-d6), #(ppm): : 0.9-2.5(14H, m), C1.40(18H, S), 2.07(3H, S), 3.6-4.6(5H, m), 4.99(1H, q, J=7Hz), 5.15(2H, S), 6.5-6.9(1H, m), 7.39(5H, S), 7.7-9.1(5H, m), 9.55(1H, broad S) (2) Step 2 EMI247.1 D-Lac(OH)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-D-GluOH (4) was prepared in substantially the same manner as the step 2 of . Example 12 from compound (3). N.M.R.(D2O), #(ppm): 1.3-2.8(14H, m), 1.45(18H, S), 3.9-4.6(6H, m) (3) Step 3 EMI247.2 Di-trifluoroacetic acid salt of D-Lac-L-Ala-#-D Glu(&alpha;-OH)-(L)-mesoDAP-(D)-NHNH2-(L)-D-GluOH (5) was prepared in substantially the same menner as the step 3 of Example 12 from compound (4). N.M.R.(D2O), #(ppm): 1.1-2.7(m), 1.35(3H, d, J=7Hz), 1.42(3H, d, J=7Hz), 3.9-4.6(6H, m) (4) Step 4 . - EMI248.1 D-Lac-L-Ala-#-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-ss-AlaOH (6) was prepared in substally the same manner as the step 4 of Example 12 from compound (5). Example 37 (1) Step 1 EMI248.2 D-Lac (OAc) -L-Al2-y-D-Glu (:-OBZ1) - (X) -Boc- (D) - mesoDAP-(L)-NHNHBoc-(L)-L-AlaOH (3) was prepared in substantially the same manner as the step 1 of Example 12 from comoounds (1) and (2). N.M.R.(DMSO-D6), #(ppm): 1.2-2.4(19H, m), 1.43(18H, S), 2.10(33, S), 3.8-4.8(53, m), 5.04(1H, q, J=7EZ), 5.19(2H, S), 6.5-7.0(1H, m), 7.42(5H, S), 7.7-8.9(5H, m), 9.61(1H, broad S) (2) Step 2 EMI249.1 D-Lac-(OH)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-L¯AlaOH (4) was prepared in substantially the same manner as the step 2 of Example 12. N.M.R.(D2O), #(ppm): 1.3-2.8(19H, m), 1.45(18H, S), 3.9-4.6(6H, m) (3) Step 3 , EMI249.2 Di-teifluoroacetic salt of D-Lac(OH)-L-Ala #-D-Glu(&alpha;-OH)-(L)-mesoDAP-(D)-NHNH2-(L)-L-Ala(OH)(5) was prepared in substantially the same manner as the step 3 of Example 12 from compound (4). N.M.R.(D2O), #(ppm): 1.2-2.7(10H, m), 1.39(3H, d, J=7Hz), 3.9-4.7(6H, m) (4) Step 4 EMI250.1 D-Lac-(OH)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-L- Ala(OH) (6) was prepared in substantially the same monner as the step 4 of Example 12 from compound (5). [&alpha;]D=-41.0(C=0.42, water) N.M.R.(D2O), #(ppm): 1.37(3H, d, J=7Hz), 1.43(6H, d, J=7HZ), 1.2-2.5(10H, m), 3.8(1H, t, J=6Hz), 4.1-4.5(5H, m) Example 38 EMI251.1 D-Lac-(OAc)-L-Ala-#-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP-(D) NHNHBoc-(L)-D-Phe(OH) (3) was prepared in substantially the same manner as the step 1 of Example 12 from compound (1) and (2). NMR(DMSO-d6), #(ppm): 1.0-2.4(16H, m), 1.39(18H, s), 2.05 (3H. s), 2.8-3.2 (2H, m), 3.7-4.7 (5H, m), 4.99 (lH, q, J=7Hz), 5.16 ( 2H, s), 6.65 (1H, broad d,J= 8Hz),7.23 (5H, s), 7.39 (5H, s), 7.6-8.9 (5H, m), 9.56 (1H, broad s) (2) Step 2 EMI251.2 D-Lac-(OH)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-D-PheOH (4) was prepared in substantially the same manner as step 2 of Example 12 from compound (3). I.R. (Nujol) : 3270, 1720 (shoulder), 1645 (broad), 1520 (broad) cm-1 (3) Step 3 EMI252.1 Di-trifluoroacetic acid salt of D-Lac(OH)-L-Ala-#-D-Glu (&alpha;-OH)-(L)-mesoDAP-(D)-NHNH2-(L)-D-PheOH (5) was prepared in substantially the same manner as the step 3 of Example . 12 from compound -(4). N.M.R.(D2O), #(ppm): 1.1-2.7(10 H, m), 1.46(3H, d, J=7Hz 1.50 -(3H, d, J=7E'z), 2.8-3.5 (2E, m), 3.9-4.7 (6H, m) 7.41 (5H, s) (4) Step 4 EMI252.2 D-Lac-(OH)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D-PheOH (6) was prepared in substantially the same manner as the step 4 of Example 12 from compound (5). [&alpha;]D=-28.6 (c=0.511 water) N.M.R.(D2O), #(ppm): 1.1-2.5(10H, m), 1.36(3H, d, J=7Hz), 1.42 (3H, d, J=7Hz), 3.14 (2H), 4.0-4.5 (5H, m), 7.1-7.5 (5H, m). Example, 39 (1) Step 1 EMI254.1 D-Lac-(oAc)-L-Ala-#-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-SarOH (3) was prepared in substantially the same manner as the step 1 of Example 12 froze compounds (1) and (2). N.M.R. (DMSO-D6), #(ppm): 1.0-2.4(16H, m), 1.35 (18H, s), 2.03 (3H, s), 2.80 and 3.05 (3E, a pair of singlets), 3.6-4.5 (6H, m), 4.98 (1H, q, J=7Hz), 5.13 (2H, s), 6.5-7.0 (1H, m), 7.3 (1H, m), 7.35 (5H, s), 7.7-9.0 (4h; M), EMI254.2 D-Lac-(OH)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-Sar OH (4) was prepared in substantially the same manner as the step 2 of Exan,ple 12 from compound 3. N.M.R.(D2O), #(ppm): 1.1-2.5(16H, m), 1.41(9H, S), 1.43 (9H, s), 2.93 and 3.18 (3E; a pair of singlets), 3.7-4.5 (7H, m). (3) Stew 3 EMI255.1 Di-trifluoroacetic acid salt of D-Lac(OH)-L-Ala-#-D- Glu(&alpha;-OH)-(L)-mesoDAP-(D)-NHNH2-(L)-Sar OH (5) was prepared in substantially the same manner as step 3 of Example 12 from compound (4). N.M.R. (D2O), #(ppm): 1.0-2.6 (10H, m), 1.35 (3H, d J=7Hz), 1.41 (3H; d, J=7Hz), 2.93 and - - 3.17 (3E, a pair of singlets), 3.8-4.6 (7H, m). (4) Step 4 EMI255.2 D-Lac-(OH)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-Sar OH (6) was prepared in substantially the same manner as the step 4 of Example 12 from compound (5). [&alpha;]D=-37.6 (C=0.402, water) N.M.R.(D2O), #(ppm): 1.1-2.5(10H, m), 1.35(3H, d, J=7Ez), 1.41 (3H, d, J=7Hz), 2.96 and 3.20 (3H, a pair of singlet), 3.70-4.0 (1H, m), 4.0-4.6 (6H, m). Example 40 (1) Step 1 EMI257.1 D-Lac-(OH)-L-Ala-#-D-Glu(&alpha;-OBzl)- (L) -30c- (D)-meso DAP- (D) NHNHBoc-(L)-D-AlaOH (3) was prepared in substantially the same manner as step 1 of Example', 12 from compounds (1) and (2) . 6),#(ppm): 0.9-2.6(37H,m), 2.10(3H,s), 3.7-4.7(5h,m), 5.01(1H,q,J=Hz),5.19(2H,s) 6.6-7.0(1H,m), 7.42(5H,s),7.7-8.9(5H,m), 9.60(1H,broad s) .(2) Step 2 . - EMI258.1 D-Lac-(OH)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso DAP-(D) NHNH#Boc-(L)-D-AlaOH (4) was prepared in substantially the same manner as the step 2 of Example 12 from compound (3) (3) Step 3 EMI258.2 Di-trifluoroacetic acid salt of D-Lac (OH)-L-Ala-#-D- Glu(&alpha;-OH)-(L)-meso DAP-(D)-NHNH2-(L)-L-Ala(OH) (5) was prepared in substantially the same manner as the step 3 of Example 12 from compound (4). NMR (D2O), #(ppm): 1.36(3H, d, J=7Hz), 1.41 (6H, d,J=7Hz), 1.1-2.7 (10H, m), 3.9-4.7(6H,m) (4) Step 4 EMI259.1 D-Lac-(OH)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D-AlaOH (6) was prepared in substantially the same manner as the step 4 of Example 12. [&alpha;]D=-17.4 (C=0.305, water) NMR (D2O), #(ppm): 1.38(3H, d, J=7Hz), 1.41 (3H, d,J=7Hz), 1.44(3H, d, J=7Hz), 1.2-2.6(10H,m) 3.84(1H, t, J=6Hz), 4.1-4.6(5H,m) The following compounds were prepared in sub stantially the same manner as that of Steps 1 and 2 of Example 1, respectively. Example 41 (1) Step 1 EMI260.1 N.M.R.(DMSO-d6), #(ppm): 0.80-2.40(44H, m), 3.67-4.67 (4H, m), 6.70 (1H, d, J=7Hz), 7.83 (1H, d, J=7Hz), 8.03 (2H, d, J=7Hz), 8.60 (1H,s), 9.53 (1H, s) (2) Step 2 EMI260.2 N.M.R. (D2O), #(ppm): 0.84 (3H, t,J=7Hz), 1.36 (3H, d, J=7Hz), 1.0-2.60 (20 H, m), 3.80 (1H, t, J=7Hz), 4.10-4.52 (3H, m) Example 42 (1) Step 1 EMI261.1 The compound (3) was prepared in substantially the same manner as the step 1 of Example 12. N.M.R.(DMDO-d6), #(ppm): 1.00-2.40 (10H, m), 1.24 (3H, t, J=7Hz), 1.40 (18H,s), 3.80-4.48 (4H, m), 5.04 (2H, s), 5.12 (2H,s), 6.74 (1H, d, J=7Hz), 7.36 (10H, s), 8.04(1H, d, J= 7Hz), 8.32 (1H, d, J=7Hz), 8.68 (1H,broad s), 9.60 (1H, s). (2) Step 2 EMI261.2 The compound (4) was prepared in substantially the same manner as the step 2 of Example 12. N.M.R. (D2O), #(ppm): 1.36-2.66 (13H, m), 1.43 (18H, s) 3.83-4.43 (4H, m). (3) Step 3 EMI262.1 The compound (5) was prepared in substantially the same matiner as the atep 1 of Example 1. N.M.R. (DMSO-d6), #(ppm): 1.25 (3H, d, J=7Hz), 1.40 (18H, s), 1.30 - 2.40 (10H, m), 3.83 4.50 (4H, m), 5.06 (2E, s), 6.76 (1H, d, J=7Hz. 7.38 (5H, s), 8.13 (2H, d, J=7Hz) 8.70 (1H, broad s), 9.60 (1h; S). EMI262.2 The compound (6) was prepared in substantially the same 'manner as the step 4 of Example 12. N.M.R. (D2O), #(ppm): 1.34 (3H, d, J=7Hz), 1.10-2.43 (10H, m) 3.71 (1H, t, J=7Hz), 3.91-4.30 (3H, m), 5.10 (2H, s), 7.40 (5H, s). (5) Step 5 . EMI263.1 The compound (7) was prepared in, substantially the same manner as the Step: 2 of Example 11. N.M.R. (D2O), #(ppm): 1.52 (3H, d, J=7Hz), 1.20-2.52 (10H, m) 3.76 (1H, t, J=7Hz), 4.00-4.40 (3H, m). ,The following compounds were prepared in substantially the same mariner as step 1 to 4 of Example 12, respectively: Example 43 (1) Step 1 D-Lac-(oAc)-L-Ala-#-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc. N.M.R.(DMDO-d6), #(ppm): 1.1-2.5(16H, m), 1.38(18H, s), 2.04 (3H, s), 3.8-4.7 (16H, m), 4.95 (1H, q, J=7Ez), 5.10 (2H, s), 7.30 (5H, s), 8.08 (2E, broad t, J=8Hz). (2) Step 2 D-Lac-(OH)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc I.R. (Nujol): 1720, 1650, 1525 cm-1 (3) Step 3 D-Lac-(OH)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-mesoDAP-(D)-NHNH2 (trifluoroacetic acid salt) N.M.R. (D2O), #(ppm): 1.40 (3H, d, J=7Hz), 1.45 (3H, d, J=7Hz), 1.2-2.7 (10H, m), 4.0-4.7 (5H, m). (4) Step 4 D-Lac-(OH)-L-Ala-#-D-Glu(&alpha;-OH)-(L)-mesoDAP [&alpha;]D=-21.3 (c=0.258, water) N.M.R. (D2O), #(ppm): 1.1-2.5 (10H, m), 1.35 (3H, d, J=7Hz), 1.42 (3H, d, J=7Hz), 3.88 (1H, t, J=6Hz), 4.0-4.5 (4H, m). Example 44 (1) Step 1 Benzyloxycarbonyl-L-Ala-#-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-D-AlaOH I.R. (ujol) : 3290, 1720, 1650, 1630,. 1530 cm-1 N.M.R. (CD3OD), #(ppm): 1.39 (18H, s), 3.75-4.55 (5H, m) 5.06 (2H, s), 5.12 (2H, s) 7.23 (10H, s). (2) Step 2 L-Ala-#-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)-NHNH- Boc-(L)-D-AlaOH m.p. 174 (dec) I.R. (Nujol) : 3300, 1655, 1525 N.M.R. (D2O), #(ppm): 1.45 (18H, s), 3.98-4.60 (5H, m) (3) .,Step ,3 Heptanoyl-L-Ala-#-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- NHNHBoc-(L)-D-AlaOH I.R. (NUjol) : 3300, 1720,(shoulder), 1650 cm-1 N.M.R. (DMSO-D6), ppm) : 0.88 (3H, t, J=7Ez), 1.0-2.4(44H, m), 4.0-4.6(5H, m) (4) Step 4 Heptanoyl-L-Ala-#-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)-D- AlaOH [&alpha;]D=-26.0 ( c=0.2, water) I.R. (NUjol) : 3250, 1720, 1640 cm-1 N.M.R. (D2O), #(ppm): 0.86 (3H, t, J=7Hz), 1.0-2.5 (26H, m), 3.84 (1H, t, J=7Hz), 4.2-4.56 (4H, m) Example 45 (1) Step 1 Acetoxyacetyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso- DAP-(D)-NHNHBoc-(L)-D-AlaOH I.R. (Nujol) : 3280, 1720, 1650, 1520 N.M.R. (CD3OD), # (ppm) : 1.47, (18H,s), 2.14 (3H, s), 4.07-4.70 (5H, m), 4.63 (2H, s) (2) Step 2 Glycoloyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D- AlaOH I.R. (Nujol) : 3280, 1720, 1630, 1530 cm-1 N.M.R. (D2O), #(ppm) : 1.41, (3H, d, J=7Hz), 1.43 (3H, d, J=7Hz), 3.83 (1H, t, J=7Hz), 4.14 (2H, s), 4.2-4.55 (4H, m). Example 46 (1) Step 1 O-Acetyl-D-Mandelyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc- (D)-mesoDAP-(D)-NHNHBoc-(L)-D-AlaOH I.R. (Nujol) : 3280, 1720, 1650, 1520 cm-1 N.M.R. (CD3OD), #(ppm) : 1.39, (18H, s), 2.15 (3H, s), 3.9-4.6(5H, m), 5.87 (1H, s), 7.38 (5H, s) (2) Step 2. D-Mandelyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- D-AlaOH I.R. (Nujol) : 3270, 1715, 1640, 1520 cm-1 N.M.R. (D2O), #(ppm) : 1.35 (3H, d, J=7Hz), 1.43 (3H, d, J=7Hz), 3.80, (1H, t, J=7Hz), 4.1 4.5 (4E, m), 5.18 (19, s), 7.32 (5E, s) Example 4 7 (1) Step 1 Phenylacetyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso- DAP-(D)-NHNHBoc-(L)-D-AlaOH I.R. (Nujol) : 3280, 1720, (shoulder), 1650, 1520 N.M.R. (CD3OD), #(ppm) : 1.40 (18H, s), 3.59 (2H, s), 3.94-4.50 (5H, m), 7.27 (5H, s) (2) Step 2 Phenylacetyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- D-AlaOH I.R. (Nujol) : 3250, 1715, 1640, 1530 cm-1 N.M.R. (D2O), &gamma;(ppm) : 1.36 (3H, d, J=7Hz), 1.40 (3H, d, J=7Ez), 3.65 (2E, s), 3.80 (1H, t, J=7Hz), 4.20-4.55 (4H, m), 7.36 (5H, s) Example 48 (1) Step 1 Benzyloxycarbonyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-D-AlaOH I.R. (Nujol) : 3270, 1715 (shoulder), 1650, 1520 cm N.M.R. (CD3OD), #(ppm) : 1.41 (18H, s), 3.95-4.50 (5H, m), 5.07 (2H, s), 7.28 (5H, s) (2) Step 2 Benzyloxycarbonyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP- (L)-D-AlaOH [&alpha;]D= -57.4 (c=0.24, water) I.R. (Nujol) : 3250, 1700 (shoulder), 1640, 1520 cm-1 N.M.R. (D2O), #(ppm) : 1.40 (6H, d, J=8Hz), 3.86 (1H, t, J=6Hz), 4.07-4.50 (4E, m), 5.10 (2E, s), 7.40 (5H, s) Example 49 (1) Step 1 Benzyloxycarbonyl-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-meso- DAP-(L)-GlyOH I.R. (Nujol) : 3260, 1730-1630 (broad) cm N.M.R. (DMSO-d6), #(ppm) : 1.20-2.40 (10H, m), 1.40 (18H, s), 3.76 (2H, d, J=7Hz), 4.0-4.5 (3H, m) 5.08 (2E, s), 5.15 (2H, s), 7.40 (10E, s) (2) Step 2 &gamma; -D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDap-(d)-NHNHBoc-(L)- GlyOH I.R. (Nujol) : 3250 (broad), 1720-1620 (broad) cm-1 N.M.R. (D2O), # /ppm) : 1.20-2.70 (28H, m), 3.83 (1H, t, J=7Hz), 3.94 (2H, s), 4.0-4.5 (2H, m) (3) Step 3 Heptanoyl-&gamma; -D-Glu(&alpha; -OH)-(L)-Boc-(D)-mesoDAP-(D) NHNHBoc-(L)-GlyOH I.R. (Nujol) : 3250, 1720 (shoulder), 1650 (broad) cm N.M.R. (DMSO-d6), #(ppm) : 0.86 (3H, t, J=7Hz), 1.0 2.4 (38 H, m), 3.70 (2H, a, J=7Hz), 4.0-4.5 (3H, m) (4) Step 4 Heptanoyl-&gamma; -D-Glu(&alpha; -OH)-(L)-mesoDAP-(L)-GlyOH [&alpha; ]D=-18.0 (c=0.2, water) I.R. (Nujol) : 3300, 1720, 1640 (broad) cm N.M.R. (D2O), #(ppm) : 0.84 (3H, t, J=7Hz, 1.0 2.60 (20 H, m), 3.80 (1H; t, J=7Ez), 3.96 (2H, 5), 4.20-4.48 (2H, m) Example 50 (1) Step 1 EMI270.1 To ad mixture of Boc-(D)-mesoDAP-(L)-D-AlaOH (1) (361 mg.) and triethylamine (202 mg.) in 50% aqueous dioxane (20 ml.) was added Z-D-Glu(OSu)OBZ1 (2) (440 mg.) and the reaction mixture was concentrated and washed with ethyl acetate. The organic layer was acidified -with diluted hydrochloric acid and extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and evaporated to give a foamy residue, which was pulverized with isopropyl ether and collected by filtration to give a white powder (520 mg.) of Z-y D-Glu(&alpha; -(L)-Boc-(D)-mesoDAP-(L)-D-AlaOH (3). I.R. (Nujol): 330, 1720, 1690, 1640, 1530 cm-1 N.M.R. (DMSO-d6), #(ppm): 1.38 (9H, s), 1.00-2.66 (13H, m), 3.66-4.50 (4H, m), 5.07 (2H, s), 5.15 (2E, s), ".38 (10E, s) . (Z) Step 2 EMI271.1 Z-&gamma; -D-Glu(&alpha; -OBzl)-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOH (3) (502 mg) was dissolved in acetic acid (20 ml) and hydro- genated over 10% palladium-charcoal (100 mg) . The cataly st was removed by filtration and the filtrate was evaporat- ed to give an oil, to which toluene was added and evaporat ed to give a pasty residue. This residue was dissolved in water and submitted to 2 column o HP-20 (50 ml), a macro- porous non-ionic adsorption resin. The column was eluted successively with water and metahnol-water (1:4). Evapo ration of the latter fractions gave a white foam, which was dissolved in water and lyophillized to give a white powder (290 mg) of &gamma; -D-Glu(&alpha; -OH)-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOH (4). I.R. (Nujol):3250, 1720-1630 (broad), 1530 cm-1 N.M.R. (D2O), #(ppm): 1.48 (9H, s), 1.10-2.66 (13 H, m), 3.77 (1H, t, J=7Hz), 4.00-4.66 (3H, m). (3) Step 3 EMI272.1 To a mixture ol, &gamma; -D-Glu(&alpha; -OH)-(L) -Boc- (D) -mesoDAP (L)-D-AlaOH (4) (280 mg) and triethylamine (175 mg) in methanol (5 ml) was added a solution of stearic anhydride (478 mg) in chloroform (10 ml) and the mixture was kept for 3 days at room temperature. The reaction mixture was concentrated and the residue was dissolved in ethyl acid. tate. The ethyl acetate was washed successively with diluted hydrochloric-acid and water, dried over magnesium sulfate and evaporated to give a foamy residue, which was pulverized with ether and collected to give a white powder (310 mg) of stearoyl-&gamma; -D-Glu(&alpha; -OH)-(L)-Boc-(D)-mesoDAP- (L)-D-AlaOH (5). I.R. (Nujol): 3300, 1710, 1695; 1660 1620 (broad), 1540 cm-1 'N.,M.R. (CD3oD), 6 #(ppm): 0.90 (3 H, t, J=5 Hz), 1.33 (30 H, s), 1.44 (9H, s), 1.16-2.66 (15H, m), 3.66-4.66 (4 H, m). (4) Step 4 EMI273.1 Stearoyl-&gamma; -D-Glu(&alpha; -OH)-(L)-Bpoc-(D)-mesoDAP-(L)-D AlaOH (5) (308 mg) was added to trifluoroacetic acid (5 ml) and the mixture was stirred for 1 hour at room tempe rature. The reaction mixture was concentrated and tri turated with ether to give a white powder, which was wash- ed with ether and methanol to give stearoyl-&gamma; -D-Glu(&alpha; -OH) (L)-mesoDAP-(L)-D-AlaOH(6) (230)mg.) as a white powder. i.R. (Nujol): 3300, 1730, 1 1640, 1530 cm-1 N.M.R. (D2O#NaOD), #(ppm): 0.86 (3H, t, J=6 Hz), 1.30 (30H, m), 1.00-2.66 (15H, m), 3.21 (1H, ti J=7 Hz), 4.00-4.20 (3 E, m). Example 51 EMI274.1 Compound (2)(4.75 g) was dissolved in a mixture dioxane (30 ml) and water (30 may containing tri Sethylamine (1.01 g). To this solution, there was added compound (1) (4.4 g) and the resulting solution was left for 1 day at ambient temperature. The re action mixture was concentrated and the concentrates were subjected to extraction with ethylacetate. The organic layer was washed with water, dried over magnesium sulfate (Mg S04) and then evaporated to give a a formy.residues, which were pulverized with diiso-. propylether and collected by filtration to give compound (3)(5.77 g) white powder. I.R. (Nujol):2170, 1730-1620 (broad) N.M.R. (DMSO-d6), #(ppm):1.37 (18H, s), 1.18-2.33 (13H, m), 3.66-3.84 (4H, m), 5.06 (2E, s), 5'.16 (2H, s), 7.36 (10H, s) EMI275.1 Compound (3) (3.88 g) was dissolved in acetic acid (100 ml) and hydrogenated over palladium-charcoal (300 mg). Caralyst, i.e. palladium-charcoal was removed by filtration and the filtrate was evaporated under reduced pressure to give an oily paste, to which toluene was added. The resulting solution was evaporated to g.ive white powder residues, which were washed with diisopropylether and collected by filtration to give compound (4)(2.l0 g) as white powd,e'r. I.R. (Nujol): 3300-2300 (broad), 1720-1620 (broad) N.M.R. (D2O), #(ppm):1.47 (18H, s), 1.33-2.66 (13H, m), 3.66-4.50 (4H, m) EMI275.2 EMI276.1 Compound (1)(596 mg) was dissolved in methanol (30 ml), and to this solution, there ere added tri ethylamine (202 mg) and haptanoic anhydride (2)(363 mg) successively. The reaction mixture was kept for 3 days at: ambient temperature, and then concentrated. The concentrates were subjected to extraction with ethylacetate. The organic layer was washed with 10% aqueous hydrochloric acid and water, and dried over magnesium sulfate (MgSO4) and then evaporated to give a foamy residue, which was pulverized with ether and collected by filtration to give compound (3)(470 mg) as white powder. I.R. (Nujol):3300, 1740-1730 (broad) N.M.R. (DMSO-D6), #(ppm):0.89 (3H, t, J=7Hz), 1.00-2.40 (23H, m), 3.66-4.66 (4H, m) EMI276.2 Compound (3)(430 mg) was dissolved in trifluoroacetic acid (10 ml) and the 'solution was kept for 30 minutes at ambient temperature. The solution was evaporated to give an oily paste which was dissolved in 0.1N-sulfuric acid (13 ml) and water (8 ml) and cooled in an ice-bath. To this solution, ' there was added aqueous NaIO4 (278 mg in 5 ml water) under stirring, and the stirring was continued for 1 hour. The resulting reaction mixture was treated with aqueous NtHS03 solution untill purple color of the solution disappeared. The pH of the solution was made neutral by addition of aqueous NaHCO3 solution and the whole volume of the solution was concentrated. The pH'of the solution was adjusted again to 2.0 and the hole solution was submitted to column o of HP-20 resin (50 ml).' The column was eluted with water and then methanol-water (1:2). The latter fractions wee evaporated gave a white for, my substance, which was dissolved in water and then the solution was lyophillized to give compound (4)(240 mg) as white powder, I.R. (Nujol) : 3250, 1740, 1666"-1640 (broad) N.M.R. (D2O), #(ppm):0.82 (3H, t, J=6Hz), 1.00-2.60 (20H, m), 1.35 (3H, d, J=8Hz), 3.81 (1H, t, J=7Hz), 4.40-4.80 (3H, m) EMI277.1 EMI278.1 Compound (1)(596 mg) was dissolved in methanol (30 ml) and chloroform (5 ml), and to this solution, there were added triethylamine (202 mg) and lauric anhydride (2) (609 mg) successively. The reaction mixture was treated substantially in the same manner as the Step 1 of Example 52 to-give compound (3)(570 mg) as white powder. I.R. (Nujol): 5230, 1725-1610 (broad) N.M.R. (DMSO-d6), 6 (ppm) : 0.84 (3H, t,, J=7Hz), 1.30 (18H, s), 1.00-2.40 (33H, m), 3.80 4.40 (H, m) EMI278.2 Compound (3) (510 mg) was dissolved in trifluoroacetic acid (10 ml) and the solution was kept for 30 minutes at ambient temperatdure. Hereafter, the reaction mixture was treated substantially in the same manner as the Step 2 of Example 52 to give compound (4)(250 mg) as white powder. I.R'. '(Nujol) : 3300, 1720, 1660-1620 (broad) N.M.R. (CD3OD), #(ppm): 0.90 (3H, t, J=7Hz), 1.00-2.60 (33H, m), 3.75 (1H, t, J=7Hz), 4.20-4.80 (3H, m) Example SA (1) Step 1' , ,", I EMI279.1 Compound (1) (596 mg) was dissolved in methanol (30 ml), and to this solution, there were added tri ethylamine (202 mg) and manderic anhydride (2)(267 mg) successively. The reaction mixture was treated substantially in the same manner as the Step 1 of Example 52 to give Compound (3) (330 mg) as white powder IR(Nujol): 3300, 1730 -. 1640(broad) 0025842 NMR(DMSO-d6), #ppm: 1.39 (18H, s), 1.16-2.33 (13H, m), 3.70-4.50 (4H, m), 5.00 (1H, broad s), 7.40 (5H, broad s) EMI280.1 Compound (3) (479 mg) was dissolved in trifluoroacetic acid (10 ml) and' the solution was kept for 30 minutes at ambient temperature. Hereafter, the reaction mixture was treated substantially in the same manner as the Step 2 of Example 53 to give Compound (4) (190 mg) as white powder. IR(Nujol): 3250, 1720, , 1660 - 1620 (broad) NMR(D2O), #ppm: 1.36 (3H, d, J=7Hz), 1.20-2.60 (lOE,m)1,.3.80(lH,t,J=6Ez), 4.10 - 4.60 (3H, m), 5.20 (1H, s), 7.42 (5H, s) Example 55 (1) Step 1 EMI281.1 Compound (1)(1.51 g) was dissolved in a mixture of methanol (15 ml) and water (10 ml). To this solution, there was added 1N-NaOH solution (4.0 ml) and the solution was kept for 2 hours at ambient temperature The reduction mixture was concentrated after adjusting the pH of the solution to 7.,0. The residual aqueous solution was diluted with water. After extraction 'with ether, aqueous layer was acidified to pH 2 with, 1N-HCl to separate an oily product, which was extracted with ethylacetate. The organic layer was washed 'with R20 and dried over Mg SO4 Evaporation of the solvent gave a white foam, which was pulverized with diisopropyl ether to give Compound (2) (1.16' g) as white powder. I.R. (Nujol):3250, 1740-1620 (broad) N.M.R. (DMSO-d6), #'(ppm):1.36 (18H, s), 11.00-2.40 (13H, m), 3.66-4.50 (4H, m), 5.03 (2H, s), 7.36 (5H, s) (2) Step 2 EMI282.1 Compound (2) (1.03 g.) was dissolved in trifluoro- acetic acid (10 ml.) and the solution was kept for 30 minutes at ambient temperature. Hereafter, the reaction mixture was treated substantially in the same manner as ,the Step, 2 of Example 2 to give Compound (3) (0.6 g.) as s white power. I.R. (Nujol): 3300, 1700, 1660-1620 (broad) N.M.R. (D2O), #(ppm) 1.36 (3H, d, J=7Hz), 1.20-2.60 (10H, m), 3.76 (1H, t, J=7Hz), 3.96-4.50 (3H, m), 5.08 (2E, s ), 7.40 (5H, s) (3) . Step 3 EMI282.2 Compound (3) (374 mg.) was dissolved in acetic acid (30 ml.) and hydrogenated over palladium-charcoal (100 mg.). Catalyst was removed by filtration and the filtrate was evaporated under reduced pressure to give an o"ly paste, to which tolUene was added. Evaporation of toluene gave white powder residue The residue was dissolved in water and submitted to column of HP-20 resin (100 ml.). The column was eluted with water.' Evaporation of the fractions containing the product was evaporated to, give a pasty residue, which was dissolved in H2O and the solution was lyophillized to give Compound (4) (200 mg.) as white powder. I.R. (Nujol)' : 3250-2500 (broad) 1680-1500 (broad) N.M.R. (D2O), #(ppm):1.36 (3H, d, J=7Hz), 1.20-2.60 (10H, m), 3.75 (1H, t, J=7Hz), 3.80 (lH, t, J=7Ez), 4.00-4.50 (2H ,m) Example 56 (1) Step 1 EMI284.1 Compound (1) was dissolved in dichloromethane (20 ml.) and N-methyl-morpholine (308 mg.) was added. This solution was cooled in 2 dry ice,,-- acetone bath (-17--19 C) under stirring, and to the solution, isobutylchlorocarbonate (417 mg.) was added. The reaction mixture was allowed to react for 20 minutes at the same temperature. To the resulting'reaction mixture was added to the solution of Compound (2) (1.41 g. ) in Z mixture of dichloromethane (40 ml.) and N, N-dimethylformamide (4 ml) containing bis (trimethyl silyl)acetamide (3 ml.). The reaction mixture was stirred for 2 hours at -18 C a-10 C and concentrated under reduced pressure to give an oily residue which was dissolved in ethylacetate (100 ml.) and washed with 0.5N-Hcl. The organic' layer was washed with brine and dried over MgSO4. Evaporation of the solvent gave a white foam which was throughly washed with ether to afford Compound (3) (2.42 g.) as white powder, mp. 145-1490C (decomp.) I.R. (Nujol): 3280, 1780. 1720. 1650 N.M.R. (CD3OD), #(ppm): 3.93 (2H, s), 5.18 (4H, s), 7.38 (10H, s). (2) Step 2 EMI285.1 To a solution of Compound (3) (2.36 g.) in methanol (25 ml.), there was added 1N-NaOh (5.6 ml.) and the mixture was stirred for 5 hours at ambient temperature. The reaction mixture was concentrated in vacuum, and to the residue, there was added 1N-HCl (6 ml.) and the solution was subjected to extraction' 'with ethylacetate, The organic layer was washed with 0.5N-HCl (30 ml.), dried over MgSO4 and evaporated in vacuum. The residual oil was treated with diethyl ether to give Compound (4) (1.8-6 g.) as white powder. I.R. (Nujol): 3300, 1680 (broad), 1625 N.M.R. (CD3OC), #(ppm): 1.46 (18H, s), 3.95 (2H, s) 4.00-4.50 (4E, m), 5.13 (2s, s) t 7.45 (5H, s) (3) Step 3 EMI286.1 Compound (4) (1. B g.) was added to trifluoroacetic acid (10 ml.) ) and the mixture was stood for 100 minutes at ambient temperature. The reaction mixture was eva- porated and the residue was triturated with ethyl ether to give a solid. The solid was dissolved in water (45 ml). To this solution, was added IN-H2SO4 (4.4 ml.) and NaIO4 (930 mg.) at 0 C. After stirring for 2 hours at 0 C, the reaction mixture was treated with aqueous NaHSO3, concentrated to about 10 ml, adjusted to pH 2 with IN-NaOH and submitted to column of HP-20 resin (200 ml.). The column was eluted with water-methanol '(3:2) and the f;actions were combined and evaporated, and then the residue was lyophilized to give Compound (5) (680 mg.). I.R. (Nujol): 3270, 1700, 1640, 1520 N.M.R. (D2O), #(ppm): 1.3-2.6 (14H, m), 3.83 (1H, t, J=7Hz), 3.95 (2H, s), 4.05-4.50 (3H, m), 5.11 (2H, s), 7.40 (5H, s). (4) Step 4 EMI286.2 A solution of Compound (5) (550 mg.) in water (6 ml.,) was hydrogenated over 10% palladium-carbon (180 mg.) under an atmospheric pressure of hydrogen gas. After the catalyst was filtered off, the filtrate was evaporated in vacuum and lyophylized to give Compound (6)(45Omg). I.R. (Nujol): 3250, 1720 (shoulder), 1630, 1530 N.M.R. (D2O), #(ppm): 1.3-2.6 (14H, m), 3.74 (1H, t, J= 6Hz), 3.85 (2E, s), 3.99-4.50 (3E, m). Example 57 EMI287.1 To a mixture of Compound (1) (674 mg.) and N-methylmorpholine (202 mg.) in dichloromethane (30 ml.), there was added isobutyl chloroformate (273 mg.) at -15#-20 C and the mixture was stirred for 30 minutes at the same temperature. The mixture was cooled to -40 C, and to this, there was added trimethyl silyl ester of compound (2), which was prepared from Compound (2) (910 mg.) and bis (trimethylsilyl) acetamide (3 ml,) by, stirring in a mixture of dichloromethane (20 ml.) and N, N-dimethylformamide (2 ml.). This mixture was stirred for 1 hour at -15#-20 C., and after evaporation of the solvent, the residue was dissolved in ethylacetate (100 ml.),and then the 'solution was washed successively with 2% HCl and water, dried over MgSO4 and evaporated. The residue was pulverized with isopyropyl ether to give Compound (3) (1.25 g.). N.M.R. (CDCl3), #)ppm): 1.43 (27H, s), 1.3-2.4 (10H, m), 3.8-4.5 (5H, m), 5.13 (2H, s), 7.33 (5H, s). (2) Step 2 EMI288.1 To a solution of Compound (3) (1.08 g.) in 50% aqueous methanol (10 ml.) was added 1N-NaOH (3 ml.) and the mixture was stirred for 3 hours at ambient temperature. The reaction mixture was neutralized with IN hydrochloric acid (3 ml.) and evaporated. The residue was dissolved izi trifluoroacetic acid (5 ml.) and stirred for 15 minutes -at ambient temparature. After evaporatuion of triflu oroacetic acid, 'the residue was pulverized with diethyl ether. The powder thus obtained was dissolved in water (10 ml.), and 1N hydrochloric acid (1.7 ml.) was added thereto. To this solution, was added a solution of NaIO4 (354 mg.) in water (2 ml.) at o DC, and, the mixture was stirred forlhour at the same temperature. After excess of NaIO4 was decomposed by adding sodium sulfite, the reaction mixture was adjusted to pH 4 with 1N aqueous solution of sodium hydroxide and then concentrated to about 3 ml. The concentrate was subjected to column chromatography on non-ionic adsorption resin "Diaion BP-20: (Trade Mark, manufactured by Mitsubishi Chemical Industries Ltd.) (60 ml.) and elution was carried out with water. The fractions containing the object compound was lyophilized to give compound (4) (140 mg.). I.R. (KBr): 3500-2500, 1720, 1650 N.M.R. (D2O), #(ppm): 1.3-2.7 (10H, m), 3.90-4.50 (3H, m), 4.00 (2H, s). Example 58. EMI289.1 To 2 mixture of Compound (1) (560 mg.) and N-methyl morpholine (202 mg.) in dichloromethane (30 ml.), there was added isobutyl chloroformate (273 mg.) at -15--20 C 'and the mixture was stirred for 30 minutes at the same temperature. The mixture was cooled to -40 C and, to this, there was added trimethylsilyl ester of Compound (2), which. was prepared from Compound (2) (910 mg.) and bis (trimethylsilyl) acetamide (3 ml..) by stirring in a mixture of dichloromethane (20 ml.) and N, N-dimethyl formamide (2 ml.). The mixture was stirred forl hour at -15--20 C, and then treated in the same manner as the Step 1 of Example 57 to give Compound 3 (1 g.). I.R. (Nujol): 3300, 1740, 1660 N.M.R. (CD3OD), #(ppm): 1.58 (18H, s), 1.95 (3H, s), 1.50-2.50 (10H, m), 3.88 (2H, s), 3.8-4.5 (3H, m). (2) step 2 EMI290.1 Compound (3) (0.95 mg.) was added to trifluoro ,acetic acid (5 ml.) and the 'solution was stirred for 15 minutes at ambient temperature. A evaporation of CF3COOH, the residue was dissolved in water (10 ml) and 1N-HCl (1.7 ml) was added thereto. This solution was cooled to 0 C and a solution of NaIO4 (364 mg) in water (5ml) was added thereto and the mixture was stirred for 1 hour at the same temperature. An excess of the reagent was decomposed, by adding Na2SO3, and then the mixture was neutralized to pE 3 with lN-NaOE and submitted to column of HP-20 (20 ml.). The column, after wasching with H2O, was eluted with methanol: water (1:1). The fractions were concentrated, and the residue was dissolved in 50% ag. acetic acid (10 ml.) and hydrogenated over 10% palladium carbon (100mg). After removal of the catelyst, the filtrate was concentrated. The residue was dissolved in H2O and, evaporated in order to remove a trace of acetic acid. This operation was repeated further' two times. The residue was lyophilized to give Compound (4) (200 mg). I. R. (Nujol): 3250, 1715, 1640 N.M.R. (D2O), #(ppm): 1.5-2.1 (10H, m), 2.1 (3H, s), 3.8-4.5 (3H, m), 4.0 (2H, s). Example 59 EMI292.1 To a cooled mixture of Compound (1) (2.43 g.) and N-methylmorpholine (0.71 g.) in methylene chloride (40 m,l.) was added dropwise isobutyl chloroformate (960 mg.) and the mixture was stirred for 20 minutes at 0 OC, To this mixture was added 2 solution of Compound (2) (2.83 g.) in a mixture of methylene chloride (20 ml.) and dimetylformamide (10 ml.) containing bis (trimethyl silyl)acetamide (2 ml.) The reaction mixture was stirred for 2 hours and then concentrated to give an oily residue, which was dissolved in ethyl acetate, washed with water and dried over magnesium sulfate. Evaporation of the solvent gave a white foam, which was pulverized with isopropyl ether to give Compound (3) (4.20 g.,) as white powder. I.R. (Nujol): 3300, 1740-1640 (broad) cm-1 N.M.R. (DMSO-d6), #(ppm): 1.37 (18H, s), 1.17-2.40 (10H, m). 3.70-4.40 (3H, m). 5.03 (2H, s). 5.17 (2H, s), 7.37 (10H, s). EMI293.1 To a solution of Compound (3) (1.46 g.) in 50% aqueous methanol (10 ml.) was added IN sodium hydroxide (4.10 ml.) and the mixture was stirred for 2 hours at room temperature. The reaction mixture was concentrated and the resulting aqueous solution was diluted with water. After washing with ether, the aqueous layer was acidified with 1 N hydrochloric acid to pE 2 and extracted with ethyl a"cetate. The extract was washed with water, dried over magnesium sulfate to give a white foam, which was pulverized with isopropyl ether to give Compound (4) (1.20 g.) as white powder. I.R. (Nujol): 3400, 1740 1650 (broad) cm-1 N.M.R. (DMSO-d6), #(ppm): 1.37(18H, s), 1.17-2.40 (10H, m), 3.70-4.33 (3w, m), 5.03 (2E, s) , 7.37 (5H, s). EMI293.2 Compound (4) (1.05 g.) was dissolved in trifluor- acetic acid (5 ml.) and stirred for 15 minutes at room temperature. Evaporation of the solvent gave an oily residue, to which toluene was added and evaporated. The residue was dissolved in 0.1N sulfuric acid (35 ml.) and cooled in an ice-bath. , To this solution was added n solution of sodium periodate (640 mg.) in water (5 ml.) and the mixture was stirred for I hour at the same tem perature. The reaction mixture was treated with aqueous sodium bisulfite solution until the dark brown color of the solution was disappeared. After adjusting the pE of the solution to 4.0, the solution was concentrated to about 4 ml. and the pH was adjusted to 2.0. This solution was applied to a column of HP-20 (60 ml.) and eluted with water. Subsequent elution with 505 aqueous methanol gave fractions containing' the object product, which were combined and evaporated to give a pasty residue. This residue was dissolved in, water and lyophillized to give Compound (5) (0.453 g.) as white powder. N.M.R. (D2O), #(ppm): 1.17-2.70 (10H, m), 3.83 (1H, t, J=7Hz), 4.0-4.60 (2H, m), 5.13 (2H, s), 7.43 (5H, s). (z) Step 4 EMI294.1 Compound (5) (0.40 g.) was dissolved in water (20 ml.) and hydrogenated over 10% palladium-charcoal (50 mg.). The catalyst was removed by filtration and the filtrate was applied to a column of HP-20 (50 ml.) and eluted with water. Evaporation of the fractions, containing the. object compound gave a pasty residue, which was dissolved in water and lyophillized to give Compound (6) (260 0 mg.) as white powder. I.R. (Nujol): 3500-2500 (broad), 1710 (shoulder), 1620 cm-1 N.M.R. (D2O) #(ppm): 1.20-2.60 (10Hz, m), 3.60-3.92 (2H, m), 4.0-4.20 (1H, m). Example 60 (1) Step 1 EMI295.1 Compound (1) (2.30 g.) was dissolved in acetic acid (40 ,ml) and hydrogenated over 10%-palladium -chacoal (300 mg.). The catalyst was removed by filtration and the filtrate was evaporated under reduced pressure s give an oily paste, to which toluene was added. Evaporz- tion of toluene afforded white powder residue, which was throughly washed with diisopropyl .ether and collected by filtration' to give Compound (2) (1.70 g.) as white powder. I.R. (Nujol): 3500-2500 (broad), 1740-16,0 (broad) N.M.R. (D2O), d(ppm): 1.50 (18H, s), 1.16-2.83 (10H, m), 3.83 (1H, t, J=7Hz), 4.0-4.50 (2H, m). (2) Step 2 EMI296.1 Compound (2) (800 mg.) was dissolved, in methanol (10 ml.) and heptanoic anhydride (380 mg.) was added thereto. The reaction mixture was kept overight at ambient temperature. Evaporation of the solvent gave an oily paste, which was triturated with diisopropyl ether to give Compound (3) (800 mg.) as white powder. - I.R. (Nujol): 3300, 1740-1650 (broad). N.M.R. (DMSO-d6), #(ppm): 0.83-2.40 (41H, m), 3.83-4.50 (3H, m). ,t3)- Step 3 EMI296.2 Compound (3) , (750 mg.) was dissolved in trifluoroacetic acid (4 ml. ) and kept for 15 minutes at ambient temperature. Evaporation of trifluoacetic acid gave an oily paste, which was suspended in toluene. Evaporation of toluene afforded white foamy residue, which was dissolved in 0.1 N-E2SO4 (30 ml.) and cooled in an ice bath. To this stirred solution, there was added aqueous NaIO4 (350 mg. in 10 ml. H2O) and stirring was continued for l.hour. The resulting reaction mixture was treated with aqueous NaHSO3 solution until the purple color of the solution. disappeared. . pH of the solution was made neutral by adding solid NaECO3 and the whole volume. was concentrated . to about 5 ml. . pH of the solution was adjusted again to 2.0 and the whole solution was submitted to Column of HP-20 resin (100 ml.). The column was eluted with water and then Methanol-water (4:6). Evaporation of the latter fractions collected gave white foam, which was dissolved in water and lyophilized to give Compound (4) (180 mg.) as white powder. I.R. (Nujol): 3300-2400 (broad) , 1720, 1630 N.M.R. (D20), 6 (ppm) : 0.84 (3H, t, J=7Hz), 1.0-2.60 (20H, m), 3.80 (1H, t, J=7Hz), 4.20-4.40 (2H, m). Example 61 (1) Step 1 EMI298.1 To a mixture of Boc-(D)-mesoDAP-(L)-D-AlaOH(1) (3.40g) and triethylamine (1.90g) in 50% aqueous dioxane (80 ml) was added Z-L-Ala-D-Glu(&gamma;-OSu)OBzl(2) (5.lOg) and the mixture left left overnight at room temperature. After evaporation of dioxane, the remaining aqueous solution was acidified with 1N hydrochloric acid and extracted with ethyl acetate. The extract was washed with .water, dried over magnesium sulfate and evaporated to give Z-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOH(3) (7.30g) as white foam. I.R. (Nujol): 3300, 2600-2400, 1710, 1650cm-1 N.M.R. (DMSO-d6), d: 1.0-2.50 (25E, m), 3.80-4.50 (5H, m), 5.05 (2H, S), 5.15 (2E, S) , 7.40 (10E, S) (2) Step 2 EMI299.1 A solution of Z-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-BOc-(D)- mesoDAP-(L)-D-AlaOH(3) (7.0g) in acetic acid 860 ml) was hydrogenated over 10% palladum-charcoal (0.50g). The catalyst was remove by filtration and the filtrate was evaporated to give a white foam, which was dissolved in water (40ml) and applied to a column of HP-20 (150ml). The column was washed, with water and eluted with methanol-water (3:7). The eluate was concentrated and lyophillized to give L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(L)-D-AlaOH(4) (4.30g) as white powder. I.R. (Nujol): 3300, 2600-2400, 1720 (shoulder), 1660 (broad)cm-1 N.M.R: (D2O), #: 1.20-2.50 (10H, m), 1.40 (9H, S), 1.36 (3H, d, J=7HZ), 1.54 (3H, d, J=7HZ), 3.90-4.50 (4E, m). EMI300.1 Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)- D-AlaOH(5) was prepared from L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc- (D)-mesoDAP-(L)-D-AlaOH(4) and stearic anhydride in sub - stantially the same manner. as that of Step 1 of: Example 1. I.R. (Nujol): 3300, 1710, 1635, 1520 cm-1 N.M.R. (CD3OD-CDCl3), #: 0.90 (3H, t, J=7HZ), 1.33 (30H, S), 1.43 (9H, S), 1.00-2.66 (18H, m), 3.60 4.60 (5H, m) (4) step 4 EMI300.2 Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D- AlaOH(6) was preapared from Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)- (L)-30c-(D)-mesoDAP-(L)-D-AlaOH(5) in substantially the same manner as that of Step 2 of Example 1. I.R. (Nujol): 3300, 1730, 1650-1620, 1530 cm-1 N.M.R: (D2O+NaOD), #: 0.90 (3H, t, J=7Hz), 1.00-2.66 (51H, m), 3.24 (1H, t, J=7Hz). 4.00-4.66 (4E, m). Example 62 (1) Step 1 EMI301.1 Z-D-Ala-&gamma;-D-Glu-(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)'-D-AlaOH(3) was preapared from Boc-(D)-mesoDAP (D)-NHNHBoc-(L)-D-AlaOH(1) and Z-D-Ala-D-Glu(&gamma;-OSu)OBzl(2) in substantially the same manner as that of SteP of Example 1. I.R. (Nujol): 3300, 2600 (shoulder), 1730, 1670, 1630 cm-1 N.M.R. (DMSO-d6), #: 1.00-2.60 (34H, m), 3.88-4.40 (5H, m). (2) Step 2 EMI303.1 D-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc- (L)-D-AlaOH(4) was prepared from Z-D-Ala-&gamma;-D-Glu(&alpha;-OBzl=- (L)-Boc-(D)-mesoDAP-(D)-NHBoc-(L)-D-AlaOH(3) in substantially the same manner as that of Step. 2 of Example 61. I.R. (Nujol): 3300, 2600-2400 (shoulder), 1720 (shoulder), 1660 cm N.M.R. (D2O), #: 1.00-2.60 (34H, m), 3.88-4.40 (5E, m). (3) Step 3 EMI303.2 To a cooled solution of D-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- Boc-(D)-mesoDAP-(D)-NHNHBOc-(L)-D-AlaoH(4) (1.35g) in 50% aqueous acetone (10 ml) was added IN sodium hydroxide. O-Acetyl-D-mandelyl chloride (0.61g) was added dropwise at 0 C, during which time the pH was maintained at 8.0 9.0. ,After stirring for 1 hour at the same time, the reaction mixture was adjusted to pE 7.0 with IN hydrochloric acid and acetone was evaporated. The resulting aqueous solution was adjusted to pE 2.0 with IN hydrochloric acid and extracted with ethyl acetate. The extract was washed with'water, dried over magnesium sulfate an,d'concentrated to give a residue,-which was pulverized with ether to give O-acetyl-D-mandelyl-D-Ala- &gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-D- AlaOH(5) (1.35g) as a solid. I.R. (Nujol): 3300, 1720, 1650, 1520 cm-1 N.M.R. (CD3OD), #: 1.43 (18H, S), 1.00-2.66 (16H, m), 2.15 (3H, S), 4.00-5.00 (5H, m), 5.95 (1H, S), 7.35 (5H,S). (4) Step 4 EMI304.1 To 2 solution of O-acetyl-D-madelyl-D-Ala-&gamma;-D- Glu (&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-D-AlOH(6) (1.25g) in 2 mixture of methanol (20 ml) and water (lOml) was added IN sodium hydroxide (4.5ml). After stirring the mixture for 1 hour at room temperature, the pE of the mixture was adjusted to 6.0. After evaporation of methanol, the resulting aqueous solution was adjusted to pE 2.0 with IN hydrochloric acid and extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and concnetrated. The residue was washed with ether to give D-mandelyl-D-Ala-&gamma;-D-Glu (&alpha;-OH)-(L)-Boc-(D)-mesoDAP-NHNHBoc-(L)-D-AlaOH(6) (0.96g) as a solid. I.R. (Nujol): 3280, 1720-1650, 1520 cm-1 N.M.R. (CD3OD), #: 1.43 (18H, S), 1.00-2.66 (16H, m), 3.83-4.66 (5H, m), 5.10 (1H, S), 7.17-7.66 (5H, m). (5) Step 5 EMI305.1 D-Mandelyl-D-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D AlaOE (7) was prepared from D-mandelyl--D-Ala-y-D-Glu (a- OH)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-D-AlaOH(6) in substantially the same manner as that of Step 2 of Example 1 I.R. (Nujol): 3280, 1720, 1630-1610, 1520 cm-1 N.M.R. (D2O), #: 1.32 (3H, d, J=7Hz), 1.40 (3H, d, J=7Hz), 1.20-2.40 (10H, m), 3.74 (1H, t, J=6Hz), 4.00-4.50 (4H, m), 5.18 (1H, S), 7.42 (5H, S). Example (1) -Step 1 EMI306.1 Heptanoyl-D-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-D-AlaOH(2) was prepared from D-Ala-&gamma;-D- Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-D-AlaOH(1) in substantially the same manner as that of Step of 1 t Example 1. I.R. (Nujol): 3250, 1720, 1660-1640, 1530 cm-1 N.M.R. (CD3OD), #: 0.90 (3H, t, J=7Hz) 1.00-2.60 (44E, m), 3.90-4.60 (5H, m). (2) Step 2 EMI307.1 Heptanoyl-D-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D- AlaOH(3) was prepared from heptanoyl-D-Ala-&gamma;-D-Glu(&alpha;-OH)- (L)-Boc-(D)-mesoDAP-(L)-D-AlaOH(2) in substantially the same manner as that of Step 2 of 'Example 1. I.R. (Nujol): 3300, 1720, 1620, 1520 cm-1 N.M.R. (D2O), #: 0.80 (3H, t, J=6Hz), 1.36 (6H, d, J=7Hz), 1.00-2.60 (18H, m), 3.76 (1H, t, J=7Hz), 4.00-4.50 (4H, m). Example 64 (1) Step 1 EMI308.1 Z-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)Boc-(D)-mesoDAP-(L)- GlyOH (3) was prepared from Boc-(D)-mesoDAP-(L)-GlyOH-(1) and Z-L-Ala-(D)Glu(&alpha;-Osu)OBzl (2) in substantially the same manner as that of Step 1 of Example 61. I.R. (Nujol) : 3300, 2600 - 200, 1720, 1690, 1650 cm-1 N.M.R. (DMSO-d6), #(ppm): 1.30 (3H, d, J-7Hz), 1.10-2.50 (19H, m), 3.80 (2$, d, J=7Ez), 3.80-4.50 (4H, m), 5.05 (2H, s), 5.18 (2HH, s), 7.40 810H, s). (2) Step 2 EMI309.1 L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)-GlyOH (4) was prepared from Z-L-Ala--D-Glu(&alpha;-OBzl)-(L)-Boc- (D)-mesoDAP-(L)-GlyOH (3) in substantially the same manner as that of Step 2 of Example 61. I.R. (Nujol): 3300, 2600-2400 (broad), 1720, 1650 (broad) cm-1 N.M.R. (D2O), #: 1.56 (3H, d, J-7Hz), 1.40 (9H, s), 1.20-2.50 (10H, m), 3.92 (2H, S), 4.0-4.40 (4H, m). EMI309.2 Arachidonyl-1-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso- DAP-(L)-GlyOE (5) was prepared from t-Ala-y-D-Glu(-OE)- (L)-Boc-(D)-mesoDAP-(L)-GluOH (4) and N-hydroxyphthalimido ester of arachidonic acid in substantially the same manner as that of Step 3 of Example 61. I.R. (Nujol): 3300, 1720, 1640, 1530 cm-1. N.M.R. (DMSO-d6), #(ppm): 0.83 (3H, m), 1.1-2.9 (42R, m), 3.82 (2E, s), 4.05-4.50 (4R, m), - 5.20 -5.50 (8R, m). (4) Step 4 EMI310.1 Aranchodonyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- GlyOH (6) was prepared form arachidonyl-L-Ala-&gamma;-D- Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)-GlyOH (5) in substantially the same manner as the Step 2 of Example 1. I.R. (Nujol): 3270, 1720, 1635, 1530 cm-1 N.M.R. (D2O=NaOD), #: 0.85 (3H, m), 1.1-2.9 (33H, m), 3.23 (1H, t, J=7Hz), 3.76 (2H, s), 4.1-4.5 (3H, m), 5.32 (8H, m). Example 65 EMI311.1 (1) Example 65-1 BOC(D)-meso-DAP(L)GlyOH-(D)-NHNHBoc (1) (7.7 g) was dissolved in water (1:0 ml) and the solution was adjusted to pH 8 with N-methylmorpholine. To the solution was added a dioxane solution (180 ml) of D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)(oSu) (2) (contain ing 26.7 m mole of compound (2) as activated ester). The mixture was stirred for four hours at ambient temperature. Dioxane was distilled off under reduced pressure and the resulting mixture was washed with ether .(100 ml) and adjusted to pH 3 with 5% aqueous hydrochloric acid. The solution was extracted with ethyl acetate (300 ml and 150 ml and the extract was washed with water and dried over ann,ydrous magnesium sulfate and then evaporated to dryness. The residue, was crystallized from 2 mixture of chloroform and ether (1:3) to give D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc (D)-meso-DAP(L)GlyOH-(D)-NHNHBoc (3) (10.8 g). mp 105-113 C (dec.). N.M.R. (CD3OD), #(ppm): 1.3-1.8 (30H, m), 2.08 (3H, s), 2.1-2.4' (4H, m), 3.92 (2H, s), 4.2-4.6 (4H, m), 4.8-5.1 (1H, m), 5.17 (2H,s), 7.33 (5H, s) (2) Example '65-2 D-Lac(oAC)-L-Ala-&gamma;-D-Glu(OH)oBzl (5,.2 g) was dis solved in methylene chloride (60 ml) and N methylmorpholine (1.10 g) was added thereto. To the mixture was added dropwise isobutyl chlo roformate (1.50 g) at -10- -15 C and the mixture was stirred at -10 - -15 C for thirty minutes. To the mixture was added a solution, prepared by dissolving bis (trimethylsilyl)acetamide (9 ml) and Boc(D)meso-DAP(L)GlyOH-(D)-NHNHBoc (1= (4.60 g) in a mixture of methylen chloride (50 ml) and dimethylaformamide (10 ml). The resulting solution was stirred at -10 - -150C for two hours and at 0 C for an hour and then concentrated to about 30 ml. To the concentrate were added ethyl acetate (700 ml) and 2% aqueous hydrochloric acid (100 ml). The ethyl acetate layer was separated and washed with water and then dried over anhydrous magnesium sulfate. Ethyl acetate was evaporated to dryness under reduced pressure and the residue thus obtained was washed with ether to give D-Lac(oAC)-L-Ala- &gamma;-D-Glu(&alpha;-&alpha;Bzl)-(L)-Boc-(D)-meso-DAP(L)GlyOH-(D)- NHBoc (3) (8.2 g) of which N.M.R. spectrum was identical with that of the product prepared in Example 653-1 Example 66 EMI313.1 ZDAP(OH)GlyOH (1) (80 mg) was added to 2 solution of D-Lac(oAC)-L-Ala-&gamma; ;-D-Glu(oSu)oBzl (2) (59 mg) in dimethylformamide (4 ml) containing triethylamine (0,03 ml) at OOC. The' mixture was stirred overnight at ambient temperature and then evapo- rated to dryness. to the residue thus obtained was added dil. hydrochloric acid and then extra- ction was carried out with ethyl acetate. The extract was washed with water and evaporated to dryness. The residue was recrystallized from, a mixture of hexane and chloroform to give D-Lac (3) (86 mg) N.M.R. (CD3OD), #(ppm) : 1.35 (3H, d, J=7Hz), 1.43 (3H, d, J=7Hz), 1.3-2.2 (8H, m), 2.12 (3H, 2), 2.30 (2H, m) , 3.95 (2H, s), 4.0-4.6 (4H, m), 5.12 (2H, s), 5.18 (2H, s), 7.36 (1OH, s) Example 67 EMI314.1 Z-meso-DAPGlyOH(1)(1.23 g) and bis (trimethylsilyl) 'acetamide (4.00 g) were suspended in methylene chloride (50 ml) and the suspension was stirred at ambinet temperature for hours. On the other hand, D-Lac-(oAc)-L-Ala-&gamma;-D-Glu(OH)oBzl (2) dicyclohexylamine salt (2.34 g) was dissolved in methylene chloride (30 ml), and triethylamine hydrochloric acid salt (0.54 g) was added at ambient temperature to the solution while strirring. The stirring was continued for two hours and the reaction mixture was cooled to -30 C and a solution of isobutyl chloroformate (0.53 g) in methylene chloride (50 ml) was added dropwise thereto. The resulting mixture was reacted for twenty minutes at the same temperature. To the reaction mixture was added dropwise c methylene chloride solution of Z-meso-DAPGlyOH prepared above and the resulting mixture was stirred at -300C for an hour. The reaction mixture was reacted at ambinet tempe- rature for four hours and filtered. The filtrate was washed with 10% aqueous hydrochloric acid and concentrated under reduced pressure and the residue thus obtained was extracted with ethyl acetate. The ethyl acetate layer was washed with water and drier over anhydrous magnesium sulfate and concentrated under reduced pressure to give an oily D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-Z-meso-DAPGlyOH (3 g) N.M.R. (CD3OD), 6 #(ppm) 1.35(3H,d,J=7Hz), 1.43(3H,d,J=7Hz) 1.3-2.2(8H,m), 2112(3H,s), 2.30(2H,m), 3.95(2H,s), 4.0-4.6(4H,m), 5.12(2H,s), 5.18(2H,s), 7.36(10H,s) Example 68 EMI315.1 To 2 mixture of D-Lac(oAc)-L-Ala-&gamma;-D-Glu(OH)(&alpha;-oBzl) (1)(653 mg) and N-hydroxysuccinimide (178 mg) in dioxane (7 ml) was added N,N'-dicyclohexyl- carbodiimide (320 mg). The mixture was stirred at 100C for ten minutes and further stirred at ambient temperature for 14 hours. The reaction mixture was filtered and the filtrate was evaporated to dryness and the residue was, dissolved in dioxane, (4.5 ml). A 3ml portion of this solution was added to a mixture of Z-(L)-mesoDAP-(D)GlyOH(270 mg), and N-methyl morphorine (156 l) in dioxane (4 ml) and the mixture was stirred at ambient temperature. After 4.5 hpurs, S 0.9 ml portion of the above dioxane solution and N-methylmorphorine (100 l) was added and the mixture was stirred at the same temperature. After 4.5 hours an additional 0.6 ml o the above dioxane solution was added and the mixture was stirred for 1.25 hours. The reaction mixture was wasched with ether, acidified to pEi 2 with z diluted aqueous hydrochloric acid and extracted with a mixture of ethyl acetate and methylene chloride, containing 1N hydrochloric acid, water and brine, drier over magnesium sulfate and evaporated to give an amorphous solid (660 mg) which was dis solved in chloroform and triturated with ether to give D-Lac(oAC)-L-Ala-&gamma;-D-Glu(&alpha; ;-oBzl)-(D)- Z-(L)-mesoDAP-(D)-GlyOH (3) (450 mg) N.M.R. (CDCL3-CD3OD), #(ppm) . 1.37 (3H, d, 3 1.45 (3E d J=7HZ), 1.45 (3H, d, J=7Hz), 1.2-1.9 (6H, m), 2.0-2.5 (4H, m), 3.93 (2H, broad s), 4.1-4.7 C3H, m), 5.10 (2H, s), 5.17 (2H, s). Example 69 EMI317.1 D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-aBzl)-(L)¯Boc-(D)meso -DAP(L)GlyOH-(D)-NHNHBoc (1) (9.4 g) was hydrogenated in acetic acid (100 ml) over 10% palladium black (2.0 g) for 2 hours under 1.5 hydrogen atmospheric pressure at ambient temperature. After completion of the reaction, the catalyst was filtered off and the filtrate was e evaporated to dryness under reduced pressure. The residue was triturated with ether to give D-Lac(oAC)-L-Ala-&gamma;- D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso-DAP-(L)GlyOH-(D)- NHNHBoc (2) (7.50 g). N.M.R. (CD3OD), #(ppm) : 1.3-1.9 (m), 2.10 (3H,s), 2.1-2.4 (4H, m), 3.90 (2H, s), 4.2-4.6 (4H, m), 4.8-5.1 (1H,m) Example 70' EMI318.1 D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso-DAP(L)- Gly(OH)-(D)-NHNHBoc (1) (1.65 g) was dissolved in 508 aqueous methanol (32 ml) and the solution was stirred for 2.5 hours at ambient temperature, maintaining the pH at 9.0 with 5% aqueous solution of potassium carbonate. The solution was evapo rated to dryness under reduced pressure. The -residue was adjusted to pR 5 with 5% aqueous hydro- chloric acid and then passed through z column packed with a macroporous non-ionic adsorption resin, HP20 (500 ml).- The resin was washed with water (200 ml) and eluted with a mixture of methanol 'and water (1:1 volume). The eluate was evaporated to dryness and the residue was washed with eth'er to give D- . Lac-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-meso-DAP(L)GlyOH- (D)-NHNHBoc (2) (1.24 g). I.R.(Nujol): 3270, 3200-2600, 1720, 1640 cm-1 N.M.R. (CD3OD), #(ppm) : 1.47 (18H, s), 3.93 (2H, s) Example 71 EMI319.1 D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-meso- DAP(L)GlyOH-(D)-NHNHBoc (1) (1.0 g) was dissolved in 50% aqueous methanol (20 ml), and 1N aqueous sodium hydroxide (3.7 ml) was added thereto. The resulting solution was stirred for two hours at ambient temperature and concentrated to about 5 ml). The concentrate was adjusted to pH 3 and passed through a col't=i packed both a macroporous non.ionic adsorption resin, HP20 (24 ml). The column was washed with water (lOD ml) and eluted with a mixture o,f methznol and water (1:1) and the eluate was evaporated to dryness under reduced pressure. The residue thus obtained was washed with ether to give d-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- Boc-(D)-meso-DAP(L)GlyOH-(D)-NHNHBoc.(2)(660 mg) which was' identified with the product prepared in Example 70. Example 72 EMI321.1 A mixture of D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(D)- Z-(L)-mesoDAP-(D)-GlyOH (1) (440 mg) and 10% palladium black (90 mg) in acetic acid C 5 ml ) was stirred under hydrogen atmosphere for four hours. Addtional 10% palladium black (60 mg) and acetic acid ( ml) were added to the reaction mixture and the stirring was continued under hydrogen atnos- phere for four hours. The reaction mixture was filtered. The filtrate 'was concentrated under reduced pressure and the residue was dissolved in water. The aqueous solution was evaporated to dryness. The residue was again dissolved in water and concentrated. The concentrate was lyophilized to give D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-OH) (D)-meso-DAP(D)GlyOH (2) (301 mg). N.M.R. (D2O), #(ppm) : 1.42 (3H, d, J=7HZ), 1.47 (3H, d, J=7Hz), 2.14 (3H, s), 1.0-2.8 (10H, m), 3.80 (1H, t, J=7Hz), 3.94 (2H, s), 4.1-4.6 (3H, m) 5.02 (1H, q, J=7Hz) Example 73 EMI322.1 - A solution of D-Lac (oAc) -L-Ala-&gamma;-D-Glu(&alpha;-OBzl) -Z- DAP(OH)GlyOH in methanol (1) (20 mg) was hydro generated over 10% palladium black (50 mg). The reaction mixture' was filtered and the filtrate was evaporated to dryness to give D-Lac(oAc)-L- Ala-&gamma;-D-Glu(&alpha;-OH)-DAP(OH)GlyOH (2) (10 mg), whose structure was confirmed in comparision of data of the products prepared in Example 72 Example 74 EMI323.1 To a mixture of D-Lac(oAC)-L-Ala-D-Glu(OH)oBzl (1) (2.45 g) and succinic acid (740 mg) in dioxane (20 ml) was added N,N'-dicyclohexylacarbodiimido (1.2S g) at 12 C and the mixture was stirred at ambient temperature for 16 hours. The reaction mixture was filtered and N,N'-dicyclohexylurea was washed with dioxane. The filtrate and the washings were combined and con centrated. The concentrate was dissolved in dioxane (18 ml). This solution was used for the next reaction,. To a mixture of Z-(&alpha;)-L-DAP-(#)-GlyOH (2) (1.21 g) and N-methylmorpholine (1.02 ml) in water (20 ml) was added the above solution at 50C and the mixture was stirred at 5 C for 40 minutes and at ambient tempera ture for 4 hours. An additional N-methylmorpholine (0.2 ml) was added to the reaction, mixture and the resulting mixture was stirred at the same temperature for two hours. The reaction mixture was concnetrated and the concentrated was diluted with water. The solut ion was washed with ether and acidified with dil. hydrochloric acid to pK 2. To the solution was added a mixture of methylene chloride and ethyl acetate and -the mixture was shaked and then filtered to give in- soluble materials and the organic layer. The organic layer was washed kith water, dried over magnesium sulfate and concnetrated. The residue was combined with the insoluble materials described above and dissolved in a mixture of chloroform and methanol (1:1). The solution was concentrated and the con centrate was triturated with a mixture of ethyl acetate and ether (1 2) to give a powder (1.8 g), which was dissolved in a mixture of chloroform and methanol and ethyl acetate (1:1: :1) and concentrated. - The concentrate was triturated with a mixture of ethyl acetate and ether t5:1) to give D-Lac(oAc)-L-Ala-&gamma;-D-Glu(c-oBzl)- (&alpha;)-(Z)-(#)-L-DAP-(&alpha;)-GlyOH (3) (1.654 g). N.M.R. (CDCl3.-CD3OD), #(ppm) : 1.37 (3H, d, J=7Hz), 1.46 (3H, d, J=7Hz), 2.11 (3H, s), 1.2 -2.6 (10H, m), 3.95 (2H, s), 4.0 - 4.6 (4H, m), 4.96 ClR, q, J=7Hz), 5.08 (2H, s), 5.15 82H, s), 7.33 (10H, s). Example 75 EMI325.1 A s'oluti,on of D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(&alpha;)- (1) (1.59 g) in acetic acid (40 ml) was hydrogenated over 10% palladium black (500 mg) for 4 hours. The reaction mixture was filtered and the filter cake was washed with 50% aqueous methanol. The filtrate and the washing were combined zad evaporated and pumped to give a residue tl,S g). Contaminated acetic acid was removed by co-eveporation with water and this operation was repeated once more. The residue was dissolved in water and lyophilized to give D-Lac(oAc)-L-Ala-y D-Glu(&alpha;-OH)-(&alpha;)-L-DAP-(&alpha;)-GlyOH (2) (1.10 g). N.M.R. (D2O), # #(ppm) : 1.43 (3H, d, J=7Hz), 1.48 (3H, d, J=7Hz), 1.3-2.7 810H, m), 2.15 (3H, s), 3.80 (1H, broad t, J=6Hz), 3.95 (2H, s), 4.0-4.6 (3H, m), 5.05 (1H, q, J=7Hz) Example 76 (1) Step 1 EMI327.1 D-Lac-(oAc)-L-Ala-&gamma;-L-Glu(&alpha;-OBzl)-(L)-Boc-(D)-meso-DAP(L)- GlyOH-(D)-NHNHBoc (3) was prepared form Boc (D9-meso DAP-(L)GlyOH-(D)-NHNHBoc (1) and D-Lac(oAC)-L-Ala-L Glu(&alpha;-OBzl)(=) in substantially the same manner as that of Example 65-1. IR(Nujol): 3300, 1735, 1695 1645 cm-1 NMR(CD3OD): 1.40(9H, S), 1.42(9H,S), 2.08(3H, S), 3.90(2H, broad S), 4.00#5.00 (5H, m), 5.10(2H, S), 7.30(5H, S) EMI328.1 D-Lac(OH)-L-Ala-&gamma;-L-Glu(&alpha;-OH)-(L)-Boc-(D)-meso-DAP-(L)- GlyOH-(D)-NHNHBoc (4) was prepared in substantially the same manner as that of Example 71. NMR(CD3OD), #(ppm): 1.44(9H, S), 1.46(9H, S), 3.90(2H, broad S), 4.00#4.60 (5H, m) Example 77 EMI329.1 L-Lac(OAC)-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-meso- DAP(L)-GlyOH-(D)-NHNHBoc (3) was prepared from Boc (D)mesoDAP-(L)-GlyOH-(D)-NHNHBoc (1) and L-Lac(OAC)-L-Ala -D-Glu(&alpha;-OBzl) (2) in substantially the same manner as that of Example 65-1. EMI329.2 L-Lac(OH)-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso-DAP(L)- GlyOH-(D)-NHNHBoc (4) was prepared in substantially the same manner as that of Example 71. Example 78 (1) - Step 1 EMI330.1 EMI331.1 D-Lac(OAC)-D-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-meso-DAP(L)- GlyOH-(D)-NHNHBoc (3) was prepared from Boc (D)-mesoDAP (L)-GlyOH-(D)-NHNHBoc (1) and D-Lac(OAC)-D-Ala-L Glu(&alpha;-OBzl) (2) in substantially the same manner as that of Example 65-1. NMR (CD3OD), #(ppm): 1.40(9H,s), 1.42(9H,s), 2.06(3H,s), 3.90(2H,broad s), 3.90#5.00(5H,m), 5.15(2H,s), 7.35(5H,s) (2) Step 2 EMI331.2 D-Lac(OH)-D-Ala-&gamma;-L-Glu(&alpha;-OH)-(L)-Boc-(D)-meso-DAP(L)- GlyOH-(D)-NHNHBoc (4) was prepared in substantially the same manner as that of Example 71. IR (Nujol) : 3300, 1740, 1690, 1740 (Broad) cm 1 NMR (CD3OD), #(ppm): 3.90 (2H, broad s), 4.00#4.60 (5H, m) Example 79 (1) Step 1 EMI333.1 D-Lac(OAC)-D-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-meso-DAP- (D)-NHNHBoc-(L)-GlyOH (3) was prepared from Boc (D)mesoDAP-(D)-NHNHBoc-(L)-GlyOH (1) and D-Lac(oAC)-D-Ala -D-Glu(&alpha;-OBzl) (2) in substantially the same manner as that of Example 65-1. N.M.R. (CD3OD), #(ppm): 1.41 (18H, s), 2.12 83H, s), 3.92 (2H, broad s), 4.00-5.10 (5H, m), 5.16 (2H, s), 7.36 (5H, s) (2) Step 2 EMI333.2 D-Lac(OH)-D-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D) NHNHBoc-(L)-GlyOH (4) was prepared in substantially the same manner as that of Example 71. N.M.R. (CD3OD), #(ppm): 1.41 (18H, s), 3.92 (2H, broad s), 4.00-4.60 (5H, m) The following compounds were prepared in sub stantially the same manner as that of Steps 1 and 2 of Example 1. Example 80 (1) Step 1 Benzenesulfonyl-L-Ala-&gamma;-D-glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH NMR (CD3OD),, #(ppm) : 1.24 (3H, d, J=7Hz), 1.47 (18H, s), 1.25-2.46 (10H, m), 3.94 (2H, s), 3.82-4.54 (4H, m), 7.55-8.00 (5H, m) (2) Step 2 Benzenesulfonyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP- (L) -GlyOH N}R (D2O), 6(ppm) : 1.38 (3H, d, J=7Hz), 1.5-2.42 (1OH, m), 3.67-4.42 (4H, m), 4.10 (2H, s), 7.54-7.97 (5H, m) Example 81 (1 Step 1 Cinnamoyl-L-al-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-GlyOH was prepared in substantial- ly the same manner as that of Step 1 of Example 1. NMR (CD3OD), #(ppm) : 1,34 (13H, m), 1.44 (18H, s), 3.95 (2H, s), 3.90-4.67 (4H, m), 6.74 (1H, d, J=7Hz), 7.57 (1H, d, J=16Hz), 7.32-7.70 (5H, m) (2) Step 2 Cinnymoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(D)- NHNH2-(L)-GlyOH was prepared in substantially the same manner as that of Step 3 of Example 11. NMR (D2O), #(ppm) : 1.47 (3H, d, J=7Hz), 1.34-2.42 (10H,m), 3.95 (2H, s), 3.78-4.58 (4H, m). 6.64 (1H, d, J-l6Hz), 7.37-7.70 (6P m) (3) Step 3 Cinnamoyl-L-al-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- GlyOH was prepared in substantially the same manner as that of Step 4 of Example 11. NMR (D20), (ppm) : 1.46 (3H, d, J=7Hz), 1.28-2.44 (1OH, m), 3.72 (1H, t, J=7Hz), 3.88 (2H, s), 4.20-4.46 (4H, m), 6.67 (1H, d, J=7Rz), 7.38-7.46 (6H, m) Example 82 EMI336.1 To a mixture of D-Lac(oAC)-L-Ala-D-GluOBzl (2) Cl. 20 g) and N-methylmorpholine (0.28 ml) in methylene chloride (17 ml) was added isobutyl chlorocarbonate (0.33 'm1)..- The resulting mixture was stirred at -150C to -10 C for 30 minutes and then cooled to -400C. To the resulting mixture was added a mixture of Z-D-LysOH (1)(725 ml) and bis(trimethylsilyl)acetamide (3 ml) in dimethylformamide (3 ml) and methylene chloride (8 ml) at 400 C. The resulting mixture was stirred at -15 C to -100C for an hour and gradually allowed to warm to ambient temperature. The resulting mixture was concentrated, taken up into ethyl acetate (80 ml) and washed with dil hydrochloric acid, water and brine, in turn. The concentrate was dried over magnesium sulfate and the solvent was distilled off to give an oil which was crystallized from a mixture of chloroform and isopropyl ether to give D-Lac(OAc)-L Ala-Y-D-Glu(a-OBtl) -c-Z-D-LysOH (3)(1.60 g). NMR (DMSO-&alpha;), #(ppm) : 1.28 (3H, d, J=7Hz), 1.37 (3H, d, J=7Hz), 1.0-2.4 (10H, m), 2.10 (3H, s), 3.1 (2H, m), 4.0 (1H, m), 4.40 (2H, broad t, J=7Hz), 5.05 (1H, q, J=6.5Hz), 5.10 (2H, s), 5.20 (2H, s), 7.42 (1OH, s), 7.3-8.0 (2H, m), 8.0-8.4 (2H, m) Step 2 EMI337.1 A solution of D-Lac(OAc)-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)- #-Z-D-LysOH (3)(l.50 g) in acetic acid (40 ml) was hydrogenated over 108 palladium black (500 mg) at ambient temperature under an atmospheric pressure of hydrogen. The reaction mixture was filtered and the catalyst was washed with 50% aqueous methanol. The filtrates were combined and evaporated. Acetic acid was removed by co-evaporation with water. The residue was dissolved in water and lyophilized to give D- Lac(OAc)-L-ala-&gamma;-D-Glu(&alpha;-OH)-#-D-LysOH (4) (1.00 g). NMR (D20), 6(ppm) : 1.42 (3H, d, J=7Hz), 1.47 (3H, d, J=7Hz), 2.16 (3H, s), 1.2-2.5 (lOH, m), 3.0-3.4 (2H, m), 3.83 (1H, t, J=6Hz), 4.1-4.6 (2H, m), 5.07 (1H, q, J=7Hz) (3) Step 3 EMI338.1 To a solution of D-Lac(OAc)-L-Ala-&gamma;-D-Glu(&alpha;-OH)- #-D-LysOH (4)(930 mg) in a mixture of methanol (9 ml) and water ( mi) was added dropwise 1N sodium hydroxide (6 ml). The resulting solution was stirred at 50C for an hour and at ambient temperature for two hours. The reaction mixture was neutralized to pH 7 with 1N hydrochloric acid and concentrated. The concentrate was adjusted to pH 2.2 with iN hydrochloric acid and chromatographed on a macroporous non-ionic adsorption resin, HP 20 (90 ml), eluting with water. Fractions containing the object compound (5) were collected, concentrated and lyophilized to give D-Lac(OH)-L-Ala-&gamma;-D-Glu(&alpha;-OH)- #-D-LysOH (5)(700 mg). [&alpha;]D = -17.1tC (C=0.509, water) NMR (D2O), #(ppm) : 1.36 (3H, d, J=7Hz), 1.42 (3H, d, J=7Hz), 1.1-2.6 (10H, m), 3.19 (2H, broad t, J=7Hz), 3.83 (lR, t, J=6Hz), 4.1-4.5 (3H, m) Example 83 (1) Step 1 EMI339.1 D-Lac(OAC)-L-Ala-ss-D-Asp(&alpha;-OBzl)-(L)-Boc-(D)- meso-DAP-(D)-NHNHBoc-(L)-GlyOH (3) was prepared from D-Lac(OAc)-L-Ala-D-Asp(OH)OBzl (1) and Boc-(D)-mesoDAP-(D)-NHNHBoc-(1)GlyOH (2) in substantially the same manner as that of Example 66. m.p. 120 - 1230C (dec.) I.R. (Nujol) : 3550, 3300. 1730, 1650, 1550 cm-1 NMR (DMSO-d6), (ppm) : 1.0-19 (30OH; m), 2.06 (3H, s), 3.0-5.0 (13H, m). 3.18 (2H, s), 5.14 (2H, s), 6.63 (1H, m), 7.40 (5H, s), 7.9-8.6 (6H, m), 9.56 (1H, s) (2) Step 2 EMI340.1 To 2 suspension of D-Lac(OAc)-L-Ala-ss-D-Asp(&alpha;-OBzl)- (L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (3) (0.74 g) in water (10 ml) was added 1N sodium hydroxide (3.0 ml) at 0 C and the mixture was stirred for 1 hour at the same temperature. The reaction mixture was neutralized to pH 3 with 1N hydrochloric acid (3.0 ml) and evaporated to-give an oil, which was dissolved in water (3 ml) and applied to a column of HP-20 (20 ml). The column was washed with water and eluted with methanol: water (7:3) and 'the eluate was evaporated to give an oil (0.42 g), which was then dissolved in trifluoroacetic acid (5 ml) and stirred for 15 minutes at room tem terature. After evaporation of trifluoroacetic acid, the resulting residue was pulverized with ether and filtered to give a powder, which was dissolved in IN sulfuric acid (2.5 ml) and sodium periodate (0.09 g) was added at 0 C. After stirring for 10 minutes at the same . temperature, the reaction mixture was treated with 0.5N aqueous sodium hydrogen sulfite (0.2 ml). This solution was neutralized to pH 2 with 1M sodium carbonate (1.4 ml) and evaporated and methanol (3 ml) was added and an undissolved material was filtered off. The filtrate was evaporated to give an oil (0.30 g), which was dissolved in a small amount of water and applied to a column of HP-20 (40 ml). The column was eluted with water and the eluate was evaporated to give an oil (140 mg), which was again applied to a column of HP-20 (60 ml) and eluted wiTh water. The eluate was evaporated and the residue was dissolved in a small amount of water and lyophi- lized to give D-Lac-L-Ala-ss-D-Asp(&alpha;-OH)-(L)- mesoDAP-(L)-GlyOH (4) (120 mg) ass a white powder I.R. (Nujol) : 3270,1720, 1640, 1520 cm 1 NMR (D2O), #(ppm) : 1.36 (3H, d, J=7Hz), 1.38 (H, d, J=7Hz), 1.2-2.1 (6H, m), 2.6-3.0 (2H, m). 3.87 (1H, t, J=6Hz), 3.95 (2H, s), 4.1-4.5 (4H, m) Example 84 (1) Step 1 EMI341.1 EMI342.1 To a mixture of Boc-L-Ala-D-Glu(OH)OMe (1) (1.94 g), L-Lys(#-Z)-GlyOEt (2)(1.67 g) and 1-4-chlorobenzenesulfonyloxy)-6-chlorobenzo triazole (1.72 g) in methylene chloride (100 ml) was added N-methylmorpholine (1.01 g) and the mixture was stirred for 2 days at room tempera- ture. The reaction mixture was washed sccessive- ly with 5% aqueous sodium bicarbonate, water, 5% hydrochloric acid and water and dried over magnesium sulfate. After evaporation of the solvent, the resulting crystalline mass was filtered and washed with ether to give Boc-L Ala-&gamma;-D-Glu(&alpha;-OMe)-L-Lys(#-Z)-GlyOEt (3) (1.34 g). m.p. 126 - 127 C I.R. (Nujol) : 3550, 3255, 1750, 1720, 1700, 1680, 1d60, 1650, 1640 cm 1 NMR (CD3OD), 6(ppm) : 1.22 (3H, t, J=7Hz), 1.30 (3H, d, J=7HZ), 1.42 (9H, s), 1.34-1.60 (6H, m), 2.70 (2H, t, J=7Hz), 3.08 (2H, m), 3.68 (3H, s), 3.92 (2H, s), 4.15 (2H, q, J=7Hz), 4.00-4.42 (3H, m), 5.07 (2H, s), 7.34 (SH, s) (2) Step 2 overnight at room temperature. Methanol was evaporated and the resulting aqueous layer was adjusted to pH 5.5 with diluted hydrochloric acid and washed with ethyl acetate. The aqueous layer was acidified to pH 1 with diluted hydrochloric acid and extracted with ethyl acetate. The extract was washed with water saturated with sodium chloride, dried over magnesium sulfate and evapo- rated to give an amorphous solid (0.50 g). This solid was dissolved in MeOH (15 ml) and hydro genated over 5% palladium-charcoal (0.10 g). After removal of the catalyst by filtration, the filtrate was evaporated and the resulting residue was pulverized with acetone to give D-Lac-L-Ala- &gamma;-D-Glu(&alpha;-OH)-L-Lys-GlyOH (,0.25 g) as a powder. I.R. (Nujol) : 3350, 1710, 1670-1640 cm-1 NMR (D2O+NaHCO3), #(ppm) : 1.37 (3H, d, J=7Hz), 1.44 (3H, d, J=7Hz), 1.34-2.00 (8H, m), 1.84-2.25 (2H, m), 3.04 (2H, t, J=7Hz), 3.79 (2H, s), z 4.17-4.50 (3H, m) Example 85 (1) Step 1 EMI343.1 To a mixture of Boc-L-Ala-D-Glu(OH)OMe (1) (1.33 g), L-Lys(#-Boc)-GlyOEt (2) (2.02 g) and 1-(4 chlororbenzenesulfonyloxy)-6-chlorobenzotriazole (1.38 g) in methylene chloride (50 ml) was added N-methylmorphorine (0.808 g) at 0 C and the mixture was stirred for 30 minutes 2t the same temperature and for 2 days at room temperature. The reaction mixture was washed successively with 5% aqueous sodium bicarbonate, water, 5% hydro chloric acid and water, dried over magnesium sulfate and evaporated to give a crystalline mass, which was washed with ether to give Boc-L-Ala-&gamma;- D-Glu(&alpha;-OMe)-L-Lys(#-Boc)-GlyOEt (3)(1.96 g). m.p. 163-4 C T.R. (Nujol) : 3550, 3275, 1740, 1690, 1650 cm NMR (DMSO-d6), 6(ppm) : 1.17 (3H, t, J=7Hz), 1.32 (3H, d, J=7Hz), 1.35 (18H, s), 1.42-1.54 (8H, m), 2.08-2.18 (ZH, m), 3.25-2.82 (ZM, m), 3.62 (3H, s), 3.80 (2H, d, J=6Hz), 4.07 (2H, q, J=7Hz), 3.80-4.07 (3H, m), 6.58-6.77 (2H, m), 7.83-8.25 (3H, m) (2) Step 2 EMI344.1 To a solution of Bor-L-Ala-y-D-Glu(a-oMe)-Lo Lys(#-Boc)-GylOET (3) (0.50 g) in methanol (5 ml) was added 1N sodium hydroxide (2 ml) at 0 C and the mixture was stirred for 1 hour at the same temperature and overnight at room remperature. The reaction mixture was evaporated and the residue was dissolved in water and washed with ethyl acetate. The aqueous layer was acidified with diluted hydrochloric acid to pH 2 and ex tracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and evaporated to give an oil (0.37 g). This oil was dissolved in ethyl acetate (10 ml) and a saturated solution of hydrogen chloride in ethyl acetate' (5 ml) was added at 0 C The mixture was stirred for 10 minutes at the same temperature and for 30 minutes at room temperature. The re sulting precipitate was filtered and washed with ethyl acetate to give L-Ala-y-D-Glu(a-OR)-L-Lys- GlyOH (4)(0.17 g) as a powder. I.k. (Nujol) : 3450, 3200, 1730, 1680, 1660-1640 cm-1 NfS (D'20), a (ppm) : 1.65 (3H, d, J=7Hz), 1.92-1.42 (8H, m), 2.34 (2R, t, J=6Rz), 2.64 (2H, t, J=6Hz), 3.95 (2H, s), 4.10-4.67 (3H, m) Example 86 (1) Step 1 EMI345.1 EMI346.1 D-Lac(OAc)-L-Ala-D-Add(OH)oBz(3) was prepared from O-acetyl-D-lactyl chloride (1) and L-Ala-D-GluOBzl (2) in substantially the same manner as that of Step 1 of Example 1. I.R. (CHCl3) : 3400, 3300, 1730, 1710, 1665 cm-1 NMR (CDCl3), 6(ppm) : 1.36 (3H, d, J=7Hz), 1.41 (3H, d, J=7Hz), 1.4-2.0 (4H, m), 2.08 (3H, s), 2.2-2.4 (2H, m), 4.4-4.7 (2H, m), 4.9-5.2 (1H, m), 5.10 (2H, s), 6.96 (1H, d, J=8Hz), 7.15 (, d, J=8Hz), 7.20 (5H, s), 7.4-8.2 (1H, broad s) (2) Step 2 EMI346.2 D-Lac(OAc)-L-Ala-#-D-Aad(&alpha;-OBzl)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH (5) was prepared from D-Lac(OAc)-L-Ala-D-Aad-D-Aad(OH)oBz(3) and Boc-(D) mesoDAP-(D)-NHNHBoc-(L)-GlyOH (4) in substantially the same manner as that of Example 66. m.p. 108 - 1100C I.R. (Nujol) : 3260,.1725, 1670, 1650, 1630, 1540, 1520 cm-1 NMR (CDCl3), #(ppm) : 1.40 (3H, d, J=7Hz), 1.4-2.0 (13H, m), 1.44 (18H, s), 2.10 (3H, s), 2.1-2.5 (2H, m), 3.90 (2H, s), 3.8-4.2 (1H, m), 4.3-4.6 (3H, m), 4.7-5.1 (1H, m), 5.12 (2H, s), 7.30 (5H, s) (3) Step 3 EMI347.1 D-Lac-L-Ala-#-D-Aad(&alpha;-OH)-(L)-meso-DAP-GlyOH (6) was prepared from D-Lac(OAc)-L-Ala-#-D-Aad- (&alpha;-OBzl)-(L)-Boc-(D)-mesoDap-(D)-NHNHBoc-(L)- GlyOH (5) in substantially the same manner as that of Step 2 of Example 83 I.R. (Nujol) : 3270, 1720, 1620, 1530 cml NMR (D20), #(ppm) : 1.36 (3H, d, J-7Hz), 1.43 (3H, d, J=7Hz), 1.5-2.1 (10H, m), 2.2-2.5 (2H, m), 3.84 (1H, t, J=6Hz), 3.96 (2H, s), 4.1-4.5 (4H, m) Example 87 (1) Step 1 EMI348.1 D-Lac(OAc)-L-Ala-&gamma;-Abu-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-GlyOH (3) was prepared in substantial- ly the same manner zs that of Example 66. NMR (CDC13), #(ppm) : 1.2-2.0 (4H, m), 1.42 (18H, s), 2.0-2.5 (2H, m), 2.15 (3H, s), 3.1-3.4 (2H, m), 3.8-4.1 (2H, m), 4.3-4.7 (1H, m), 4.9-5.2 (1H, m), 5.5-6.0 (2H, m), 7.3-7.6 (2H, m), 7.6-8.1 (2H, m) (2) Step 2 EMI348.2 D-Lac(OH)-L-Ala-&gamma;-Abu-(L)-mesoDAp-(L)-GlyOH (4) was prepared in substantially the same manner as ,that of Example 83 NMR (D2O), 6 (ppm) : 1.39 (3H, d, J=7Hz); 1.40 (3H, d, J=7Hz), 1.5-2.1 (8H, m), 2.33 (2H, t, J=7Hz), 3.21 (2H, t, J=Hz), 3.79 (1H, t, J=7Hz), 3.95 (2H, s), 4.1-4.5 (4H, m) The following compounds were prepared in sub stantially the same manner as Steps 1 and 2 of Example 1, respectively. Example 88 (1) Step 1 Thienylacetyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc. NMR (DMSO-d6), #(ppm) : 1.36 (18H, s), 1.00-2.33 (10H, m), 3.66 (2H, s), 3.83-4.33 (3R, m), 6.87 (2H, m), 7.27 (1H, m), 7.83-8.66 (3H, m), 9.02 (2H, broad s) (2) Step 2 Thienylacetyl-&gamma;-D-Glu-(&alpha;-OH)-(L)-mesoDAP. NMR (D2O), #(ppm) : 1.20-2.60 (10H, m). 3.78 (IH, t, J=7Hz), 3.86 (2H, s), 4.28 (1H, t, J=7Hz), 7.04 (2H, m), 7.32 (2H, m) Example 89 (1) Step 1 EMI350.1 Phenoxyacetyl-D-Glu(&alpha;-oBzl) (1) (742 mg) was dissolved in methylene chloride and N-methylmorpholine (202 mg) was added thereto. This solution was cooled under a dryice-carbontetrachloride and isobutylchloroformate (274 mg) was added thereto. The mixture was allowed to react for 60 minutes at the same temperature. To the resulting reaction mixture was added the solution Boc-(D)-mesoDAP-(D)-NHNHBoc (2)(808 mg) in a mixture of methylene chloride (20 ml), dimethylformamide (2- ml) and bis (trimethylsilyl)- acetamide (2 ml). The reaction mixture was stirred for two hours and concentrated in vacuo to give an oily residue, which was dissolved in ethyl acetate, washed with 1N hydrochloric acid and brine, dried over magnesium sulfate. Evaporation of the solvent gave a white foam, which was pulverized with isopropylether to give a phenoxyacetyl-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc (3) (1.21 g). NM,R (CD30D), 6 (ppm) : 1.42 .(18H, s), 3.9-4.6 (3H, m), 4.54 (2H, s), 5.17 (ZH, s), 6.85-7.30 (SH, m), 7.35 ,(5H* s) (2) Step 2 EMI351.1 Phenoxyacetyl-y^D-Glu (a-oB:l) - (L) -Boc- (D) -mesoDAP- (D)-NHNHBoc (3)(1.13 g) was dissolved in methanol (20 ml) and 1N sodium hydroxyde (3.0 ml) was added thereto at ambient temperature. The reaction mix ture was stirred for 4 hours at the same temperature and concentrated under reduced pressure to give an oily residue, which was dissolved in a mixture of ethyl acetate (60 ml), water (10 ml) and 1N hydro chloric acid (4 ml). The organic layer was with brine, dried over magnesium sulfate and then con centrated in vacuo to give phenoxyacetyl-&gamma;-D-Glu(&alpha;-OH)- (L)-Boc-(D)-mesoDAP-(D)-NHNHBoc (4) (670 mg). NMR (CDJOD), 6(ppm) : 1.43 (18H, s), 4.00 4.70 (3H, m), 4.60 (2R, s), 7.24-7.50 (SH, m) (3) Step 3 EMI352.1 Phenoxyacetyl-""-D-Glu(a-OH) - CL) -Boc- (D) -mesoDAP- (D) - NHNHBoc t4)(615 mg) was dissolved in trifluoroacetic acid (3 ml) and the solution was kept for an hour at ambient temperature. The solvent was distilled off to give an oily paste, which was pulverized with ether to give a white powder. The powder was dissolved in a mixture of water (25 ml) and lN sulfuric acid and the solution was cooled in an ice-bath To the solution was added sodium periodate (300 mg) and the mixture was stirred for two hours at 00C. The mixture was treated with an aqueous sodium bisulfite and then passed through a column packed with a macroporous non-ionic adsorption resin, HP-20. . Elution was carried out with a mixture of water and methanol (7:3) and the eluate was concentrated in vacuo to give a white powder, which was dissolved in water and lyophilized to give phenoxy acetyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP (5) (150 mg). NMR (D2O+NaHCO3), #(ppm) : 1.25-2.35 10H, m), 3.72 (lR, t, J=6Hz), 4.00-4.35 (2R, m), 4.63 (2H, s), 7.0-7.S (iH, m) Example 90 (1) Step 1 EMI353.1 n-Octanoyl-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAp-(D) NHNHBoc-(L)-D-AlaOH (3) was prepared in substantially the same manner as step (1) of Example 89 from com pounds (1) and (2). NMR (DMSO-d6+D20), #(ppm) : 0.83 (3H, t, J=6Hz), 1.37 (18H, s), 3.80-4.50 (4H, m), 5.08 (2H, s), 7.33 (5H, s), 7.66-8.33 (6H, m), 9.20 (1H, broad s) {2) Step 2 EMI354.1 n-Octanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-D-AlaOH (4) was prepared in substantially the same manner as step 2 of Example 89 from compound (3). NMR (DMSO-d6+D2O), #(ppm) : 0.87 (3H, t, J=6Hz), 1.35 (18H, s), 4.00-4.66 (4H, m), 7.66 8.33 (6R, m), 9.55 (2H, broad s) (3) Step 3 EMI354.2 n-Octanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D-AlaOH (5) was prepared in substantially the same manner as step 3 of Example 89 from compound (4). NMR (D2O), 6(ppm) : 0.88 (3H, t, J=7Hz), 1.40 (3H, d, J=7Hz), 1.00-2.50 (22H, m), 3.80 (1H, t, J=7Hz), 4.00-4.50 (3H, m) Example 91 (1) Step 1 EMI355.1 Phenylcarbamoyl-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP- (D)-EHNHBoc (3) was prepared in substantially the same manner as step 1 of Example 89 from Compounds (1) and (2). NMR (CD3OD) #(ppm) : 1.41 818H, s), 3.09-4.62 (3H, m), 5.19 (2H, s), 6.95-7.52 (1OH, m) (2) Step 2 EMI356.1 Phenylcatbamoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc (4) was prepared in substantially the same manner as step (2) of Example 89 from compound (3). NMR (CD3OD) #(ppm) : 1.48 (1SH, s), 3.95-4.55 (3H, m), 7.32 (5H, s) (3) Step 3 EMI356.2 Phenylcarbamoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP (5) was prepared in substantially the same manner as step 3 of Example 89 from Compound (4). NMR (D2O+NaOD) #(ppm) : 1.1-2.6 (10H, m), 3.16 (1H, m), 4.00-4.20 (2H, m), 7.00-7.45 (5H, m). Example 92 (1) Step 1 EMI357.1 &alpha;-Ethylhexanoyl-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc (3) was prepared in, substantially the same manner as step 1 of Example 89 from Compounds (1) and (2). NMR (CD30D) 6(ppm) 0.86 (6H, m), 1.45 (18H, s), 3.90-4.30 (3H, m), 5.16 (2H, s), 7.36 (SH, s). (2) Step 2 EMI358.1 &alpha;-Ethylhexanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc (4) was prepared in substantially the same manner as step 2 of Example 89 from compound (3). NMR (CD3OD) #(ppm) : (0.88 (6Hz, m), 1.43 (18H, s), 4.02 (1H, m), 4.36 (2H, m). (3) Step 3 EMI358.2 &alpha;-Ethylhexanoyl-&gamma;-D-Glu(&alpha;-OH) - (L) -mesoDAP (5) was prepared in substantially the same manner as step 3 of Example 89 from Compound 4). NMR (D2O) #(ppm) : 0.83 (6H, m), 1.08-2.56 (19H, m), 3.82 (1H, t, J=7Hz), 4.23-4.48 (2H, m). Example 93 (1) Step 1 EMI359.1 To a solution of &gamma;-D-Glu-(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc (1)(800 mg) in the mixture of water (8 ml) and dioxane (8 ml) were added N-hydroxy succinylnicofiinate (330 mg) and triethylamine (364 mg). The reaction mixture was left for 20 hours at ambient temperature and concentrated in vacuo. To the residue was added 1N hydrochloric acid (3 ml) and the mixture was passed through a column packed with a macroporous non-ionic adsorption resin, HP 20 (120 ml). The fraction eluted with a mixture of water and methanol (2:3) was concentrated in vacuo to give nicotinoly-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc (2). NMR (CD3OD), d(ppm) : 1.44 (18H, s), 3.9-4.6 (3H, m), 7.59 (1H, d.d., J=8 & 5Hz), 8.35 (1H, m), 8.75 (1R, d, J=SHz), 9.11 (1H, m) (2) SteP 2 EMI360.1 Nicotinoyl-#-D-Glu(&alpha;-OH)-(L)-mesoDap (3) was prepared in substantially the same manner as Step 2 of Example 89 from Compound (2). NMR (D2O), # (ppm) : 1.25-2.60 (10H, m), 3.87 (1H, t, J=6Hz), 4.23 (1H, m), 4.51 (1H, m), 7.98 (1H, d.d., J=6 & 8Hz), 8.71 (1H, d, J=8Hz), 8.88 (1H, d, J=6Hz), 9.10 (1H, s) Example 94 (1) Step 1 EMI360.2 EMI361.1 D-Lac(oAc)-&gamma;-D-Glu(alpha;-oBzl)-(L)-Boc-(D)-mesoDap-(D)- NHNHBoc (3) was prepared in substantially the same manner as Step 1 of Example 59 from Compounds (1) and (2). IR (Nujol) : 3280, 1730, 1660, 1530 cm 1 NMR (CD3OD), #(ppm) : 1.38 (18H, s), 2.05 (3H, s), 3.85-4.60 (3H, m) (2) Step 2 EMI361.2 To a solution of D-Lac(oAc)-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc- (D)-mesoDAP-(D)-NHNHBoc (4)(1.14 g) in methanol (15 ml) was added 1N sodium hydroxide (6.2 ml). The reaction mixture was left for 3.5 hours at ambient temperature and 1N hydrochloric acid (6.2 ml) was added thereto. The mixture was concentrated in vacuo and the residue was passed a column packed with a macroporous non-ionic adsorption resin, HP 20 (100 ml) and eluted with a mixture of water and methanol ( 1:1 ). The fractions containing the object Compound (4) were collected and concentrated in vacuo to give D-Lac(OH) &gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc (4) (510 mg). IR (Nujol) : 3300, 1720(sh), 1650, 1520 cm NMR (CD3OD), #(ppm) : 1.45 (18H, s), 3.97-4.70 (4H, m) (3) Step 3 EMI362.1 D-Lac(OH)-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP (5) was prepared in substantially the same manner as Step 3 of Example 59 from Compound (4). IR (Nujol) : 3250 (sh), 1720, 1650, 1530 cm-1 NMR (D2O), #(ppm) : 1.25-2.50 (1OH, m), 1.36 (3E, d, J-7Hz), 3.91 (1H, t, J=7Hz), 4.28-4.45 (3H, m) Example 95 (1) Step 1 EMI363.1 -&alpha;Ethylhexanoyl-&gamma;-D-Glu(&alpha;-pBzl)-(L)-Boc-(D)-mesoDAP (D)-NHNHBoc-(L)-D-AlaOH (s) was prepared in substant- ially the same manner as step 1 of Example 89 from compounds (1) and (2). NMR (DMSo-d6+D2O), #(ppm) : 0.80-1.00 (6H, m), 1.40 (18H, s), 1.00-2.33 (22H, m), 4.00-4.50 (4H, m), 5.10 (2H, s), 7.33 (5H, s), 7.66-8.33 (6H, m), 9.50 (1H, broad s) (2) Step (2) EMI364.1 &alpha;-Ethylhexanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-D-AlaOH (4) was prepared in substantially the same manner as step 2 2:of Example. 89 from compound (3). NMR (DMSO-d6+D2O), #(ppm) : 0.83-1.00 (6H, m), 1.43 (18H, s), 1.00-2.33 (22H, m), 3.50-4.66 (4H, m), 7.66-8.33 (6H, m), 9.53 (2H, broad s) (3) Step 3 EMI364.2 &alpha;-Ethylhexanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D- AlOH (5) was prepared in substantially the same manner as step 3 of Example 89 from compound (4). NMR (D2O), #(ppm): 0.84 (6H, t, J=7Hz), 1.24-2.30 (19H, m), 1.36 (3H, t, J=7Hz), 3.82 (1H, t, J=6Hz), 4.25-4,44 (3H, m) Example 96 (1) Step 1 EMI365.1 Hexanoyl-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-D-AlaOH (3) was prepared in substantially the same manner as step 1 of Example 89 from compound (1) and (2). NMR (DMSO-d6+D2O), #(ppm) : 0.83 (3H, t, J=7Hz), 1.44 (18H, s), 3.83-4.50 (4R, m), 5.13 (2H, s), 7.33 (5H, s), 7.73-8.73 (5H, m), 9.56 (1H, broad s) (2) Step 2 EMI366.1 Hexanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)mesoDAP-(D)-NHNHBoc- (L)-D-AlaOH (4) was prepared in substantially the samo manner as step 2 of Example 89. NMR (DMSO-d6-D2O), #(ppm) : 0.86 (3H, t, J=7Hz), 1.37 (18H, s), 3.83-4.33 (4H, m) 7.66-8.77 (6H, m) (3) Step 3 EMI366.2 Hexanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D¯AlOH (5) was prepared in substantially the same manner as step 3 of Example 89 from compound (4). NMR (DMSO-d6+D2O), #(ppm) : 0.80 (3H, t, J=7Hz), 1.38 (5H, d, J=7Hz), 1.28-2.40 (18H, m), 3.75 (1H, t, J=7Hz), 4.20-4.35 (3H, m) Example 97 Cl) Step 1 EMI367.1 Phenoxyacetyl-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-D-AlaOH (3) was prepared in substantially the same manner as step 1 of Example 89 from compound (1) and (2). NMR (DMSO-d6+D2O), #(ppm) : 1.38 (18H, s), 3.66-4.50 (4H, m), 4.53 (2H, s), 5.15 (2H, s), 6.87-7.33 (5H, m), 7.37 (SH, s), 7.85-8.60 (6H, m), 9.57 (1H, broad s) (2) Step 2 EMI368.1 Phenoxyacetyl-&gamma;-G-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-D-AlaOH (4) was prepared in substantially the same manner as step 2 of Example 89 from compound (3). NMR (DMSO-d6+D2O), #(ppm) : 1.40 (18H, s), 3.73-4.50 (4H, m), 4.53 (2H, s) 6.90-7.43 (SR; m), 7.73-8.66 (6H, m), 9.50 (2H, broad s) (3) Step 3 EMI368.2 Phenoxyacetyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D-AlaOH (5) was prepared in substantially the same manner as step 3 of Example 89 from compound (4). NMR (D20), #(ppm) : 1.39 (3H, d, J-7Hz), 1.60-2.50 (10H, m), 3.85 (1H, t, J=7Hz), 4.00-4.50 (3H, m), 4.64 (2H, s), 6.80-7.50 (5H, m) Example 98 Step 1 EMI369.1 Phenylcarbamoyl-&gamma;-D-Glu(&alpha;-oBzl)-(L9-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-D-AlaOH (3) was prepared in substan ,,tially the same manner as step 1 of Example 89 from compounds (1) and (2). NMR (DMSO-d6+D2O), #(ppm) : 1.37 (18H, s), 3.83-4.50 (4H, m), 5.13 (2H, s), 7.33 (5H, s), 6.50-7.20 (SH, m), 7.33-8.50 (7H, m), 9.50 (1H, broad s) (2) Step 2 EMI370.1 Phenylcarbamoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-D-AlaOH (4) was prepared in substantially the same manner as step 2 of Example 89 from compound (33. NMR (DMSO-d6+D2O), #(ppm) : 1.42 (18H, s), 3.83-4.20 (4H, m), 6.40-7.50 (5H, m), 7.66-8.60 C7R,, m), 9.50 (2H, broad s) (3) Step 3 EMI370.2 Phenylcarbamoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D- AlaOH (5) was prepared in substantially the same manner as step 3 of Example 89. NMR (D2O), #(ppm) : 1.40 (5H, d, J=7Hz), 1.30-2.50 (10H, m), 3.76 (1H, t, J=7Hz), 4.20-4.50 (3H, m), 7.00-7.70 (SH, m) Example 99 (1) Step 1 EMI371.1 D-Lac(oAc)-&gamma;-G-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-D-Ala OH (3) was prepared in substantially the same manner as step 1 of Example 89 from compounds and (2). NMR (DMSO-d6+D2O), #(ppm) : 1.40 (18H, s), 2.06 (3H, s), 1.10-2.30 (16H, m), 3.66-4.57 (5H, m), 5.13 (2H, s), 7.37 (SH, s), 7.66-8.38 (6H, m), 9.56 (1H, broad s) (2) Step 2 EMI372.1 D-LAC(OH)&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-D-AlaOH (4) was prepared in substantially the same manner as step 2 of Example 89 from compound (3). NMR (CD3OD), # #(ppm) : 1.40 (9H, s), 1.43 (9E, s), 1.33-2.50 (16H, m), 3.83-4.66 (5H, m) (3) Step 3 EMI372.2 D-Lac (OH) -y-D-Glu (&alpha;-OH) - CL) -mesoDAP- CL) -D-AlaOH (5) was prepared in substantially the same manner as step 3 of Example 89 from compound (4). NMR (D2O), #(ppm) : 1.32 (3H, d, J=7Hz), 1.33 (3H, d, J-7Hz), 1.20-2.40 (1OH, m), 3.82 (1H, t, J=7Hz), 4.20-4.44 (4H, m) Example 100 EMI373.1 Z- L -Ala-&gamma;-G-Glu-(&alpha;-oBzl)-(L)-mesoDAP-(L)-D- AlaOH (3) was prepared in substantially the same manner as step I of Example 32 from compounds (1) and (2). NMR (DMSO-d6), 6(ppm) : 1.23 (6H, d, J=7Hz), 1.20-2.30 (1OH, m), 4.0-4.63 (5H, m), 5.07 (2H, s), 5.15 (2H, s), 7.40 (5H, s), 7.73-8.50 (3H, m), 9.63 (1H, d, J=7Hz) (2) Step 2 EMI373.2 L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Tfa-(D)-mesoDAP-(L)-D-AlaOH (4) was prepared in substantionally the same manner as step 2 of Example 52 from compound (3). NMR tD2O), #(ppm) : 1.43 (3H, d, J=7Hz),'1.60 (3H, d, J-7Hz), 1.40-2.70 (1OH, m), 4.00-4.50 (5H, m) (3) Step 3 EMI374.1 L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Tfa-(D)-mesoDAP-(L)-D-Ala(OH) (4)(810 mg) was dissolved in a mixture of methylene chloride (30 ml), methanol (3 ml) and triethylamine (594 mg). To this solution was added retinoic acid N-hydroxysuccimide ester (584 mg) and thermixture lJas reacted for two days at ambient temperature. Triethylamine (150 mg) was added to the reaction mix ture and reacted for another day further. The result ing mixture was evaporated and the oily residue was extracted with ethyl acetate after acidification with 1N sulfuric acid. The organic layer was washed with water, dried over magnesium sulfate and evaporated to give a yellow foamy residue (1.10 g) which was throu ghly washed with a mixture of ethyl ether and isopropylether to give retinoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)- (L)-Tfa-(D)-mesoDAP-(L)-D-AlaOH (5) (940 mg.). NMR (DMSO-d6), #(ppm) : 1.00 (6H, s), 1.03 (3H, d, J=7Hz), 1.23 (3H, d, J=7Hz), 1.0-2.40 (16H, m), 1.66 (3H, s), 1.93 (3H, s), 2.25 (3H, s), 4.0-4.50 (SH, m), 5.83-6.50 (SH, m), 6.70-7.30 (1H, m), 7.70-8.40 (4H, m) (4) Step 4 EMI375.1 Retinoyl-L-Ala-y-D-Glu (a-OH) - CL) -Tfa- (D) -mesoDA?- (L)-D-AlaOR' (5)(0.90 g) was dissolved in a mixture of water (15 ml) and 1N sodium hydroxide (4.50 ml). The resulting solution was maintained for 2 hours at ambient temperature and then acidified with 1N sulfuric acid. The mixture was extracted with n-butanol (100 ml). The organic layer was washed three times with water (20 ml) and evaporated to give a yellow solid residue which was throughly washed with ethyl ethre to give retinoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- mesoDAP-(L)-D-AlaOH (6). NMR (DMSO-d6), o(ppm) : 1.06 (6H, s), 1.20 (3H, d, J=7Hz), 1.30 (3R, d; J=7Hz), 1.73 (3H, s), 2.00 (3M, s), 2.30 (3H, s), 1.00-2.50 (16H, m), 3.30-3.70 (1H, m), 4.00-4.66 (4H, m), 5.86-6.50 (SR, m), 6.70-7.30 (1H, m), 7.70-8.30 (4H, m) Example 101 (1) Step 1 EMI376.1 Z-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Tfa-(D)-mesoDAP-(L)-GlyOH (3) was prepared in substantially the same manner as step 1 of Example 100 from compounds (1) and (2). NMR (DMSO-d6), 6 (ppm) : 1.23 (3H, d, J=7Hz), 1.20-2.50 (10H, m), 3.75 (2H, d, J=6Hz), 4.0-4.60 (4H, m), 5.03 (2H, s), 5.13 (2H, s), 7.10-7.30 (1H, broad), 7.33 (10H, s), 7.83-8.50 (3H, m), 9.60 (1H, d, J=7Hz) (23 Step 2 EMI377.1 L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Tfa-(D)-mesoDAP-(L)-GlyOH (4) was prepared in substantially the same manner as step 2 of Example 100 from compound (3). NMr (D2O), #(ppm) : 1.56 (3H, d, J=7Hz), 1.20-2.63 (10H,m), 3.95 (2H, s), 4.00-4.50 (4H, m) (3) Step 3 EMI377.2 Retinoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Tfa-(D)-mesoDAP- (L)-GlyOH (5) was prepared in substantially the same manner as step 3 of Example 100 from compound (4). NMR (DMSO-d6), #(ppm) : 1.00 (6E, s), 1.06 (3H, d, J=7Hz), 1.00-2.40 (16H, m), 1.66 (3H, s), 1.90 (3H, s), 2.33 (3H, s), 3.70 (2H, broad), 4.0-4.50 (4H, m), 5.83-6.50 (5H, m), 6.70-7.30 (1H, m), 7.70-8.40 (4H, m) (4) Step 4 EMI378.1 Retinoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-GlyOH (6) was prepared in substantially the same manner as step 4 of Example 100 from compound (5). NMR (DMSO-d6), 6(ppm) : 1.00 (6H, s), 1.23 (3H, d, J=7Hz), 1.70 (3H, s), 1.96 (3H, s), 2.26 (3H, s), 1.00-2.50 (16H, m), 3.50 (1H, broad s), 3.76 (2H, broad s), 4.0-4.50 (4H, m), 5.70-7.30 (6H, m), 7.70-8.30 (4H, m) Example 102 (1) Step 1 EMI379.1 Nicotinoyl-y-D-Glu (-OH) - CL) -Boc- CD) -mesoDAP- CD) - NHNHBoc-(L)-D-AlaOH (2) was prepared in substantially the same manner as step 1 of Example 93 from com- pound (1). NMR (D2O), #(ppm) : 1.43 (18H, s), 1.35-2.66 (13H, m), 3.87 (1H, t, J=7Hz), 4.00-4.66 (3H, m), 7.90 (1H, m), 8.50-9.20 (3H, m) (2) Step 2 EMI379.2 Nicotinoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D-AlaOH (3) was prepared in substantially the same manner as step 2 of Example 93 from compound (2). NMR (NaOD-D2O), (ppm) : 1.33 (3H, d, J=8Mz), 1.20-2.50 (10H, m), 3.20 (1H, t, J=6Hz), 4.04-4.60 (3H, m), 7.64 (1H, dd, J=4and 8Hz), 8.33 (1H, dd, J=2 and 8Hz), 8.72 (1H, dd, J=2 and 4Hz), 8.94 (1H, dd, J= J=1.5 and 2Hz) Example 103 (1) Step 1 EMI380.1 D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Z-(D)-mesoDAP- (D)-NHNHZ-(L)-GlyOR (3) was prepared in substantially the same manner as step 1 of Example 89 from compounds (1) and (2). NMR (CD3OD), #(ppm) : 1.36 (3H, d, J=7Hz), 1.44 (3H, d, J=7Hz), 2.07 (3H, s), 1.3-2.4 (1OH, m), 3.92 (2H, s), 4.1-4.6 (4H, m), 5.07 (2H, s), 5.13 (2H, s), 5.15 (2H, s), 7.32 (15H, s) Example 104 (1) Step 1 EMI381.1 Heptanoyl-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-D-PheOH (3) was prepared in substantially the same manner as step 5 of Example 89 from compounds '(1) and (2). NMR (DMSO-d6), #(ppm) : 0.7-2.4 (41H, m), 2.8-3.2 (2E, s), 3.4-4.8 (4H, m), 5.15 (2H, s), 6.7 (1H, m), 7.26 (5H, s), 7.40 (5E, s), 7.8 (1H, m), 8.2 (2H, m), 8.7 (1H, m), 9.60 (1H, broad s). (2) Step 2 EMI382.1 Heptanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-D-PheOH (4) was prepared in substantially the same manner as step 2 of Example 89.,- NMR (CD3OD), #(ppm) : 0,91 (3H, m), 1.1-2.7 (20H, m), 1.46 (18H, s), 3.1 (2H, m), 3.8-4.6 (4H, m), 7.19 (5H, s) (3) Step 3. EMI383.1 Heptanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-PheOH (5) was prepared in substantially the same manner as st 3 of Example 89. NMR (D2O-NaOD), #(ppm) : 0.83 (3H, t, J=6Hz), 1.0-2.1 (16H, m) 2.28 (4H, t, J=7.5Hz), 3.10 (2H, AB part of ABX system, J=14,8,4Hz), 3.15 (1H, t, J=7.5Hz), 4.16 (2H, broad t, J=8Hz), 4.50 (1H, dd, J=8,4Hz), 7.3 (5H, m) Example 105 (1) Step I EMI383.2 EMI384.1 Heptanoyl-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-&gamma;-AbuOH (3) was prepared in substantially the same manner as step 1 of Example 89 from compounds (1) and (2). NMR (DMSO-d6), #(ppm) : 0.7-2.6 (27H, m), 1.40 (18H, s), 2.8-4.6 (5H, m), 5.11 (2H, s), 6.65 (1H, m), 7.34 (SH, s), 7.82 (2H, m), 8.16 (1H, d, J=7Hz), 8.60 (lH,, m), 9.52 (1H, broad s). (2) Step 2 EMI384.2 Heptanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-&gamma;-AbuOH (4) was prepared in substantially the same manner as step 2 of Example 89. IR (Nujol) : 1700(broad), 1640(broad), 1520(broad) cm-1 NMR (CD3OD ), #(ppm) : 0.88 (3H, m), 1.1-2.6 (27H, m), 1.43 (18H, s), 3.8-4.6 (3H, m) (3) Step 3 EMI385.1 Heptanol-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-&gamma;-AbuOH (5) was prepared in substantially the same manner as step 3 of Example 89. IR (Nujol) : 1710, 163S and 1540 cm 1 NMR (D20), 6 #(ppm) : 0.85 (3H, brt, J=6Hz), 1.0-2.8 (24H, m), 3.28 (2H, t, J=6.5Hz), 3.83 (1H, t, J=6Hz), 4.1-4.5 (2H, m). Example 106 EMI385.2 EMI386.1 Phenoxyacetyl-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-D-LeuOH (3) was prepared in substantially the same manner as step 1 of Example 89 from compounds Cl) and (2). NMR (DMSO-d6), #(ppm) : 0.7-2.4 (19H, m), 1.40 (18H, s), 3.6-4.7 (4H, m), 4.55 (2H, s), 5.15 (2H, s), 6.5-8.8 (10H, m), 7.34 (5H, s), 9;S5 (1H, broad s). (2) Step 2 EMI386.2 Phenoxyacetyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc-(L)-D-LeuOH (4) was prepared in substantially the same manner as step i of Example 89. NMR (CD3OD), #(ppm) : 0.90 (6H, broad d, J-5Hz), 1,3-2.7 (13H, m), 1.43 (18H, s), 3.8-5.0 (4H, m), 4.60 (2H, s), 6.8-7.6 (5H, m) (3) Step 3 EMI387.1 Phenoxyacetyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D-LeuOH (5) was prepared in substantially the same manner as step 3 of Example 89. NMR (CD3OD), #(ppm) : 0.88 (6H, m), 1.2-2.7 (13H, m), 3.73 (lH, brs), 4.2-4.7 (3H, m), 4.55 (2H, s), 6.8-7.5 (5H, m) Example 107 (1) Step 1 EMI387.2 EMI388.1 A suspension of D-TryOH(oBzl)(596 mg) in a. mixture of bis(trimethylsilyl)acetamide (2 ml), dimethylformamide (2 ml) and methylene chloride (2 ml) was stirred at ambient temperature for two hours. The resulting solu- tion was added to a solution of the mixed anhydride of D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc (1)(1.64 g) in a mixture of methylene chloride (10 ml) and ethyl acetate (i ml). The. reaction mixture was stirred at -150C for an hour and kept over night in a refrigerator. The resulting solution was concentrated, taken up into ethyl acetate (50 ml) and washed in turn with dil. hydrochloric acid, water (X2) and brine. The resulting solution was dried over mag nesium sulfate and the solvent was distilled off to gve an amorphous solid (Z'.ll g). The solid was triturated with ether and supernatant was discarded to give D-' Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-Bzl)-(L)-Boc-(D)-mesoDAP (D)-NHNHBoc-(L)-D-TyrOH (oBzl)(2)(1.74 g). (2) Step 2 EMI389.1 1N Sodium hydroxide (18 ml) was added to a solution of D-LaccoAc)-L-Ala-y-D-Glu(a-oSzl)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc-(L)-D-TyrOH (oBzl)(2)(1.74 g) in a mixture of methanol (15 ml) and water (7 ml) and the solution was stirred at 5 C for 30 minutes and at ambient ten perature for 1.S hours. The reaction mixture was neutralized to pH 7 with 1N hydrochloric acid and. concentrated in vacuo. The concentrate was diluted with water, acidified to pH 7 with 1N hydrochloric acid and then extracted with ethyl acetate. The extract was washed with water and brine, dried over magnesium sulfate and evaporated to give D-Lac(OH)-L-Ala-&gamma;-D-Glu(&alpha;-OH)- (L)-Boc-(D)-ntsoDAP-(D)-SHNHBoc-(L)-D-TyrOH (oBzl)(7,). Step 3 EMI389.2 D-Lac(OH)-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D- TyrOH(oBzl)(4) was prepared in substantially the same manner as step 3 of Example 89. (4) Step 4 EMI390.1 A solution of D-Lac(OH)-(L)-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- mesoDAP-(L)-D-TryOH(oBzl)(4)(258 mg) in a mixture of 0.25N hydrochloric acid (2 ml) and methanol (8 ml) wns hydrogenated over 10% palladium black (120 mg) for 21.5 hours. The reaction mixture was filtered and the filtrate was evaporated to dryness. The--residue was dissolved in methanol (5 ml) and the solution was treated with IN sodium hydroxide (1.5 ml) at 5 C. The resulting solution was neutralized to pH 7, concentrated, adjusted to pH 2 and passed through a column packed with HP 20 (16 ml). Elution was carried out with aqueous methanol and then menanol. Fractions containing the object compound were collected, evapo rated, dissolved in water and then lyophillized to give D-Lac(OH)-L-Ala-&gamma;-D-Glu(&alpha;OH)-(L)-mesoDAP-(L)-D-TyrOH (S),(100 mg). NMR (D2O), #(ppm) : 1.0-2.5 (10H, m), 1.38 (3H, d, J=7Rz), 1.41 (3H, d, J=7Hz), 2.6-3.4 (2H, m), 3.74 (1H, t, J=6Hz), 4.0-4.6 (5H, m), 6.82 (2H, d, J=9Hz), 7.10 (2H, d, J=9Hz) Example 108 (1) Step 1 EMI391.1 Heptanoyl-ss-D-Asp(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc (3). was prepared in substantially the same manner as step 1 of Example 89 from compounds (10) and (2). NMR (CDCl3), #(ppm) : 0.7-1.0 (3H, m), 1.0-2.0 (32H, m), 2.0-2.5 (2H, m), 2.8-3.1 (2H, m), 4.1-4.9 (2H, m), 4.9-5.1 (1H, m), 5.27 (2H, s), 5.5-6.0 (1H, m), 7.0-7.3 (2H, m), 7.50 (5H, s), 8.9-9.2 (1H, m), 9.2-9.6 (1H, m) EMI392.1 Heptanoyl-ss-D-Asp(&alpha;-OH)-(L)-mesoDAP (4) was prepared in substantially the same manner as steps 1 and 2 of Example 89 from compound (3). NMR (D2O), #(ppm) : 0.84 (3H, t, J=6Hz), 1.2-2.0 (14H, m), 2.2-2.4 (2H, m), 2.5-3.0 (2H, m), 3.75 (1H, t, J=6Hz), 4.0-4.3 (2H, m) Example 109 (1) Step 1 EMI393.1 Mandelyl(oAc(-#-D-Aad(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP (D)-NHNHBoc (3) was prepared in substantially the same manner as stcp 1 of Example 89 from compounds (1) and (2). NMR (CDCl3), #(ppm) : 1.4 (18H, s), 1.2-2.0 (10H, m), 2.16 (3H, s), 2.0-2.4 (2H, m), 4.0-4.2 (1H, m), 4.3-4.7 (2H, m), 5.08 (2H, s), 5.3-5.4 (1H, m), 6.08, (1H, s), 6.7-7.1 (3H, m), 7.30 (10H, s), 8.8-9.0 (1H, m) EMI394.1 Mendelyl-#-D-Aad(&alpha;-OH)-(L)-mesoDAP (4) was prepared in substantially the same manner as steps 2 and 3 of Example 89 from compound (3). NMR (D2O), #(ppm) : 1.2-2.0 (10H, m), 2.1-2.4 (3H, m), 3.6-3.9 (1H, m), 4.2-4.5 (2H, m), 5.17 (1H, s), 7.42 (5H, s) Example 110 (1) Step 1 EMI395.1 Heptanoyl-#-D-Aad(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(D)- NHN'HBoc (3) was prepared in substantially the same manner as step 1 of Example 89 from compounds (1) and (2). (2) Step 2 EMI396.1 Heptannoyl-#-D-Aad(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc (3) was prepared in substantially the same manner as step 2 of Example 89. NMR (CD3OD) : 0.7-1.1 (3H, m), 1.1-2.1 (36H, m), 2.1-2.6 (4H, m), 3.9-4.6 (3E, m) IR (Nujol) : 3270, 1700, 1640, 1520, 1160 cm (3) Step 3 EMI396.2 Heptanoyl-#-D-Aad(&alpha;-OH)-(L)-mesoDAP (5) was prepared in substantially the same manner as step 3 of Example 89. NMr (D2O), #(ppm) : 0.7-1.0 (3H, m), 1.1-2.1 (18H, m), 2.1-2.5 (4H, m), 3.76 (1H, t, J=6Hz), 4.2-4.4 (2H, m) IR (Nujol) : 3260, 171S, 162S, 1540 Example 111 (1) Step 1 EMI398.1 To a solution of L-Ala-&gamma;-D-Glu(&alpha; ;-OH)-(L)-Boc-(D)- mesoDAP-(L)-D-AlaOH (2) (561 mg) in the mixture of methylene chloride (Z0 ml) and bis(trimethylsilyl)- acetamide (3.25 g) was added a solution of 2 hexadesyl-3-acetoicosanoyl chloride (1)(630 mg) += ethylene chloride (5 ml)4 The reaction mixture was left for s days at ambient temperature and concentrated to give, an oily residue to which water (20 ml) and ether (50 ml) were added. The organic layer was separated, dried over magnesium sulfate and concentrated in vacuo. The residual paste was column chromatographed on silicic acid and eluted with a mixture of chloroform and methanol ( i: i ) to give a 2-hexadesyl-3-acetoxneicosanoyl-L- Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOH (3) (283 mg). NMR (CDCl3+CD3OD), #(ppm) : 0.85 (6H, m), 1.94 (3H, s), 3.62-4.55 (m), 5.02 (lH, m), 6.34 (1H, m), 6.98 (1H, m) Step Step 2 ¯¯¯¯¯¯ ¯¯¯¯¯ ¯¯¯¯¯¯ EMI399.1 2-Hexadesyl-3-acetoxyeicosanoyl-L-Ala-y-D-Glu( -OH)-(L) Boc-(D)-mesoDAP-(L)-D-Ala-OH(3)(200 mg) was dissolved in trifluoroacetic acid (2 ml) and the mixture was left for 30 minutes at ambient temperature. The reaction mixture was concentrated end the residual oil :as dissolved in n-butanol (15 ml) and then 1N sodium hydroxide (l ml) was added thereto. After standing for 2 hours at ambient temperature, water (10 ml) and n-butanol (20 ml) were added to the reaction mixture. The n-butanol layer was. separated and concentrated in vacuo to give 2-hexadesyl 3-hydroxyeicosanoyl-L-Ala-&gamma;-D-Glu (&alpha;-OH)-(L)-mesoDAP- (L)-D-AlaOH (4) (150 mg.). NMR (CD3OD), #(ppm) : 0.89 (6H, m), 3.65 (1H, m), 4.00 (1H, m), 4.25-4.60 (4H, m). Example 112 (1) Step 1 EMI401.1 (Pentaacetyl-D-Gluconyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc- (D)-mesoDAP-(L)-GlyOH (2) was prepared in substantially the same manner as step 1 of Example 1. IR (Nujol): 3350-3300, 1730-1710. 1700-1690 1650 cm 1 EMI401.2 (Pentaacetyl-D-Gluconyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- mesoDAP- (L) -GlyOH (3) was prepared in substantially the same manner 25 step 2.of Example 17. N.M.R. (CD3OD),±(ppm): 1.37 (3s, d, J=7Ez), 1.50-2.34 (10H, m), 2.00 (9H, s), 2.10 (3H, s), 2.17 (3H, s), 3.92 (2H, s), 3.95-4.50 (6H, m), 5.10-5.75 (4H, m). (3) Step 3 EMI402.1 D-Gluconyl-L-Ala-&gamma;-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- GlyOH (4) was prepared in substantially the same manner as step 2 of Example 19. N.M.R. (D2O), #(ppm): 1.44 (3H, d, J=7Hz), 1.34-2.50 (10E, m), 3.75 (2E, s), 3.85 (2H, d, J=10Hz), 3.84-4.67 (8E, m) Example 113 (1) Step 1 EMI402.2 EMI403.1 5-(N-Z-5-oxo-4-oxazolidinyl)valeryl-L-Ala-&gamma;-D-Glu- (&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (2) was prepared in substantially the same manner as Step 1 of Example 1. N.M.R. (CD3OD), #(ppm): 1.38 (3H, d, J=7Hz), 1.50 (18H, s), 1.38-2.50 (18H, m), 4.00 (2H, s), 4.10-4.60 (5H, m), 4.27 (2E, s), 6.60 (2H1 ABq, J=4 and 6Ez), 7.43 (5H, s) (2) Step 2 EMI403.2 -Aminopimelyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(D)-NHNHBoc-(L)-GlyOH (3) was prepared in substantially the same manner as step 2 of Example 11. N.M.R. (CD3OD), #(ppm): 1.35 (3H, d, J=7Hz), 1.42 (18E, s), 1.34-2.50 (18E, m), 3.92 (2H, s), 3.63-4.50 (5E, m) (3) Step 3 EMI404.1 &alpha;-Aminopimelyl-L-Ala-&gamma;-D-Glu-(&alpha;-OH)-(L)-mesoDAP-(L)- GlyOH (4) was prepared in substantially the same - manner as step 2 of Example 17. N.M.R. (D2O), #(ppm). 1.38 (3H, d, J=7Hz), 1.33-2.50 (18H, m), 3.73 (1H, t, J=7Hz), 3.83 (1H, t, J=7Hz), 3.97 (2H, s), 4.07-4.30 (3H, m) Example 114 (1) Step 1 EMI405.1 L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)-AlaOH (1.64 g) (1) was dissolved in a mixture of dioxane (30 ml) and water (30 ml). To this solution, triethylamine (606 mg) was added. To the mixture was added 10-(2,3-dimethoxy-5-meEhyl-1,4-benzoquino-6-yl) decanoic acid N-hydroxy-succini=ide ester (872 mg). The reaction mixture was kept at room temperature for 24 hours. The reaction mixture was concentrated and extracted with ethylacetate. The organic layer was washed successively with aqueous hydrochloric acid, water and brine, and dried over magnesium sulfate. Evaporation of the solvent gave a foam,' which was pulvirized with ether to afford 10-(2,3-dimethoxy-5- methyl-1,4-benzoquino-6-yl).decanoyl-L-Ala-y-D-Glu(=- OH)-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOH (2) (0.97 g). IR(Nujol) : 3280, 1710, 1640, 1610 cm N1(CDCl3), 6 : 1.48 (9E, s), 2.00 (3H, s), 4.00 (6H, s), 3.66-4.66 (5E, m) EMI406.1 10-(2,3-dime.hoxy-5-methyl-1,4-benzoquino-6-yl)decanoyro L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOH (2) (0.945 g.) was dissolved in trifluoroacetic acid (20 ml). The solution was kept for 1 hour at room temperature. The reaction mixture was concentrated in vacuo. The residue was dissolved in water. The pE of the. aqueous solution was adjusted to 2-3, and the whole solution was subjected to Ep-20 column (100 ml). The column was eluted with a mixture of water and MeOE-E20 (1:2). Evaporation of the latter fractions gave an orange foam, which was dissolved in water and lyophillized to give 10-(2,3-dimethoxy-5-methyl-l,- benzoquino-6-yl)-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- D-AlaOh (3) (0.80 IR(Nujol) : 3300, 1720, 1640, 1610, 1530 cm NMR(CD3CD) , # :. 2.00 (3H, s) , 3.92 (6E, s) 3.60-4.50 (5E, m) Example 115 (1) Step 1 EMI407.1 10-(2,3,4-Trimethoxy-6-methyl phenyl)-decanoyl-L-Ala &gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOH (2) was prepared in substantially the same manner as that of Step 1 of Example 114 IR(Nujol) : 1710, 1640, 1530 cm-1 NMR(CDCl3) : # 1.46 (9H, s), 2.27 (3H, s), 3.90 (9H, s), 4.00-5.00 (5H, m) 6.50 (1H, s) (2) Step 2 EMI408.1 10-(2,3,4-Trimethoxy-6-methylphenyl)-decanoyl-L-Ala &gamma;-D-Glu(&alpha;-OH)-(L)-D-AlaOH (3) was prepared in substantially the same manner as that of ste, p 2 of Example 114 tR(Nujol) : 3260, 1720, 1620, 1530 = NMR(CD3OD) : 6 2.26 (3H, s), 3.83 (9E, s), 6.60 (1H, s) Example 116 (1) Step 1 EMI408.2 EMI409.1 O-Stearoyl-Lac-L-Ala-&gamma;-D-Glu(&gamma;-OH)-(L)-Boc-(D)- mesoDAP- ('a) -D'-AlaOH (2) was prepared in substantially the same manner as step 1 of Example 114 IR(Nujol) : 3300, 1720, 1630 NMR(CDCl3), 6 : 0.90 (3E, m), 4.15-4.90 (5E, m), 5.17 (lE, m) (2) Step 2 EMI409.2 O-Stearoyl-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- D-AlaOE (3) was prepared in substantially the same manner as step 2 of Example 114 IR(Nujol) : 3370, 1740, 1650 (sh), 1630 NMR(D2O-NaHCO3), , # : 0.87 (3E, m), 3.74 (lE, m), 4.0-4.5 (4E, m), 5.10 (lE, m), [&alpha;]D=-38.24 (C=0.30, 5% NaHCO3) Example 117 (1) Step 1 EMI410.1 n-Tetracosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(L)-D-AlaOH (2) was prepared in substantially the same manner as that of step 1 of Example 114 IR(Nujol) : 33DQ, 1750, 1630 cm NMR(CDCL3), # : 0.89 (3h, m), 4.0-4.9 (5H, m) (2) Step 2 EMI411.1 n-Tetracosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAp-(L)- -D-AlaOH (3) was prepared in substantially the same manner as that of step 2 of Example 114 IR(Nujol) : 3280, 1730, 1630 cm-1 NMR(D2O + NaHCO3), # : 0.88 (3H, m), 3.72 (1H, m), 3.95-4.6 (4H, m) Example 118 (1) Step 1 EMI411.2 (D)-Boc-mesoDAP (1) (580 mg) was dissolved in a nixture of methanol (10 ml), methylene chloride (40 ml) and triethylamine (404 mg). To this solution was.added stearoyl-L-Ala-D-Glu(&alpha;-OBzl)OSu (1.34 g). The resulting solution was left overnight at ambient temperature, evaporated and extracted with ethyl acetate after acilification. The organic layer was washed with water, dried over magnesium sulfate and evaporated to give stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)- mesoDAP-(3) (1.10 g). IR(Nujol) : 3300, 2700r2500 (broad), 1720 (broad), 1650 (sh), 1630 cm-1 NMR (DMSO-d6) : # 0-88 (3H, m), 1.0-2.50 (54H, m), 4.0-4.50 (4H, m), 5.12 (2H, s), 7.36 (5H, s), 7.84 (1H, d, J=7Hz), 8.04 (1E, d, J=7Ez), 8.28 (1H, d, J=7Hz) (2) Step 2 EMI412.1 Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-DAP (3) (1.10 g) was dissolved in acetic acid (80 ml) and hydrogenated over 10% palladium black (120 mg). The catalyst was removed by filtration and the filtrate was evaporated to give a gummyresidue which was dissolved in trifluoroacetic acid (5 ml). After standing for 15 minutes at ambient temperature, the solvent was evaporated to give a foam which was triturated with di ethyl ether to give stearoyl-L Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP (4) (0.90 g). IR(Nujol) : 3300, 2600-2300, 1720, 1650 (sh) 1630 cm1 NMR(NaOD-D20) : 6 0.84 (3E, m), 1.0-2.60 (45E, m), 3.10-3.40 (lE, m), 4.0-4.50 (3E, m) Example .119 (1) Step 1 EMI413.1 Stearoyl-&gamma;-D-Glu(&alpha;-OBzl) - (L) -Boc- (D) -mesoDAP (3) was prepared in substantially the same manner as step 1 of Example 118 IR(Nujol) : 3300, 2600-2300 (broad), 1750-1700 (broad), 1650 (broad) cm NMR(DMSO-d6) : 6 0.86 (3H, m), 1.0-2.40 (5E, m), 4.0-4.50 (3H, m), 5.13 (2H, s), 6.90 (1H, m), 7.36 (SE, S), 7.70-8.30 (2H, m) (2) Step 2 EMI414.1 Stearoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP (4) was prepared in substantially the same manner that of step 2 of Example 118 IR(Nujol) : 3250 (sh), 1720, 1640 NMR(NAOD-D26) : 6 0.80-2.80 (45E, m), 3.12-3,40 (1H, m), 4.0-4.32 (2H, m) Example 120 (1) Step 1 EMI414.2 2-Hexadecyloctadecanoyl-&gamma;-D-Glu(&gamma;-OBzl)-(L)-Boc- (D)-mesoDAP (3) was prepared in substantially the same manner as that of step 1 of Example 118 IR(Nujol) : 3300, 1730 (broad), 1680, 1640 NMR(CDCl3) : 6 0.87-2.87 ('77H, m), 4.33-4.80 (3E, m), 5.16 (2w; s), 7.33 (5H, s) (2) Step 2 EMI415.1 2-He3xadecyloctadecanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP (4) was prepared in substantially the same manner as that of step 2 of Example 118 -l IR(Nujol) : 3250, 1720, 1630 cm l NMR(CDCl3) : # 0.68-2.68 (77H, m), 3.68-4.00 (1H, m), 4.16-4.83 (2H, m) Example 121 (1) Step 1 EMI415.2 EMI416.1 2-Hexadecyloctadecanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)- Boc-(D)-mesoDAP-(L)-D-AlaOH (3) was prepared in substantially the same manner as that of step I of Example 118 IR(Nujol) : 3300, 1745, 1660 (sh), 1640 cm 1 (2) Step 2 EMI416.2 2-Hexadecyloctadecanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- mesoDAP- (L)-D-AlaOH (4.) was prepared in substantially the same manner as that of step 2 of Example 118 IR(Nujol) : 3270, 1730, 1630 cm-1 NMR(CF3CO2H) : # 0.92 (6H, m) 4.30-5.00 (5H, m) Example 122 (1) Step 1 EMI417.1 2-Docosyltetracosanoyl-L-Ala-y-D-Glu (a- OBzl) - (t) Boc- (D) -mesoDAP- (L) -D-klaOH: (3) was prepared in substantially the same manner as that of step. 1 of Example 118, IR(Nujol) .: 3250, 1750 (sh), 1715 (sh), 1690, 1660, 1640 cm 1 (2) Step 2 EMI418.1 2-Docosyltetracosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- mesoDAP-(L)-D-AlaOH (4) was prepared in substantially the same manner as that of step 2 of Example 118. IR(Nujol) : 3300, 1720, 1645-1625 (broad) NMR (CDCl3) : 6 0.67-3.00 (107E, m), 4.33-4.67 (3E, m) Example 123 (1) Step 1 EMI418.2 2-Docosyltetracosanoyl-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc- (D)-mesoDAP (3) was prepared in substantially the same manner as that of step 1 of Example 118. IR(Nujol) : 3300, 1740 (sh) , 1720 (broad) 1690, 1640 NMR(CDCl3) : # 0.86-2.50 (101H, m), 4.10-4.83 (3H, m), 5.13 (2H, s), 7.30 (5H, s) EMI419.1 2-Docosyltetracosanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP (4) was prepared in substantially the same manner as that of step 2 of Example 118. IR(Nujol) : 3300, 1720, 1640-1620 (broad) cm NMR(CDCl3) : # 0.68-2.86 (101H, m) 4.33-4.86 (2H, m) Example 124 (1) Step 1 EMI419.2 EMI420.1 . 2-Docosyltetracosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)- Boc-(D)-mesoDAP-(L)-D-AlaOH (1) (1.50 g) was dissolved in a mixture of tetrahydrofuran (50 ml) and methylene dichloride (20 ml). To this solution was added etheral solution (6 ml) of dia20meihane (O Mole solution) under stirring and reacted for 1 hour. The excess of diazomethane was destroyed by adding acetic acid Snd the resulting solution was evaporated to give a waxy residue, which was subjected t: a silica gel column. Elution with chloroform-methanol (20:1) and subsequent evaporation gave 2-docosyl tetracosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBZl)-(L)-Boc-(D)- mesoDAP-(L)-D-Ala(OMe)-(D)-OMe (2) (0.90 g). IR(Nujol) : 3300, 1755 (sh), 1745, 1690, 1660, 1640 cm-1. NMR(CDCl3) : # 0.86-2.50 (116H, m), 3.68 (3H, m), I NMR(CDC1 ) 3' 3.72 (3H, s), 4.16-4. 83 (5E, m), . 5.15 (2E, s3, ?.33 (4E, s) EMI420.2 2-Docosyltetracosanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)- Boc-(D)-mesoDAP-(L)-D-Ala(OMe)-(D)-OMe (3) (1.0 g). was dissolved in acetic acid (40 ml) and then treated with hydrogen chloride saturated acetic acid (2 ml). After standing for 2 hours at ambient temperature, the solution was evaporated to give a white residue, which was thoroughly washed with diisopropylether to afford 2-docosyltetracosanoyl-L- Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-mesoDAP-(L)-D-Ala(OMe)-(D)- OMe (4) (0.90 g). IR(Nujol) : 3300, 1750, 1660, 1640 cm-1 NMR(CDCl3) : # 0.68-3.00 (107H, m), 3.68-4.00 (6E, broad), 4.33-5.86 (4E, m), 5.16 (2E, s), ?-36 (5H, s) Example 125 (1) Step 1 EMI421.1 To Åa solution of Boc-(D)-mesoDAP-(L)-D-AlaOH-(D)- NHNHBoc (2) (2.76 g) and triethylamine in aceton-water (2:1, 90 ml) was added a solution of O-acetylbenziloyl &gamma;-D-Glu(&alpha;-OBzl)-l-succinimidyl ester (3.4 g : 5.8 mM) in acetone at O C with stirring. Stirring was continued overnight, allowing the temperature of the mixture to reach to room temperature. After evapolation of acetone, the residue was added ethyl acetate (60 ml), and the organic layer was washed with dil sodium bicarbonate, saturated'sodium chloride, dil hydrochloric acid and water. After drying over magnesium sulfate, the solvent was removed in vacuo and triturated with isopropyl ether to give O-acetyl- benziloyl-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP-(L)- D-AlaPH-(D)-NHNHBoc (3) (4.63 g). NMR(CDCl3) : 6 1.0-2.0 (29E, m), 2.05 (3H, s), 2.0-2.6 (2H, m), 4.0-5.0 (4H, m), 5.13 (2H, s), 5.66 (1H, broads), 6.80 (3H, m), 7.07 (2H, m), 7.33 (15E, s), 8.94 (1H, s) IR(Nujol) : 3300, 1735, 1670, 1520, 1240, 1165, 700 cm EMI422.1 To a solution of O-acetylbenziloyl-&gamma;-D-Glu(&alpha;-OBzl)-(L) Boc-(D)-mesoDAP-(L)-D-AlaOH-(D)-NHNHBoc (3) (4.2 g) in methanol (25 ml) was added 1N sodium hydroxide (16 ml) at 0 C with stirring. The mixture was stirred in an ice bath for 30 minutes and then at room temperature for 30 minutes. After addition of IN hydrochloric acid (16 ml), the solvent was removed in vacuo, and the residue was dissolved in ethyl acetate (60 ml) and water (40 ml). The organic layer was washed with saturated sodium chloride and and dried over magnesium sulfateievavorated and then triturated with diethyl ether to give benziloyl-y D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOH-(D)- NENEBoc (4) (2.97 g), NMR(CD3OD) : 6 1.23 (2E, d, 7Hz), 1.0-2.0 (26H, m), 2.0-2.6 (2H, m), 3.9-4.7 (4H, m), 7.1-7.7 (10H, m) IR(Nujol) : 3300, 1720, 1650, 1510, 1240, 1160, 700 (3) Step 3 EMI423.1 Benziloyl-y-D-Glu( o-OH)- (L)-Boc- (D) -mesoDAP- (L)- D-AlaOH-(D)-NRNRBoc (4) (2.5 g) was treated with trifluoroacetic acid (10 ml) for 15 minutes at room temperature. Resulting trifluoroacetic acid salt of benziloxy-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- D-AlaOH-(D)-NHNH2 (2.44 g) was dissolved in 1N sulfuric acid (-18 ml) and added sodium metaperiodate (0.62 g) at 0 C with stirring. After stirring for 20 minutes at OOC, the reaction mixture was treated with sodium bisulfite, and put on a column of Hp-20 (170 ml). After removal of inorganic salts with water, elution was carried out with methanol-water (1:1).. The eluate was lyophilized to give benziloyl-&gamma;-D-Glu(&alpha;-OH)- (L)-mesoDAP-(L)-D-AlaOH (5) (1.0 g) [&alpha;]D21=+ 11.90 (CO.36 H2O) NMR(D2O) : # 1.36 (3H, d, 7Hz), 1.3-2.1 (8H, m), 2.1-2.5 (2H, m), 3.76 (1H, t, 6Hz), 4.0-4.6 (3H, m), 7.45 (10H, d, 3Hz) IR(Nujol) : : 3300, 1710, 1645, 1520, 1220, 700 cm Example 126 (1) Step 1 EMI424.1 Diphenylacetyl-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP- (L)-D-AlaOH-(D)-NHNHBoc (3) was prepared in substantially the same manner as that of step 1 of Example 125. NMR(DMSO-d6) : 5 1.0-2.3 (31s, m), 3.7-4.5 (4E, m) 5.0 (1H, s), 5.06 (2E, s), 6.3-7.0 (1H, m), 7.23 (10H, s), 7.28 (5H, s), 7.5-8.1 (3H, m), 7.3-9.0 (2H, m), 9.5 (1H, s) IR(Nujol) : 3300, 1725, 1630, 1525, 1220, 1160, 700 EMI425.1 Diphenylacetyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (L)-D-AlaOH-(D)-NHNHBoc (4) was prepared in substantially the same manner as that of step 2 of Example 125. NMR(CD3OD) : 6 1.36 (3R, d, J=7Ez), 1.3-2.5 (28H, m), 3.9-4.6 (4H, m), 5.10 (1H, s), 7.30 (103, d, J=3Ez) IR(Nujol) : 3300, 1720, 1650, 1520, 1220, 1160, 700 (3) Step 3 EMI426.1 Diphenylacetyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D-AlaOH (5) was prepared in substantially the same manner as that of step 3 of Example 125 [&alpha;]D22=+ 4.02 (C 0.2 H2O) NMR(D2O) : # 1.35 (3H, d, J=7Hz), 1.3-2.6 (10H, m), 3.73 (1H, t, J=6Hz), 4.0-4.6 (3H, m), 5.20 (1H, s), 7.36 (10H, s) IR(Nujol) : 3250, 1720, 1620, 1525, 1220, 700 Example 127 (1) Step 1 EMI426.2 Cinnamoyl-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP-(L)- D-AlaOH-(D)-NHNHBoc (3) was prepared in substantially the same manner as that of step 1 of Example 125. NMR(CD3OD) : 6 1.1-2.6 (31s, m), 3.9-4.7 (4E, m), 5.19 (2H, s), 6.67 (1H, d, J=16Hz), 7.1-7.9 (1H, m) IR(Nujol) : 3260, 1730, 1650, 1625, 1520, 1160 (2) Step 2 EMI427.1 Cinnamoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)- D-AlaOH-(D)-NHNHBoc (4) was prepared in substantially the same manner as that of step 2 of Example 125. NMR(CD3OD) : # 1.1-2.6 (31H, m), 3.9-4.7 (4H, m), 6.67 (1H, d, J=16Bz), 7.3-7.9 (6E, m) IR(Nujol) : 3260, i740, 1690, 1655; 1620, 1550, 1160 (3) Step 3 EMI427.2 Cinnamoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D-AlaOH (5) was prepared in substantially the same manner as that of step 3 of Example 125. 22 =+ 5.69 (C 0.22 H2O) NMR(D2O) : # 1.38 (3H, d, J=7Hz), 1.5-2.6 (10H, m), 3.74 (1H, t, J=6Ez), 4.1-4.6 (3E, m), 6.65 (1H, d, J=16Hz), 7.2-7.7 (6H, m) IR(Nujol) : 3250, 1720, 1650, 1620, 1530, 1220 Example 128 (1) Step 1 EMI428.1 Adamantane-1-carbonyl-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)- mesoDAP- (L) -D-AlaOH- (D) -NHNHBoc (3) was prepared in substantially the same manner as that of step 1 of Example 125. NMR(DMSO-d6) : 6 1.0-2.3 (46E, m), 4.0-4.5 (4H, m), 5.10 (2H, s), 6.5-6.9 (lE, Tn), 7.33 (5H, s), 7.5-8.6 (5H, m), 9.53 (1H, s) IR(Nujol) : 3300, 1740 (sholder), 1720, 1685, 1630, 1520, 1240, 1160, 700 cm-1 (2) Step 2 EMI429.1 Adamantane-1-carbonyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(L)-D-AlaOH-(D)-NHNHBoc (4) was prepared in substantially the same manner as that of step 2 of Example 125. NMR(CD3OD) : # 1.3-2.5 (46H, m), 3.9-4.6 (4H, m) IR(Nujol) : 3300, 1720, 1640, 1520, 1240, 1160 (3) Step 3 EMI429.2 Adamantane-1-carbonyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- D-AlaOH (5) was prepared in substantially the same manner as that of step 3 of Example 125. [&alpha;]D22=- 2.64 (c 0.23 H2O) NMR(D20) : 6 1.40 (3E, d, J=7Ez), 1.2-2.6 (25H, m), 3.80 (1H, t, J=6Hz), 4.2-4.5 (3E, m) IR(Nujol) : 3250, 1720, 1635, 1520 Example 129 (1) Step 1 EMI430.1 To a solution of D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP- (L)-GlyOH (1) (1.2 g) in water (5 ml) was added trietbylamine (0.96 g) and a solution of benzyloxy carbonyloxyimino-2-phenylacetonitrile (0.69 g) in acetone (5 ml) at 0 C with stirring and the mixture was stirring over night at room temperature. After evapolation of acetone to the residue was added water (5 ml) and ethyl acetate (5 ml). The aqueous layer was separated, washed with ethyl acetate (5 ml), acidified with 1N-hydrochloric acid, and extracted with ethyl acetate (20 ml). The extract was washed with water (5ml x 2) and dried over magnesium sulfate. Evaporation of the solvent gave 1.42 g (94.7%) of D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Z-(D)-mesoDAP-(L)-GlyOH (2). (2) Step 2 EMI431.1 To a solution of D-Lac-L-Ala-y-D-Glu(-OH)-(L)-Z-(D)- mesoDAP-(Is)-GlyOR (2). (1.42 g) in methanol (30 ml) was added a solution of diazomethane in diethyl ethcr at 0 C with stirring. The mixture was stirred for 4 hours at 0 C and for 2 hours at room temperature and allowed to stand overnight, After addition of acetic acid (0.1 ml) the solvent was evaporated in vacuo and crystallized from ethyl acetate to give D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OMe)-(L9-Z-(D)-mesoDAP-(L)- GlyOMe-(D)-OMe (3) (1.30 g). NMR(CD3OD) : 6 1.33 (3E, d, J=7Ez), 1.36 (3E, d, J=7Hz), 1.5-2.5 (10H, m), 3.67 (9H, s) 3.95 (2R, s), 4.0-4.6 (4H, m), 5.06 (2H, s), 7.47 (5E, s) IR(Nujol) : 3310, 1760, 1740, 1690, 1660, 1630, 1550, 1280 (3) Step 3 EMI432.1 A solution of D-Lac-L-Ala-y-D-Glu(&alpha;-OMe)-(L)-Z-(D)- mesoDAP- (L)-GlyOMe- tD) -OMe (3) in 80g methanol (30 ml) was hydrogenolyzed in the presence of 10% palladium charcoal (0.12 g). After the catalyst was removed, the solvent was evapolated in vacuo and Crystallized from methanol-diethylether to give D-Lac-L-Ala-&gamma;- D-Glu(&alpha;-OMe)-(L)-mesoDAP-(L)-GlyOMe-(D) (4) (0.86 g). NMR(D2O) : 6 1.43 (3E, d, J=7Ez), 1.53 (3H, d, J=7Ez), 1.5-2.6 (10H, m), 3.6-3.8 (1H, m), 3.77 (9H, s), 4.03 (2H, s) 4.1-4.6 (4H, m) IR(Nujol) : 3370, 1730, 1630, 1520, 1210 cm-1 Example 130 EMI433.1 A solution of Z-(L)-mesoDAP-(L)-GlyOH (2)(186 mg) in water ( ml) was adjusted to pH 8 with triethylamine and a solution of D-Lac(oAc)-L-Ala-D-Glu(oSu) (&alpha;-oBzl) (1)(260 mg) in dioxane (2 ml) was added thereto. The mixture was stirred at ambient temperature for five hours, maintaining the pH 8 with triethylamine, and then evaporated. The aqueous layer was diluted with water (10 ml) and adjusted to pH 4 with 1N hydrochloric acid. This.solution was washed with ethyl acetate and adjusted to pE 2 with 1N hydrochloric acid and then extracted with ethyl acetate. The extract was washed with a saturated sodium chloride, dried over magnesium sulfate and evaporated to give D-Lac(oAc)-L-Ala-&gamma;-D- Glu(&alpha;-oBzl)-(D)-Z-(L)-mesoDAP-(L)-GlyOH (3)(203 mg). N.M.R. (CD3OD), # (ppm): 1.38 (3H, d, J=7Hz), 1.45 (3H, d, J=7Hz), 1.4-2.0 (6H, m), 2.10 (3H, s), 2.0-2.3 (4H, m), 3.93 (2H, s), 4.1-4.7 (4H, m), 4.9-5.1 (1H, m), 5.12 (2H, s), 5.20 (2H, s), 7.37 (10H, s) Example 131 EMI434.1 A solution of D-Lac(oAc)-L-Ala-y-D-Glu(-OBzL)-B)-Z- (L)-mesoDAP-(L)-GlyOH (1)(180 mg) in methanol (30 ml) was hydrogenated over 10% palladium-black (50 mg) under an ordinary atmospheric pressure of hydrogen. The reaction mixture was filtered and the filtrate was concentrated. The concentrate was dissolved in methanol (1 ml) and triturated with ether and then filtered. The powder obtained was washed with ether to give D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(D)- mesoDAP-(L)-GlyOH (2)(98 mg). N.M.R. (D2O), # (ppm): 1.38 (3H, d, J=7Hz), 1.43(3H, d, J=7Hz), 1.5-2.2 (10H, m), 2.0 (3H, s), 3.90 (2H, s), 4.0-4.5 (5H, m) Example 132 EMI435.1 A solution of D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(D)- mesoDAP-(L)-GlyOH (1)(105 mg) im methanol (5 ml) was stirred at ambient temperature for three hours, maintaining the pH at 9 with 5% aqueous potassium carbonate. The solution was evaporated and the residue was adjusted to pH 3.5 and put on a column of activated carbon. The column was washed with water and eluted with 70t aqueous acetone. The eluate was evaporated and the residue was dissolved in methanol C0.S ml) and triturated with ether. The precipitate thus obtained was filtered and washed ether to give D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OH)-mesoDAP-(L)-GlyOH (2) (60 mg). N.M.R. (D2O), # (ppm): 1.38 (3H, d, J=7Hz), 1.44 (3H, d, J=7Hz), 1.7-2.5 (10H, m), 3.98 (2H, s), 4.08 (1H, t, J=6Hz), 4.2-4.5 (5H, m) Example 133 EMI436.1 To a cold mixture of D-Lac(oAc)-L-Ala-&gamma;-D-Glu(OH)(&alpha;-oBzl) ( 1.05 g) and N-hydroxysuccinimide (317 mg) in a mixture of dioxane (10 ml) and tetrahydrofuran 2 ml) was added N,N'-dicyclohexylcarboiimide (557 mg). The mixture was stirred at 10 C for ten minutes and at t temperature overnight. The precipitated N,N'-dicyclohexylurea was filtered oUf and washed with dioxane and then filtered. The combined filtrate was evaporated and the residue was dissolved in dioxane (6 ml). To this solution was added a solution of Boc-(D)meso-DAP-(D)GlyOH (2) (600 mg) and N-methylmorpholine (0.57-mi) in dimethylformamide (6 ml). The resulting solution was stirred at 0C for D minutes and the stirring was continued at ambient temperature for 2.3 hours and then an additional N-methylmorpholine (0.10 ml) was added thereto. rae mixture was stirred at the same temperature for 2 hours. The reaction mixture was concentrated1 diluted with water and then washed with ether. The aqueous layer was cooled, acid acidified to pH 2 with iN aqueous hydrochloric acid and then extracted four times with a mixture of methylene chloride and ethyl acetate (1:1). The combined extracts were washed twice with water and brine, dried over anhydrous magnesium sulfate and then evaporated to give amorphous solid. (1.2 g). The solid was dissolved in methylene chloride (2 ml) and diluted with ether t30 ml) to give an oily precipitate and the supernatant was decanted. This operation was repeated three times The resulting precipitate was dissolved in methylene chloride and the solution was evaporated and pumped to give D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc- (D)meso-DAP- (D)-GlyOH (3) (932 mg) as an amorphous solid. N.M.R. (CDCl3-CD3oD), # (ppm): 1.38 (3H, d, J=7Hz), 1.47 (9H, s), i.49 (3H, d, J=7Hz), 1.2-2.0 (6E, m), 2.0-2.5 (4H, m), 2.15 (3H, 5), 3.g9 C2H, broad s), 5.02 (1H, q, J=7Hz), 5.20 (2H, s), 7.39 (5H, s) Example 134 EMI438.1 iN Aqueous odium hydroxide (4.6 ml) was added to a solution of D-Lac(oAc)-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc- (D)-meso-D/P-(D)-GlyOH (1) (865 mg) in a mixture of methanol (3 ml) and water (4 ml) was stirred at ambient temperature for two hours. The reaction mixture was cooled to 0 C, neutralized to pH 7 with 1N aqueous hydrochloric acid and then concentrated. The concentrate was diluted with water and washed with ether. The aqueous layer was concentrated and the concentrate was acidified to pH 2 with IN aqueous hydrochloric acid and then chromatographed on a macroporous non-ionic adsorption resin, HP20 (40 ml) elutiug with 50% aqueous methanol, The eluate was concentrated, triturated in ether and then evaporated to give D-Lac-L-Ala-&gamma;-Glu(&alpha;-OH)-(L)- (D)-meso-DAP-(D)-GlyPH (2)(600 mg). N.M.R. (D2O), # (ppm): 1.0-2.8 (16H, m), i,43 (9H, s), 3.83-4.5 C4H, m), 3.96 (2H, s) Example 135 EMI439.1 D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-meso-DAP-(D)- GlyOH (1)(560 mg) was dissolved in tetrahydrofuran (5 ml) and the solution was stirred at ambient temperature for 15 minutes. The reaction mixture was evaporated to dryness. The residue was triturated with ether and the supernatant was discarded. The residue thus obtained was pumped to give a solid materials (647 mg). The solid materials were dissolved in water and the solution was adjusted to pH 3.0 with iN aqueous hydrochioric acid and chromatographed on a macroporous non-ionic adsorption resin, HP20 (40 ml). The fractions containing the object. compound we;e collected1 concentrated and then lyophilized to give Do Lac-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-meso-DAP(D)GlyOH (2)(324 mg.) N.M.R. (D2O), # (ppm): 1.1-2.5 (10H, m), 1.37 (3H, d, J=7Hz), 1.43 (3H, d, J=7Hz), 4.01 (2H, s), 4.09 (1H, t, J=6Hz), 4.2-4.6 (4H, m), [&alpha;]D25 = - 35.4 (C=0.26, water) Example 136 EMI441.1 To a solution of n-octanoyl-&gamma;-D-Glu(&alpha;-OH) -(L)-mesoDAP- D-AlaOH (1)(150 mg) in methanol (150 ml) was added conc. hydrochloric acid (1 ml) was added at ambient temperature, The mixture was stood for two weeks at the same temperature. To the reaction mixture was added triethylamine in order to adjust the pH of the solution to 7 to 8. Evaporation of the solvent in vacuo gave an oily residue, which was extracted with ethyl acetate. The extract was washed with water and brine, and then dried over magnesium sulfate. After evaporation of the solvent in vacuo, the residue was pulverized with isopropyl ether to give n-octanoyl-&gamma;-D-Glu(&alpha;-oMe)-(L)- mesoDAP-D-AlaoMe-(D)-oMe (2)(102 mg). NMR (CDCl3), #(ppm) : 0.90 (3H, t, J=7Hz), 1.00-2.33 (25H, m), 3.73 (9H, s), 4.33-4.66 (4H, m), 6.50-7.50 (5H, m). Example 137 (1) Step 1 DL-2,3-Diacetoxypropionyl-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)- (L)-Z-(D)-mesoDAP-(D)-NHNHZ-(L)-GlyOH was prepared substantially in the same manner as that of Step l of Example 1. NMR (CDCl3), #(ppm) : 1.36 (3H, d, J=7Ez), 2.01 (3H, s), 2.12 (3E, s), 3.95 C2H, s), 4.25-4.65 (6H, m), 5.03-5.30 (8H, m), 7.35 (15H, s) C2) Step 2 DL-2,3-Diacetoxypropionyl-L-Ala-&gamma;-D-Glu(&alpha;-OH) (L)-mesoDAP-(L)-GlyOH was prepared substantially in the same manner as that of Step 3 of Example 27. NMR (D2O), #(ppm) : 1.42 (3H, d, J=7Hz), 2.10 (3H, s), 2.21 (3H, s), 3.83 (1H, m), 3.96 (2H, s), 5.30 (1H, t, J=5Hz) (3) Step 3 DL-2,3-Dihydroxypropionyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)- (L)-mesoDAP-(L)-GlyOH was prepared substantially in the same manner as that of Step 2 of Example 12. NMR (D2O), #(ppm) : 1.47 (3H, d, J=7Hz), 3.85 (2H, d, J=4Hz), 4.00 (2H, s), 4.27-4.63 (5H, m) Example 138 (1) Step 1 Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP- (L)-D-AlaOH was prepared substantially in the same manner as that of Step 1 of Example 27. NMR (DMSO-d6), #(ppm) : 0.80-2.40 (60H, m), 4.10-4.60 (5H, m), 5.12 (2H, s), 7.33 (5H, s), 7.80-8.43 (4H, m), 6.80-7.10 (1H, m). (2) Step 2 Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)- mesoDAP-(L)-D-AlaoMe-(D)-oMe was prepared sub stantially in the same manner as tHat of Step 1 of Example 124. NMR (CDCl3). #(ppm) : 0.68-2.53 (65H, m), 3.67 (3H, s), 3.70 (3H, s), 4.10-4.70 (5H, m), 5.13 (2H, s), 6.33-6.67 (1H, m), 7.00 (1H, d, J=8Hz), 7.30 (5H, s), 7,30-7.70 (2H, m) C3) Step 3 Stereaoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D- AlaoMe-(D)oMe was prepared substantially in the same manner as that of Step 2 of Example 124. NMR (DMSO-d6), #(ppm) : 0.68-2.50 (51H, m), 3.68 (3H, s), 3.77 C3H, s), 4.0-4.70 - (5H, m), 7.80-8.50 (5H, m) Example 139 (1) Step 1 Stereaoyl-L-Ala-&gamma;-D-Glu(&alpha;-oMe) - (L) -Boc- (D) -mesoDAP- (D) -oMe- (L) -D-AlaoMe was prepared substantially in the same manner as that of Step 1 of Example 124. NMR (CDCl3), #(ppm) : 0.80-2.68 (60H, m), 3.90 (9H, s), 4.33-4.66 (5H, m). (2) Step 2 Stereaoy-L-Ala-&gamma;-D-Glu(&alpha;-oMe)-(L)-mesoDAP-(D)- oMe-(L)-D-AlaoMe was prepared substantially in the same manner as that of Step 2 of Example 124. NMR (CDCl3-CD3OD), #(ppm) : 0.68-2.50 (51H, m), 3.87 (6H, s), 3.90 C3H, s), 4.27-4.66 (SH, m) Example 140 (1) Step 1 Stearoyl-L-Val-&gamma;-D-Glu-(&alpha;-oBzl)-(L)-Boc-(D)- mesoDAP-(L)-D-AlaOH was prepared substantially in the same manner as that of Step 1 of Example 27. NMR (DMSO-d6), #(ppm) : 0.70-2*50 (64H, m), 4.0-4.60 (SH,.m), 5.15 (2H, s), 6.70 7'.10 (1H, m), 7.36 (SH, s), 7.50-8.50 (4H, m). (2) Step 2 Stearoyl-L-Val-&gamma;-D-Glu-(&alpha;-OH)-(L)-mesoDAP-(D)- AlaOH was prepared substantially in the same manner as that of Step 3 of Example 27. NMR (DMSO-d6), #(ppm) : 0.68-2.50 (55H, m), 3.67-3.9O (1H, m), 4.0-4.50 (4H, m), 7.50-8.40 (4H, m) Preparation 115 (1) Step 1 EMI445.1 Stearoyl-L-Ser(oBzl)-D-Glu(a-oBzl) t2) was prepared substantially in the same manner as Preparation 85. NMR (CDCl3-CD3OD), a(ppm) : 0.90 (3H, m), 1.1-1.9 (30H, m), 1.95-2.65 (6H, m), 3.60-3.90 (3H, m), 4.32 (2H, s), 5.19 (2H, s), 7.35 (10H, s) EMI445.2 Stearoyl-L-Ser(oBzl)-D-Glu-(&alpha;-oBzl)-&gamma;-OSu (3) was prepared substantially in the same manner as Preparation 86. NMR (CDC13, #) : : 0.89 (3H, m), 1.28 (30H, s), 2.81 (4H, s), 4.56 (2H, s), 5.20 (2H, s), 7.33 (5H, s), 7.36 (5H,.s) Preparation 116 (1) Step 1 EMI446.1 Z-(L)-Boc-(D)-mesoDAP-(L)-D-AlaoBzl (1) (11.0 g) was dissolved in methanol (100 ml) and the. solution of diazomethane in ether was added thereto. After stirring for 15 minutes, the resultant mixture was treated with acetic acid, concentrated in vacuo. The residue was dissolved in ethyl acetate and washed with 3% sodium bicarbonate, dried over magnesium sulfate and then concentrated in vacuo to give Z-(L)- Boc-(D)-mesoDAP-(L)-D-Ala(oBzl)-(D)-GMe (2) (9.1 g). NMR (CDCl3), 6(ppm) : 1.3-2.0 (18H, m), 3.72 (3H, s), 4.32 (iH, m), 4.82 (1H, t, J=7), 5.12 (2H, s), 5.18 (2H, s), 5.59 (1H, d, J=8), 6.82 (1H, d, J=8), 7.37 (10H, s) (2) Step 2 EMI446.2 Z-(L)-Boc-(D)-mesoDAP-(L)-D-Ala(oBzl)-(D)-OMe (2) (9.1 g) was dissolved in a mixture of methanol (100 ml) and water (20 ml), and hydrogenated under 32 atomospheric pressure of hydrogen over 10% palladium-carbon. After removal of the catalyst, the mixture was concentrated and treated with ether to give a crystalline mass (5.7 g), which was purified by using HP20 to give Boc-(D)- mesoDAP-(L)-D-AlaOH-(D)-OMe t3) (5.02 g). NMR (CDCl3), GCppm) : 1.30-2.00 (18H, m), 3.72 (3H, s), 3.90-4.45 (3H, m) Preparation 117 EMI447.1 Z-(D)-mesoDAP-(D)-NHNHZ-(L)-D-AlaOH (2) was prepared substantially in the same manner as Preparation 63. mp. 161-165 C (dec.) Preparation 118 (1) Step 1 EMI447.2 Z-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOMe-(D)-NHNHBoc (2) was prepared substantially in the same manner as step Preparation 53. NMR (DMSO-d6), 6 (ppm) : 1.05-1.95 (2H, m), 3.65 (3H, s), 3.70-4.65 (3H, m), 5.08 (2H, s), 6.70 (1H, m), 7.35 (5H, s), 8.34 (2H, m), 8.68 (1H, m), 9.61 (1H, s) (2) Step 2 EMI448.1 Z- (L) -mesoDAP- (L) -D-AlaOMe (3) was prepared substantially in the same manner as step 2 of Preparation 53. NMR (CD3OD), #(ppm) : 1.35 (3H, d, J = 7Hz), 1.45-2.10 (6H, m), 3.71 (3H, s), 4.15 (1H, m), 4.42 (1H, q, J = 7Hz), 5.11 (2H, s), 7.36 (5H, s) (3) Step 3 EMI448.2 Z-(L)-Boc-(D)-mesoDAP-(L)-D-AlaOMe (4) was preparated substantially in the same manner as step 3 of Preparation 53. NMR (CDCl3), (ppm) : 1.35 (3H, d, J=7Hz), 1.43 C9H, s), 3.69 (3H, s), 4.16 (1H, m), 4.41 (1H, q, J=7Hz), 5.10 (2H, s), 7.34 (5H, s) (4). Step 4 EMI449.1 Boc-(D)-mesoDAP-(L)-D-AlaOMe (S) was prepared substantially in the same manner as step 4 of. Preparation 53. NMR (CD3OD), #(ppm) : 1.2-2.0 (18H, m), 3.77 (3H, s), 3.7-4.1 (2H, m), 4.51 (1H, q, J=7Hz) Preparation 119 (1) Step 1 EMI449.2 Stearoyl-L-Ala-D-GluOMe (2) was prepared substantially in the same manner as Preparation 85. NMR (CDCl3-CD3OD), #(ppm) : 0.90 (3H, m), 1.30 (30H, s), 1.42 (9H, s), 3.79 (3H, s) (2) Step 2 EMI449.3 Stearoyl-L-Ala-D-Glu( -OMe) (&gamma;-OSu) (3) was prepared substantially in the same manner as Preparation 86. NMR (CDCl3), #(ppm) : 0.89 (3H, m), 1.30 (30H, s), 1.45 (9H, s), 2.88 (4H, s), 4.4-4.9 (2H, m), 6.61 (1H, d, J=7Hz), 7.57 (1H, d, J=7Hz) Preparation 120 EMI451.1 Boc-L-Ala-D-Glu(&alpha;-OBzl) (1) (1.68 g) was to trifluoroacetic acid (10 ml) and the mixture was stirred for 15 minutes at ambient temperature. After evaporation of trifluoroacetic acid, the residue was dissolved in dioxane (30 ml). The solution was neutralized with triethylamine and then a solution of D-LacOSu (0.77 g) in methyl cyanide (10 ml) was added thereto. The resulting mixture was stirred for S hours at ambient temperature and the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate and the ethyl acetate layer was washed with water (30 ml x 2), dried over magnesium sulfate and then concentrated under reduced pressure to give an oil. The oil was chromatographed on silica gel and eluted with a mixture of chloroform and methanol (20:1) to give D-Lac-L-Ala-D-Glu(a-OBzl) (2, (o. 77 g). NMR (CDCl3), 6 (ppm) : 1.40 (6H, d, J=7Hz), 1.8-2.6 (4H, m), 4.2-4.8 (3H, m), 5.17 (2H, s), 7.35 (5H, s) Preparation 121 (1) Step 1 EMI452.1 Phenylacetyl-D-Glu(&alpha;-OBzl) (2) was prepared substantially in the same manner as Preparation 85. NMr (CDCl3), #(ppm) : 1.80-2.50 (4H, m), 3.50 (2H, s), 4.50-4.90 (1H, m), 5.13 (2H, s), 6.33 (1H, d, J = 8Hz), 7.26 (5H, s), 7.33 (5H, s), 9.76 ClH, s) (2) Step 2 EMI452.2 Phenylacetyl-D-Glu(&alpha;-OBzl)-&gamma;-OSu (3) was prepared substantially in the same manner as Preparation 86. NMR (CDCl3), #(ppm) : 2.06-2.72 (4H, m), 2.76 (4H, s), 3.66 (2H, s), 4.60-4.88 (1H, m), 5.20 (2, s), 6.64 (1H, d, J=8Hz), 7.40 (5H, s), 7.48 (5H, s) Preparation 122 (1) Step 1 EMI453.1 Phenylacetyl-L-Ala-D-Glu(&alpha;-OBzl) (2) was prepared substantially in the same manner as Preparation 85. NMR (CDCl3), # (ppm) : 1.23 C3H, d, J=7Hz), 1.80-2.50 (4H, m), 3.53 (2H, s), 4.33-4.80 (2H, m), 5.10 (2H, s), 6.96 (1H, d, J=7Hz), 7.30 (5H, s), 7.40 CSH, s), 7.60 ClH, d, J=7Hz), 8.83 (1H, s) (2) Step '2 EMI453.2 Phenylacetyl-L-Ala-D-Glu(&alpha;-OBzl)-&gamma;-OSu (3) was preapared substantially in the same manner as Preparation 86. NMR (CDC13), #(ppm) : 1.23 (3H, d, J=7Hz), 1.84-2.67 (4H, m), 2.76 (4H, s), 3.53 (2H, s), 4.40-4.86 (2H, m), 5.13 (2H, s), 6.40 ClH, d, J=8Hz), 7.27 (5H, s), 7.33 (5H, s) Preparation 123 (1) Step 1 EMI454.1 n-Octanoyl-L-Ala-D-Glu(&alpha;-OBzl) (2) was prepared substantially in the same manner as Preparation 85. NMR (CDCL3), #(ppm) : 0.68-2.50 (22H, m), 4.40-4.80 (2H, m), 5.15 (2H, s), 6.70 (1H, d, J=7Hz), 7.30 (5H, s), 7.54 (1H, d, J = 7Hz), 9.50 (1H, s) (2) Step 2 EMI454.2 n-Octanoyl-L-Ala-D-Glu(&alpha;-OBzl)-&gamma;-OSu (3) was prepared substantially in the same manner as Preparation 86. NMR (CDC13), ), # # (ppm) :.O.92 (3H, t, J=7Hz), 1.10-1.80 (15H, m), 2.0-2.80 (4H, m), 2.82 (4H, s), 4.50-4.84 (2H, m), 5.24 (2H, s), 6.68 (1H, d, J=8Hz), 7.44 (5H, s), 7.68 (1H, d, J=8Hz) Preparation 124 (1) Step 1 EMI455.1 n-Octanoyl-D-Glu(&alpha;-OBzl) (2) was prepared substantially in the same manner as Preparation 85. NMR (CDCL3), #(ppm) : 0.87 (3H, t, J = 7Hz), 1.0-2.60 (16H, m), 4.50-5.00 (1H, m), 5.20 (2H, s), 6.35 (1H, d, J=7Hz), 7.40 (5H, s), and 9.90 (1H, s) (2) Step 2 EMI455.2 n-Octanoyl-D-Glu(&alpha;-OBzl)-&gamma;-OSu (3) was prepared substantially in the same manner as Prepation 86. NMR (CDCL3), #(ppm) : 0.90 (3H, t, J = 7Hz), 1.20-1.80 (12H, m), 2.16-2.80 (4H, m), 2.86 (4H, s), 4.68-4.96 (1H, m), 5.62 (2H, s), 6.52 (1H, d, J=8Hz), 7.48 (5H, s) Preparation 125 EMI456.1 Boc-(D)-mesoDAP-(D)-NHNHBoc (2) was prepared substantially in the same manner as Preparation 20. NMR (CD3OD-D2O). #(ppm) : 1.50-2.20 (24H, m), 3.60-3.90 (1H, m), 4.00-4.20 (1H, m) Example 141 (1) 'Step 1 EMI457.1 Lauroyl-L-Ala-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(L)-D- Ala(QH) (3) was prepared substantially in the same manner as step 1 of Example 118. NMR (DMSO-d6) : 6, 0.80-2.50 (48H, m), 4.0-4.50 (5H, m) , 5.10 (2H, s), 6.80-7.00 (1H, m), 7.33 (5H, s), 7.70-8.40 (4H, m) (2) Step 2 EMI458.1 Lauroyl-L-Ala-D-Glu(&alpha;-OMe)-(L)-Boc-(D)-mesoDAP-(L) D-Ala(oMe)-(D)-oMe (4) was prepared substantially in the same manner as step 1 of Example 124; NMR (CDCL3) : a, 0.80-2.50 (48H, m), 3.73 (9H, s) 4.10-4.70 (5H, m), 5.30 (1H, d, J = 8Hz), 6.50 (1H, broad s), 6.96 (1H, d, J=8Hz), 7.33-7.65 (2H, m) (3) Step 3 EMI458.2 Lauroyl-L-Ala-&gamma;-D-Glu(&alpha;-oMe)-(L)-mesoDAP-(L)-D-Ala(oMe)- (D)-oMe hydrochloric acid salt (5) was prepared substantially in the same manner as step 2 of Example 124. NMR (DMSO-d6) : 6, 0.80-2.40 (39H, m), 3.68 (6H, s), 3.78 (3H, s), 3.88-4.00 (1H, m), 4.12-4.50 (4H, m), 8.04 (2H, t, J=8Hz), 8.20 (2H, t, J=8Hz), 8.64 (2H, broad) Example 142 (1) Step 1 EMI459.1 Stearoyl-L-Ser(oBzl)-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP- (L)-D-AlaOH (3) was prepared substantially in the same manner as step 1 of Example 118. NMR (CDCL3-CD3OD), #(ppm) : 0.88 (3H, m), 1.1-1.4 (30H, m), 1.45 (9H, s), 3.6-3.9 (2H, m),. 4.53 (2H, s), 5.15 (2H, s), 7.31 (10H, s) (2) Step 2 EMI460.1 Stearoyl-L-Ser-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)- D-Ala(OH) (4) was prepared substantially in the same manner as step 2 of Example 89. NMR (CDCl3-CD3OD), #(ppm) : 0.90 (3H, m), 1.30 (30H, s), 1.46 (9H, s), 2.1-2.55 (4H, m), 3.65-4.80 (7H, m) (3) Step 3 EMI460.2 Stearoyl-L-Ser-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D- Ala(OH) (5) was prepared substantially in the same manner as step 3 of Example 89. NMR (CDCl3, CD3OD), #(ppm) : 0.90 (3H, m), 1.05-2.60 (45H, m), 4.02 (1H, m), 4.30-4.95 (6H, m) Example 143 (1) Step 1 EMI461.1 Stearoyl-L-Ser-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP- (L) -D-Ala- (D)-oMe (3) was prepared substantially in the same manner as step 1 of Example 118. NMR (CDCl3-CD3OD), #(ppm) : 0.90 (3H, s), 1.28 (30H, s), 1.40 (9H, s), 3.74 (3H, s), 4.05-4.60 (SH, m), 5.18 (2H, s), 7.36 (5H, s) (2) Step 2 EMI462.1 Stearoyl-L-Ala-y-D-Glu(a-OH) - t oc(D) -mesodap- (L) D-Ala(OH)-(D)-oMe (4) was prepared substantially in the same manner as step 2 of Example 89. NMR (CDCl3-CD3OD), #(ppm) : 0.89 (3H, m), 1.30 (30H, s), 1.46 (9H, s), 3.77 (3H, s), 4.05-4.60 (5h, m) (3) Step 3 EMI462.2 Stearoyl-L-Ser-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D-Ala(OH)- (D)-oMe hydrochloric acid salt (5) was prepared substantially in the same manner as step 3 of Example 89. NMR (DMSO-d6), a(ppm) : 0.85 (3H, m), 3.74 (3H, s), 3.8-4.55 (5H, m) Example .144 (1) Step i EMI463.1 Stearoyl-L-Ser-&gamma;-D-Glu(&alpha;-oBzl)-(L)-Boc-(D)-mesoDAP-(L)- D-AlaOMe (3) was prepared substantially in the same manner as step 1 of Example 118. NMR (CDCl3-CD3OD), 6 #(ppm) 0.88 (3H, m), 1.27 (30H, s), 1.42 (9H, s), 3.71 (3H, s), 4.03-4.65 (SH, m), 5.18 (2H, s), 7.35 (5H, s) (2) Step 2 EMI463.2 Stearoyl-L-Ser-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)- D-AlaOMe (4) was prepared substantially in the same manner as step 2 of Example 89. NMR (CDCl3-CD3OD), 6 (ppm) : 0.88 (3H, m), 1.31 (30H, s), 1.46 (9H, s), 3.73 (3H, s), 4.00-4.65 (SH, m) C3) Step 3 EMI464.1 Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D-AlaOMe hydrochloric acid salt (5) was prepared substantially in the same manner as step 2 of Example 124. NMR (DMSO-d6), 6 (ppm) : 0.86 (3H, m), 3.68 (3H, s), 3.85 (1H, s), 4.10-4. 50 (4H, m) Example 145 (1) Step 1 EMI464.2 EMI465.1 Stearoyl-L-Ala-y-D-Glu(-OMe) -'CL) -Boc(D) -mesoDAP - CL) - D-AlaOH (3) was prepared substantially in the same manner as step 1 of Example 118. NMR (CDCl3-CD3OD), #(ppm) : 0.89 (3H, m), 1.28 t30H, s), 1.45 (9H, s), 3.76 (3H, s) (2) Step 2 EMI465.2 Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OMe)-(L)-mesoDAP-(L)-D- AlaOH hydrochloric acid salt (4) was prepared substantially in the same manner as step 2 of Example 124. NMR (CDCl3-CD3OD), #(ppm) : 0.98 (3H, m), 1.0-2.5 (38H, m), 3.73 (3H, s), 3.94 (1H, m), 4.20-4.57 (4H, m) Example 146 (1) Step 1 EMI466.1 Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OMe)-(L)-Boc-(D)-mesoDAP-(L)- D-AlaOMe (3) was prepared substantially in the, same manner as step 1 of Example 118. NMR (CDC13-CD30D), 6(ppm) : 0.92 (3H, m), 1.31 (30H, s), 1.48 (9H, s), 3.77 (6H, s) (2) Step 2 EMI466.2 Stearoyl-L-Ala-Y-D-Glu(:-oMe) - (L) -mesoDAP- (L) -D-Ala- (D)-OMe hydrochloric acid salt (4) was prepared substantially in the same manner as step 2 of Example 124. NMR (CDCl3-CD3OD), b(ppm) : 0.90 (3H, m), 1.08-2.47 (48H, m), 3.74 (3H, s), 3.85 (3H, s), 3.93-4.09 (1H, m), 4.25-4.80 (4H, m) Example 147 (1) Step 1 EMI467.1 Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-oMe)-(L)-Boc-(D)-mesoDAP-(L)- D-AlaOMe (3) was prepared substantially in the same manner as step 1 of Example 118. NMR (CDCl3-Cd3OD), #(ppm) : 0.88 (3H, m), 1.28 (30H, s), 1.46 (9H, s), 3.75 (6H, s) (2) Step 2 EMI468.1 Stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OMe)-(L)-mesoDAP-(L)-D-AlaOMe hydrochloric acid salt (4) was prepared substantially in the same manner as step 2 of Example 124. NMR (CDCl3-CD3OD), #(ppm) : 0.89 (3H, m), 1.0-2.5 (48H, m), 3.75 (6H, s),' 3.95 (1H, m), 4.15-4.95 (4H, m) Example 148 (1) Step 1 EMI469.1 Phenylacetyl-L-Ala-y-D-Glii(a-O3zl)- (L)-Boc-(D)-mesoDAP- (D)-NHNHBoc (3) was prepared substantially in the same manner as step 1 of Example 118. NMR (CD3OD), #(ppm) : 1.47 (18H, s), 3.60 (2H, s), 5.20 (2H, s), 7.33 (5H, s), 7.40 (5E, s) EMI470.1 Phenylacetyl-L-Ala-&gamma;-D-Glu-(&alpha;-OH)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc (4) was prepared substantially in the same manner as step 2 of Example 89. NMR (CD3OD), 6 (ppm) : 1.47 (18H, s), 3.60 (2H, s), 4.00-4.66 (4H, s), 7.30 (5H, s) (3) Step 3 EMI470.2 Phenylacetyl-L-Ala-&gamma;-D-Glu-(&alpha;-OH)-(L)-mesoDAP- (5) was prepared substantially in the same manner as step 3 of Example 89. NMR (D2O), #(ppm) : 1.40 (3H, d, J = 8Hz), 3.60 (2H, s), 3.80 (1H, m), 4.24 (2H, t, J=7Hz), 7.36 (5H, s) Example 149 (1) Step 1 EMI471.1 Phenylacetyl-&gamma;-D-Glu-(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc (3) was prepared substantially in the same manner as step 1 of Example 118. NMR (CD3OD), 6 #(ppm) : 1.47 (18H, s), 3.65 (2H, broad s), 5.17 (2H, s), 7.30 (SH, s), 7.36 (3H, s) (2) Step 2 EMI472.1 Phenylacetyl-&gamma;-D-Glu-(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(D)- NHNHBoc (4) was prepared substantially in the same manner as step 2 of Example 89. (3) Step 3 EMI472.2 Phenylacetyl-&gamma;-D-Glu-(&alpha;-OH)-(L)-mesoDAP was prepared substantially the same manner as step 3 of Example 89. NMR (D2O), #(ppm) : 1.20-2.50 (10H, m), 3.64 (2H, s), 3.72 (1H, t, J=7Hz), 4.24 (1H, t, J=7Hz), 4.30 (1H, t, J=7Hz), 5.36 (SH, s) Example 150 (1) Step 1 EMI473.1 (12-Hydroxy)stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(L)-GlyOH (2) was prepared substantially in the same manner as step 1 of Example 1. NNR (cD3OD), #(ppm) : 0.90 (3H, t, J=5Hz), 1.25 (9H, s), 1.15-1.83 (39H, m), 2.15-2.42 (4H, m), 3.93 (2H, s), 4.25-4.53 (5H, m) EMI474.1 (12-Hydroxy)stearoyl-L-Ala-&gamma;-D-Dlu(&alpha;-OH-(L)-mesoDAP- (L)-GlyOH (3) was prepared substantially in the same manner as step 2 of Example 1. NMR (DMSO-d6), #(ppm) : 0.83 (3h, t, J = 5Hz), 1.16-1.66 (39H, m), 1.92-2.25 (4H, m), 3.73 (2H, broad s), 4.07-4.25 (SH, m) Example 151 (1) Step 1 EMI474.2 EMI475.1 &alpha;-D,L-Hydroxypalmitoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)- mesoDAP-(L)-GlyOH (2) was prepared substantially in the same manner as step 1 of Example 1. NMR (CD3OD), 6 (ppm) : 0.92 (3H, t, J=5Hz), 1.30-1.75 (37H, m), 1.45 (9H, s), 2.30-2.63 (2H, m), 3.97 (2H, s), 4.00-4.58 (5H, m) (2) Step 2 EMI475.2 a-D,L-Hydroxypalmitoyl-L-Ala-y-D-Glu( -OH)- (L)-mesoDAP- (L)-GlyOH (3) was prepared substantially in the same manner as step 2 of Example 1. NMR (DMSO-d6), 6Cppm) : 8.66 (3H, t, J=5Hz), 1.23-1.75 (37H, m), 2.08-2.23 (2H, m), 3.63 (2H, broad s), 4.13-4.43 (SH, m) Example i52 (1) Step 1 EMI476.1 (12-D,L-Acetoxy)stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc- (D)-mesoDAP-(D)-NHNHBoc-(L)-GlyOH (2) was prepared substantially in the same manner as step 1 of Example I. NMr (CDE3OD), #(ppm) : 0.90 (3H, t, J = 5Hz), 1.30-1.73 (37H, m), 1.43 (9H, s), 2.02 (3H, s), , 2.13-2.36 (4H, m), 3.95 (2H, s), 4.33-4.S3 (SH, m) EMI477.1 (12-D,L-Acetoxy)stearoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)- mesoDAP-(L)-GlyOH (3) was prepared substantially in the same manner as step 2 of Example 1. NMR (CD3OD), #(ppm) : 0.87 (3H, t, J = 5Hz), 1.28-1.73 (37H, m), 2.00 (3H, 5), 2.13-2.33 (4H, m), 3.92 (2H, s), 4.30-4.50 (5H, m) Example 153 (1) Step 1 EMI477.2 EMI478.1 D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Z-(D)-mesoDAP-(L)- GlyOMe-(D)-OMe (3) was prepared substantially in the same manner as step 1 of Example 118. NMR (CD3OD), 6 (ppm) : 1.37 (6H, d, J=7Hz), 1.3-2.5 (10H, m), 3.67 (3H, s), 3.70 (3H, s), 3.95 (2H, s), 4.0-4.6 (5H, m), 5.09 (2H, s), 5.17 (2H, s), 7.35 (10H, s) (2) Step 2 EMI478.2 D-Lac-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)- GlyOMe-(D) OMe (4) was prepared substantially in the same manner as Example 72. NMR (D2O), #(ppm) : 1.37 (3H, d, J = 6Hz), 1.41 (3H, d, J = 6Hz), 1.5-2.4 (10H, m), 3.73 (3H, s), 3.82 (3H, s), 4.00 (2H, s), 4.0-4.5 (5H, m) Example 154 (1) Step 1 EMI479.1 Phenylacetyl-y-D-Glu(a-OBzl)- (L) -Boc- (D) -mesoDAP- (L) - D-Ala-(D)-NHNHBoc (3) was prepared substantially in the same manner as step 1 of Example 118. NMR (CDCl3-CDÕD), #(ppm) : 1.48 (18H, s), 3.62 (2H, s), 3.67 (1H, m), 5.19 (2H, s), 7.34 (SH, s), 7.39 (5H, s) (2) Step 2 EMI480.1 Phenylacetyl-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)- D-Ala-(D)-NHNHBoc (4) was prepared substantially in the same manner as step 2 of Example 89. NMR (DMSO-d6), # (ppm) : 1.30 (3H, d, J=7), 3.55 (2H, s), 3.8-4.8 (4H, m), 6.77 (1H, d, J = 8), 7.36 (5H, s), 7.8-8.9 (5H, m), 8.63 (1H, s) (3) Step 3 EMI480.2 Phenylacetyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D-AlaOH (5) was prepared substantially in the same manner as step 3 of Example 89. NMR (D20), #(ppm) : 1.39 (3H, d, J=7Hz), 1.20-2.55 (10H, m), 3.66 (2H, s), 3.80 (1H, t, J=6Hz), 4.20-4.55 (3H, m)', 7.36 (5H, s) Example 155 (1) Step 1 EMI481.1 n-Octanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP- (L)-D-Ala-(D)-NHNHBoc (3) was prepared substantially in the same manner as step 1 of Example 118. NMR (CDCl3-CD3OD), b(ppm) : 0.90 (3H, m), 1.15-2.53 (46H, m), 4.27-4.69 (5H, m), 5.21 (2H, s), 7.40 (5H, s) (2) Step 2 EMI482.1 n-Octanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-Boc-(D)-mesoDAP-(L)- D-Ala-(D)-NHNHBoc (4) was prepared substantially in the same manner as step 2 of Example 89. NMR (DMSO-d6), # #(ppm) : 0.6-2.4 (49H, m), 3.8-4.6 (5H, m), 6.71 (1H, m), 7.75-8.80 (5H, m), 9.60 (1H, s) (3) Step 3 EMI482.2 n-Octanoyl-D-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP-(L)-D- AlaOH (5) was prepared substantially in the same manner as step 3 of Example 89. NMR (D2O), #(ppm) : 0.87 (3H, m), 1.1-2.6 (28H, m), 3.85 (1H, t, J = 6), 4.2-4.6 (4H, m) Example 156 (1) Step 1 EMI483.1 n-Octanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP- (D)-NHNKBoc (3) was prepared substantially in the same manner as step 1 of Example li8. NMR (CDCl3), #(ppm) . 0.68-2.50 (46H, m), 4.16-4.83 (4H, m), 5.14 (2H, s), 6.70-7.0 (broad, 1H), 7.36 CSH, s), 7.70-8.0 (broad, 1H), 9.20 (lH, s) (2) Step 2 EMI484.1 n-Octanoyl-L-Ala-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP (4) was prepared substantially in the same manner as steps 2 and 3 of Example 89.. NMR (D2O), #(ppm) : 0.68-2.50 (28H, m), 3.67-4.00 (1H, m), 4.16-4.50 (3H, m) Example 157 (1) Step 1 EMI484.2 n-Octanoylal-Ala-&gamma;-D-Glu(&alpha;-OBzl)-(L)-Boc-(D)-mesoDAP- (D)-NHNHBoc (3) was prepared substantially in the same manner as step 1 of Example 118. NMR (CDC13), 6 (ppm) : 0.70-2.50 (43H, m), 4.0-4.80 (3H, m), 5.20 (ZH, s), 5.50-5.80 (1H, m), 6.30-6.60 (2H, m), 6.80-7.10 (2H, m), 7.35 (5H, s), 9.10 (1H, s) -(2) 2 '-' step 2 EMI485.1 n-Octanoyl-&gamma;-D-Glu(&alpha;-OH)-(L)-mesoDAP (4) was prepared substantially in the same manner as steps 2 and 3 of Example 89. NMR (D2O), #(ppm) : 0.68-2.60 (25H, m), 3.80 (1H, t, J = 7Hz), 4.16-4.50 (2H, m)

Claims: Pantent Claims 1. A compound of the formula or its salt: EMI486.1 wherein R1 is hydrogen or acyl; Rb is hydrogen , methyl, isopropyl, hydroxy methyl, protected hxdroxymethyl or benzyl; R2 and R9 are each hydrogen, carboxy, pro tected carboxy, or a group of the'formula: EMI486.2 wherein Ra2 is mono- or dicarboxy (or protected carboxy) lower alkyl or.ar(carboxy or protected carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy, Rb is hydrogen or lower alkyl; RP is hydrogen, carboxy, protected carboxy with proviso that when one of R2 and Rq is hydrogen, then the other is carboxy or protected carboxy or a group of the formula: : EMI486.3 wherein Ra2 and Rb2 are each as defined above, Rr is hydrogen or amino protective group, m is an integer 1 to 3; and n is an integer O to 2, provided that when R1 is hydrogen, t-butoxycarbonyl or N-acetylmuramyl is is methyl, m is an integer 2 and n is an integer 1, then R2 is hydrogen, protected carboxy or a group of the formula: : EMI487.1 wherein R2is mono- or di-carboxy a (or protected carboxy) lower alkyl having 1 and 3 to 6 carbon atoms, &alpha;-carboxyethyl, &alpha;-protected carboxyethyl, ar-(carboxy or protected carboxy) lower alkyl whose aryl moiety maybe substituted by hydroxy 2 and Rb is as defined above, and when R1 is lactoyl, is is methyl, m is an integer 2, n is an integer 1, Rp is carboxy, Rq is carboxy and Rr is hydrogen, then R2 is hydrogen, carboxy, protected carboxy or a group of the formula: : EMI487.2 wherein Ra2 is mono or di-carboxy lower alkyl having 2 to 6 carbon atoms, mono or di-protected carboxy lower alkyl having 1 to 6 carbon atoms or ar-(car boxy or protected carboxy) (lower) alkyl whose aryl moiety may be substituted by hydroxy. 2. A compound according to the claim 1, wherein R1 is hydrogen or acyl, 1 is hydrogen, methyl, isopropyl, hydroxymethyl Rb or benzyl, R2 and R9 are each hydrogen, carboxy or a group of the formula: EMI488.1 wherein Ra2 is mono-or di-carboxy lower alkyl or ar(carboxy)lower alkyl whose aryl moiety 2 may be substituted by hydroxy, Rb is hydrogen or lower alkyl, RP is hydrogen or carboxy, with proviso that when one of R2 and R9 is hydrogen, then the other is carboxy, or a group of the formula: EMI488.2 wherein Ra2 and Rb2 are each defined above, and Rr is hydrogen. 3. A. compound according to the claim 1, wherein n is an integer 0 and m is an integer 1. 4. A compound according to the claim 3, wherein R1, i, R2,Rp,Rq and Rr are each as defined in the preceding claim 2. 5. A compound according to the claim 1, wherein n is an integer 0 and m is an integer 2. 6. A compound according to the claim 5, wherein RÚ, Rb1, Rê,Rp,Rq and Rr are each as defined in the preceding claim 2. 7. A compound according to the claim 1, wherein n is an integer 0 and m is an integer 3. 8. A compound according to the claim 7, wherein RÚ,Rb1,Rê,Rp,Rq and Rr are each as defined in the preceding claim 2. 9. A compound accor,ding to the claim 1, wherein n is an integer 1 and m is an integer 1. 10. A compound according to the claim 9, wherein RÚ,Rb1,Rê,Rp,Rq and Rr are each as defind in the preceding claim 2. 11. A compound according to the claim ii wherein n is an integer 1 and . m is an integer 2. 12. A compound according to the claim 11,wherein RÚ,Rb1,Rê,Rp,Rq and Rr are each as defind in the preceding claim 2. 13. A compound according to the claim '1, wherein n is an integer 1 and m is an integer 3. 14. A compound according to the claim 13, wherein RÚ,Rb1,Rê,Rp,Rq and Rr are each as defind in the preceding claim 2. 15. A compound according to the claim 1;, wherein n is an integer 2 and m is an integer 1. 16. A compound according to the claim 15,wherein RÚ,Rb1,Rê,Rp,Rq and Rr are each as defind in the preceding claim 2. 17. A compound according to the claim 1, wherein n is an integer 2 and m is an integer 2. 18. A compound according to the claim 17, wherein RÚ,Rb1,Rê,Rp,Rq and Rr are each as defind - in the preceding claim 2. 19. A compound according to the claim 1, wherein n is an integer 2 ad m is an integer 3. 20. A compound according to the claim 19, wherein RÚ,Rb1,Rê,Rp,Rq and Rr are each as defind in the preceding claim 2. 21. A compound according to the claim 1, wherein R1 is hydrogen. 22. A compound according to the claim 1, wherein R1 is acyl. 23. A compound according to the claim 1, wherein R2 and Rq are each hydrogen or protected carboxy, Rp is hydrogen or protected carboxy, with proviso that when one of R2 and Rq is hydrogen, then the other is protected carboxy. 24. A compound according to claim 1, wherein Rê is a group of the formula: EMI491.1 wherein Ra2 and Rb2 are each as defined in claim 1, RP is as defined in claim 1 and Rq is hydrogen, carboxy or protected carboxy. 25. A compound according to claim 1, whjerein Rê is hydrogen,carboxy or protected carboxy, RP is as defined in claim 1, and Rq is a group of the formula: EMI491.2 wherein R2a and R are each as defined in claim 1. 26. A compound according to the claim 1, wherein the protected carboxy for R2 r Rp and/or Rq is esterified carboxy. 27. A pharmaceutical composition comprising as an ingredient a compound as defined in proceeding claim 1 or its pharmaceutically acceptable salt. The starting compound having the general formula EMI492.1 wherein RÚ,Ra2,Rb2,Rq and Rr are each as defined in claim 1, provided that when R1 is hydrogen or t-butoxycar bonyl and Rb2 is hydrogen, then Ra2 is mono- or di-carboxy lower alkyl having 1 and 3 to 6 carbon atoms, &alpha;-carboxyethyl or a (carboxy)-lower alkyl whose aryl moiety may be substituted by hydroxy. 29. The compound having the formula VI-7: EMI492.2 30. The compound having the general formula VI-11: EMI493.1 wherein Rr has the same meaning as defined in claim 1 and Y is an amino protective group, in particular a group which can be removed by subjecting at first to the reaction for eliminating amino protective group to give -CO.NHNH2 group and thxsubjecting the reaction product to the reaction of this step to give -COOH group. 31. A process for preparation of a compound of the formula: EMI494.1 wherein Rl is hydrogen or acyl; Rb1 is hydrogen, methyl, isopropyl, hydroxymethyl protected hydroxymethyl or benzyl; R2 and R9 are, each hydrogen, carboxy, protected carboxy, or a group of the formula: EMI494.2 wherein Ra2 is mono- or dicarboxy (or protected carboxy) lower alkyl or ar(carboxy or prote.cted carboxy)- lower alkyl whose aryl moiety may be substituted by hydroxy, Rb2 is hydrogen or lower alkyl; Rp is hydrogen, carboxy, protected carboxy with proviso that when one of R2 and Rq is hydrogen, then the other is carboxy or protected carboxy or a group of the formula: EMI495.1 wherein Ra2 and Rb2 are each as defined above; Rr is hydrogen or amino protective group, m is an integer 1 to 3; and n is an integer 0 to 2, provided that when RÚ is hydrogen, t-butoxycarbonyl or N-acetylmuramyl, Fb is methyl, m is an integer 2 and n is an integer 1, then R2 is hydrogen, protected carboxy or a group of the formula: EMI495.2 wherein Ra2 is mono- or di-carboxy (or protected carboxy) lower alkyl having 1 and 3 to 6 carbon atoms, &alpha;-carboxyethyl, a-protected carboxyethyl, ar- (carboxy or protected carboxy) lower alkyl whose - aryl moiety may be substituted by hydroxy - and is as defined above, and when RÚ is lactoyl, Rb1 is methyl, m is an integer 2, n is an integer 1, RB is carboxy, Rq is carboxy and Rr is hydrogen, then Rê is hydrogen, carboxy, protected carboxy or a group of the formula: : EMI495.3 wherein Ra2 is mono or di-carboxy lower alkyl having 2 to 6 carbon atoms mono or di-protected carboxy lower alkyl having 1 to 6 carbon atoms or ar(carboxy @@@ or protected carboxy) (lower) alkyl whose @@@ aryl moiety may be substituted by hydroxy, which comprises (i) reacting a compound of the formula or its salt: EMI496.1 with a compound of the formula or its salt: EMI496.2 to give a compound of the formula or its salt: EMI496.3 wherein RÚ is acyl, RP is c is acyl R1 is hydrogen protected carboxy, Ref is amino protective group and Rb1, n, m, Rê and Rq are each as defined above; (ii) subjecting a compound of the formula or its salt: : EMI497.1 to removal reaction of an acyl group for Rc1 to give a compound of the formula or its salt: EMI497.2 wherein Rc1, Rb1, n, Rp, m, Rê, Rq and R1r are each as defined above; (iii) reacting a compound of the formula or its salt: EMI497.3 With an acylating agent of the formula or its reactive derivate: Rc1-OH to give a compound of the formula: EMI498.1 wherein Rc1, Rb1, n, Rp, m, Rê, Rq and R1r are each as defined above; (iv) subjecting a compound of the formula or its salt: EMI498.2 to removal reaction of protective groups to give a compound of the formula or its salt: EMI498.3 wherein R2p is hydrogen or carboxy, Rê' and ç are each hydrogen, 7 carboxy, or a group of the formula: EMI499.1 2 wherein Ra is mono- or di-carboxy lower alkyl or ar(carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy and Rb2 is as defined above, R1, Rb1, n, R1p, m, Rê, Rq and R1r are each as defined above; (v) - reacting a compound of the formula or its salt: EMI499.2 with a compound of the formula or its salt: : EMI499.3 to give a compound of the formula or its salt: EMI499.4 wherein R9 is hydrogen or protected carboxy, and RÚ, Rb1, n, R1p, m, Ra2, Rb2, R1r and R1q are each as defined above; (VI) reacting a compound of the formula or its salt: EMI500.1 with a compound of the formula or its reactive derivative R1r-OH to give a compound of the formula or its salt: EMI500.2 wherein Rc1, Rb1, n, Rp, m, Rê, Rp and R1r are each as defined above; and (VII) reacting a compound of the formula: EMI500.3 (wherein R1, Rb1, n, R9, m, R2, Rr and R9 are each as defined above provided that at least one of RP, R2 and R9 are carboxy, or alternatively at least Ra2 is mono- or di- carboxy lower alky,l or ar(carboxy)lower alkyl whose aryl moiety may be substituted by hydroxy) with an esterifying agent to give a compound of the formula: EMI501.1 wherein RÚ, Rb1, n, and are each as de fined above, and Rc2 and R4q are each hydrogen, carboxy, protected carboxy, esterified carboxy or a group of the formula: : -CON-Ra2 wherein Ra2 is mono-or di-carboxy Rb2 (or protec carboxy lower alkyl, ar(carboxy or protected carboxy)lower alkyl whose aryl moiety may be substituted by hydroxy or ar(esterified carboxy)lower alkyl whose aryl moierty may be substituted by hydroxy and Rb2 is as defined above, R3p is 3 hydrogen, carboxy, protected carboxy or esterified carboxy provided that at least one of Rc2, R4q and R3p is esterified carboxy, or alternatively at least Ra2 is mono- or di esterified carboxy lower alkyl or ar(esteri- fied carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy. .32. A process for preparing a compound of the formula or its salt: EMI502.1 which comprises reacting a compound of the formula or its salt: EMI502.2 with a compound of the formula or its'salt: EMI502.3 wherein Rc1,R1p,R1r,Rb1,n,m,Rê and Rq are each as defined in claim 1. 33. A process for preparing a compound of the formula or its salt: EMI502.4 which comprises subjecting a compound of the formula or its salt: EMI503.1 to removal reaction of an acyl group for R1 wherein RÚ. Rb1, n, m, m, R2, Rq and R1r are each as defined in claim 1. 34. A process for preparing a compound of the formula or its salt: EMI503.2 which comprises reacting a compound of the formula or its salt: EMI503.3 with an acylatting agent of the formula or its reactive derivative: Rc1-OH wherein Rc1, Rb1, n, Rp, m, Rê, Rq and R1r are each as defined in claim 1. A process for preparing a compound of the formula Or its salt: EMI504.1 which comprises subjecting a compound of the formula or its salt: EMI504.2 to removal reaction of protective groups, wherein R2p, Rê',R7q, RÚ,Rb1,n,R1p,m,Rê,Rq and R1r are each as defined in claim 1. 36. A process for preparing a compound of the formula or its salt: EMI505.1 which comprises reacting a compound of the formula or its salt: EMI505.2 with a compound of the formula or its salt: EMI505.3 wherein R1q,RÚ,Rb1,n,R1p,m,Ra2,Rb2,R1r and R1q are each as defined in claim 1. 37. A process for preparing a compound of the formula: EMI506.1 which comprises reacting a compound of the formula or its salt: EMI506.2 with a compound of the formula or its reactive derivative: R1r-OH wherein Rc1,Rb1,n,Rp,m,Rê,Rq and R1r are as defined in claim 1. 38. A process for preparing a compound of the formula: EMI506.3 wherein RÚ,Rb1 Rb1,n and m are each as defined in claim 1, and Rc2 and R4q are each hydrogen, carboxy, protected carboxy, esterified carboxy or a group of the formula: EMI507.1 wherein Ra2 is mono- or di carboxy (or protected car,boxy) lower alkyl, esterified carboxy lower alkyl, ar(carboxy or protected carboxy)lower alkyl whose aryl moiety may be substituted by hydroxy or ar(esterified carboxy)lower alkyl whose aryl moiety may be substituted by hydroxy and Rb2 is as defined above, g is hydrogen, carboxy, protected 3 carboxy or esterified carboxy provided that at least one of Rc2,R4q and R3p is esterified carboxy, or alternatively at least Ra2 is mono-or di- esterified carboxy lower alkyl or ar(esterified carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy.]. which comprises reacting a compound of the formula: EMI507.2 (wherein RÚ,Rb1,n,Rp,m,Rê,Rr and Rq are each as defined in claim 1 provided that at least one of Rp,ê and Rq are carboxy, or alternatively at least Ra is mono- or di- carboxy lower alkyl or arCcarboxy)lower alkyl whose aryl moiety may be substituted by hydroxy) with an esterifying agent.

Inventors: AOKI, HATSUO, ARATANI, MATSUHIKO, HASHIMOTO, MASASHI, HEMMI, KEIJI, IGUCHI, EIKO, IMANAKA, HIROSHI, KITAURA, YOSHIHIKO, KOHSAKA, MASANOBU, KURODA, YOSHIO, NAKAGUCHI, OSAMU, OKADA, SATOSHI, TAKENO, HIDEKAZU, TANAKA, HIROKAZU
Applicants: FUJISAWA PHARMACEUTICAL CO., LTD.
Application year: 1980
Main classification: C07K7
IPC codes: C07K1, C07K5, A61P35, C07K9, A61K39, A61P31, A61P37, A61K38